WO2015103453A1 - Heteroaryl substituted nicotinamide compounds - Google Patents

Heteroaryl substituted nicotinamide compounds Download PDF

Info

Publication number
WO2015103453A1
WO2015103453A1 PCT/US2015/010006 US2015010006W WO2015103453A1 WO 2015103453 A1 WO2015103453 A1 WO 2015103453A1 US 2015010006 W US2015010006 W US 2015010006W WO 2015103453 A1 WO2015103453 A1 WO 2015103453A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
nicotinamide
cyano
hydroxy
fluoro
Prior art date
Application number
PCT/US2015/010006
Other languages
French (fr)
Inventor
Joseph B. Santella
Sreekantha Ratna KUMAR
John V. Duncia
Daniel S. Gardner
Venkatram Reddy PAIDI
Satheesh Kesavan NAIR
John Hynes
Hong Wu
Natesan Murugesan
Kandhasamy SARKUNAM
Piramanayagam ARUNACHALAM
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52355270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015103453(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to TN2016000271A priority Critical patent/TN2016000271A1/en
Priority to AU2015204045A priority patent/AU2015204045A1/en
Priority to CA2935329A priority patent/CA2935329A1/en
Priority to MX2016008723A priority patent/MX2016008723A/en
Priority to ES15700518T priority patent/ES2804707T3/en
Priority to EP15700518.2A priority patent/EP3089973B1/en
Priority to SG11201605340QA priority patent/SG11201605340QA/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to KR1020167020884A priority patent/KR20160101191A/en
Priority to JP2016544410A priority patent/JP6475252B2/en
Priority to EA201691343A priority patent/EA201691343A1/en
Priority to MA39162A priority patent/MA39162A1/en
Priority to CN201580011617.6A priority patent/CN106061967B/en
Publication of WO2015103453A1 publication Critical patent/WO2015103453A1/en
Priority to PH12016501164A priority patent/PH12016501164A1/en
Priority to IL246474A priority patent/IL246474A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Definitions

  • the present invention generally relates to heteroaryl substituted nicotinamide compounds useful as kinase inhibitors, including the modulation of IRAK-4.
  • heteroaryl substituted nicotinamide compounds useful as kinase inhibitors, including the modulation of IRAK-4.
  • heteroaryl substituted nicotinamide compounds compositions comprising such compounds, and methods of their use.
  • the invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to kinase modulation and methods of inhibiting the activity of kinases, including IRAK-4 in a mammal.
  • Toll/IL-1 receptor family members are important regulators of inflammation and host resistance.
  • the Toll like receptor (TLR) family recognizes molecular patterns derived from infectious organisms including bacteria, fungi, parasites, and viruses (reviewed in Kawai, T. et al, Nature Immunol, 11 :373-384 (2010)).
  • Ligand binding to the receptor induces dimerization and recruitment of adaptor molecules to a conserved cytoplasmic motif in the receptor termed the Toll/IL-1 receptor (TIR) domain.
  • TIR Toll/IL-1 receptor
  • TIR Toll/IL-1 receptor
  • TIR Toll/IL-1 receptor
  • TIR Toll/IL-1 receptor
  • the IL-1 receptor family also contains a cytoplasmic TIR motif and recruits MyD88 upon ligand binding (reviewed in Sims, J.E. et al, Nature Rev. Immunol, 10:89-102 (2010)).
  • IRAK4 plays a critical and non-redundant role in initiating signaling via MyD88 dependent TLRs and IL-1R family members. Structural data confirms that IRAK4 directly interacts with MyD88 and subsequently recruits either IRAKI or IRAK2 to the receptor complex to facilitate downstream signaling (Lin, S. et al, Nature, 465:885-890 (2010)).
  • IRAK4 directly phosphorylates IRAKI to facilitate downstream signaling to the E3 ubiquitin ligase TRAF6, resulting in activation of the serine/threonine kinase TAK1 with subsequent activation of the NFKB pathway and MAPK cascade (Flannery, S. et al, Biochem. Pharmacol., 80: 1981-1991 (2010)).
  • a subset of human patients was identified who lack IRAK4 expression (Picard, C. et al, Science, 299:2076-2079 (2003)). Cells from these patients fail to respond to all TLR agonists with the exception of TLR3 as well as to members of the IL-1 family including IL- ⁇ and IL-18 (Ku, C. et al, J.
  • IRAK4 in mice results in a severe block in IL-1, IL-18 and all TLR dependent responses with the exception of TLR3 (Suzuki, N. et al, Nature, 416:750-754 (2002)).
  • deletion of either IRAKI Thomas, J.A. et al, J. Immunol, 163:978-984 (1999); Swantek, J.L. et al, J. Immunol, 164:4301-4306 (2000) or IRAK2 (Wan, Y. et al, J. Biol Chem., 284: 10367-10375 (2009)) results in partial loss of signaling.
  • IRAK4 is the only member of the IRAK family whose kinase activity has been shown to be required for initiation of signaling.
  • Replacement of wild type IRAK4 in the mouse genome with a kinase inactive mutant (KDKI) impairs signaling via all MyD88 dependent receptors including IL-1, IL-18 and all TLRs with the exception of TLR3 (Koziczak-Holbro, M. et al, J. Biol. Chem., 282: 13552-13560 (2007); Kawagoe, T. et al, J. Exp. Med, 204: 1013- 1024 (2007); and Fraczek, J. et al, J. Biol. Chem., 283:31697-31705 (2008)).
  • IRAK4 KDKI mice show greatly reduced disease severity in mouse models of multiple sclerosis (Staschke, K.A. et al, J. Immunol, 183:568-577 (2009)), rheumatoid arthritis (Koziczak-Holbro, M. et al., Arthritis Rheum., 60: 1661-1671 (2009)), atherosclerosis (Kim, T.W. et al, J. Immunol, 186:2871-2880
  • IRAK4 inhibitors will block all MyD88 dependent signaling.
  • MyD88 dependent TLRs have been shown to contribute to the pathogenesis of multiple sclerosis, rheumatoid arthritis, cardiovascular disease, metabolic syndrome, sepsis, systemic lupus erythematosus, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, autoimmune uveitis, asthma, allergy, type I diabetes, and allograft rejection (Keogh, B. et al, Trends Pharmacol. Sci., 32:435-442 (2011); Mann, D.L., Circ. Res., 108: 1133-1145 (2011); Horton, C.G.
  • Oncogenically active MyD88 mutations in diffuse large B cell lymphomas have been identified that are sensitive to IRAK4 inhibition (Ngo, V.N. et al, Nature, 470: 115-121 (2011)).
  • Whole genome sequencing also identified mutations in MyD88 associated with chronic lymphatic leukemia suggesting that IRAK4 inhibitors may also have utility in treating leukemias (Puente, X.S. et al, Nature, 475: 101-105 (2011)).
  • IRAK4 inhibitors will also block signaling by members of the IL-1 family.
  • Neutralization of IL-1 has been shown to be efficacious in multiple diseases including gout; gouty arthritis; type 2 diabetes; auto-inflammatory diseases including Cryopyrin-Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult onset stills; systemic onset juvenile idiopathic arthritis; stroke; Graft- versus-Host Disease (GVHD); smoldering multiple myeloma; recurrent pericarditis; osteoarthritis; emphysema (Dinarello, C.A., Eur. J. Immunol, 41 : 1203-1217 (2011) and Couillin, I. et al, J.
  • IL-1 has also been shown to be a critical link to adaptive immunity, driving
  • IRAK4 inhibitors are predicted to have efficacy in TH17 associated diseases including multiple sclerosis, psoriasis, inflammatory bowel diseases,
  • WO 2013/106612, WO 2013/106614, and WO 2013/106641 disclose substituted pyridyl compounds useful as kinase inhibitors, including the modulation of IRAK4.
  • the present invention relates to a new class of heteroaryl substituted nicotinamide compounds found to be effective inhibitors of protein kinases including IRAK-4. These compounds are provided to be useful as pharmaceuticals with desirable stability, bioavailability, therapeutic index, and toxicity values that are important to their drugability.
  • the present invention provides to compounds of Formula (I) that are useful as inhibitors of IRAK-4, and are useful for the treatment of proliferative diseases, allergic diseases, autoimmune diseases and inflammatory diseases, or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides a method for inhibition of IRAK-4 comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the present invention also provides a method for treating proliferative, metabolic, allergic, autoimmune and inflammatory diseases, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • One embodiment provides a method for treating inflammatory and autoimmune diseases wherein the treatment of inflammatory diseases is even more preferred.
  • inflammatory and autoimmune diseases include, but are not limited to, Crohn's disease, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis, cryopyrin-associated periodic syndromes (CAPS), TNF receptor associated periodic syndrome (TRAPS), familial Mediterranean fever (FMF), adult onset stills, systemic onset juvenile idiopathic arthritis, multiple sclerosis, neuropathic pain, gout, and gouty arthritis.
  • CPS cryopyrin-associated periodic syndromes
  • TRAPS TNF receptor associated periodic syndrome
  • FMF familial Mediterranean fever
  • adult onset stills systemic onset juvenile idiopathic arthritis, multiple sclerosis, neuropathic pain, gout, and gouty arthritis.
  • One embodiment provides a method for treating gout and gouty arthritis.
  • An alternate preferred embodiment is a method for treating metabolic diseases, including type 2 diabetes and atherosclerosis.
  • the present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for use in therapy.
  • the present invention also provides the use of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the manufacture of a medicament for the treatment of cancers.
  • the present invention also provides processes and intermediates for making the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
  • the first aspect of the present invention provides at least one compound of Formula (I):
  • HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3- d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-lH- pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rt,;
  • Ci_ 4 alkyl is H, F, CI, Br, -CN, -OH, Ci_ 4 alkyl, Ci_ 4 fluoroalkyl, Ci_ 4 hydroxyalkyl, Ci_ 4 alkoxy, -NH 2 , -NH(Ci_ 4 alkyl), -N(C M alkyl) 2 , -NH(Ci_ 4 hydroxyalkyl), -NH(Ci_ 4
  • cycloalkyl) 2 (OH), -(Ci_ 4 alkylenyl)NHC(0)(Ci_ 4 alkylenyl)OC(0)(Ci_ 3 alkyl), -(Ci_6 alkylenyl)NHS(0) 2 (Ci_ 4 alkyl), -(Ci_ 6 alkylenyl)P(0)(Ci_ 4 alkoxy) 2 , -(Ci_ 6 fluoroalkylenyl)NH(Ci_ 4 alkyl), -(Ci_ 6 alkylenyl)C(0)NH(Ci_ 4 alkyl), -(Ci_ 6 fluoroalkylenyl)C(0)NH(Ci_ 4 alkyl), -(Ci_ 6 fluoroalkylenyl)C(0)NH(Ci_ 4 hydroxyalkyl), or -(Ci_ 6 fluoroalkylenyl)OP(0)(OH) 2 ;
  • -CH 2 CF (tetrahydropyranyl), wherein R x is a cyclic group selected from C 3 _ 6 cycloalkyl, tetrazolyl, 1,1-dioxidotetrahydrothiophenyl,
  • C3-6 cycloalkyl or C4-6 cycloalkenyl each substituted with zero to 3 substituents independently selected from F, -OH, -CN, Ci_ 3 alkyl, Ci_ 3 alkoxy, -S(C 1-3 alkyl), -NO 2 , -S(0) 2 (Ci_ 3 alkyl), Ci_ 4 hydroxyalkyl, -C(Ci_ 3 alkyl)(OH)(C 3 _ 6 cycloalkyl), -CH 2 C(0)NH(Ci_ 3 alkyl), -NHC(0)(Ci_ 3 alkyl), -NHC(0)(Ci_ 4 hydroxyalkyl), -C(0)NH(Ci_ 3 alkyl), -C(0)NH(Ci_ 3 deuteroalkyl), -C(0)NH(C 3 _ 6 cycloalkyl), -NHC(0)0(Ci_ 3 alkyl), -NHS(0) 2 (Ci_ 3 alkyl), pyridinyl
  • tetrahydropyranyl piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from -OH, Ci_ 3 alkyl, Ci_ 3 fluoroalkyl, Ci_ 4 hydroxyalkyl, Ci_ 3 alkoxy, -C(0)(Ci_ 4 alkyl), -S(0) 2 (Ci_ 4 alkyl), -S(0) 2 NH(Ci_ 4 alkyl), -NH(Ci_ 3 alkyl), -N(Ci_ 3 alkyl) 2 , -0(Ci_ 3 alkylenyl)N(Ci_ 3 alkyl) 2 , -CH 2 (morpholinyl), azetidinyl, oxetanyl, tetrahydropyranyl,
  • Ci_7 alkyl or C 2 _ 6 alkenyl each substituted with zero to three substituents independently selected from F, -OH, and -CN; -(Ci_ 4 alkylenyl)0(Ci_ 4 alkyl), -(Ci_ 4 alkylenyl)0(Ci_ 4 fluoroalkyl), -(Ci_ 6 alkylenyl)NH 2 , -(Ci_ 6
  • alkylenyl)S(0) 2 (Ci_ 3 alkyl), -(Ci_ 6 fluoroalkylenyl)NH(Ci_ 3 alkyl), or -(Ci_ 6 alkylenyl)NHC(0)(Ci_ 4 fluoroalkyl);
  • R y is C 3 _ 6 cycloalkyl, azetidinyl, oxetanyl, oxazolyl, pyridinyl, tetrahydropyranyl, or morpholinyl, each substituted with zero to 2 substituents independently selected from F, -OH, and Ci_ 3 alkyl;
  • the HET group is a heteroaryl group having at least one nitrogen heteroatom, wherein one nitrogen heteroatom of the HET group forms a bond to a carbon atom adjacent to the nitrogen heteroatom in the pyridine ring.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein HET i a heteroaryl selected from:
  • R a is H, F, CI, Br, -CN, -OH, -CH 3 , -CHF 2 , -OCH 3 , -NH 2 , -N(CH 3 ) 2 , -NHCH 2 CH 2 OH, -NHCH 2 C(CH 3 ) 2 OH, -NHCH 2 CHFC(CH 3 ) 2 OH, -C(0)NH 2 ,
  • R x is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl,
  • each cyclic group is substituted with zero to 3 substituents independently selected from F, -OH, -CH 3 , -C(CH 2 ) 2 OH, -OCH 3 , -C(0)CH 2 CN, -S(0) 2 CH 3 , -S(0) 2 NH 2 , -NHC(0)CH 3 , -N(S(0) 2 CH 3 ) 2 ,
  • cyclopropyl cyclopentyl, cyclopentenyl, or cyclohexyl, each substituted with zero to 2 substituents independently selected from F, -OH, -CN, -CH 3 , -OCH 3 , -SCH 3 , -N0 2 , -S(0) 2 CH 3 , -C(CH 3 ) 2 OH, -C(CH 3 )(OH)(cyclopropyl),
  • HET is a heteroaryl selected from:
  • each of said heteroaryl is substituted with R a and R b ; and Ri, R 2 , R a , and R b are defined in the first aspect.
  • Q is selected from:
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrazolyl substituted with R a and R b ; and Ri, R 2 , R a , and R b are defined in the first
  • R a and R b and compounds in which Q is included in this embodiment are compounds in which R a is pyridazinyl; R b is H; Ri is
  • R 2 is -CH(CH 3 ) 2 .
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is indolyl substituted with R a and R b ; and Ri, R 2 , R a , and R b are defined in the first aspect.
  • R a and R b are compounds in which Q is substituted with R a and R b ; and compounds in which Q is . Also included in this embodiment are compounds in which R a is CI or -CN; R b is H; Ri is
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrrolo[2,3-b]pyridinyl substituted with R a and R b ; and Ri, R 2 , R a , and R b are defined in the first as ect. Included in this embodiment are com ounds in which is substituted with R a and R b ; and compounds in which Q is
  • R a is H, F, CI, -CN, -C(0)NH 2 , -NHC(0)CH 3 , -CH 2 NHC(0)CH(CH 3 ) 2 , -CH 2 NHC(0)CH 2 C(CH 3 ) 2 OH,
  • Ri is:
  • R x is a cyclic group selected from cyclopropyl, piperazinyl, oxetanyl, and phenyl, wherein each cyclic group is substituted with zero to 3 substituents
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrrolo[2,3-d]pyrimidinyl substituted with R a and R b ; and Ri, R 2 , R a , and R b are defined in the first aspect. Included in this embodiment are compounds in which Q is
  • R a is H, -NH 2 , N(CH 3 ) 2 ,
  • R 2 is -CH(CH 3 ) 2 ,
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrazolo[3,4-b]pyridinyl substituted with R a and R b ; and Ri, R 2 , R a , and R b are defined in the first aspect. Included in this embodiment are compounds in which is
  • R a is F, CI, Br, -CN, -OH, -CH 3 , -CHF 2 , -OCH 3 , -C(0)NH 2 , or -CH 2 NHC(0)CH 2 CH(CH 3 ) 2 ;
  • R b is H or -NH 2 ;
  • Ri is:
  • R x is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl, 1,1- dioxidotetrahydrothiophenyl, 1 , 1 -dioxidothiomorpholmyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl,
  • tetrahydropyranyl piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with a substituent selected from -OH, -OCH 3 , -CH 2 CHF 2 ,
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrazolo[3,4-d]pyrimidinyl substituted with R a and R b ; and Ri, R 2 , R a , and R b are defined in the first as ect. Included in this embodiment are com ounds in which is substituted with R a and R b ; and compounds in which Q is
  • R a is H or -NH 2 ;
  • R b is H;
  • Ri is -CH 2 CHFC(CH 3 ) 2 OH or -CH 2 CHFC(CH 2 CH 3 ) 2 OH; and
  • R 2 is -CH 2 CH 3 , -CH(CH 3 ) 2 , or cyclopropyl.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl substituted with Ra and Rb; and Ri, R 2 , Ra, and Rb are defined in the first aspect. Included in this embodiment are compounds in which Q .
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is imidazo[4,5-b]pyridinyl substituted with Ra and Rb; and Ri, R 2 , Ra, and Rb are defined in the first aspect. Included in this embodiment are compounds in which Q is
  • R a is CI or -CN; Rb is H or -NH 2 ; Ri is -CH 2 CHFC(CH 3 ) 2 F or -CH 2 CHFC(CH 3 ) 2 OH; and R 2 is -CH 2 CH 3 ,
  • -CH(CH 3 ) 2 -CH 2 CH 2 CN, cyclopropyl, methylcyclopropyl, cyclobutyl, oxetanyl, tetrahydrofuranyl, or pyrazolyl substituted with -CH 3 , CHF 2 , -CH 2 CH 3 , -CH 2 CH 2 CN, -CH 2 CHF 2 , -CH 2 CH 2 CH 3 , CH 2 CHFCH 3 , -CH 2 CH 2 CH 2 F, -CH(CH 3 ) 2 , or
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is purinyl substituted with R a and Rb; and Ri, R 2 , Ra, and Rb are defined in the first aspect.
  • R a and Rb and compounds in which Q is N . Also included in this specification
  • Ra is H, -NH 2 , -NHCH 2 CH 2 OH, or
  • R b is H
  • Ri is -CH 2 CHFC(CH 3 ) 2 F or -CH 2 CF 2 C(CH 3 ) 2 OH
  • R 2 is -CH(CH 3 ) 2 .
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrrolo[2,3-b]pyridinyl or pyrazolo[3,4-b]pyridinyl; Ra is H, F, CI, Br, -CN, -OH, -CH 3 , -CHF 2 , -OCH 3 , -C(0)NH 2 , -NHC(0)CH 3 , -CH 2 NHC(0)CH(CH 3 ) 2 ,
  • R b is H or -NH 2 ;
  • Ri is:
  • R x is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl,
  • each cyclic group is substituted with zero to 3 substituents independently selected from F, -OH, -CH 3 , -C(CH 2 ) 2 OH, -OCH 3 , -C(0)CH 2 CN, -S(0) 2 CH 3 , -S(0) 2 NH 2 , -NHC(0)CH 3 , -N(S(0) 2 CH 3 ) 2 , and oxetanyl, benzyl;
  • cyclopropyl cyclopentyl, cyclopentenyl, or cyclohexyl, each substituted with zero to 2 substituents independently selected from F, -OH, -CN, -CH 3 , -OCH 3 , -SCH 3 , -N0 2 , -S(0) 2 CH 3 , -C(CH 3 ) 2 OH, -C(CH 3 )(OH)(cyclopropyl),
  • the second aspect of the invention provides a compound of Formula (I) or a salt thereof, within the scope of the first aspect, wherein: HET is a heteroaryl selected from pyrazole, indole, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-d]pyrimidine, pyrazolo[3,4-b] pyridine, pyrazolo[3,4-d]pyrimidine, or purine, wherein said heteroaryl is substituted with zero or one substituent selected from F, CI, Br, -OH, -CN, -CH 3 , -NH 2 , -N(CH 3 ) 2 , -NHCH 2 C(CH 3 ) 2 OH, -NHC(0)CH 3 , -NHCH 2 CH 2 OH, -C(0)NH 2 , hydroxypyrrolidine, and pyridazine;
  • Ri is:
  • R 2 is:
  • R x is C 3 _ 6 cycloalkyl, oxetane, tetrahydrofuran, or
  • tetrahydropyran each substituted with zero to 2 substituents selected from F, -OH, and -CH 3 ;
  • One embodiment provides a compound of Formula (I) or a salt thereof wherein HET is a pyrazole substituted with zero or one substituent selected from F, CI, Br, -OH, -CN, -CH 3 , -NH 2 , -N(CH 3 ) 2 , -NHCH 2 C(CH 3 ) 2 OH, -NHC(0)CH 3 , -NHCH 2 CH 2 OH, -C(0)NH 2 , hydroxypyrrolidine, and pyridazine. Included in this embodiment are compounds in which HET is pyrazole substituted with pyridazine. Also included in this
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein HET is a bicyclic heteroaryl selected from indole, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-d] pyrimidine, pyrazolo[3,4-b]pyridine, pyrazolo[3,4-d]pyrimidine, or purine, wherein each of said bicyclic heteroaryl is substituted with zero or one substituent selected from F, CI, Br, -OH, -CN, -CH 3 , -NH 2 , -N(CH 3 ) 2 , -NHCH 2 C(CH 3 ) 2 OH, -NHC(0)CH 3 ,
  • HET HET-NHCH 2 CH 2 OH, -C(0)NH 2 , hydroxypyrrolidine, and pyridazine. Included in this embodiment are compounds in which HET is:
  • each of said heteroaryl is substituted with zero or 1 substituent selected from F, CI, Br, -OH, -CN, -CH 3 , -NH 2 , -N(CH 3 ) 2 , -NHCH 2 C(CH 3 ) 2 OH, -NHC(0)CH 3 ,
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein HET is a bicyclic heteroaryl selected:
  • R a is H, F, CI, Br, -OH, -CN, -CH 3 , -NH 2 , -N(CH 3 ) 2 , -NHCH 2 C(CH 3 ) 2 OH, -NHC(0)CH 3 , -NHCH 2 CH 2 OH, -C(0)NH 2 , or hydroxypyrrolidine.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein
  • HET is ; and wherein R a is CI or -CN.
  • R a is CI or -CN.
  • HET is: ; and wherein Ra is H, F, CI, -CN, -C(0)NH 2 , or -NHC(0)CH 3 .
  • HET is: and wherein R a is F, CI, Br, -OH, -CN, or -CH 3 . Included in this embodiment are compounds in which Ra is CI or -CN. Also included in this embodiment
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein R a is H, F, CI, or -CN. Included in this embodiment are compounds in which R a is -CN. Also included in this embodiment are compounds in which Ra is CI.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Ri is Ci_7 alkyl substituted with 1 to 4 substituents independently selected from F, -OH, -OCH 3 , -OCH(CH 3 ) 2 , -OC(CH 3 ) 3 , -C(0)NHCH 3 , -NH(CH(CH 3 ) 2 ), -NHS(0) 2 CH 3 ,
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Ri is bicyclo[2.2.1]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or 1 ,3- diazaspiro[4.5]decane-2,4-dione.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein Ri is C 3 -6 cycloalkyl substituted with 1 to 3 substituents independently selected from F, -OH, -NO2, -CH3, -C(CH 3 ) 2 OH, -C(0)NH(CH 3 ), -C(0)NH(CD 3 ), -C(0)NH(CH 2 CH 3 ), -C(0)NH(cyclopropyl), -NHC(0)CH 3 , -NHC(0)OCH 3 ), -NHS(0) 2 CH 3 , -S(0) 2 CH 3 , -SCH 3 , pyridine, methylimidazole, methylpyrazole, and thiazole.
  • substituents independently selected from F, -OH, -NO2, -CH3, -C(CH 3 ) 2 OH, -C(0)NH(CH 3 ), -C(0)NH(CD 3 ), -C(0)NH(CH 2 CH 3 ), -C(0)NH(cyclo
  • Ri is cyclohexyl substituted with 1 to 2 substituents independently selected from F, -OH, -N0 2 , -CH 3 , -C(CH 3 ) 2 OH, -C(0)NH(CH 3 ),
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein R 2 is C 2 _6 alkyl substituted with zero to three substituents independently selected from F and -OH. Included in this embodiment are compounds in which R 2 is -CH 2 CH 3 ,
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein R 2 is -(CH 2 )o-3-R x wherein R x is C 3 -6 cycloalkyl, oxetane, or tetrahydropyran, each substituted with zero to 2 substituents selected from F, -OH, and -CH 3 . Included in this embodiment are compounds of Formula (I) in which R 2 is tetrahydropyran,
  • fluorotetrahydropyran -CH 2 (fluorocyclobutyl), -CH 2 (hydroxycyclobutyl), -CH 2 (oxetane), -CH 2 (methyloxetane), or C 3 -6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, and -CH 3 .
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein R 2 is adamantane, benzothiazole, or bicyclo[2.2. l]heptan-l-ol.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein R 2 is phenyl substituted with -OH, -CN, -CH 2 OH, -C(CH 3 ) 2 OH, -OCH 3 , -C(0)NH 2 , -C(0)NH(CH 3 ), -NHC(0)CH 3 , -NHS(0) 2 CH 3 , -S(0) 2 NH 2 , pyrazole, triazole, or methyl tetrazole.
  • the third aspect of the invention provides a compound of Formula (I) or a salt thereof, within the scope of the first aspect, wherein:
  • HET is a heteroaryl selected from:
  • R a is H, F, CI, Br, -OH, -CN, -CH 3 , -NH 2 , -N(CH 3 ) 2 , -NHCH 2 C(CH 3 ) 2 OH, -NHC(0)CH 3 , -NHCH 2 CH 2 OH, -C(0)NH 2 , hydroxypyrrolidine, or pyridazine;
  • Ri is:
  • cyclohexyl substituted with 1 to 2 substituents independently selected from F, -OH, -N0 2 , -CH 3 , -C(CH 3 ) 2 OH, -C(0)NH(CH 3 ), -C(0)NH(CD 3 ),
  • -CH 2 (hydroxycyclobutyl), -CH 2 (oxetane), -CH 2 (methyloxetane), or C 3 _ 6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, and -CH 3 ; (iii) adamantane, benzothiazole, or bicyclo[2.2.1]heptan-l-ol; or
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein
  • HET is ;
  • R a is F, CI, Br, -OH, -CN, or -CH 3 ;
  • Ri is -CH 2 CHFCH(CH 3 )OH, -CH 2 CHFC(CH 3 ) 2 OH, -CH 2 CF 2 C(CH 3 ) 2 OH,
  • R 2 is -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , or -CH 2 CH 2 CH(CH 3 ) 2 .
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein:
  • R a is H, F, CI, -CN, -CH 3 , or -C(0)NH 2 ;
  • Ri is -CH 2 CHFC(CH 3 ) 2 OH, -CH 2 CHFC(CH 3 ) 2 OP(0)(OH) 2 , -CH 2 CHFC(0)NHCH 3 , or cyclohexyl substituted with -C(0)NHCH 3 , -NHC(0)CH 3 , or -S(0) 2 CH 3 ;
  • R 2 is C 3 _6 cycloalkyl substituted with zero to 3 substituents independently selected from F,
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein: HET i a heteroaryl selected from:
  • R a is F, CI, Br, -OH, -CN, or -CH 3 ;
  • Ri is -CH 2 CHFCH(CH 3 )OH, -CH 2 CHFC(CH 3 ) 2 OH, -CH 2 CF 2 C(CH 3 ) 2 OH,
  • R 2 is -CH(CH 3 ) 2 .
  • ne embodiment provides a compound of Formula (I) or a salt thereof, wherein
  • X is CH or N
  • Ri is -CH 2 CH 2 C(CH 3 ) 2 OH, -CH 2 CHFC(CH 3 ) 2 OH, or -CH 2 CHFC(CH 3 ) 2 OP(0)(OH) 2 ; and R 2 is -CH(CH 3 ) 2 .
  • One embodiment provides a compound of Formula (I)or a salt thereof, wherein said compound is selected from: (R)-6-(5-cyano-lH-indol-l-yl)-N-(2-fluoro-3-hydroxy- 3-methylbutyl)-4-(isopropylamino)nicotinamide (1); (R)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (2); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (3); (R)-6-(5 -cyano- 1H-
  • nicotinamide (93); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((2-hydroxy-2- methylpropyl)amino)-N-((tra/75)-4-(( 2 H 3 )methylcarbamoyl)cyclohexyl)nicotinamide (94); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4- nitrocyclohexyl)nicotinamide (95); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((tra/75)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (96); methyl((tra/75)-4-(6-(5-
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
  • Ra is defined in the second aspect. Included in this embodiment are compounds in which R a is -CI and -CN.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
  • R 2 is defined in the second aspect. Included in this embodiment are compounds in which R 2 is C 2 -6 alkyl substituted with zero to three substituents independently selected from F and -OH. Also included in this embodiment are compounds in which R 2 is an unsubstituted C 2 - 5 alkyl.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
  • Ri is defined in the second aspect. Included in this embodiment are compounds in which Ri is Ci_ 7 alkyl substituted with 1 to 3 substituents independently selected from F and -OH. Also included in this embodiment are compounds in which Ri is C 2 - 6 alkyl substituted with one hydroxy group and zero to 2 fluorine substituents.
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
  • One embodiment provides a compound of Formula (I) wherein said compound is:
  • One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
  • the compound of this embodiment is a prodrug of the compound of Example 133.
  • ne embodiment provides a compound of Formula (I) wherein said compound is
  • One embodiment provides compounds of the Formula (I) having IRAK4 IC 50 values of ⁇ 0.05 ⁇ .
  • One embodiment provides compounds of the Formula (I) having IRAK4 IC 50 values of ⁇ 0.025 ⁇ .
  • One embodiment provides compounds of the Formula (I) having IRAK4 IC 50 values of ⁇ 0.015 ⁇ .
  • One embodiment provides compounds of the Formula (I) having IRAK4 IC 50 values of ⁇ 0.01 ⁇ . Crystal Forms
  • the compound of Example 133 is provided as a crystalline material comprising Form N-1.
  • This crystalline form of the compound of Example 133 comprises a neat crystalline form referred to herein as "Form N-1" or "N-1 Form” of Example 133.
  • N-1 Form of the compound of Example 133 is characterized by unit cell parameters approximately equal to the following:
  • N-1 form of Example 133 is characterized by a simulated powder x-ray diffraction (PXRD) pattern substantially in accordance with the pattern shown in Figure 1.
  • PXRD powder x-ray diffraction
  • N-1 Form of Example 133 is characterized by fractional atomic coordinates substantially as listed in Table 2.
  • the compound of Example 133 is provided as a crystalline material comprising Form N-2.
  • This crystalline form of the compound of Example 133 comprises a neat crystalline form referred to herein as "Form N-2" or "N-2 Form” of Example 133.
  • N-2 Form of the compound of Example 133 is characterized by unit cell parameters approximately equal to the following:
  • N-2 form of Example 133 is characterized by a simulated powder x-ray diffraction (PXRD) pattern substantially in accordance with the pattern shown in Figure 2.
  • PXRD powder x-ray diffraction
  • N-2 Form of Example 133 is characterized by fractional atomic coordinates substantially as listed in Table 3.
  • references made in the singular may also include the plural.
  • “a” and “an” may refer to either one, or one or more.
  • the phase “compounds” refers to at least one compound.
  • a compound of Formula (I) includes a compound of Formula (I) and two or more compounds of Formula (I).
  • any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
  • ⁇ is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.
  • alkyl refers to both branched and straight-chain saturated aliphatic hydrocarbon groups containing, for example, from 1 to 12 carbon atoms, from 1 to 6 carbon atoms, and from 1 to 4 carbon atoms.
  • alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4- methylpentyl.
  • Me methyl
  • Et ethyl
  • propyl e.g., n-propyl and i-propyl
  • butyl e.g., n-butyl, i-butyl, sec-butyl, and t-butyl
  • pentyl e.g., n-penty
  • cycloalkyl refers to a group derived from a non- aromatic monocyclic or polycyclic hydrocarbon molecule by removal of one hydrogen atom from a saturated ring carbon atom.
  • Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl.
  • the subscript defines with more specificity the number of carbon atoms that a particular cycloalkyl group may contain.
  • C3-C6 cycloalkyl denotes cycloalkyl groups with three to six carbon atoms.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the compounds of Formula (I) can be provided as amorphous solids or crystalline solids. Lyophilization can be employed to provide the compounds of Formula (I) as amorphous solids.
  • solvates e.g., hydrates of the compounds of Formula (I) are also within the scope of the present invention.
  • solvate means a physical association of a compound of Formula (I) with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • Solvate encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art.
  • compounds of Formula (I) subsequent to their preparation, can be isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound of Formula (I) ("substantially pure"), which is then used or formulated as described herein.
  • substantially pure compounds of Formula (I) are also contemplated herein as part of the present invention.
  • Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the present invention is intended to embody stable compounds.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to act as an inhibitor to IRAK4, or effective to treat or prevent autoimmune and/or inflammatory disease states, such as multiple sclerosis and rheumatoid arthritis.
  • treating cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease- state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e., arresting its development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state.
  • the compounds of the present invention are intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium (D) and tritium (T).
  • Isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
  • methyl (- CH 3 ) also includes deuterated methyl groups such as -CD 3 .
  • Compounds in accordance with Formula (I) can be administered by any means suitable for the condition to be treated, which can depend on the need for site-specific treatment or quantity of Formula (I) compound to be delivered.
  • compositions comprising a compound of Formula (I) and one or more non-toxic, pharmaceutically- acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier” materials) and, if desired, other active ingredients.
  • carrier non-toxic, pharmaceutically- acceptable carriers and/or diluents and/or adjuvants
  • the compounds of Formula (I) may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • compositions of the present invention may, for example, be administered orally, mucosally, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intrasternally in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.
  • the pharmaceutical carrier may contain a mixture of mannitol or lactose and microcrystalline cellulose. The mixture may contain additional
  • a lubricating agent e.g., magnesium stearate and a disintegrating agent such as crospovidone.
  • the carrier mixture may be filled into a gelatin capsule or compressed as a tablet.
  • the pharmaceutical composition may be administered as an oral dosage form or an infusion, for example.
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
  • the pharmaceutical composition may be provided as a tablet or capsule comprising an amount of active ingredient in the range of from about 0.1 to 1000 mg, preferably from about 0.25 to 250 mg, and more preferably from about 0.5 to 100 mg.
  • a suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, can be determined using routine methods.
  • any pharmaceutical composition contemplated herein can, for example, be delivered orally via any acceptable and suitable oral preparations.
  • exemplary oral preparations include, but are not limited to, for example, tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs.
  • Pharmaceutical compositions intended for oral administration can be prepared according to any methods known in the art for manufacturing pharmaceutical compositions intended for oral administration.
  • a pharmaceutical composition in accordance with the invention can contain at least one agent selected from sweetening agents, flavoring agents, coloring agents, demulcents, antioxidants, and preserving agents.
  • a tablet can, for example, be prepared by admixing at least one compound of Formula (I) with at least one non-toxic pharmaceutically acceptable excipient suitable for the manufacture of tablets.
  • excipients include, but are not limited to, for example, inert diluents, such as, for example, calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents, such as, for example, microcrystalline cellulose, sodium croscarmellose, corn starch, and alginic acid; binding agents, such as, for example, starch, gelatin, polyvinyl-pyrrolidone, and acacia; and lubricating agents, such as, for example, magnesium stearate, stearic acid, and talc.
  • inert diluents such as, for example, calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate
  • granulating and disintegrating agents such as,
  • a tablet can either be uncoated, or coated by known techniques to either mask the bad taste of an unpleasant tasting drug, or delay disintegration and absorption of the active ingredient in the gastrointestinal tract thereby sustaining the effects of the active ingredient for a longer period.
  • exemplary water soluble taste masking materials include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl-cellulose.
  • Exemplary time delay materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.
  • Hard gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) with at least one inert solid diluent, such as, for example, calcium carbonate; calcium phosphate; and kaolin.
  • at least one inert solid diluent such as, for example, calcium carbonate; calcium phosphate; and kaolin.
  • Soft gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) with at least one water soluble carrier, such as, for example, polyethylene glycol; and at least one oil medium, such as, for example, peanut oil, liquid paraffin, and olive oil.
  • at least one water soluble carrier such as, for example, polyethylene glycol
  • at least one oil medium such as, for example, peanut oil, liquid paraffin, and olive oil.
  • An aqueous suspension can be prepared, for example, by admixing at least one compound of Formula (I) with at least one excipient suitable for the manufacture of an aqueous suspension.
  • excipients suitable for the manufacture of an aqueous suspension include, but are not limited to, for example, suspending agents, such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl- cellulose, sodium alginate, alginic acid, polyvinyl-pyrrolidone, gum tragacanth, and gum acacia; dispersing or wetting agents, such as, for example, a naturally-occurring phosphatide, e.g., lecithin; condensation products of alkylene oxide with fatty acids, such as, for example, polyoxyethylene stearate; condensation products of ethylene oxide with long chain aliphatic alcohols, such as, for example heptadecaethylene-oxycetanol;
  • condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as, for example, polyoxyethylene sorbitol monooleate; and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, such as, for example, polyethylene sorbitan monooleate.
  • An aqueous suspension can also contain at least one preservative, such as, for example, ethyl and n- propyl p-hydroxybenzoate; at least one coloring agent; at least one flavoring agent; and/or at least one sweetening agent, including but not limited to, for example, sucrose, saccharin, and aspartame.
  • Oily suspensions can, for example, be prepared by suspending at least one compound of Formula (I) in either a vegetable oil, such as, for example, arachis oil; olive oil; sesame oil; and coconut oil; or in mineral oil, such as, for example, liquid paraffin.
  • An oily suspension can also contain at least one thickening agent, such as, for example, beeswax; hard paraffin; and cetyl alcohol.
  • at least one of the sweetening agents already described hereinabove, and/or at least one flavoring agent can be added to the oily suspension.
  • An oily suspension can further contain at least one preservative, including, but not limited to, for example, an antioxidant, such as, for example, butylated hydroxyanisol, and alpha-tocopherol.
  • Dispersible powders and granules can, for example, be prepared by admixing at least one compound of Formula (I) with at least one dispersing and/or wetting agent; at least one suspending agent; and/or at least one preservative.
  • Suitable dispersing agents, wetting agents, and suspending agents are as already described above.
  • Exemplary preservatives include, but are not limited to, for example, anti-oxidants, e.g., ascorbic acid.
  • dispersible powders and granules can also contain at least one excipient, including, but not limited to, for example, sweetening agents; flavoring agents; and coloring agents.
  • An emulsion of at least one compound of Formula (I) thereof can, for example, be prepared as an oil-in- water emulsion.
  • the oily phase of the emulsions comprising compounds of Formula (I) may be constituted from known ingredients in a known manner.
  • the oil phase can be provided by, but is not limited to, for example, a vegetable oil, such as, for example, olive oil and arachis oil; a mineral oil, such as, for example, liquid paraffin; and mixtures thereof. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
  • Suitable emulsifying agents include, but are not limited to, for example, naturally-occurring phosphatides, e.g., soy bean lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as, for example, sorbitan
  • a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • An emulsion can also contain a sweetening agent, a flavoring agent, a preservative, and/or an antioxidant.
  • Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art.
  • the compounds of Formula (I) can, for example, also be delivered intravenously, subcutaneously, and/or intramuscularly via any pharmaceutically acceptable and suitable injectable form.
  • injectable forms include, but are not limited to, for example, sterile aqueous solutions comprising acceptable vehicles and solvents, such as, for example, water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in- water microemulsions; and aqueous or oleaginous suspensions.
  • Formulations for parenteral administration may be in the form of aqueous or nonaqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • the active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (i.e., CAPTISOL®), cosolvent solubilization (i.e., propylene glycol) or micellar solubilization (i.e., Tween 80).
  • suitable carriers including saline, dextrose, or water, or with cyclodextrin (i.e., CAPTISOL®), cosolvent solubilization (i.e., propylene glycol) or micellar solubilization (i.e., Tween 80).
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • a non-toxic parenterally acceptable diluent or solvent for example as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed, including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • a sterile injectable oil-in-water microemulsion can, for example, be prepared by 1) dissolving at least one compound of Formula (I) in an oily phase, such as, for example, a mixture of soybean oil and lecithin; 2) combining the Formula (I) containing oil phase with a water and glycerol mixture; and 3) processing the combination to form a microemulsion.
  • an oily phase such as, for example, a mixture of soybean oil and lecithin
  • combining the Formula (I) containing oil phase with a water and glycerol mixture and 3) processing the combination to form a microemulsion.
  • a sterile aqueous or oleaginous suspension can be prepared in accordance with methods already known in the art.
  • a sterile aqueous solution or suspension can be prepared with a non-toxic parenterally-acceptable diluent or solvent, such as, for example, 1,3-butane diol; and a sterile oleaginous suspension can be prepared with a sterile non-toxic acceptable solvent or suspending medium, such as, for example, sterile fixed oils, e.g., synthetic mono- or diglycerides; and fatty acids, such as, for example, oleic acid.
  • Pharmaceutically acceptable carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-alpha-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, polyethoxylated castor oil such as CREMOPHOR® surfactant (BASF), or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone,
  • Cyclodextrins such as alpha-, beta-, and gamma-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
  • the pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.
  • the pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings.
  • Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.
  • the amounts of compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex, the medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods.
  • the daily dose can be administered in one to four doses per day. Other dosing schedules include one dose per week and one dose per two day cycle.
  • the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
  • the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
  • Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
  • compositions of this invention comprise at least one compound of Formula (I) and optionally an additional agent selected from any pharmaceutically acceptable carrier, adjuvant, and vehicle.
  • Alternate compositions of this invention comprise a compound of the Formula (I) described herein, or a prodrug thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the compounds of the invention modulate kinase activity, including the modulation of IRAK-4.
  • Other types of kinase activity that may be modulated by the compounds of the instant invention include, but are not limited to, the Pelle/IRAK family and mutants thereof.
  • compounds of Formula (I) have utility in treating conditions associated with the modulation of kinase activity, and particularly the selective inhibition of IRAK-4 activity or the inhibition of IRAK and other Pelle family kinases. Such conditions include TLR/IL-1 family receptor associated diseases in which cytokine levels are modulated as a consequence of intracellular signaling.
  • the compounds of Formula (I) have advantageous selectivity for IRAK-4 activity, preferably from at least 20 fold to over 1,000 fold more selective.
  • the terms "treating” or “treatment” encompass the treatment of a disease state in a mammal, particularly in a human, and include: (a) preventing or delaying the occurrence of the disease state in a mammal, in particular, when such mammal is predisposed to the disease state but has not yet been diagnosed as having it; (b) inhibiting the disease state, i.e., arresting its development; and/or (c) achieving a full or partial reduction of the symptoms or disease state, and/or alleviating, ameliorating, lessening, or curing the disease or disorder and/or its symptoms.
  • TLR/IL-1 family receptor associated diseases include inflammatory diseases such as Crohn's disease, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease; autoimmune diseases such as Graves' disease, rheumatoid arthritis, systemic lupus erythematosis, psoriasis; auto-inflammatory diseases including CAPS, TRAPS, FMF, adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis; metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma- related bone disorder; proliferative disorders such as acute myelogenous leukemia, chronic myelogenous leukemia; angiogenic disorders such as
  • the specific conditions or diseases that may be treated with the inventive compounds include, without limitation, pancreatitis (acute or chronic), asthma, allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs.
  • Preferred methods of treatment are those wherein the condition is selected from Crohn's disease, ulcerative colitis, allograft rejection, rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and pemphigus vulgaris.
  • preferred methods of treatment are those wherein the condition is selected from ischemia reperfusion injury, including cerebral ischemia reperfusions injury arising from stroke and cardiac ischemia reperfusion injury arising from myocardial infarction.
  • Another preferred method of treatment is one in which the condition is multiple myeloma.
  • kinase inhibitors of the present invention inhibit the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also referred to as cyclooxygenase-2 (COX-2), IL-1, IL-6, IL-18, chemokines.
  • PGHS-2 prostaglandin endoperoxide synthase-2
  • COX-2 cyclooxygenase-2
  • IL-1 IL-6
  • IL-18 chemokines.
  • additional IRAK-4-associated conditions include edema, analgesia, fever and pain, such as neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain.
  • inventive compounds also may be used to treat veterinary viral infections, such as lentivirus infections, including, but not limited to equine infectious anemia virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, and canine immunodeficiency virus.
  • lentivirus infections including, but not limited to equine infectious anemia virus
  • retrovirus infections including feline immunodeficiency virus, bovine immunodeficiency virus, and canine immunodeficiency virus.
  • the compounds of Formula (I) are useful in treating cancers associated with the MyD88 L265P mutation, including but not limited to, activated B cell-like subset of diffuse large B cell lymphoma (ABC-DLBCL); ref: Ngo, V.N. et al, Nature, 470: 115-119 (2011); Waldenstrom's macroglobulinemia (WM); ref: Treon, S.P. et al, N. Engl. J. Med., 367:826-833 (2012); chronic lymphocytic leukemia (CLL); cutaneous diffuse large B cell lymphoma; and primary central nervous system lymphoma; ref: Wang, J.Q. et al., Frontiers Immunol., 5:367-377 (2014).
  • ABS-DLBCL diffuse large B cell lymphoma
  • the compounds of Formula (I) are useful in treating cancers associated the overexpression of TLR2/activated IRAKI including myelodysplastic syndrome (MDS); ref: Rhyasen, G.W. et al, Cancer Cell, 24:90-104 (2013).
  • MDS myelodysplastic syndrome
  • Rhyasen G.W. et al, Cancer Cell, 24:90-104 (2013).
  • IRAK-4-associated condition or "IRAK-4 -associated disease or disorder” are used herein, each is intended to encompass all of the conditions identified above as if repeated at length, as well as any other condition that is affected by IRAK-4 kinase activity.
  • the present invention thus provides methods for treating such conditions, comprising administering to a subject in need thereof a therapeutically-effective amount of at least one compound of Formula (I) or a salt thereof.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination to inhibit IRAK-4 and/or treat diseases.
  • the methods of treating IRAK-4 kinase-associated conditions may comprise administering compounds of Formula (I) alone or in combination with each other and/or other suitable therapeutic agents useful in treating such conditions. Accordingly, "therapeutically effective amount” is also intended to include an amount of the combination of compounds claimed that is effective to inhibit IRAK-4 and/or treat diseases associated with IRAK-4.
  • Such other therapeutic agents include corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, PROGRAF®); anti-malarials such as hydroxychloroquine; cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-a inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor,
  • therapeutic agents when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians ' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
  • PDR Physicians ' Desk Reference
  • such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the
  • the present invention also provides pharmaceutical compositions capable of treating IRAK-4 kinase-associated conditions, including TLR and IL-1 family receptor mediated diseases as described above.
  • the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.
  • the order of reactions can be modified to change the overall synthesis to allow for variations at different positions of the molecule at different stages of the preparation.
  • the chloride 1 may be reacted with an amine first to form the mono-chlorinated ester 2.1.
  • Subsequent reaction with a heterocyclic nucleophile may form the disubstituted intermediate 2.2.
  • Hydrolysis of the ester to acid 2.3 followed by amide bond formation can afford the final analog 2.4.
  • 6- Bromo-4-choronicotinic acid may be reacted with a halogenating reagent, such as oxalyl chloride, to afford the acid chloride 4.1.
  • a halogenating reagent such as oxalyl chloride
  • This may be further reacted with an amine in the presence of a base, such as DIPEA or TEA, in an appropriate solvent, such as DCM, to afford the amide 4.2.
  • Amide 4.2 may be reacted with a heterocyclic amine in the presence of a metal catalyst, such as Pd, in a solvent to afford compound 4.3.
  • compound 4.3 may be reacted with an amine in the presence of a base at elevated temperature to afford compound 4.4.
  • R 1 group can be made via functionalization after incorporating onto the pyridine scaffold.
  • an appropriately protected amine, sulfide or ester may be coupled to the pyridine acid 6.1 via standard amide bond forming conditions to form 6.2.
  • Compound 6.2 may be further manipulated (amine deprotection/functionalization; sulfide oxidation; ester hydrolysis/amide or heterocycle formation) to form compounds of the general formula 6.3.
  • Substitution on the heterocyclic substituent may be accomplished via the methods outlined in Scheme 7.
  • an appropriately functionalized precursor such as compound 7.1 (R x is a functional group such as an amine, ester or halogen)
  • reaction with a variety of reagents, such as amines, aryl cross coupling partners, cyanide may form compounds of the formula 9.2 (R x ).
  • compound 7.3 may be converted to compound 7.4 via reaction with an aldehyde in the presence of a reducing agent.
  • the phrase "dried and concentrated” generally refers to drying of a solution in an organic solvent over either sodium sulfate or magnesium sulfate, followed by filtration and removal of the solvent from the filtrate (generally under reduced pressure and at a temperature suitable to the stability of the material being prepared).
  • DIPEA N,N-diisopropylethylamine
  • HATU 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • n-BuLi n-butyl lithium
  • Pd 2 (dba) 3 tris-(dibenzylideneacetone)dipalladium
  • TFA trifiuoroacetic acid
  • THF tetrahydrofuran
  • Method B XBridge Phenyl (4.6x150mm), 3.5 ⁇ , Mobile Phase A: 95:5 water/MeCN, 0.05% TFA; Mobile Phase B: 95:5 MeCN/water, 0.05% TFA; 1 mL/min, 12 min gradient.
  • Method C Ascentis Express C18 (2.1x50mm), 2.7 ⁇ , Mobile Phase A: 95:5 water/MeCN, 10 mM NH 4 OAc; Mobile Phase B: 5:95 water/MeCN, 10 mM NH 4 OAc; 1.1 mL/min, 3 min gradient, 50 °C.
  • Method D Ascentis Express C18 (2.1x50mm), 2.7 ⁇ , Mobile Phase A: 95:5 water/MeCN, 0.01% TFA; Mobile Phase B: 5:95 water/MeCN, 0.01% TFA; 1.1 mL/min, 3 min gradient, 50 °C.
  • Method E Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7 ⁇ ; Mobile Phase A: 5:95 MeCN:water with 10 mM ammonium acetate; Mobile Phase B: 95:5
  • MeCN water with 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
  • Method F Column: Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7 ⁇ ; Mobile Phase A: 5:95 MeCN:water with 0.1%> trifluoroacetic acid; Mobile Phase B: 95:5
  • MeCN water with 0.1% trifluoroacetic acid; Temperature: 50 °C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
  • Method G Ascentis Express CI 8 (4.6x50mm), 2.7 ⁇ , Mobile Phase A: 95:5 water/MeCN, 10 mM NH 4 OAc; Mobile Phase B: 5:95 water/MeCN, 10 mM NH 4 OAc; 4 mL/min, 4 min gradient, 50 °C.
  • Method H Ascentis Express C18 (2.1x50mm), 2.7 ⁇ , Mobile Phase A: 95:5 water/MeCN, 0.1% TFA; Mobile Phase B: 5:95 water/MeCN, 0.1% TFA; 1.1 mL/min, 3 min gradient, 50 °C.
  • Method I Column: Waters Acquity UPLC BEH CI 8, 2.0 x 50 mm, 1.7 ⁇ ; Mobile Phase A: 10:90 MeCN:water with 0.1% trifluoroacetic acid; Mobile Phase B: 90: 10 MeCN:water with 0.1 %> trifluoroacetic acid; Temperature: 40 °C; Gradient: 0-100%> B over 1.5 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
  • Method J Column: Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7 ⁇ ; Mobile Phase A: 100% water with 0.05% trifluoroacetic acid; Mobile Phase B: 100% MeCN with 0.05%) trifluoroacetic acid; Temperature: 40 °C; Gradient: 20-100%) B over 1.8 minutes, then a 0.2-minute hold at 100% B; Flow: 0.8 mL/min; Detection: UV at 220 nm.
  • First-eluting isomer 3-(2-azido-l-fluoroethyl)-3-(benzyloxy)oxetane, Isomer 1 (0.25 g, 1.00 mmol, 77% yield);
  • Second-eluting isomer 3-(2-azido-l-fluoroethyl)-3- (benzyloxy)oxetane, Isomer 2 (0.19 g, 0.73 mmol, 53% yield).
  • a Parr bottle was charged with 20% palladium hydroxide on carbon (100 mg, 0.142 mmol) under nitrogen, and the catalyst was wetted with methanol.
  • the vessel was charged with a solution of 3-(2-azido-l-fluoroethyl)-3-(benzyloxy)oxetane, Isomer 2 (122 mg, 0.486 mmol) in methanol (5 mL) and BOC-anhydride (0.135 mL, 0.583 mmol), and the mixture was degassed by thrice evacuating the vessel under vacuum and
  • Step 1 To a solution of K 2 C0 3 (34.8 g, 2 equiv.) in DMF (280 niL), L-serine methyl ester hydrochloride (1 equiv.), potassium iodide (10.8 g, 0.5 equiv.) and benzyl bromide (38 mL, 2.5 equiv.) were added. The mixture was stirred for 16 h at room temperature. The reaction mixture was concentrated under reduced pressure to remove excess of DMF and then diluted with EtOAc. The organic layer was washed with brine and water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated.
  • Step 2 To an ice cool solution of methyl 2-(dibenzylamino)-3- hydroxypropanoate (15 g, 1 equiv.) in THF (95 mL), DAST (13.1 mL, 1.23 equiv.) was added dropwise under N 2 -atmosphere and the reaction mixture was stirred for 14 h at room temperature. The reaction mixture was quenched with aqueous 10% NaHC0 3 solution at 0 °C and extracted into ethyl acetate (twice). The organic layers were collected, dried over anhydrous sodium sulfate, filtered and concentrated.
  • Step 3 (R)-Ethyl 3-(dibenzylamino)-2-fluoropropanoate was prepared according to the method as described for the synthesis of (R)-methyl 3-(dibenzylamino)-2- fluoropropanoate.
  • Step 4 To a solution of (R)-ethyl 3-(dibenzylamino)-2-fluoropropanoate (15 g, 1 equiv.) in THF (150 mL), methyl magnesium bromide (3M in diethyl ether) (15 mL, 2.5 equiv.) was added dropwise at 0 °C under N 2 atm. The reaction mixture was slowly allowed to attain room temperature and stirred for 1 h. The reaction mixture was quenched with saturated aqueous ammonium chloride at 0 °C and extracted into ethyl acetate (twice). The organic layers were collected, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by flash column
  • Step 5 To a solution of (R)-4-(dibenzylamino)-3-fluoro-2-methylbutan-2-ol (44 g, 146 mmol) in MeOH (400 mL) was added Pd/C (3.11 g, 29.2 mmol) and PdOH 2 (2.05 g, 14.6 mmol) and the mixture was evacuated and backfilled with H 2 gas and stirred for 18 h. The reaction mixture was filtered through CELITE® using 500 mL of methanol and the filterate was concentrated to afford (R)-4-amino-3-fluoro-2-methylbutan-2-ol (16.8 g, 95% yield).
  • Step 1 To a solution of ethyl 4,6-dichloronicotinate (10 g, 45 mmol) in DMA (40 mL) was added propan-2-amine (5.3 g, 91 mmol) and DIPEA (31.7 mL, 182 mmol). The reaction mixture was stirred at room temperature for 48 h. The reaction mixture was diluted with MTBE and washed water (3x). The organic layer was dried over Na 2 S0 4 , filtered and concentrated to afford the crude product.
  • Step 2 To a solution of ethyl 6-chloro-4-(isopropylamino)nicotinate (7 g, 28.8 mmol) in EtOH (70 mL) was added water (30 mL) and LiOH (2. lg, 87 mmol). The mixture was stirred for 3 h, concentrated and acidified with 1.5 N HCl. The resultant solids were collected and dried to afford 6-chloro-4-(isopropylamino)nicotic acid (5.3 g, 85% yield) as a white solid.
  • Step 3 To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (2.9 g, 13.51 mmol) in DMF was added (R)-4-amino-3-fluoro-2-methylbutan-2-ol (1.637 g, 13.51 mmol), HATU (6.16 g, 16.21 mmol), and DIPEA (9.44 mL, 54.0 mmol). The reaction mixture was stirred for 18 h. The reaction mixture was diluted with ethyl acetate and washed with water (3x).
  • Example 4 The Examples in Table 4 were prepared using the methods outlined for Example 1 using the appropriate starting material and amine. The absolute stereochemistry of the diastereomers was undetermined.
  • Step 1 To a stirred solution of (trans)-4-((tert-butoxycarbonyl)amino) cyclohexanecarboxylic acid (250 mg, 1.03 mmol), PyBOP (535 mg, 1.03 mmol) and Hunig's Base (0.538 mL, 3.08 mmol) in DMF (5 mL) at 25 °C was added methanamine, HCl (104 mg, 1.541 mmol). After 2 hours, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (3x).
  • Step 2 To a stirred solution of tert-butyl ((trans)-4-(methylcarbamoyl) cyclohexyl)carbamate (250 mg, 0.975 mmol) in dioxane (5 mL) at 25 °C was added 4N HCl in dioxane (2.438 mL, 9.75 mmol). The reaction mixture was stirred for 3 hours then was concentrated from methylene chloride (5x) to provide (trans)-4-amino-N- methylcyclohexanecarboxamide, HCl (150 mg, 71.8% yield) as a tan solid.
  • Step 3 To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (100 mg, 0.466 mmol), PyBOP (242 mg, 0.466 mmol) and Hunig's Base (0.244 mL, 1.398 mmol) in DMF (3 mL) at 25 °C was added (trans)-4-amino-N- methylcyclohexanecarboxamide, HCl (90 mg, 0.466 mmol). After 1 hour, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (3x).
  • Step 4 To a stirred solution of 6-chloro-4-(isopropylamino)-N-((tra/?s)-4- (methylcarbamoyl)cyclohexyl)nicotinamide (20 mg, 0.057 mmol) in 6: 1 tert-butanol/ DMA (1 mL) at room temperature was added lH-indole-5-carbonitrile (8.06 mg, 0.057 mmol), and K 2 CO 3 (23.50 mg, 0.170 mmol). The reaction vessel was purged with N 2 for 5 mins then added BrettPhos precatalyst (2.264 mg, 2.83 ⁇ ) and again purged for 5 mins.
  • Example 79 using the appropriate starting material and amine.
  • Step 1 To a stirred solution of tert-butyl ((ls,4s)-4-hydroxycyclohexyl) carbamate (1.00 g, 4.64 mmol) and triethylamine (3.24 mL, 23.22 mmol) in CH 2 CI 2 (10 mL) at 0 °C were added methanesulfonyl chloride (0.543 mL, 6.97 mmol) dropwise. The mixture was stirred at 0 °C for 15 min then diluted with water. The layers were separated and the organic layer was rinsed with saturated sodium bicarbonate (lx) followed by brine (lx).
  • Step 2 To a stirred solution of (ls,4s)-4-((tert-butoxycarbonyl)amino)cyclohexyl methanesulfonate (3.20 g, 10.91 mmol) in DMF (40 mL) at room temperature was added potassium thioacetate (1.869 g, 16.36 mmol). The reaction mixture was heated at 80 °C behind a safety shield for 7 hours, then at room temperature for 48 hours. The reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (2x), saturated ammonium chloride (lx), saturated sodium bicarbonate (lx), and brine (2x).
  • Step 3 To a stirred solution of S-((trans)-4-((tert-butoxycarbonyl)amino) cyclohexyl)ethanethioate (820 mg, 3.00 mmol) in MeOH (5 mL) at room temperature was added sodium methoxide (648 mg, 12.00 mmol) followed by iodomethane (0.281 mL, 4.50 mmol). The flask was then stoppered and stirred for 16 hours. The reaction mixture was diluted with water then extracted with ethyl acetate (3x). The combined organic layer was rinsed with saturated ammonium chloride (lx), saturated sodium bicarbonate (lx), and brine (lx).
  • Step 4 To a stirred solution of tert-butyl ((trans)-4-(methylthio)cyclohexyl) carbamate (650 mg, 2.65 mmol) in dioxane (5 mL) and methanol (1 mL) at room temperature was added 4N HC1 in dioxane (3.31 mL, 13.24 mmol). After 20 hours, the reaction mixture was concentrated from methylene chloride (5x) to provide (trans)-4- (methylthio)cyclohexanamine, HC1 (490 mg, 92% yield) of tan solids as product.
  • Step 5 To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (236 mg, 1.101 mmol), BOP (487 mg, 1.101 mmol) and TEA (0.307 mL, 2.201 mmol) in DMF (0.5 mL) at 25 °C was added (trans)-4-(methylthio)cyclohexanamine, HC1 (200 mg, 1.101 mmol). After 2 hours, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (2x), saturated sodium bicarbonate (lx) and finally 10% LiCl (lx).
  • Step 6 A mixture of 6-chloro-4-(isopropylamino)-N-((tra/?5)-4-(methylthio) cyclohexyl) nicotinamide (100 mg, 0.292 mmol), lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (41.9 mg, 0.292 mmol), potassium carbonate (29.4 mg, 0.213 mmol), and 6:1 t-BuOH/DMA (2 mL) were mixed in a 5 mL microwave vial containing a magnetic stir bar and degassed with bubbling nitrogen for 5 minutes.
  • the mixture was treated with BrettPhos precatalyst (23.36 mg, 0.029 mmol) and degassed for another 5 minutes.
  • the vial was sealed and the reaction heated in the microwave with stirring at 145 °C for 15 minutes.
  • the reaction mixture was evaporated, diluted with DMF, filtered, purified via preparative HPLC to afford the product (16.8 mg, 12% yield).
  • Example 103 was prepared according to the general procedure described for Example 102 substituting, where appropriate the requisite amines in the synthesis.
  • Example 104 was prepared according to the general procedure described for Example 102 substituting, where appropriate the requisite amines in the synthesis.
  • Example 105
  • Example 106 was prepared in according to the general procedure described for
  • the reaction mixture was added Pd 2 (dba) 3 (0.121 g, 0.132 mmol) and degassed again for 10 min. It was then heated for 18 h at 110 °C. The reaction mass was cooled and filtered through small pad of CELITE®. The filtrate obtained was concentrated to provide crude material. The crude material was purified by flash column chromatography through silica gel and MeOH: CHC1 3 as eluent.
  • Step 1 To a solution of 3-aminotetrahydro-2H-pyran-4-ol hydrochloride (1.26 g, 8.20 mmol) and ethyl 4,6-dichloronicotinate (1.805 g, 8.20 mmol) in DMA (20 mL) was added DIPEA (7.16 mL, 41.0 mmol) and the reaction mixture was heated at 100 °C for 4 h. Water (20 mL) was added and the product was extracted with ethyl acetate (2 x 50 mL). The extracts were washed with cold water (30 mL) and brine (20 mL) then dried over Na 2 S0 4 .
  • Step 2 To a solution of ethyl 6-chloro-4-((4-hydroxytetrahydro-2H-pyran-3- yl)amino) nicotinate (1.0 g, 3.33 mmol) in DCM (20 mL) was added DAST (0.879 mL, 6.65 mmol) at -20 °C and stirred for 1 h at the same temp. The reaction was quenched with aqueous NaHC0 3 and extracted with DCM (50 mL). The extracts were washed with water (30 mL) and brine (20 mL) then dried over Na 2 S0 4 and concentrated.
  • Step 3 To a solution of ethyl 6-chloro-4-((4-fluorotetrahydro-2H-pyran-3- yl)amino)nicotinate (0.38 g, 1.25 mmol) in MeOH (5 mL) was added LiOH (0.090 g, 3.77 mmol) as 2N aq solution at 0 °C, then stirred for 1 h at 60 °C. After cooling the MeOH was removed and water (2 mL) was added and acidified to pH 4 with 1.5N HC1. The precipitated solids (0.26g, 75% yield) were collected and used directly in the next step. 1H
  • Step 4 To a solution of 6-chloro-4-((4-fluorotetrahydro-2H-pyran-3-yl)amino) nicotinic acid (0.26 g, 0.947 mmol) and 4-amino-3-fluoro-2-methylbutan-2-ol (0.115 g, 0.947 mmol) in DMF (10 mL) was added DIPEA (0.496 mL, 2.84 mmol) and HATU (0.720 g, 1.893 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h.
  • Step 5 To a solution of 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((4-fluorotetrahydro-2H-pyran-3-yl)amino)nicotinamide (300 mg, 0.794 mmol) and 1H- pyrrolo[2,3-b]pyridine-5-carbonitrile (114 mg, 0.794 mmol) in 1,4-dioxane (6 mL) was added Cs 2 C0 3 (776 mg, 2.382 mmol) and Xantphos (184 mg, 0.318 mmol).
  • the mixture was degassed with nitrogen for 15 mins, then Pd 2 dba 3 (291 mg, 0.318 mmol) was added to the reaction mixture and again degassed for 5 mins.
  • the reaction vessel was sealed and heated at 110 °C for 16 h.
  • the reaction mixture was cooled and filtered through small pad of CELITE®.
  • Step 1 To a solution of 3-aminocyclopentanol hydrochloride (1.05 g, 7.63 mmol) and ethyl 4,6-dichloronicotinate (1.679 g, 7.63 mmol) in DMA (10 mL) was added
  • Step 2 To a solution of ethyl 6-chloro-4-((3 -hydroxy cyclopentyl)amino) nicotinate (1.5 g, 5.27 mmol) in DCM (20 mL) was added DAST (1.392 mL, 10.54 mmol) slowly at -20 °C. The reaction mixture was stirred at room temperature for 2 h. After the reaction was complete, the mixture was quenched with aqueous NaHC0 3 solution and extracted with DCM (50 mL). The organic layer was washed with water (30 mL) and brine (20 mL) then dried over Na 2 S0 4 .
  • Step 3 To a solution of ethyl 6-chloro-4-((3-fluorocyclopentyl)amino)nicotinate (1.0 g, 3.49 mmol) in EtOH (10 mL) was added LiOH (0.167 g, 6.98 mmol) as 2N aq solution at 0 °C, then stirred for 3 h at room temperature. When the reaction was complete, the EtOH was removed and water (1 mL) was added and acidified to pH 4 with 1.5N HC1. The precipitated solid was collected on a filter and used in the next step without chiral separation. Yield: 88% (0.79 g).
  • Step 4 To a solution of 6-chloro-4-((3-fluorocyclopentyl)amino)nicotinic acid
  • Step 5 To a solution of 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4- ((3-fluorocyclopentyl)amino)nicotinamide (120 mg, 0.332 mmol) and lH-pyrrolo[2,3-b] pyridine-5-carbonitrile (47.5 mg, 0.332 mmol) in 1,4-dioxane (6 mL) was added Cs 2 C0 3 (324 mg, 0.995 mmol) and Xantphos (77 mg, 0.133 mmol).
  • Step 1 To a stirred solution of ethyl 4,6-dichloronicotinate (650 mg, 2.95 mmol) in DMA (10 mL) was added (lS,6R)-6-amino-2,2-difluorocyclohexanol (491 mg, 3.25 mmol) and DIPEA (2.064 mL, 11.82 mmol). The reaction mixture was heated at 130 °C for 2 hours and cooled to room temperature. DMA was removed in vacuo and the residue was partitioned between ethyl acetate and water. The layers were separated and the organic layer was dried over Na 2 S0 4 , filtered, and evaporated. The product was purified by silica gel column using 10%> ethyl acetate/pet ether to provide the desired product. LCMS m/z 335.3 (M+H).
  • Step 2 To a stirred solution of ethyl 6-chloro-4-(((lS,2R)-3,3-difluoro-2- hydroxycyclohexyl)amino)nicotinate (700 mg, 2.091 mmol) in ethanol (5 mL), THF (10 mL) and water (5 mL), was added lithium hydroxide monohydrate (263 mg, 6.27 mmol) and stirred at 25 °C for 2 h. The reaction mixture was evaporated to dryness, and neutralized with 1.5 N HCl to obtain a white solid which was filtered and dried to afford the desired compound. LCMS m/z 307.3 (M+H).
  • Step 3 To a stirred solution of 6-chloro-4-(((lS,2R)-3,3-difluoro-2- hydroxycyclohexyl)amino)nicotinic acid (500 mg, 1.630 mmol) in DMF (10 mL) was added (R)-4-amino-3-fluoro-2-methylbutan-2-ol (198 mg, 1.630 mmol), DIPEA (0.712 mL, 4.08 mmol) and HATU (620 mg, 1.630 mmol). The mixture was stirred at 25 °C for 14 h. The reaction mixture was concentrated to dryness, and extracted with ethyl acetate (3 times). The combined organic layers were dried over Na 2 S0 4 , filtered, and concentrated. The residue was purified by column chromatography using 2%
  • Step 4 A stirred solution of 6-chloro-4-((3,3-difluoro-2-hydroxycyclohexyl) amino)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (100 mg, 0.244 mmol), lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (34.9 mg, 0.244 mmol), Xantphos (85 mg, 0.146 mmol) and Cs 2 C0 3 (159 mg, 0.488 mmol) in 1,4-dioxane (10 mL) was degassed for 5 min.
  • Step 1 To a sealed vial, ethyl 4,6-dichloronicotinate (270 mg, 1.227 mmol), 1- aminopropan-2-ol (111 mg, 1.472 mmol) and DIPEA (0.262 mL, 1.472 mmol) in 2- propanol (1 mL) were stirred and heated at 100 °C for 3 h. The mixture was cooled to room temperature, concentrated and purified by a flash column, using 20-40% EtOAc in hexanes as an eluent. Ethyl 6-chloro-4-((2-hydroxypropyl)amino)nicotinate (269 mg, 1.040 mmol, 85% yield) was obtained as a white solid.
  • Step 2 To a solution of ethyl 6-chloro-4-((l-hydroxypropan-2-yl)amino) nicotinate (270 mg, 1.044 mmol) in DCM (10 mL) at -40 °C, was added DAST (0.276 mL, 2.087 mmol), the mixture was stirred at room temperature for 1 h, warmed to room temperature and stirred overnight. The reaction was quenched with aqueous sodium bicarbonate (aq). The mixture was extracted with DCM (50 mL), concentrated to give a yellow solid.
  • Step 3 To a solution of 6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinic acid (189 mg, 0.812 mmol) in DMF (1 mL), was added (R)-4-amino-3-fluoro-2-methylbutan- 2-ol (103 mg, 0.853 mmol), BOP (396 mg, 0.894 mmol) and DIPEA (0.301 mL, 1.706 mmol). The mixture was stirred at room temperature for 1 h, then added water, extracted by EtOAc, washed with aqueous NaHC0 3 and brine, concentrated.
  • Step 4 To a solution of 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((l-fluoropropan-2-yl)amino)nicotinamide (20 mg, 0.060 mmol) in t-BuOH (0.6 mL) and DMA (0.1 mL), was added 7H-pyrrolo[2,3-d]pyrimidine (7.80 mg, 0.066 mmol), BrettPhos (0.960 mg, 1.787 ⁇ ), BrettPhos precatalyst (1.428 mg, 1.787 ⁇ ) and K 2 C0 3 (24.66 mg, 0.179 mmol).
  • Step 1 In a sealed vial, a stirring mixture of ethyl 4,6-dichloronicotinate (400 mg, 1.818 mmol), (R)-2-aminopropan-l-ol (150 mg, 2.000 mmol) and DIPEA (0.678 mL, 3.82 mmol) in isopropanol (2 mL) was heated at 100 °C over night. The mixture was concentrated. The residue was purified by a flash column using 30-60% EtOAc in hexanes to give (R)-ethyl 6-chloro-4-((l-hydroxypropan-2-yl)amino)nicotinate (418 mg, 1.616 mmol, 89% yield).
  • Step 2 To a solution of (R)-ethyl 6-chloro-4-((l-hydroxypropan-2-yl)amino) nicotinate (0.39 g, 1.508 mmol) in DCM (10 mL) at -78 °C, was added DAST (0.398 mL, 3.02 mmol). The mixture was stirred and warmed to room temperature over night. The reaction was quenched with NaHC0 3 , extracted by DCM (30 mL), washed with aqueous NaHC0 3 and brine, concentrated. The residue was added THF (2 mL), MeOH (2 mL) and IN NaOH (6.03 mL, 6.03 mmol).
  • Step 3 To a solution of (R)-6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinic acid (40 mg, 0.172 mmol) in THF (2 mL), was added (R)-4-amino-3-fluoro-2- methylbutan-2-ol (20.83 mg, 0.172 mmol), BOP (84 mg, 0.189 mmol), DIPEA (0.063 mL, 0.361 mmol), the mixture was stirred at room temperature for 2 hours and concentrated.
  • Step 4 In a sealed vial, a mixture of 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(((R)-l-fluoropropan-2-yl)amino)nicotinamide (20 mg, 0.060 mmol), 1H- pyrazolo[3,4-b]pyridine-5-carbonitrile (9.01 mg, 0.063 mmol), di-tert-butyl(2',4',6'- triisopropyl-3,4,5,6-tetramethyl-[l,l '-biphenyl]-2-yl)phosphine oxide (8.88 mg, 0.018 mmol), Pd 2 (dba) 3 (8.18 mg, 8.93 ⁇ ), K 2 C0 3 (24.70 mg, 0.179 mmol) in dioxane (1 mL) was purged with nitrogen, stirred and heated at 100 °C over night.
  • Example 124 was prepared according to the general procedure for Example 123 substituting, where appropriate, the requisite amines in the synthesis.
  • Step 1 A mixture of l-chloro-2-methyl-l-oxopropan-2-yl acetate (2.0 g, 12.15 mmol) in DCM (20 mL) and TEA (3.39 mL, 24.30 mmol) was added tert-butyl (2- aminoethyl)carbamate (1.95 g, 12.15 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h then diluted with DCM and washed with water.
  • Step 2 1 -((2-((tert-Butoxycarbonyl)amino)ethyl)amino)-2-methyl- 1 -oxopropan- 2-yl acetate (2.5 g, 8.67 mmol) was dissolved in 1,4-dioxane (10 mL), cooled to -10 °C and HC1 (0.132 mL, 4.34 mmol, 4N in dioxane) was added dropwise. The reaction mixture was then allowed to stir at room temperature for 1 h.
  • Step 3 6-Chloro-4-(isopropylamino)nicotinic acid (0.5 g, 2.329 mmol) and l-((2- aminoethyl)amino)-2-methyl-l-oxopropan-2-yl acetate (0.438 g, 2.329 mmol) were dissolved in DMF (10 mL), added DIPEA (2.034 mL, 11.65 mmol) and HATU (0.886 g, 2.329 mmol) and the reaction mixture was stirred at room temperature overnight.
  • DIPEA 2.034 mL, 11.65 mmol
  • HATU 0.886 g, 2.329 mmol
  • Step 4 1 -((2-(6-Chloro-4-(isopropylamino)nicotinamido)ethyl)amino)-2-methyl- l-oxopropan-2-yl acetate (0.07 g, 0.182 mmol) and lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (0.026 g, 0.182 mmol) was dissolved in 1,4-dioxane (10 mL). To this mixture was added Na 2 C0 3 (0.019 g, 0.182 mmol) and water (1 mL).
  • the vessel was purged with N 2 and added Xantphos (0.105 g, 0.182 mmol) followed by Pd 2 (dba) 3 (0.167 g, 0.182 mmol).
  • the reaction mixture was heated at 110 °C for 18 h then cooled to room temperature.
  • the product was isolated via column chromatography and repurified via preparative HPLC to afford the product (27 mg, 30%> yield) as a white solid.
  • Step 1 To a stirred solution of (R)-methyl 3-(dibenzylamino)-2-fluoropropanoate (1.00 g, 3.32 mmol) in anhydrous THF (15 mL) at 0 °C was added 2N lithium
  • Step 2 To a stirred solution of (R)-3-(dibenzylamino)-2-fluoropropan-l-ol (400 mg, 1.463 mmol) in THF (10 mL) and DMF (10 mL) at 0 °C under nitrogen was added NaH (70.2 mg, 1.756 mmol). After 10 min iodomethane (0.092 mL, 1.463 mmol) was added. After an additional 30 min additional NaH (70.2 mg, 1.756 mmol) was added. After an additional 10 min iodomethane (0.092 mL, 1.463 mmol) was added again. The mixture was carefully quenched with the dropwise addition of water.
  • the vessel was charged with a methanol (10 mL) solution of (R)-N,N-dibenzyl- 2-fluoro-3-methoxypropan-l -amine (400 mg, 1.392 mmol) and the mixture was degassed by evacuating the vessel under vacuum and depressurizing with nitrogen. The mixture was shaken under 50 psi hydrogen for 4 hours. The mixture was degassed as previously described, and the reaction mixture was filtered under nitrogen through fiberglass filter paper. The filter cake was thoroughly rinsed with methanol (25 mL), and the filtrate was concentrated in vacuo to provide (R)-2-fluoro-3-methoxypropan-l -amine (125 mg, 75% yield) as a colorless oil as product.
  • Step 4 To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (250 mg, 1.167 mmol), BOP (516 mg, 1.167 mmol) and TEA (0.325 mL, 2.334 mmol) in DMF (5 mL) at 25 °C was added (R)-2-fluoro-3-methoxypropan-l -amine (125 mg, 1.167 mmol). After 20 hours, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (2x), saturated sodium bicarbonate (lx) and finally 10% LiCl (lx).
  • Step 5 A mixture of (R)-6-chloro-N-(2-fluoro-3-methoxypropyl)-4- (isopropylamino)nicotinamide (35 mg, 0.115 mmol), lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (16.49 mg, 0.115 mmol), potassium carbonate (31.8 mg, 0.230 mmol), and 6: 1 t-BuOH/DMA (2 mL) in a 5 mL microwave vial containing a magnetic stir bar was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (4.6 mg, 0.115 mmol), and degassed for another 5 minutes.
  • Example 128 was prepared according to the general procedure for Example 127 utilizing lH-pyrazolo[3,4-b]pyridine-5-carbonitrile in the final step.
  • Step 1 To a solution of 4-(dibenzylamino)-3-fluorobutan-2-one (1.0 g, 3.50 mmol) in DCM (4 mL) at 0 °C was added TEA (2.442 mL, 17.52 mmol). After 5 minutes, propan-2-amine (1.036 g, 17.52 mmol) and TiCl 4 (1.159 mL, 10.51 mmol) were added and stirred continued at room temperature overnight. NaCNBH 4 (1.10 g, 17.52 mmol) was added to the reaction mixture at 0 °C and again stirred at room temperature for 1 hr.
  • Step 2 A solution of (2S)-Nl,Nl-dibenzyl-2-fluoro-N3-isopropylbutane-l,3- diamine (1.0 g, 3.04 mmol) in MeOH (30 mL) was added Pd/C (0.2 g, 1.879 mmol) and PdOH 2 (0.2 g, 1.424 mmol). The vessel was charged with H 2 gas and stirred overnight. The reaction mixture was filtered through CELITE® using 500 mL of methanol and the filtrate was concentrated to afford the product (0.42 g, 93% yield) as a brown solid.
  • 1H NMR 400MHz, DMSO-d 6 ) ⁇ 5.40-5.20 (m, 1H), 3.72-3.40 (m, 1H), 3.55-3.45 (m, 3H), 1.31- 1.21 (m, 9H).
  • Step 3 6-Chloro-4-(isopropylamino)nicotinic acid (0.22 g, 1.025 mmol) in DMF
  • Step 4 A solution of 6-chloro-N-((2R)-2-fluoro-3-(isopropylamino)butyl)-4- (isopropylamino)nicotinamide (0.2 g, 0.580 mmol) and lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (0.125 g, 0.870 mmol) in 1,4 dioxane (5 mL) was added Xantphos (0.168 g, 0.290 mmol) and 3 eq of K 2 C0 3 (0.240 g, 1.740 mmol).
  • the mixture was purged with N 2 and then added Pd 2 dba 3 (0.266 g, 0.290 mmol) and again purged for 10 minutes.
  • the vessel was then heated at 110 °C for 18 h.
  • the mixture was cooled and filtered through CELITE® using 1 : 1 methanol and dichloromethane and extracted using 1.5N HC1 and ethyl acetate.
  • the water layer was neutralized with sodium carbonate and extracted with ethylacetate (3 times).
  • the combined organic extracts were washed with water, brine then dried over anhydrous Na 2 S0 4 .
  • the organics were filtered and concentrated to obtain a brown solid which was purified via column chromatography and then preparative HPLC to afford 12 mg of the diastereomeric mixture.
  • Example 129 was separated via SFC chiral chromatography to furnish Example 129 (5 mg) as an off-white solid.
  • Step 1 To a stirred solution of ethyl 4,6-dichloronicotinate (6.0 g, 27.3 mmol) in DMA (lOOmL), DIPEA (23.81 mL, 136 mmol) and 2-aminopropane-l,3-diol (2.98 g, 32.7 mmol) were added and heated at 60 °C in a round bottom flask for 4 h. Reaction mixture was cooled to room temperature, added water and extracted with ethyl acetate (3 times). The organic extracts were combined together, dried over Na 2 S0 4 , filtered and concentrated to get the brown color liquid as the required crude product.
  • DIPEA 23.81 mL, 136 mmol
  • 2-aminopropane-l,3-diol 2.98 g, 32.7 mmol
  • Step 2 Ethyl 6-chloro-4-((l,3-dihydroxypropan-2-yl)amino)nicotinate (0.1 g, 0.364 mmol) in DCM (3 mL) at -78 °C was added DAST (0.096 mL, 0.728 mmol) and then allowed to stir at room temperature for 10 min. Sodium bicarbonate in ice water was added the reaction mixture slowly and then extracted 3 times with DCM.
  • Step 3 To a solution of ethyl 6-chloro-4-((l-fluoro-3-hydroxypropan-2-yl)amino) nicotinate (0.12 g, 0.434 mmol) in EtOH (4 mL) and water (1 mL) was added LiOH (0.052 g, 2.168 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated and the residue was acidified with 1.5N HC1 to precipitate the product. The white solids were filtered and washed to afford 6-chloro-4- ((l-fluoro-3-hydroxypropan-2-yl)amino)nicotinic acid (0.1 g, 93% yield) as a white solid. LCMS 249.4 (M+H) + .
  • Step 4 A solution of 6-chloro-4-((l-fluoro-3-hydroxypropan-2-yl)amino) nicotinic acid (0.1 g, 0.40 mmol) in DMF (3 mL) was added HATU (0.23 g, 0.60 mmol), DIPEA (0.35 mL, 2.01 mmol) and (R)-4-amino-3-fiuoro-2-methylbutan-2-ol (0.058 g, 0.48 mmol). The reaction mixture was stirred at room temperature overnight. Sodium bicarbonate was added and the reaction mixture was extracted with ethylacetate (3 times). The combined organic extracts were washed with water and brine then dried over Na 2 S0 4 .
  • Step 5 A solution of 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((l- fluoro-3-hydroxypropan-2-yl)amino)nicotinamide (0.15 g, 0.426 mmol) and 1H- pyrrolo[2,3-b]pyridine-5-carbonitrile (0.092 g, 0.640 mmol) in 1,4 dioxane (3 mL) was added Xantphos (0.123 g, 0.213 mmol) and K 2 CO 3 (0.177 g, 1.279 mmol). The mixture was evacuated and backfilled with N 2 then added Pd 2 (dba) 3 (0.195 g, 0.213 mmol).
  • the mixture was evacuated and backfilled with N 2 again and then heated at 110 °C for 18 h.
  • the mixture was cooled to room temperature and filtered through CELITE® using 1 : 1 methanol and dichloromethane.
  • the crude product was purified via column
  • Step 1 (R)-Ethyl 3-(dibenzylamino)-2-fluoropropanoate (5 g, 15.85 mmol) was taken in ethanol (15 mL),water (3 mL) and to this LiOH (1.139 g, 47.6 mmol) was added and allowed to stir overnight. Ethanol and water were removed under vacuum and the crude reaction mixture was acidified using 1.5N HCl. The aqueous layer was extracted with ethylacetate and the ethylacetate layer was washed with water, dried and evaporated. The crude material was purified by combiflash using 5% MeOH in CHCI 3 to afford a brown oily product (3.5 g, 77% yield). LCMS 288.1 (M+H) + .
  • Step 2 (R)-3-(Dibenzylamino)-2-fluoropropanoic acid (0.5 g, 1.740 mmol) was taken in DMF (2 mL) and to this solution, methanamine (0.054 g, 1.740 mmol) was added along with HATU (0.662 g, 1.740 mmol) and DIPEA (1.216 mL, 6.96 mmol). The reaction mixture was allowed to stir for 4 hrs. DMF removed under vacuum and the crude was diluted with water and extracted with ethylacetate. The ethyl acetate layer was washed with 10%> NaHC0 3 , dried and evaporated. The crude brown solid was purified by combiflash (12g column) using 5% MeOH in CHC1 3 and used directly in the next reaction (some starting material remained in the product).
  • Step 3 To a solution of (R)-3-(dibenzylamino)-2-fluoro-N-methylpropanamide (800 mg, 2.66 mmol) in MeOH (5 mL) was added Pd/C (142 mg, 1.332 mmol) and Pd(OH) 2 (187 mg, 1.332 mmol). The solution was hydrogenated at 1 atm pressure for 6 hrs. The reaction mixture was diluted with ethyl acetate and passed through a small plug of CELITE®. The filtrate was concentrated and the crude product (150 mg, 47% yield) was used without further purification.
  • Step 4 6-Chloro-4-(cyclopropylamino)nicotinic acid (500 mg, 2.351 mmol) was taken in DMF (3 mL) and to this solution, (R)-3-amino-2-f uoro-N-methylpropanamide (282 mg, 2.351 mmol) was added along with HATU (894 mg, 2.351 mmol) and DIPEA (0.411 mL, 2.351 mmol). The reaction mixture was stirred at room temperature for 4 hrs TLC indicated the absence of starting material. The reaction mixture was diluted with 10% NaHC0 3 and extracted with ethyl acetate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b] pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Description

HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Application Serial No. 61/923,403, filed January 3, 2014, which is incorporated herein it its entirety.
DESCRIPTION
The present invention generally relates to heteroaryl substituted nicotinamide compounds useful as kinase inhibitors, including the modulation of IRAK-4. Provided herein are heteroaryl substituted nicotinamide compounds, compositions comprising such compounds, and methods of their use. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to kinase modulation and methods of inhibiting the activity of kinases, including IRAK-4 in a mammal.
Toll/IL-1 receptor family members are important regulators of inflammation and host resistance. The Toll like receptor (TLR) family recognizes molecular patterns derived from infectious organisms including bacteria, fungi, parasites, and viruses (reviewed in Kawai, T. et al, Nature Immunol, 11 :373-384 (2010)). Ligand binding to the receptor induces dimerization and recruitment of adaptor molecules to a conserved cytoplasmic motif in the receptor termed the Toll/IL-1 receptor (TIR) domain. With the exception of TLR3, all TLRs recruit the adaptor molecule MyD88. The IL-1 receptor family also contains a cytoplasmic TIR motif and recruits MyD88 upon ligand binding (reviewed in Sims, J.E. et al, Nature Rev. Immunol, 10:89-102 (2010)).
Members of the IRAK family of serine/threonine kinases are recruited to the receptor via interactions with MyD88. The family consists of four members. Several lines of evidence indicate that IRAK4 plays a critical and non-redundant role in initiating signaling via MyD88 dependent TLRs and IL-1R family members. Structural data confirms that IRAK4 directly interacts with MyD88 and subsequently recruits either IRAKI or IRAK2 to the receptor complex to facilitate downstream signaling (Lin, S. et al, Nature, 465:885-890 (2010)). IRAK4 directly phosphorylates IRAKI to facilitate downstream signaling to the E3 ubiquitin ligase TRAF6, resulting in activation of the serine/threonine kinase TAK1 with subsequent activation of the NFKB pathway and MAPK cascade (Flannery, S. et al, Biochem. Pharmacol., 80: 1981-1991 (2010)). A subset of human patients was identified who lack IRAK4 expression (Picard, C. et al, Science, 299:2076-2079 (2003)). Cells from these patients fail to respond to all TLR agonists with the exception of TLR3 as well as to members of the IL-1 family including IL-Ιβ and IL-18 (Ku, C. et al, J. Exp. Med., 204:2407-2422 (2007)). Deletion of IRAK4 in mice results in a severe block in IL-1, IL-18 and all TLR dependent responses with the exception of TLR3 (Suzuki, N. et al, Nature, 416:750-754 (2002)). In contrast, deletion of either IRAKI (Thomas, J.A. et al, J. Immunol, 163:978-984 (1999); Swantek, J.L. et al, J. Immunol, 164:4301-4306 (2000) or IRAK2 (Wan, Y. et al, J. Biol Chem., 284: 10367-10375 (2009)) results in partial loss of signaling. Furthermore, IRAK4 is the only member of the IRAK family whose kinase activity has been shown to be required for initiation of signaling. Replacement of wild type IRAK4 in the mouse genome with a kinase inactive mutant (KDKI) impairs signaling via all MyD88 dependent receptors including IL-1, IL-18 and all TLRs with the exception of TLR3 (Koziczak-Holbro, M. et al, J. Biol. Chem., 282: 13552-13560 (2007); Kawagoe, T. et al, J. Exp. Med, 204: 1013- 1024 (2007); and Fraczek, J. et al, J. Biol. Chem., 283:31697-31705 (2008)).
As compared to wild type animals, IRAK4 KDKI mice show greatly reduced disease severity in mouse models of multiple sclerosis (Staschke, K.A. et al, J. Immunol, 183:568-577 (2009)), rheumatoid arthritis (Koziczak-Holbro, M. et al., Arthritis Rheum., 60: 1661-1671 (2009)), atherosclerosis (Kim, T.W. et al, J. Immunol, 186:2871-2880
(2011) and Rekhter, M. et al, Biochem. Biophys. Res. Comm., 367:642-648 (2008)), and myocardial infarction (Maekawa, Y. et al., Circulation, 120: 1401-1414 (2009)). As described, IRAK4 inhibitors will block all MyD88 dependent signaling. MyD88 dependent TLRs have been shown to contribute to the pathogenesis of multiple sclerosis, rheumatoid arthritis, cardiovascular disease, metabolic syndrome, sepsis, systemic lupus erythematosus, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, autoimmune uveitis, asthma, allergy, type I diabetes, and allograft rejection (Keogh, B. et al, Trends Pharmacol. Sci., 32:435-442 (2011); Mann, D.L., Circ. Res., 108: 1133-1145 (2011); Horton, C.G. et al, Mediators Inflamm., Article ID 498980 (2010), doi: 10.1155/2010/498980; Goldstein, D.R. et al, J. Heart Lung Transplant., 24: 1721-1729 (2005); and Cario, E., Inflamm. Bowel Dis., 16: 1583-1597 (2010)).
Oncogenically active MyD88 mutations in diffuse large B cell lymphomas have been identified that are sensitive to IRAK4 inhibition (Ngo, V.N. et al, Nature, 470: 115-121 (2011)). Whole genome sequencing also identified mutations in MyD88 associated with chronic lymphatic leukemia suggesting that IRAK4 inhibitors may also have utility in treating leukemias (Puente, X.S. et al, Nature, 475: 101-105 (2011)).
In addition to blocking TLR signaling, IRAK4 inhibitors will also block signaling by members of the IL-1 family. Neutralization of IL-1 has been shown to be efficacious in multiple diseases including gout; gouty arthritis; type 2 diabetes; auto-inflammatory diseases including Cryopyrin-Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult onset stills; systemic onset juvenile idiopathic arthritis; stroke; Graft- versus-Host Disease (GVHD); smoldering multiple myeloma; recurrent pericarditis; osteoarthritis; emphysema (Dinarello, C.A., Eur. J. Immunol, 41 : 1203-1217 (2011) and Couillin, I. et al, J.
Immunol, 183:8195-8202 (2009)). In a mouse model of Alzheimer's disease, blockade of IL-1 receptor improved cognitive defects, attenuated tau pathology and reduced oligomeric forms of amyloid-β (Kitazawa, M. et al, J. Immunol, 187:6539-6549 (2011)). IL-1 has also been shown to be a critical link to adaptive immunity, driving
differentiation of the TH17 effector T cell subset (Chung, Y. et al, Immunity, 30:576-587 (2009)). Therefore, IRAK4 inhibitors are predicted to have efficacy in TH17 associated diseases including multiple sclerosis, psoriasis, inflammatory bowel diseases,
autoimmune uveitis, and rheumatoid arthritis (Wilke, CM. et al, Trends Immunol, 32:603-661 (2011)).
WO 2013/106612, WO 2013/106614, and WO 2013/106641 disclose substituted pyridyl compounds useful as kinase inhibitors, including the modulation of IRAK4.
In view of the conditions that may benefit by treatment involving modulation of protein kinases, it is immediately apparent that new compounds capable of modulating protein kinases such as IRAK-4 and methods of using these compounds could provide substantial therapeutic benefits to a wide variety of patients.
The present invention relates to a new class of heteroaryl substituted nicotinamide compounds found to be effective inhibitors of protein kinases including IRAK-4. These compounds are provided to be useful as pharmaceuticals with desirable stability, bioavailability, therapeutic index, and toxicity values that are important to their drugability. SUMMARY OF THE INVENTION
The present invention provides to compounds of Formula (I) that are useful as inhibitors of IRAK-4, and are useful for the treatment of proliferative diseases, allergic diseases, autoimmune diseases and inflammatory diseases, or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof.
The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
The present invention also provides a method for inhibition of IRAK-4 comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
The present invention also provides a method for treating proliferative, metabolic, allergic, autoimmune and inflammatory diseases, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
One embodiment provides a method for treating inflammatory and autoimmune diseases wherein the treatment of inflammatory diseases is even more preferred.
Particular, inflammatory and autoimmune diseases include, but are not limited to, Crohn's disease, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis, cryopyrin-associated periodic syndromes (CAPS), TNF receptor associated periodic syndrome (TRAPS), familial Mediterranean fever (FMF), adult onset stills, systemic onset juvenile idiopathic arthritis, multiple sclerosis, neuropathic pain, gout, and gouty arthritis.
One embodiment provides a method for treating gout and gouty arthritis.
An alternate preferred embodiment is a method for treating metabolic diseases, including type 2 diabetes and atherosclerosis. The present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for use in therapy.
The present invention also provides the use of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the manufacture of a medicament for the treatment of cancers.
The present invention also provides processes and intermediates for making the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof.
These and other features of the invention will be set forth in the expanded form as the disclosure continues.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is illustrated by reference to the accompanying drawings described below.
FIG. 1 shows the experimental (at approximately 25 °C) and the simulated (at 296 K) PXRD patterns (CuKa λ=1.5418Α) of the N-l Form of the compound of Example 133.
FIG. 2 shows the experimental (at approximately 25 °C) and the simulated (at 296 K) PXRD patterns (CuKa λ=1.5418Α) of the N-2 Form of the compound of Example 133.
DETAILED DESCRIPTION
The first aspect of the present invention provides at least one compound of Formula (I):
Figure imgf000007_0001
or a salt thereof, wherein:
HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3- d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-lH- pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rt,;
is H, F, CI, Br, -CN, -OH, Ci_4 alkyl, Ci_4 fluoroalkyl, Ci_4 hydroxyalkyl, Ci_4 alkoxy, -NH2, -NH(Ci_4 alkyl), -N(CM alkyl)2, -NH(Ci_4 hydroxyalkyl), -NH(Ci_4
fluoroalkyl), -NH(Ci_6 hydroxy-fluoroalkyl), -C(0)NH2, -CH2NHC(0)(Ci_6 alkyl), -CH2NHC(0)(Ci_6 hydroxyalkyl), -CH2NHC(0)NH(Ci_6 alkyl),
-CH2NHC(0)NHCH2(phenyl), -CH2NHC(0)N(Ci_4 alkyl)2, -CH2NHC(0)0(Ci_4 alkyl), -CH2NHC(0)(C3-6 cycloalkyl), -CH2NHC(0)(tetrahydrofuranyl),
-CH2NHC(0)CH2(C3_6 cycloalkyl), -CH2NHC(0)CH2(tetrahydropyranyl),
-CH2NHC(0)CH2(phenyl), -NHC(0)(Ci_4 alkyl), pyrrolidinyl, hydroxypyrrolidinyl, or pyridazinyl;
is H or -NH2;
is:
(i) Ci_6 alkyl, Ci_6 fluoroalkyl, Ci_6 hydroxyalkyl, Ci_g hydroxy-fluoroalkyl, -(Ci_6 alkylenyl)0(Ci_4 alkyl), -(Ci_6 alkylenyl)0(Ci_4 fluoroalkyl), -(Ci_6
fluoroalkylenyl)0(Ci_4 alkyl), -(Ci_6 fluoroalkylenyl)0(Ci_4 deuteroalkyl), -(Ci_6 fluoroalkylenyl)0(Ci_4 fluoroalkyl), -(Ci_4 fluoroalkylenyl)C(C3_6
cycloalkyl)2(OH), -(Ci_4 alkylenyl)NHC(0)(Ci_4 alkylenyl)OC(0)(Ci_3 alkyl), -(Ci_6 alkylenyl)NHS(0)2(Ci_4 alkyl), -(Ci_6 alkylenyl)P(0)(Ci_4 alkoxy)2, -(Ci_6 fluoroalkylenyl)NH(Ci_4 alkyl), -(Ci_6 alkylenyl)C(0)NH(Ci_4 alkyl), -(Ci_6 fluoroalkylenyl)C(0)NH(Ci_4 alkyl), -(Ci_6 fluoroalkylenyl)C(0)NH(Ci_4 hydroxyalkyl), or -(Ci_6 fluoroalkylenyl)OP(0)(OH)2;
(ii) -(Ci-3 alkylenyl)Rx, -(Ci_3 fluoroalkylenyl)Rx, -(Ci_3 alkylenyl)C(0)Rx, -(Ci_3 alkylenyl)C(0)NHRx, -(Ci_3 fluoroalkylenyl)C(0)Rx, or
-CH2CF=(tetrahydropyranyl), wherein Rx is a cyclic group selected from C3_6 cycloalkyl, tetrazolyl, 1,1-dioxidotetrahydrothiophenyl,
1,1-dioxidothiomorpholinyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -C(CH2)2OH, -OCH3, -C(0)CH2CN, -S(0)2CH3, -S(0)2NH2, -NHC(0)CH3, -N(S(0)2CH3)2, -CH2CH2(acetamidophenyl), -CH2CH2(methoxyphenyl),
-CH2CH2(sulfamoylphenyl), oxetanyl, benzyl, and morpholinyl;
C3-6 cycloalkyl or C4-6 cycloalkenyl, each substituted with zero to 3 substituents independently selected from F, -OH, -CN, Ci_3 alkyl, Ci_3 alkoxy, -S(C1-3 alkyl), -NO2, -S(0)2(Ci_3 alkyl), Ci_4 hydroxyalkyl, -C(Ci_3 alkyl)(OH)(C3_6 cycloalkyl), -CH2C(0)NH(Ci_3 alkyl), -NHC(0)(Ci_3 alkyl), -NHC(0)(Ci_4 hydroxyalkyl), -C(0)NH(Ci_3 alkyl), -C(0)NH(Ci_3 deuteroalkyl), -C(0)NH(C3_6 cycloalkyl), -NHC(0)0(Ci_3 alkyl), -NHS(0)2(Ci_3 alkyl), pyridinyl, imidazolyl, pyrazolyl, methylimidazolyl, methylpyrazolyl, and thiazolyl;
tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from -OH, Ci_3 alkyl, Ci_3 fluoroalkyl, Ci_4 hydroxyalkyl, Ci_3 alkoxy, -C(0)(Ci_4 alkyl), -S(0)2(Ci_4 alkyl), -S(0)2NH(Ci_4 alkyl), -NH(Ci_3 alkyl), -N(Ci_3 alkyl)2, -0(Ci_3 alkylenyl)N(Ci_3 alkyl)2, -CH2(morpholinyl), azetidinyl, oxetanyl, tetrahydropyranyl,
morpholinyl, piperazinyl, piperidinyl, methylpiperazinyl, methoxypiperidinyl, pyridinyl, pyrimidinyl, methylsulfonyl azetidinyl, and -C(0)(methylsulfonyl azetidinyl); or
pyrrolo[2,3-c]pyridinyl, bicyclo[2.2.1 Jheptan- 1 -ol, tetrahydrobenzo[d]thiazol-2- amine, or l,3-diazaspiro[4.5]decane-2,4-dione; and
Ci_7 alkyl or C2_6 alkenyl, each substituted with zero to three substituents independently selected from F, -OH, and -CN; -(Ci_4 alkylenyl)0(Ci_4 alkyl), -(Ci_4 alkylenyl)0(Ci_4 fluoroalkyl), -(Ci_6 alkylenyl)NH2, -(Ci_6
alkylenyl)S(0)2(Ci_3 alkyl), -(Ci_6 fluoroalkylenyl)NH(Ci_3 alkyl), or -(Ci_6 alkylenyl)NHC(0)(Ci_4 fluoroalkyl);
-(Ci_4 alkylenyl)Ry wherein Ry is C3_6 cycloalkyl, azetidinyl, oxetanyl, oxazolyl, pyridinyl, tetrahydropyranyl, or morpholinyl, each substituted with zero to 2 substituents independently selected from F, -OH, and Ci_3 alkyl;
C3_6 cycloalkyl, azetidinyl, oxetanyl, furanyl, tetrahydrofriranyl, pyrrolidinyl, piperidinyl, or tetrahydropyranyl, each substituted with zero to 3 substituents independently selected from F, -OH, Ci_3 alkyl, Ci_3 hydroxyalkyl, -C(0)(Ci_3 alkyl), -C(0)(Ci_3 fluoroalkyl), -C(0)(Ci_3 cyanoalkyl), -C(0)0(Ci_3 alkyl), -C(0)NH2, -C(0)NH(Ci_3 alkyl), -C(0)(difluorophenyl), -NH2, -NH(Ci_3 alkyl), -NH(Ci_3 fluoroalkyl), -NH(oxetanyl), -NHC(0)(Ci_3 alkyl), -NHC(0)(Ci_3 fluoroalkyl), -NHC(0)(C3_6 cycloalkyl), -NHC(0)(fluorophenyl), -S(0)2(Ci_3 alkyl), imidazolyl, phenyl, pyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, and methoxypyrimidinyl;
(iv) adamantanyl, hydroxyadamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, bicyclo[l .l . l]pentanyl, or hydroxy- bicyclo[2.2.1]heptanyl; or
(v) phenyl, pyrazolyl, thiazolyl, thiadiazolyl, or indazolyl, each substituted with 0 to 2 substituents independently selected from F, CI, -OH, -CN, Ci_4 alkyl, Ci_4 hydroxyalkyl, Ci_4 fluoroalkyl, Ci_4 cyanoalkyl, Ci_3 alkoxy, C3_6 cycloalkyl, -(Ci_3 alkylenyl)0(Ci_3 alkyl), -(Ci_3 alkylenyl)0(Ci_3 fluoroalkyl), -C(0)NH2, -C(0)NH(Ci_3 alkyl), -NHC(0)(Ci_3 alkyl), -NHC(0)S(0)2(Ci_3 alkyl),
-S(0)2NH2, -S(0)2(Ci_3 alkyl), pyrazolyl, methyl pyrazolyl, imidazolyl, triazolyl, methyl tetrazolyl, ethyl tetrazolyl, phenyl, pyrimidinyl,
fluoropyrimidinyl, and tetrahydropyranyl.
In the chemical structures represented by Formula (I), the HET group is a heteroaryl group having at least one nitrogen heteroatom, wherein one nitrogen heteroatom of the HET group forms a bond to a carbon atom adjacent to the nitrogen heteroatom in the pyridine ring.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein HET i a heteroaryl selected from:
Figure imgf000010_0001
Ra is H, F, CI, Br, -CN, -OH, -CH3, -CHF2, -OCH3, -NH2, -N(CH3)2, -NHCH2CH2OH, -NHCH2C(CH3)2OH, -NHCH2CHFC(CH3)2OH, -C(0)NH2,
-CH2NHC(0)CH2CH2CH3, -CH2NHC(0)CH(CH3)2, -CH2NHC(0)CH2CH(CH3)2, -CH2NHC(0)CH2C(CH3)3, -CH2NHC(0)CH2CH2CH(CH3)2,
-CH2NHC(0)CH2C(CH3)2OH, -CH2NHC(0)NHCH2CH2CH3,
-CH2NHC(0)NHCH2CH2CH2CH3, -CH2NHC(0)NHCH2(phenyl),
-CH2NHC(0)N(CH2CH3)2, -CH2NHC(0)OCH2CH3, -CH2NHC(0)OCH2CH(CH3)2, -CH2NHC(0)(cyclopropyl), -CH2NHC(0)(tetrahydrofuranyl),
-CH2NHC(0)CH2(cyclopentyl), -CH2NHC(0)CH2(cyclohexyl),
-CH2NHC(0)CH2(tetrahydropyranyl), -CH2NHC(0)CH2(phenyl), -NHC(0)CH3, hydroxypyrrolidinyl, or pyridazinyl;
is H or -NH2;
is:
(i) -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2CH2CH(CH3)2, -CH2CHFCH3, -CH2CH2CF2CH3,
-CH2CHFCH(CH3)2, -CH2CH2C(CH3)2F, -CH2CHFC(CH3)2F,
-CH2CH2CH(OH)CH3, -CH2CH2C(CH3)2OH, -CH2CHFCH(CH3)OH,
-CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH, -CH2CHFC(CH2CH3)2OH, -CH2CHFC(cyclopropyl)2(OH), -CH2CHFCH(OH)CH(CH3)2,
-CH2CH2OCH2CH3, -(CH2)3OCH(CH3)2, -(CH2)3OC(CH3)3,
-CH2CHFCH2OCH3, -CH2CHFC(CH3)2OCH3, -CH2CHFC(CH3)2OCD3, -CH2CHFC(CH3)2OCHF2, -CH2CHFC(CH3)2OCH2CH3, -CH2CH2C(0)OCH3, -CH2CH2NHC(0)C(CH3)2OC(0)CH3, -CH2CH2NHS(0)2CH3,
-CH2CH2CH(CH3)NHS(0)2CH3, -CH2CH2C(CH3)2NHS(0)2CH3,
-CH2CH2P(0)(OCH2CH3)2, -CH2CHFCH(CH3)NHCH(CH3)2,
-CH2CHFC(0)NHCH3, -CH2CH2C(0)NHCH2CH3,
-CH2CHFC(0)NHCH(CH3)2, -CH2CHFC(0)NHCH(CH3)CH2OH, or
-CH2CHFC(CH3)2OP(0)(OH)2;
(ii) -(Ci-3 alkylenyl)Rx, -(Ci_2 fiuoroalkylenyl)Rx, -(Ci_2 alkylenyl)C(0)Rx,
-CH2C(0)NHRx, -CH2CHFC(0)Rx, or -CH2CF=(tetrahydropyranyl), wherein Rx is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl,
1 , 1 -dioxidotetrahydrothiophenyl, 1 , 1 -dioxidothiomorpholinyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl,
tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -C(CH2)2OH, -OCH3, -C(0)CH2CN, -S(0)2CH3, -S(0)2NH2, -NHC(0)CH3, -N(S(0)2CH3)2,
-CH2CH2(acetamidophenyl), -CH2CH2(methoxyphenyl),
-CH2CH2(sulfamoylphenyl), oxetanyl, benzyl, and morpholinyl;
cyclopropyl, cyclopentyl, cyclopentenyl, or cyclohexyl, each substituted with zero to 2 substituents independently selected from F, -OH, -CN, -CH3, -OCH3, -SCH3, -N02, -S(0)2CH3, -C(CH3)2OH, -C(CH3)(OH)(cyclopropyl),
-CH2C(0)NHCH3, -NHC(0)CH(OH)CH3, -C(0)NHCD3, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(cyclopropyl), -NHC(0)CH3, -NHC(0)OCH3, -NHS(0)2CH3, pyridinyl, methylimidazolyl, methylpyrazolyl, and thiazolyl; tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from -OH, -OCH3, -CH2CHF2, -C(CH3)2OH, -CH2C(CH3)2OH, -C(0)CH(CH3)2, -S(0)2CH3, -S(0)2CH2CH3, -S(0)2CH(CH3)2, -S(0)2NHCH3, -S(0)2NHCH(CH3)2, -N(CH3)2,
-OCH2CH2N(CH3)2, -CH2(morpholinyl), oxetanyl, tetrahydropyranyl, morpholinyl, piperazinyl, methylpiperazinyl, methoxypiperidinyl, pyrimidinyl, methylsulfonyl azetidinyl, and -C(0)(methylsulfonyl azetidinyl); or
pyrrolo[2,3-c]pyridinyl, bicyclo[2.2.1 Jheptan- 1 -ol, tetrahydrobenzo[d]thiazol-2- amine, or l,3-diazaspiro[4.5]decane-2,4-dione; and
-CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3,
-CH(CH3)CH2CH3, -CH2CH2CH(CH3)2, -CH(CH3)CH2CH(CH3)2,
-CH(CH3)CH2OH, -CH2CH2CH(CH3)OH, -CH(CH3)CH2CH2OH,
-CH2C(CH3)2OH, -C(CH3)2CH2OH, -CH(CH3)CH(OH)CH2CH(CH3)2,
-CH2CH(OH)CH(CH3)2, -CH(CH2OH)CH2CH3, -CH(CH2OH)CH(CH3)2, -CH=CHC(CH3)2OH, -CH2CH2CN, -CH2CHF2, -CH2CF3, -CH2CHFCH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2F, -CH2CH2CH2F,
-CH2CHFCH2CH3, -CH2CH2CHFCH3, -CH(CH3)CHFCH3,
-CH(CH3)CH2CH2F, -CH2CH2C(CH3)2F, -CH2CHFC(CH3)2OH,
-CH2CF2C(CH3)2OH, -CH2C(CH3)FCH2OH, -CH(CH2F)CH2OH,
-CH2CH2OCHF2, -CH2C(CH3)OCHF2, -CH2C(CH3)2OCHF2, -CH2C(CH3)2OCH3, -CH2C(CH3)2CH2NH2, -CH2CHFC(0)NHCH(CH3)2, -CH2CH2NHS(0)2CH3, or -CH2CH2NHC(0)OC(CH3)2CF3;
(ii) -CH2(azetidinyl), -CH2(cyclopropyl), -CH2(fluorocyclobutyl),
-CH2(hydroxycyclobutyl), -CH2(oxetanyl), -CH2(methyloxetanyl),
-CH2(oxazolyl), -CH2(methylpyridinyl), -CH2(tetrahydropyranyl),
-CH2CH2(methylmorpholinyl) -CH(CH3)(cyclopropyl), -CH2CH2(morpholinyl), -CH2CH(CH3)(morpholinyl), or -CH2C(CH3)2(morpholinyl);
(iii) C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -CH2OH, -C(CH3)2OH, -C(0)NH2, -C(0)NHCH(CH3)2, -NH2, -NHCH2CF3, -NH(oxetanyl), -NHC(0)CHF2, -NHC(0)(cyclopropyl), -NHC(0)(fluorophenyl), and imidazolyl; azetidinyl substituted with -C(0)CH3, -C(0)OCH3, -C(0)OCH2CH3, -C(0)OC(CH3)3, -S(0)2CH3, fluoropyrimidinyl, or chloropyrimidinyl; tetrahydrofuranyl substituted with zero to 2 substituents independently selected from F and -OH; pyrrolidinyl substituted with zero to 1 substituent selected from -C(0)CH3, -C(0)CH2CF3, -C(0)CH2CN, -C(0)OCH3, -S(0)2CH3, -C(0)(difiuorophenyl), pyrimidinyl, fluoropyrimidinyl, and methoxypyrimidinyl; piperidinyl substituted with -S(0)2CH3, phenyl, or fluoropyrimidinyl; tetrahydropyranyl, fluorotetrahydropyranyl, or oxetanyl;
(iv) adamantanyl, hydroxyadamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, bicyclo[l.l.l]pentanyl, or hydroxy- bicyclo[2.2.1]heptanyl; or
(v) phenyl substituted with 1 to 2 substituents independently selected from F, -OH, -CN, -CH2OH, -C(CH3)2OH, -OCH3, -C(0)NH2, -C(0)NHCH3, -NHC(0)CH3, -NHC(0)S(0)2CH3, -S(0)2NH2, pyrazolyl, methyl pyrazolyl, imidazolyl, triazolyl, methyl tetrazolyl, and ethyl tetrazolyl; pyrazolyl substituted with 1 to 2 substituents independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CHF2, -CH2CHF2, -CH2CF3, -CH2CHFCH3, -CH2CH2CH2F, -CH2C(CH3)2F, -CH2CF2CH3, -CH2C(CH3)2OH, -CH2CH2OCH3,
-CH2CH(CH3)OCHF2, -CH2CH2CN, -C(0)NHCH2CH3, -S(0)2CH3, cyclopropyl, oxetanyl, phenyl, pyrimidinyl, fluoropyrimidinyl, and
tetrahydropyranyl; methyl thiadiazolyl, hydroxypropyl thiazolyl, or indazolyl. One embodiment provides a compound of Formula (I) or a salt thereof, wherein HET is a heteroaryl selected from:
Figure imgf000014_0001
wherein each of said heteroaryl is substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first aspect. Included in this embodiment are compounds in which Q is selected from:
Figure imgf000014_0002
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrazolyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first
aspect. Included in this embodiment are compounds in which is
Figure imgf000014_0003
substituted
with Ra and Rb; and compounds in which Q is
Figure imgf000014_0004
included in this embodiment are compounds in which Ra is pyridazinyl; Rb is H; Ri is
-CH2CF2C(CH3)20H; and R2 is -CH(CH3)2.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is indolyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first aspect.
Included in this embodiment are compounds in which Q is
Figure imgf000014_0005
substituted with Ra and Rb; and compounds in which Q is
Figure imgf000015_0001
. Also included in this embodiment are compounds in which Ra is CI or -CN; Rb is H; Ri is
-CH2CHFC(CH3)2OH or cyclohexyl substituted with -C(CH3)2OH or -C(0)NHCH3.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrrolo[2,3-b]pyridinyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first as ect. Included in this embodiment are com ounds in which is
Figure imgf000015_0002
substituted with Ra and Rb; and compounds in which Q is
Also included in this embodiment are compounds wherein Ra is H, F, CI, -CN, -C(0)NH2, -NHC(0)CH3, -CH2NHC(0)CH(CH3)2, -CH2NHC(0)CH2C(CH3)2OH,
-CH2NHC(0)CH2C(CH3)3, -CH2NHC(0)CH2CH(CH3)2,
-CH2NHC(0)CH2CH2CH(CH3)2, -CH2NHC(0)CH2CH2CH3, -CH2NHC(0)N(CH2CH3)2, -CH2NHC(0)NHCH2(phenyl), -CH2NHC(0)NHCH2CH2CH2CH3,
-CH2NHC(0)NHCH2CH2CH3, -CH2NHC(0)OCH2CH(CH3)2, -CH2NHC(0)OCH2CH3, -CH2NHC(0)(cyclopropyl), -CH2NHC(0)(tetrahydrofuranyl),
-CH2NHC(0)CH2(tetrahydropyranyl), -CH2NHC(0)CH2(cyclopentyl),
-CH2NHC(0)CH2(cyclohexyl), -CH2NHC(0)CH2(phenyl), or
-CH2NHC(0)NHCH2(phenyl); Rb is H;
Ri is:
(i) -CH2CHFC(CH3)2F, -CH2CH2C(CH3)2OH, -CH2CHFCH(CH3)OH,
-CH2CHFC(CH3)2OH, -(CH2)3OCH(CH3)2, -(CH2)3OC(CH3)3,
-CH2CHFCH2OCH3, -CH2CHFC(CH3)2OCD3, -CH2CHFC(CH3)2OCH2CH3, -CH2CH2NHC(0)C(CH3)2OC(0)CH3, -CH2CH2NHS(0)2CH3,
-CH2CHFCH(CH3)NHCH(CH3)2, or -CH2CHFC(0)NHCH3;
(ii) -(Ci-2 fluoroalkylenyl)Rx, -CH2C(0)Rx, or -CH2C(0)NHRx, wherein Rx is a cyclic group selected from cyclopropyl, piperazinyl, oxetanyl, and phenyl, wherein each cyclic group is substituted with zero to 3 substituents
independently selected from -OH, -CH3, and -S(0)2NH2;
(iii) cyclopentyl or cyclohexyl, each substituted with 1 to 2 substituents
independently selected from F, -OH, -CH3, -SCH3, -N02, -S(0)2CH3, -C(CH3)2OH, -C(CH3)(OH)(cyclopropyl), -C(0)NHCD3, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(cyclopropyl), -NHC(0)OCH3, pyridinyl, methylimidazolyl, methylpyrazolyl, and thiazolyl;
piperidinyl substituted with -S(0)2CH3; or
bicyclo[2.2.1]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or 1,3- diazaspiro [4.5] decane-2 ,4 -dione; and
-CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH(CH3)2,
-CH(CH3)CH2CH(CH3)2, -CH(CH3)CH2OH, -CH2CH2CH(CH3)OH,
-CH(CH3)CH2CH2OH, -CH2C(CH3)2OH, -CH(CH3)CH(OH)CH2CH(CH3)2, -CH=CHC(CH3)2OH, -CH2CF3, -CH2CHFCH3, -CH2CH2CF3, -CH(CH3)CH2F, -CH(CH3)CHFCH3, -CH(CH3)CH2CH2F, -CH2CHFC(CH3)2OH,
-CH(CH2F)CH2OH, or -CH2CHFC(0)NHCH(CH3)2;
-CH2(azetidinyl), -CH2(fluorocyclobutyl), -CH2(hydroxycyclobutyl),
-CH2(oxetanyl), -CH2(methyloxetanyl), -CH2(methylpyridinyl),
-CH2(tetrahydropyranyl), -CH2CH2(methylmorpholinyl)
-CH(CH3)(cyclopropyl), or -CH2CH2(morpholinyl);
C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -CH2OH, -C(CH3)2OH, -C(0)NH2, -NH2, -NHCH2CF3, and imidazolyl; azetidinyl substituted with -C(0)CH3, -C(0)OCH3, -C(0)OC(CH3)3, -S(0)2CH3, or fluoropyrimidinyl; tetrahydrofuranyl substituted with zero to 2 substituents independently selected from F and -OH; pyrrolidinyl substituted with zero to 1 substituent selected from -C(0)CH3, -C(0)CH2CF3,
-C(0)CH2CN, -C(0)OCH3, -S(0)2CH3, and fluoropyrimidinyl; piperidinyl substituted with -S(0)2CH3, or phenyl; tetrahydropyranyl,
fluorotetrahydropyranyl, or oxetanyl;
adamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, or hydroxy-bicyclo[2.2.1]heptanyl; or
phenyl substituted with 1 to 2 substituents independently selected from F, -OH, -CN, -CH2OH, -C(CH3)2OH, -OCH3, -C(0)NH2, -C(0)NHCH3, -NHC(0)CH3, -NHC(0)S(0)2CH3, -S(0)2NH2, pyrazolyl, imidazolyl, triazolyl, methyl tetrazolyl, and ethyl tetrazolyl; pyrazolyl substituted with 1 to 2 substituents independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH2CHF2, and tetrahydropyranyl; or indazolyl.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrrolo[2,3-d]pyrimidinyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first aspect. Included in this embodiment are compounds in which Q is
Figure imgf000017_0001
substituted with Ra and Rb; and compounds in which Q is
Also included in this embodiment are compounds in which Ra is H, -NH2, N(CH3)2,
-NHCH2CH2OH, -NHCH2C(CH3)2OH, or hydroxypyrrolidinyl; Rb is H; Ri is
-CH2CHFC(CH3)2OH or cyclohexyl substituted with -C(0)NHCH3; and R2 is -CH(CH3)2,
-CH(CH3)CH2F, -CH2C(CH3)2OH, cyclopropyl, tetrahydropyranyl, or
-CH2CH(CH3)(morpholinyl).
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrazolo[3,4-b]pyridinyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first aspect. Included in this embodiment are compounds in which is
Figure imgf000017_0002
substituted with Ra and Rb; and compounds in which Q is
Also included in this embodiment are compounds in which Ra is F, CI, Br, -CN, -OH, -CH3, -CHF2, -OCH3, -C(0)NH2, or -CH2NHC(0)CH2CH(CH3)2; Rb is H or -NH2;
Ri is:
(i) -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2
C(CH3)3, -CH2CH2CH(CH3)2, -CH2CHFCH3, -CH2CH2CF2CH3,
CH2CHFCH(CH3)2, -CH2CH2C(CH3)2F, -CH2CHFC(CH3)2F,
CH2CH2CH(OH)CH3, -CH2CH2C(CH3)2OH, -CH2CHFC(CH3)2OH, CH2CF2C(CH3)2OH, -CH2CHFC(cyclopropyl)2(OH),
CH2CHFCH(OH)CH(CH3)2, -CH2CH2OCH2CH3, -CH2CHFCH2OCH3, CH2CHFC(CH3)2OCH3, -CH2CHFC(CH3)2OCD3,
CH2CHFC(CH3)2OCH2CH3, -CH2CH2C(0)OCH3, -CH2CH2NHS(0)2CH3, CH2CH2CH(CH3)NHS(0)2CH3, -CH2CH2C(CH3)2NHS(0)2CH3, -CH2CH2P(0)(OCH2CH3)2, -CH2CHFC(0)NHCH3, -CH2CH2C(0)NHCH2CH3, -CH2CHFC(0)NHCH(CH3)2, -CH2CHFC(0)NHCH(CH3)CH2OH, or
-CH2CHFC(CH3)2OP(0)(OH)2;
-(Ci_3 alkylenyl)Rx, -(Ci_2 fiuoroalkylenyl)Rx, -(Ci_2 alkylenyl)C(0)Rx,
-CH2CHFC(0)Rx, or -CH2CF=(tetrahydropyranyl), wherein Rx is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl, 1,1- dioxidotetrahydrothiophenyl, 1 , 1 -dioxidothiomorpholmyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl,
tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents
independently selected from F, -OH, -CH3, -C(CH2)2OH, -OCH3, -C(0)CH2CN, -S(0)2CH3, -S(0)2NH2, -NHC(0)CH3, -N(S(0)2CH3)2, oxetanyl, and benzyl; cyclopropyl, cyclopentyl, cyclopentenyl, or cyclohexyl, each substituted with zero to 1 substituent independently selected from -CN, -CH3, -OCH3,
-S(0)2CH3, -C(CH3)2OH, -CH2C(0)NHCH3, -NHC(0)CH(OH)CH3,
-C(0)NHCD3, -C(0)NHCH3, -NHC(0)CH3, and -NHS(0)2CH3;
tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with a substituent selected from -OH, -OCH3, -CH2CHF2,
-C(CH3)2OH, -CH2C(CH3)2OH, -C(0)CH(CH3)2, -S(0)2CH3, -S(0)2CH2CH3, -S(0)2CH(CH3)2, -S(0)2NHCH3, -S(0)2NHCH(CH3)2, -N(CH3)2,
-OCH2CH2N(CH3)2, -CH2(morpholinyl), oxetanyl, tetrahydropyranyl, morpholinyl, piperazinyl, methylpiperazinyl, methoxypiperidinyl, pyrimidinyl, methylsulfonyl azetidinyl, and -C(0)(methylsulfonyl azetidinyl); or
pyrrolo[2,3-c]pyridinyl or tetrahydrobenzo[d]thiazol-2-amine; and
-CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3,
-CH(CH3)CH2CH3, -CH(CH3)CH2OH, -CH2CH2CH(CH3)OH,
-C(CH3)2CH2OH, -CH2CH(OH)CH(CH3)2, -CH(CH2OH)CH2CH3,
-CH(CH2OH)CH(CH3)2, -CH2CHF2, -CH2CF3, -CH2CHFCH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2F, -CH2CH2CH2F, -CH2CHFCH2CH3,
-CH2CH2CHFCH3, -CH(CH3)CHFCH3, -CH(CH3)CH2CH2F,
-CH2CH2C(CH3)2F, -CH2CF2C(CH3)2OH, -CH2C(CH3)FCH2OH, -CH2CH2OCHF2, -CH2C(CH3)OCHF2, -CH2C(CH3)2OCHF2, -CH2C(CH3)2OCH3, -CH2C(CH3)2CH2NH2, -CH2CH2NHS(0)2CH3, or
-CH2CH2NHC(0)OC(CH3)2CF3;
(ii) -CH2(cyclopropyl), -CH2(fluorocyclobutyl), -CH2(oxazolyl), or
-CH2C(CH3)2(morpholinyl);
(iii) C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -CH2OH, -C(CH3)2OH, -C(0)NHCH(CH3)2, -NH2,
-NH(oxetanyl), -NHC(0)CHF2, -NHC(0)(cyclopropyl), and
-NHC(0)(fluorophenyl); azetidinyl substituted with -C(0)OCH3,
-C(0)OCH2CH3, fluoropyrimidinyl, or chloropyrimidinyl; tetrahydrofuranyl substituted with zero to 2 substituents selected from F; pyrrolidinyl substituted with -C(0)(difiuorophenyl), pyrimidinyl, fluoropyrimidinyl, or
methoxypyrimidinyl; piperidinyl substituted with phenyl or fluoropyrimidinyl; tetrahydropyranyl, or oxetanyl;
(iv) hydroxyadamantanyl, benzo[d]oxazolyl, benzothiazolyl, bicyclo[ 1.1.1 ]pentanyl, or hydroxy-bicyclo[2.2.1]heptanyl; or
(v) phenyl substituted with 1 to 2 substituents independently selected from F, -CN, triazolyl, and methyl tetrazolyl,; pyrazolyl substituted with 1 to 2 substituents independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CHF2, -CH2CHF2, -CH2CH2CH2F, -CH2C(CH3)2F, -CH2CF2CH3, -CH2C(CH3)2OH, -CH2CH2OCH3, -CH2CH(CH3)OCHF2, -CH2CH2CN, -C(0)NHCH2CH3, -S(0)2CH3, cyclopropyl, oxetanyl, phenyl, pyrimidinyl, fluoropyrimidinyl, and tetrahydropyranyl; methyl thiadiazolyl, or hydroxypropyl thiazolyl.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrazolo[3,4-d]pyrimidinyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first as ect. Included in this embodiment are com ounds in which is
Figure imgf000019_0001
substituted with Ra and Rb; and compounds in which Q is
Also included in this embodiment are compounds in which Ra is H or -NH2; Rb is H; Ri is -CH2CHFC(CH3)2OH or -CH2CHFC(CH2CH3)2OH; and R2 is -CH2CH3, -CH(CH3)2, or cyclopropyl. One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first aspect. Included in this embodiment are compounds in which Q
Figure imgf000020_0001
Figure imgf000020_0002
. Also included in this embodiment are compounds in which Ra is -CN; Rb is H; Ri is -CH2CHFC(CH3)2OH; and R2 is -CH(CH3)2, cyclopropyl, or oxetanyl.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is imidazo[4,5-b]pyridinyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first aspect. Included in this embodiment are compounds in which Q is
Figure imgf000020_0003
substituted with Ra and Rb; and compounds in which Q is
Also included in this embodiment are compounds in which Ra is CI or -CN; Rb is H or -NH2; Ri is -CH2CHFC(CH3)2F or -CH2CHFC(CH3)2OH; and R2 is -CH2CH3,
-CH(CH3)2, -CH2CH2CN, cyclopropyl, methylcyclopropyl, cyclobutyl, oxetanyl, tetrahydrofuranyl, or pyrazolyl substituted with -CH3, CHF2, -CH2CH3, -CH2CH2CN, -CH2CHF2, -CH2CH2CH3, CH2CHFCH3, -CH2CH2CH2F, -CH(CH3)2, or
-CH2CH(CH3)OCHF2.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is purinyl substituted with Ra and Rb; and Ri, R2, Ra, and Rb are defined in the first aspect.
Included in this embodiment are compounds in which Q is
Figure imgf000020_0004
substituted with
Figure imgf000020_0005
Ra and Rb; and compounds in which Q is N . Also included in this
embodiment are compounds in which Ra is H, -NH2, -NHCH2CH2OH, or
-NHCH2CHFC(CH3)2OH; Rb is H; Ri is -CH2CHFC(CH3)2F or -CH2CF2C(CH3)2OH; and R2 is -CH(CH3)2. One embodiment provides a compound of Formula (I) or a salt thereof, wherein Q is pyrrolo[2,3-b]pyridinyl or pyrazolo[3,4-b]pyridinyl; Ra is H, F, CI, Br, -CN, -OH, -CH3, -CHF2, -OCH3, -C(0)NH2, -NHC(0)CH3, -CH2NHC(0)CH(CH3)2,
-CH2NHC(0)CH2C(CH3)3, -CH2NHC(0)CH2CH(CH3)2, -CH2NHC(0)CH2CH2CH3, -CH2NHC(0)N(CH2CH3)2, -CH2NHC(0)CH2C(CH3)2OH,
-CH2NHC(0)CH2CH2CH(CH3)2, -CH2NHC(0)NHCH2CH2CH2CH3,
-CH2NHC(0)NHCH2CH2CH3, -CH2NHC(0)OCH2CH(CH3)2, -CH2NHC(0)OCH2CH3, -CH2NHC(0)(cyclopropyl), -CH2NHC(0)CH2(cyclopentyl),
-CH2NHC(0)CH2(cyclohexyl), -CH2NHC(0)(tetrahydrofuranyl),
-CH2NHC(0)CH2(phenyl), -CH2NHC(0)CH2(tetrahydropyranyl), or
-CH2NHC(0)NHCH2(phenyl); Rb is H or -NH2;
Ri is:
(i) -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2CH2CH(CH3)2, -CH2CHFCH3, -CH2CH2CF2CH3,
-CH2CHFCH(CH3)2, -CH2CH2C(CH3)2F, -CH2CHFC(CH3)2F,
-CH2CH2CH(OH)CH3, -CH2CH2C(CH3)2OH, -CH2CHFCH(CH3)OH,
-CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH, -CH2CHFC(cyclopropyl)2(OH), -CH2CHFCH(OH)CH(CH3)2, -CH2CH2OCH2CH3, -(CH2)3OCH(CH3)2, -(CH2)3OC(CH3)3, -CH2CHFCH2OCH3, -CH2CHFC(CH3)2OCH3,
-CH2CHFC(CH3)2OCD3, -CH2CHFC(CH3)2OCHF2,
-CH2CHFC(CH3)2OCH2CH3, -CH2CH2C(0)OCH3,
-CH2CH2NHC(0)C(CH3)2OC(0)CH3, -CH2CH2NHS(0)2CH3,
-CH2CH2CH(CH3)NHS(0)2CH3, -CH2CH2C(CH3)2NHS(0)2CH3,
-CH2CH2P(0)(OCH2CH3)2, -CH2CHFCH(CH3)NHCH(CH3)2,
-CH2CHFC(0)NHCH3, -CH2CH2C(0)NHCH2CH3,
-CH2CHFC(0)NHCH(CH3)2, -CH2CHFC(0)NHCH(CH3)CH2OH, or
-CH2CHFC(CH3)2OP(0)(OH)2;
(ii) -(Ci-3 alkylenyl)Rx, -(Ci_2 fiuoroalkylenyl)Rx, -(Ci_2 alkylenyl)C(0)Rx,
-CH2C(0)NHRx, -CH2CHFC(0)Rx, or -CH2CF=(tetrahydropyranyl), wherein Rx is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl,
1 , 1 -dioxidotetrahydrothiophenyl, 1 , 1 -dioxidothiomorpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -C(CH2)2OH, -OCH3, -C(0)CH2CN, -S(0)2CH3, -S(0)2NH2, -NHC(0)CH3, -N(S(0)2CH3)2, and oxetanyl, benzyl;
cyclopropyl, cyclopentyl, cyclopentenyl, or cyclohexyl, each substituted with zero to 2 substituents independently selected from F, -OH, -CN, -CH3, -OCH3, -SCH3, -N02, -S(0)2CH3, -C(CH3)2OH, -C(CH3)(OH)(cyclopropyl),
-CH2C(0)NHCH3, -NHC(0)CH(OH)CH3, -C(0)NHCD3, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(cyclopropyl), -NHC(0)CH3, -NHC(0)OCH3, -NHS(0)2CH3, pyridinyl, methylimidazolyl, methylpyrazolyl, and thiazolyl; tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from -OH, -OCH3, -CH2CHF2, -C(CH3)2OH, -CH2C(CH3)2OH, -C(0)CH(CH3)2, -S(0)2CH3, -S(0)2CH2CH3, -S(0)2CH(CH3)2, -S(0)2NHCH3, -S(0)2NHCH(CH3)2, -N(CH3)2,
-OCH2CH2N(CH3)2, -CH2(morpholinyl), oxetanyl, tetrahydropyranyl, morpholinyl, piperazinyl, methylpiperazinyl, methoxypiperidinyl, pyrimidinyl, and -C(0)(methylsulfonyl azetidinyl); or
pyrrolo[2,3-c]pyridinyl, bicyclo[2.2.1 Jheptan- 1 -ol, tetrahydrobenzo[d]thiazol-2- amine, or l,3-diazaspiro[4.5]decane-2,4-dione; and
-CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3,
-CH(CH3)CH2CH3, -CH2CH2CH(CH3)2, -CH(CH3)CH2CH(CH3)2,
-CH(CH3)CH2OH, -CH2CH2CH(CH3)OH, -CH(CH3)CH2CH2OH,
-CH2C(CH3)2OH, -C(CH3)2CH2OH, -CH(CH3)CH(OH)CH2CH(CH3)2, -CH2CH(OH)CH(CH3)2, -CH(CH2OH)CH(CH3)2, -CH=CHC(CH3)2OH, -CH2CHF2, -CH2CF3, -CH2CHFCH3, -CH(CH3)CF3, -CH2CH2CF3,
-CH(CH3)CH2F, -CH2CH2CH2F, -CH2CHFCH2CH3, -CH2CH2CHFCH3, -CH(CH3)CHFCH3, -CH(CH3)CH2CH2F, -CH2CH2C(CH3)2F,
-CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH, -CH2C(CH3)FCH2OH,
-CH(CH2F)CH2OH, -CH2CH2OCHF2, -CH2C(CH3)2OCHF2,
-CH2C(CH3)2OCH3, -CH2C(CH3)2CH2NH2, -CH2CHFC(0)NHCH(CH3)2, -CH2CH2NHS(0)2CH3, or -CH2CH2NHC(0)OC(CH3)2CF3; (ii) -CH2(azetidinyl), -CH2(cyclopropyl), -CH2(fluorocyclobutyl), -CH2(hydroxycyclobutyl), -CH2(oxetanyl), -CH2(methyloxetanyl),
-CH2(oxazolyl), -CH2(methylpyridinyl), -CH2(tetrahydropyranyl),
-CH2CH2(methylmorpholinyl) -CH(CH3)(cyclopropyl), -CH2CH2(morpholinyl), or -CH2C(CH3)2(morpholinyl);
(iii) C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -CH2OH, -C(CH3)2OH, -C(0)NH2, -C(0)NHCH(CH3)2, -NH2, -NHCH2CF3, -NH(oxetanyl), -NHC(0)CHF2, -NHC(0)(cyclopropyl), -NHC(0)(fluorophenyl), and imidazolyl; azetidinyl substituted with -C(0)CH3, -C(0)OCH3, -C(0)OCH2CH3, -C(0)OC(CH3)3, -S(0)2CH3, fluoropyrimidinyl, or chloropyrimidinyl; tetrahydrofuranyl substituted with zero to 2 substituents independently selected from F and -OH; pyrrolidinyl substituted with zero to 1 substituent selected from -C(0)CH3, -C(0)CH2CF3, -C(0)CH2CN, -C(0)OCH3, -S(0)2CH3, -C(0)(difiuorophenyl), pyrimidinyl, fluoropyrimidinyl, and methoxypyrimidinyl; piperidinyl substituted with -S(0)2CH3, phenyl, or fluoropyrimidinyl; tetrahydropyranyl, fluorotetrahydropyranyl, or oxetanyl;
(iv) adamantanyl, hydroxyadamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, bicyclo[l.l.l]pentanyl, or hydroxy- bicyclo[2.2.1]heptanyl; or
(v) phenyl substituted with 1 to 2 substituents independently selected from F, -OH, -CN, -CH2OH, -C(CH3)2OH, -OCH3, -C(0)NH2, -C(0)NHCH3, -NHC(0)CH3, -NHC(0)S(0)2CH3, and -S(0)2NH2; pyrazolyl substituted with 1 to 2 substituents independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CHF2, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2C(CH3)2F, -CH2CF2CH3, -CH2C(CH3)2OH, -CH2CH2OCH3, -CH2CH2CN,
-C(0)NHCH2CH3, -S(0)2CH3, cyclopropyl, oxetanyl, phenyl, pyrimidinyl, fluoropyrimidinyl, and tetrahydropyranyl; methyl thiadiazolyl, hydroxypropyl thiazolyl, or indazolyl.
The second aspect of the invention provides a compound of Formula (I) or a salt thereof, within the scope of the first aspect, wherein: HET is a heteroaryl selected from pyrazole, indole, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-d]pyrimidine, pyrazolo[3,4-b] pyridine, pyrazolo[3,4-d]pyrimidine, or purine, wherein said heteroaryl is substituted with zero or one substituent selected from F, CI, Br, -OH, -CN, -CH3, -NH2, -N(CH3)2, -NHCH2C(CH3)2OH, -NHC(0)CH3, -NHCH2CH2OH, -C(0)NH2, hydroxypyrrolidine, and pyridazine;
Ri is:
(i) Ci_7 alkyl substituted with 1 to 4 substituents independently selected from F, -OH, -OCH3, -OCH(CH3)2, -OC(CH3)3, -C(0)NHCH3, -NH(CH(CH3)2), -NHS(0)2CH3, -NHC(0)C(CH3)2OC(0)CH3, -C(0)NH(tetrahydrothiophene 1,1 -dioxide), -OP(0)(OH)2, morpholine, and phenyl substituted with
-S(0)2NH2;
(ii) bicyclo[2.2.1]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or 1,3- diazaspiro[4.5]decane-2,4-dione; or
(iii) C3_6 cycloalkyl substituted with 1 to 3 substituents independently selected from F, -OH, -N02, -CH3, -C(CH3)2OH, -C(0)NH(CH3), -C(0)NH(CD3),
-C(0)NH(CH2CH3), -C(0)NH(cyclopropyl), -NHC(0)CH3, -NHC(0)OCH3), -NHS(0)2CH3, -S(0)2CH3, -SCH3, pyridine, methylimidazole, methylpyrazole, and thiazole; and
R2 is:
(i) C2_6 alkyl substituted with zero to three substituents independently selected from F and -OH;
(ii) -(CH2)o_3-Rx wherein Rx is C3_6 cycloalkyl, oxetane, tetrahydrofuran, or
tetrahydropyran, each substituted with zero to 2 substituents selected from F, -OH, and -CH3;
(iii) adamantane, benzothiazole, or bicyclo[2.2.1]heptan-l-ol; or
(iv) phenyl substituted with -OH, -CN, -CH2OH, -C(CH3)2OH, -OCH3, -C(0)NH2, -C(0)NH(CH3), -NHC(0)CH3, -NHS(0)2CH3, -S(0)2NH2, pyrazole, triazole, or methyl tetrazole.
One embodiment provides a compound of Formula (I) or a salt thereof wherein HET is a pyrazole substituted with zero or one substituent selected from F, CI, Br, -OH, -CN, -CH3, -NH2, -N(CH3)2, -NHCH2C(CH3)2OH, -NHC(0)CH3, -NHCH2CH2OH, -C(0)NH2, hydroxypyrrolidine, and pyridazine. Included in this embodiment are compounds in which HET is pyrazole substituted with pyridazine. Also included in this
embodiment are compounds in which
Figure imgf000025_0001
, wherein Ra is defined in the second aspect.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein HET is a bicyclic heteroaryl selected from indole, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-d] pyrimidine, pyrazolo[3,4-b]pyridine, pyrazolo[3,4-d]pyrimidine, or purine, wherein each of said bicyclic heteroaryl is substituted with zero or one substituent selected from F, CI, Br, -OH, -CN, -CH3, -NH2, -N(CH3)2, -NHCH2C(CH3)2OH, -NHC(0)CH3,
-NHCH2CH2OH, -C(0)NH2, hydroxypyrrolidine, and pyridazine. Included in this embodiment are compounds in which HET is:
Figure imgf000025_0002
wherein each of said heteroaryl is substituted with zero or 1 substituent selected from F, CI, Br, -OH, -CN, -CH3, -NH2, -N(CH3)2, -NHCH2C(CH3)2OH, -NHC(0)CH3,
-NHCH2CH2OH, -C(0)NH2, and hydroxypyrrolidine.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein HET is a bicyclic heteroaryl selected:
Figure imgf000025_0003
Ra is H, F, CI, Br, -OH, -CN, -CH3, -NH2, -N(CH3)2, -NHCH2C(CH3)2OH, -NHC(0)CH3, -NHCH2CH2OH, -C(0)NH2, or hydroxypyrrolidine.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein
HET is
Figure imgf000025_0004
; and wherein Ra is CI or -CN. One embodiment rovides a compound of Formula (I) or a salt thereof, wherein
Figure imgf000026_0001
HET is: ; and wherein Ra is H, F, CI, -CN, -C(0)NH2, or -NHC(0)CH3.
On embodiment provides a compound of Formula (I) or a salt thereof, wherein
HET is:
Figure imgf000026_0002
and wherein Ra is F, CI, Br, -OH, -CN, or -CH3. Included in this embodiment are compounds in which Ra is CI or -CN. Also included in this
embodiment are compounds in which HET is
Figure imgf000026_0003
One embodiment rovides a com ound of Formula I or a salt thereof wherein
Figure imgf000026_0004
-OH, -CH3, -C(0)NH2, or -NHC(0)CH3. Included in this embodiment are compounds in which Ra is CI or -CN.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein
Figure imgf000026_0005
One embodiment provides a compound of Formula (I) or a salt thereof, wherein
Figure imgf000026_0006
-NHCH2C(CH3)2OH, or hydroxypyrrolidine.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein
Figure imgf000026_0007
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Ra is H, F, CI, or -CN. Included in this embodiment are compounds in which Ra is -CN. Also included in this embodiment are compounds in which Ra is CI. One embodiment provides a compound of Formula (I) or a salt thereof, wherein
LS :
(i) -CH2CH2C(CH3)20H, -CH2CHFCH(CH3)OH, -CH2CHFC(CH3)2OH,
-CH2CF2C(CH3)2OH, -CH2CHFC(CH2CH3)2OH,
-CH2CHFC(CH3)2OP(0)(OH)2, -CH2CHFC(0)NHCH3,
-CH2CHFCH(CH3)NH(CH(CH3)2), -CH2CHFCH2OCH3, -(CH2)3-0-CH(CH3)2, -(CH2)3-0-C(CH3)3, -CH2CH2-morpholine, -CH2CH2(phenyl-S(0)2NH2), -CH2CH2NHC(0)C(CH3)2OC(0)CH3, -CH2CH2NHS(0)2CH3, or
-CH2C(0)NH(tetrahydrothiophene 1 , 1 -dioxide);
(ii) bicyclo[2.2.1]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or 1 ,3- diazaspiro [4.5 ] decane-2 ,4-dione ; or
(iii) cyclohexyl substituted with 1 to 2 substituents independently selected from F, -OH, -N02, -CH3, -C(CH3)2OH, -C(0)NH(CH3), -C(0)NH(CD3),
-C(0)NH(CH2CH3), -C(0)NH(cyclopropyl), -NHC(0)CH3, -NHC(0)OCH3), -NHS(0)2CH3, -S(0)2CH3, -SCH3, pyridine, methylimidazole, methylpyrazole, and thiazole.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Ri is Ci_7 alkyl substituted with 1 to 4 substituents independently selected from F, -OH, -OCH3, -OCH(CH3)2, -OC(CH3)3, -C(0)NHCH3, -NH(CH(CH3)2), -NHS(0)2CH3,
-NHC(0)C(CH3)2OC(0)CH3, -C(0)NH(tetrahydrothiophene 1 ,1 -dioxide), -OP(0)(OH)2, morpholine, and phenyl substituted with -S(0)2NH2. Included in this embodiment are compounds in which Ri is -CH2CH2C(CH3)2OH, -CH2CHFCH(CH3)OH,
-CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH, -CH2CHFC(CH2CH3)2OH,
-CH2CHFC(0)NHCH3, -CH2CHFCH(CH3)NH(CH(CH3)2), -CH2CHFCH2OCH3, -(CH2)3-0-CH(CH3)2, -(CH2)3-0-C(CH3)3, -CH2CH2-morpholine,
-CH2CH2(phenyl-S(0)2NH2), -CH2CH2NHC(0)C(CH3)2OC(0)CH3,
-CH2CH2NHS(0)2CH3, or -CH2C(0)NH(tetrahydrothiophene 1 ,1 -dioxide).
One embodiment provides a compound of Formula (I) or a salt thereof, wherein Ri is bicyclo[2.2.1]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or 1 ,3- diazaspiro[4.5]decane-2,4-dione. One embodiment provides a compound of Formula (I) or a salt thereof, wherein Ri is C3-6 cycloalkyl substituted with 1 to 3 substituents independently selected from F, -OH, -NO2, -CH3, -C(CH3)2OH, -C(0)NH(CH3), -C(0)NH(CD3), -C(0)NH(CH2CH3), -C(0)NH(cyclopropyl), -NHC(0)CH3, -NHC(0)OCH3), -NHS(0)2CH3, -S(0)2CH3, -SCH3, pyridine, methylimidazole, methylpyrazole, and thiazole. Included in this embodiment are compounds in which Ri is cyclohexyl substituted with 1 to 2 substituents independently selected from F, -OH, -N02, -CH3, -C(CH3)2OH, -C(0)NH(CH3),
-C(0)NH(CD3), -C(0)NH(CH2CH3), -C(0)NH(cyclopropyl), -NHC(0)CH3,
-NHC(0)OCH3), -NHS(0)2CH3, -S(0)2CH3, -SCH3, pyridine, methylimidazole, methylpyrazole, and thiazole.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein R2 is C2_6 alkyl substituted with zero to three substituents independently selected from F and -OH. Included in this embodiment are compounds in which R2 is -CH2CH3,
-CH2CH2CH3, -CH(CH3)2, -CH2CH2CH(CH3)2, -CH2CF3, -CH(CH3)CH2F,
-CH(CH3)CHF(CH3), -CH(CH3)CH2CH2OH, -CH(CH3)CH2OH, -CH(CH2F)CH2OH, -CH2C(CH3)2OH, -CH2CHFC(CH3)2OH, or -CH2CF2C(CH3)2OH.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein R2 is -(CH2)o-3-Rx wherein Rx is C3-6 cycloalkyl, oxetane, or tetrahydropyran, each substituted with zero to 2 substituents selected from F, -OH, and -CH3. Included in this embodiment are compounds of Formula (I) in which R2 is tetrahydropyran,
fluorotetrahydropyran, -CH2(fluorocyclobutyl), -CH2(hydroxycyclobutyl), -CH2(oxetane), -CH2(methyloxetane), or C3-6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, and -CH3.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein R2 is adamantane, benzothiazole, or bicyclo[2.2. l]heptan-l-ol.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein R2 is phenyl substituted with -OH, -CN, -CH2OH, -C(CH3)2OH, -OCH3, -C(0)NH2, -C(0)NH(CH3), -NHC(0)CH3, -NHS(0)2CH3, -S(0)2NH2, pyrazole, triazole, or methyl tetrazole.
The third aspect of the invention provides a compound of Formula (I) or a salt thereof, within the scope of the first aspect, wherein:
HET is a heteroaryl selected from:
Figure imgf000029_0001
Ra is H, F, CI, Br, -OH, -CN, -CH3, -NH2, -N(CH3)2, -NHCH2C(CH3)2OH, -NHC(0)CH3, -NHCH2CH2OH, -C(0)NH2, hydroxypyrrolidine, or pyridazine;
Ri is:
-CH2CH2C(CH3)2OH, -CH2CHFCH(CH3)OH, -CH2CHFC(CH3)2OH,
-CH2CF2C(CH3)2OH, -CH2CHFC(CH2CH3)2OH,
-CH2CHFC(CH3)2OP(0)(OH)2, -CH2CHFC(0)NHCH3,
-CH2CHFCH(CH3)NH(CH(CH3)2), -CH2CHFCH2OCH3, -(CH2)3-0-CH(CH3)2, -(CH2)3-0-C(CH3)3, -CH2CH2-morpholine, -CH2CH2(phenyl-S(0)2NH2), -CH2CH2NHC(0)C(CH3)2OC(0)CH3, -CH2CH2NHS(0)2CH3, or
-CH2C(0)NH(tetrahydrothiophene 1 , 1 -dioxide);
bicyclo[2.2.1]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or 1,3- diazaspiro [4.5 ] decane-2 ,4-dione ; or
cyclohexyl substituted with 1 to 2 substituents independently selected from F, -OH, -N02, -CH3, -C(CH3)2OH, -C(0)NH(CH3), -C(0)NH(CD3),
-C(0)NH(CH2CH3), -C(0)NH(cyclopropyl), -NHC(0)CH3, -NHC(0)OCH3), -NHS(0)2CH3, -S(0)2CH3, -SCH3, pyridine, methylimidazole, methylpyrazole, and thiazole; and
R2 is
-CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH(CH3)2, -CH2CF3,
-CH(CH3)CH2F, -CH(CH3)CHF(CH3), -CH(CH3)CH2CH2OH,
-CH(CH3)CH2OH, -CH(CH2F)CH2OH, -CH2C(CH3)2OH,
-CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH;
tetrahydropyran, fluorotetrahydropyran, -CH2(fluorocyclobutyl),
-CH2(hydroxycyclobutyl), -CH2(oxetane), -CH2(methyloxetane), or C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, and -CH3; (iii) adamantane, benzothiazole, or bicyclo[2.2.1]heptan-l-ol; or
(iv) phenyl substituted with one substituent selected from -OH, -CN, -CH2OH,
-C(CH3)2OH, -OCH3, -C(0)NH2, -C(0)NH(CH3), -NHC(0)CH3,
-NHS(0)2CH3, -S(0)2NH2, pyrazole, triazole, and methyl tetrazole.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein
HET is
Figure imgf000030_0001
;
Ra is F, CI, Br, -OH, -CN, or -CH3;
Ri is -CH2CHFCH(CH3)OH, -CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH,
-CH2CHFC(CH2CH3)2OH, or -CH2CHFC(CH3)2OP(0)(OH)2; and
R2 is -CH2CH3, -CH2CH2CH3, -CH(CH3)2, or -CH2CH2CH(CH3)2.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein:
Figure imgf000030_0002
Ra is H, F, CI, -CN, -CH3, or -C(0)NH2;
Ri is -CH2CHFC(CH3)2OH, -CH2CHFC(CH3)2OP(0)(OH)2, -CH2CHFC(0)NHCH3, or cyclohexyl substituted with -C(0)NHCH3, -NHC(0)CH3, or -S(0)2CH3; and
R2 is C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F,
-OH, and -CH3.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein: HET i a heteroaryl selected from:
Figure imgf000030_0003
Ra is F, CI, Br, -OH, -CN, or -CH3;
Ri is -CH2CHFCH(CH3)OH, -CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH,
-CH2CHFC(CH2CH3)2OH, or -CH2CHFC(CH3)2OP(0)(OH)2; and
R2 is -CH(CH3)2. ne embodiment provides a compound of Formula (I) or a salt thereof, wherein
Figure imgf000031_0001
X is CH or N;
Figure imgf000031_0002
Ri is -CH2CH2C(CH3)2OH, -CH2CHFC(CH3)2OH, or -CH2CHFC(CH3)2OP(0)(OH)2; and R2 is -CH(CH3)2.
One embodiment provides a compound of Formula (I)or a salt thereof, wherein said compound is selected from: (R)-6-(5-cyano-lH-indol-l-yl)-N-(2-fluoro-3-hydroxy- 3-methylbutyl)-4-(isopropylamino)nicotinamide (1); (R)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (2); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (3); (R)-6-(5 -cyano- 1H- pyrrolo [2,3 -b]pyridin- 1 -yl)-4-(ethylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (4); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy- 3-methylbutyl)-4-((2,2,2-trifluoroethyl)amino)nicotinamide (5); (R)-6-(5 -cyano- 1H- pyrrolo[2,3-b]pyridin-l-yl)-4-(cyclobutylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl) nicotinamide (6); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy- 3 -methylbutyl)-4-((tetrahydro-2H-pyran-3 -yl)amino)nicotinamide (7); 6-(5 -cyano- 1 H- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((S)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H- pyran-3-yl)amino)nicotinamide (8); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)- 1 -hydroxypropan-2-yl)amino) nicotinamide (9); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(cyclopentylamino)-N-(2-fluoro-3- hydroxy-3-methylbutyl)nicotinamide (10); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- l-yl)-N- (3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (11); 6-(5 -cyano- 1H- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-4- yl)amino)nicotinamide (12); 4-((ls,3S)-adamantan-l-ylamino)-6-(5-cyano-lH- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (13); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l -yl)-N-(4-hydroxybicyclo[2.2.1 Jheptan- 1 -yl)-4- (isopropylamino)nicotinamide ( 14); N-(3 -(tert-butoxy)propyl)-6-(5 -cyano- 1 H-pyrrolo [2,3-b]pyridin-l-yl)-4-(isopropylamino)nicotinamide (15); (R)-6-(5 -cyano- 1H- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-hydroxybicyclo [2.2. l]heptan-l-yl)amino)nicotinamide (16); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -methylcyclopropyl)amino)nicotinamide (17); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-((l-methylcyclopropyl)amino)nicotinamide (18); (R)-6-(5 -cyano- 1H- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopentylamino) nicotinamide (19); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(((3 -methyloxetan-3 -yl)methyl)amino)nicotinamide (20); 6-(5 - cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4- hydroxybutan-2-yl)amino)nicotinamide (21); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- N-((S)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((4-hydroxybutan-2-yl)amino)nicotinamide (22); (S)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide (23); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxy cyclopentyl) amino)nicotinamide (24); diastereomer 1; 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxy cyclopentyl)amino)nicotinamide (25); diastereomer 2; 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-hydroxycyclopentyl)amino)nicotinamide (26);
diastereomer 3; 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-((3-hydroxycyclopentyl)amino)nicotinamide (27); diastereomer 4; (R)-6- (5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((( 1 - hydroxycyclobutyl)methyl)amino)nicotinamide (28); (R)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((oxetan-3 -ylmethyl)amino) nicotinamide (29); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3 -methylbutyl)-4-(((lR,2R)-2-hydroxycyclopentyl)amino)nicotinamide (30); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(cyclobutylamino)-N-(2-fluoro-3- hydroxy-3-methylbutyl)nicotinamide (31); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino) nicotinamide (32); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(ethylamino)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (33); (R)-6-(5-chloro-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (34); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-((2-hydroxy-2-methylpropyl)amino)nicotinamide (35); 6-(5-chloro-lH- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-4- yl)amino)nicotinamide (36); (R)-6-(5-chloro-lH-indol-l-yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)nicotinamide (37); (R)-6-(5-fluoro-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (38); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)-6-(7H-pyrrolo
[2,3-d]pyrimidin-7-yl)nicotinamide (39); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-6- (7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (40); (R)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(7H-pyrrolo [2,3-d]pyrimidin-7-yl)nicotinamide (41); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- ((2-hydroxy-2-methylpropyl)amino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (42); N-(3-hydroxy-3-methylbutyl)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tetrahydro- 2H-pyran-4-yl)amino)nicotinamide (43); N-(3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (44); (R)-6-(5- acetamido- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-
(isopropylamino)nicotinamide (45); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxyphenyl)amino)nicotinamide (46); 6-(5 - cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(3-isopropoxypropyl)-4-(isopropylamino) nicotinamide (47); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3- hydroxybutyl)-4-(isopropylamino)nicotinamide (48); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((2S)-2-fluoro-3-hydroxybutyl)-4-(isopropylamino)nicotinamide (49); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((3 -sulfamoylphenyl)amino)nicotinamide (50); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -methoxyphenyl)amino)nicotinamide (51); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-(((R)-2-fluoro-3-hydroxy-3-methylbutyl)amino)nicotinamide (52); (R)-6- (5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((3,3-difluorocyclobutyl)amino)-N-(2-fluoro- 3 -hydroxy-3 -methylbutyl)nicotinamide (53); (R)-4-((3-acetamidophenyl)amino)-6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)
nicotinamide (54); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-(methylcarbamoyl)phenyl)amino)nicotinamide (55); (R)-4- ((3-carbamoylphenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (56); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 - yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -(methylsulfonamido)phenyl)amino) nicotinamide (57); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-(4- sulfamoylphenethyl)nicotinamide (58); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-(2-hydroxypropan-2-yl)phenyl)amino) nicotinamide (59); (R)-4-((4-carbamoylphenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methy lbutyl)nicotinamide (60); 6-(5 -cyano- 1 H- pyrrolo[2,3-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((l s,4S)-4- hydroxy-4-methylcyclohexyl)amino)nicotinamide (61); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((tra/?5)-4-hydroxy-4- methylcyclohexyl)amino)nicotinamide (62); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- 4-(isopropylamino)-N-(2-(methylsulfonamido)ethyl)nicotinamide (63); (R)-4- (benzo[d]thiazol-6-ylamino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (64); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 - yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((( 1 -fluorocyclobutyl)methyl)amino) nicotinamide (65); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((3-cyanophenyl) amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (66); (R)-4-((4-(lH-l ,2,4- triazol-l-yl)phenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (67); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 - yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-(l -methyl- lH-tetrazol-5-yl)phenyl) amino)nicotinamide (68); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-((4-( 1 -methyl- 1 H-tetrazol-5 -yl)phenyl)amino)nicotinamide (69); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-((l,l-dioxidotetrahydrothiophen-3- yl)amino)-2-oxoethyl)-4-(isopropylamino)nicotinamide (70); (R)-6-(5 -cyano- 1H- pyrrolo[2,3-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3-
(hydroxymethyl)phenyl)amino)nicotinamide (71); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin- l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((2S)-3-fluorobutan-2-yl)amino) nicotinamide (72); N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-6-(5-cyano-lH- pyrrolo[2,3-b]pyridin- 1 -yl)-4-(isopropylamino)nicotinamide (73); (R)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(isopropylamino)-6-( 1 H-pyrrolo [2,3 -b]pyridin- 1 - yl)nicotinamide (74); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (75); (R)-6-(5-chloro-lH- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino) nicotinamide (76); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-((2-hydroxy-2-methylpropyl)amino)nicotinamide (77); 6-(5 - cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 - fluoropropan-2-yl)amino)nicotinamide (78); 6-(5 -cyano- lH-indo 1-1 -yl)-4-
(isopropylamino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (79); 6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-4-(isopropylamino)-N-((tra/?s)-4- (methylcarbamoyl)cyclohexyl)nicotinamide (80); 4-(isopropylamino)-N-((tra/?s)-4- (methylcarbamoyl)cyclohexyl)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (81); N- ((tra/75)-4-(methylcarbamoyl)cyclohexyl)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (82); N-((tra/?5)-4- acetamidocyclohexyl)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tetrahydro-2H-pyran-4- yl)amino)nicotinamide (83); N-((trans)-4-acetamidocyclohexyl)-4-(isopropylamino)-6- (7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (84); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(cyclopropylamino)-N-((tra/?5)-4-(methylcarbamoyl)cyclohexyl) nicotinamide (85); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/?5)-4- (methylcarbamoyl)cyclohexyl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (86); N-((tra/75)-4-acetamidocyclohexyl)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (cyclopropylamino)nicotinamide (87); N-((trans)-4-acetamidocyclohexyl)-6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (88); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(((S)-l-hydroxypropan-2-yl)amino)-N- ((lr,4S)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (89); 6-(5 -cyano- 1 H-pyrrolo
[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4-(isopropylcarbamoyl)cyclohexyl) nicotinamide (90); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/?5)-4- (cyclopropylcarbamoyl)cyclohexyl)-4-(isopropylamino)nicotinamide (91); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/75)-4-(ethylcarbamoyl)cyclohexyl)-4- (isopropylamino)nicotinamide (92); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((2- hydroxy-2-methylpropyl)amino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)
nicotinamide (93); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((2-hydroxy-2- methylpropyl)amino)-N-((tra/75)-4-((2H3)methylcarbamoyl)cyclohexyl)nicotinamide (94); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4- nitrocyclohexyl)nicotinamide (95); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((tra/75)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (96); methyl((tra/75)-4-(6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino) nicotinamido)cyclohexyl)carbamate (97); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((tra/75)-4-hydroxycyclohexyl)-4-(isopropylamino)nicotinamide (98); 6-(5-cyano-lH- pyrrolo[2,3-b]pyridin- 1 -yl)-N-((trans)-4-hydroxy-4-methylcyclohexyl)-4-
(isopropylamino)nicotinamide (99); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (ethylamino)-N-((tra/75)-4-(2-hydroxypropan-2-yl)cyclohexyl)nicotinamide (100); 6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-4-(isopropylamino)-N-((tra/75)-4-(methylthio) cyclohexyl)nicotinamide (101); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (isopropylamino)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl)nicotinamide (102); 6-(5- cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (103); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin-l-yl)-4-(cyclopropylamino)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl) nicotinamide (104); 4-((3-carbamoylphenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin-l-yl)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl)nicotinamide (105); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorotetrahydro-2H-pyran-4-yl)amino)nicotinamide (106); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -fluorotetrahydro-2H- pyran-4-yl)amino)nicotinamide (107); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((S)- 2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -fluorotetrahydro-2H-pyran-4-yl)amino) nicotinamide (108); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (109); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((S)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorocyclopentyl)amino)nicotinamide (110); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- 4-((3 ,3 -difluoro-2-hy droxy eye lohexyl)amino)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (111); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((3,3-difluoro-2- hydroxycyclohexyl)amino)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (112); N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((l-fluoropropan-2-yl)amino)-6-(7H- pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (113); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)- 1 -fluoropropan-2-yl)amino) nicotinamide (114); N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)-l-fluoropropan-2- yl)amino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (115); N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-(((S)-l-fluoropropan-2-yl)amino)-6-(7H-pyrrolo[2,3-d] pyrimidin-7-yl)nicotinamide (116); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)- 1 -fluoropropan-2-yl)amino)nicotinamide (117); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((R)-l-fluoropropan-2-yl)amino)nicotinamide (118); (S)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(( 1 -fluoropropan-2-yl)amino)-N-(3 -hydroxy-3 -methylbutyl)nicotinamide (119); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-4-((l -fluoropropan-2-yl)amino)-N- (3 -hydroxy-3 -methylbutyl)nicotinamide (120); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)-l-fluoropropan-2-yl)amino) nicotinamide (121); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(((S)-l -fluoropropan- 2-yl)amino)-N-((lr,4S)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (122); (R)-l-(4- (ethylamino)-5 -((2-fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)pyridin-2-yl)- 1 H- pyrrolo[2,3-b]pyridine-5-carboxamide (123); (R)-l-(4-(cyclobutylamino)-5-((2-fluoro-3- hydroxy-3 -methylbutyl)carbamoyl)pyridin-2-yl)- 1 H-pyrrolo [2,3 -b]pyridine-5 - carboxamide (124); l-((2-(6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino) nicotinamido)ethyl)amino)-2-methyl-l-oxopropan-2-yl acetate (125); 6-(5 -cyano- 1 H- pyrrolo[2,3-b]pyridin-l-yl)-N-(2-(2-hydroxy-2-methylpropanamido)ethyl)-4- (isopropylamino)nicotinamide (126); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- (2-fluoro-3-methoxypropyl)-4-(isopropylamino)nicotinamide (127); (R)-6-(5 -cyano- 1H- pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-methoxypropyl)-4-(isopropylamino) nicotinamide (128); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3- (isopropylamino)butyl)-4-(isopropylamino)nicotinamide (129); 6-(5 -cyano- 1 H-pyrrolo [2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3-(isopropylamino)butyl)-4-(isopropylamino) nicotinamide (130); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3 -methylbutyl)-4-((l-fluoro-3-hydroxypropan-2-yl)amino Nicotinamide (131); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(cyclopropylamino)-N-(2-fluoro-3- (methylamino)-3-oxopropyl)nicotinamide (132); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (133); (R)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(l H-pyrazolo [3,4-d]pyrimidin-l-yl)nicotinamide (134); (R)-6-(5-chloro-l H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino) nicotinamide (135); (R)-6-(5 -chloro-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- (cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (136); (R)-6-(5 - chloro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino Nicotinamide (137); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (ethylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (138); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (139); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4- (cyclopropylamino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (140); (R)- 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (141); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbuty l)-4-((tetrahydro-2H-pyran-3 - yl)amino)nicotinamide, diastereomer 1 (142); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-((S)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-3 -yl)amino) nicotinamide, diastereomer 2 (143); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(l H-pyrazolo [3, 4-d]pyrimidin-l-yl)nicotinamide (144); (R)-6-(5- cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(cyclobutylamino)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (145); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(3 - hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (146); (R)-6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((2,2,2- trifluoroethyl)amino)nicotinamide (147); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N- ((tra/75)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (148); (R)-N-(3-ethyl-2-fluoro-3-hydroxypentyl)-4-(isopropylamino)-6-(l H-pyrazolo [3, 4-d] pyrimidin- 1 -yl)nicotinamide (149); 6-(5-chloro- 1 H-pyrazolo[3 ,4-b]pyridin- 1 -yl)-N- ((tra/75)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (150); 6- (5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -y l)-N-(3 -hydroxy-3 -methylbutyl)-4-((tetrahydro- 2H-pyran-4-yl)amino)nicotinamide (151); 6-(5 -chloro- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)- 4-(isopropylamino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (152); (R)- N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(5 -hydroxy- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- (isopropylamino)nicotinamide (153); 6-(5 -chloro- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- (isopropylamino)-N-(2-morpholinoethyl)nicotinamide (154); (R)-N-(2-fluoro-3-hydroxy- 3 -methylbutyl)-4-(isopropylamino)-6-(5 -methyl- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)nicotinamide (155); (R)-4-(cyclopropylamino)-6-(5-fluoro-l H-pyrazolo [3, 4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (156); (R)-6-(5 -fluoro- 1 H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino) nicotinamide (157); (R)-6-(5-bromo-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (158); 6-(5 -cyano- 1 H- pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((tra/?s)-4- hydroxy cyclohexyl)amino)nicotinamide (159); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-4-(isopropylamino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (160); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N-((tra/?5)-4- (methylsulfonyl)cyclohexyl)nicotinamide (161); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- l-yl)-4-(isopropylamino)-N-((tra/75)-4-((2H3)methylcarbamoyl)cyclohexyl)nicotinamide (162); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-((4-fluorocyclohexyl)amino)nicotinamide (163); ~N-((trans)-4- acetamidocyclohexyl)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(isopropylamino) nicotinamide (164); N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-6-(5-cyano-lH- pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)nicotinamide (165); 6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4-(methylsulfonamido) cyclohexyl)nicotinamide (166); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2,2- difluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (167); (R)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)-6-(3 -(pyridazin-4-yl)- 1 H-pyrazol- 1 -yl)nicotinamide (168); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-((2,2- difluoro-3 -hydroxy-3 -methylbutyl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (169); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)-6- (9H-purin-9-yl)nicotinamide (170); (R)-6-(2-amino-9H-purin-9-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (171); (R)-N-(2-fluoro-3 - hydroxy-3-methylbutyl)-6-(2-((2-hydroxyethyl)amino)-9H-purin-9-yl)-4- (isopropylamino)nicotinamide (172); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((ls,4s)-4-hydroxy-4-(l-methyl-lH-pyrazol-5-yl)cyclohexyl)-4-(isopropylamino) nicotinamide (173); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-fluoro-4-(l- methyl-lH-pyrazol-5-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (174); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4-(thiazol-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (175); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((ls,4s)-4-hydroxy-4-(l-methyl-lH-imidazol-2-yl)cyclohexyl)-4-(isopropylamino) nicotinamide (176); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4- (pyridin-3-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (177); 6-(5-cyano-lH- pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4-(pyridin-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (178); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((1 s,4s)-4-hydroxy-4-(pyridin-4-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (179); 6- (5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-fluoro-4-(thiazol-2-yl)cyclohexyl)- 4-(isopropylamino)nicotinamide (180); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- (( 1 s,4s)-4-fluoro-4-( 1 -methyl- 1 H-imidazol-2-yl)cyclohexyl)-4-(isopropylamino) nicotinamide (181); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/75)-4-fluoro-4-(l- methyl-lH-imidazol-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (182); 6-(5- cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2,4-dioxo-l,3-diazaspiro[4.5]decan-8-yl)-4- (isopropylamino Nicotinamide (183); (S)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (isopropylamino)-N-(4-(pyridin-4-yl)cyclohex-3-en-l-yl)nicotinamide (184); (R)-6-(2- (dimethylamino)-7H-pyrrolo [2,3 -d]pyrimidin-7-yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)nicotinamide (185); (R)-6-(2-amino-7H-pyrrolo
[2,3-d]pyrimidin-7-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino) nicotinamide (186); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(2-((2-hy droxy-2- methylpropyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(isopropylamino)nicotinamide (187); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-6-(2-((2-hydroxyethyl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-4-(isopropylamino)nicotinamide (188); N-((R)-2-fluoro-3- hydroxy-3 -methylbutyl)-6-(2-((S)-3-hydroxypyrrolidin- 1 -yl)-7H-pyrrolo[2,3-d] pyrimidin-7-yl)-4-(isopropylamino)nicotinamide (189); N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)-6-(2-((R)-3-hydroxypyrrolidin-l-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4- (isopropylamino)nicotinamide (190); and (R)-4-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin- 1 -yl)-4-(isopropylamino)nicotinamido)-3 -fluoro-2-methylbutan-2-yl dihydrogen phosphate.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
Figure imgf000040_0001
wherein Ra is defined in the second aspect. Included in this embodiment are compounds in which Ra is -CI and -CN.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
Figure imgf000041_0001
wherein R2 is defined in the second aspect. Included in this embodiment are compounds in which R2 is C2-6 alkyl substituted with zero to three substituents independently selected from F and -OH. Also included in this embodiment are compounds in which R2 is an unsubstituted C2-5 alkyl.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
Figure imgf000041_0002
wherein Ri is defined in the second aspect. Included in this embodiment are compounds in which Ri is Ci_7 alkyl substituted with 1 to 3 substituents independently selected from F and -OH. Also included in this embodiment are compounds in which Ri is C2-6 alkyl substituted with one hydroxy group and zero to 2 fluorine substituents.
One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
Figure imgf000041_0003
One embodiment provides a compound of Formula (I) wherein said compound is:
Figure imgf000042_0001
One embodiment provides a compound of Formula (I) or a salt thereof, wherein said compound is:
Figure imgf000042_0002
The compound of this embodiment is a prodrug of the compound of Example 133.
ne embodiment provides a compound of Formula (I) wherein said compound is
Figure imgf000042_0003
or salts thereof.
One embodiment provides compounds of the Formula (I) having IRAK4 IC50 values of < 0.05 μΜ.
One embodiment provides compounds of the Formula (I) having IRAK4 IC50 values of < 0.025 μΜ.
One embodiment provides compounds of the Formula (I) having IRAK4 IC50 values of < 0.015 μΜ.
One embodiment provides compounds of the Formula (I) having IRAK4 IC50 values of < 0.01 μΜ. Crystal Forms
Table 1
Figure imgf000043_0001
In one embodiment, the compound of Example 133 is provided as a crystalline material comprising Form N-1. This crystalline form of the compound of Example 133 comprises a neat crystalline form referred to herein as "Form N-1" or "N-1 Form" of Example 133.
In one embodiment, the N-1 Form of the compound of Example 133 is characterized by unit cell parameters approximately equal to the following:
Cell dimensions:
a = 14.86 A
b = 5.41 A
c = 14.93 A
a = 90.0°
β = 115.7°
γ = 90.0°
Space group: P2i
Molecules of Example 133/asymmetric unit: 2
Volume/Number of molecules in the unit cell = 540 A3
Density (calculated) = 1.308 g/cm3,
wherein the unit cell parameters of Form N-1 are measured at a temperature of about 296 K.
In another embodiment, N-1 form of Example 133 is characterized by a simulated powder x-ray diffraction (PXRD) pattern substantially in accordance with the pattern shown in Figure 1.
In yet an even further embodiment, the N-1 Form of Example 133 is characterized by fractional atomic coordinates substantially as listed in Table 2. Table 2
Fractional Atomic Coordinates of Example 133, Form N-1 Calculated at 296 K;
Atomic Coordinates (xlO4)
Figure imgf000044_0001
Figure imgf000044_0002
In one embodiment, the compound of Example 133 is provided as a crystalline material comprising Form N-2. This crystalline form of the compound of Example 133 comprises a neat crystalline form referred to herein as "Form N-2" or "N-2 Form" of Example 133.
In one embodiment, the N-2 Form of the compound of Example 133 is characterized by unit cell parameters approximately equal to the following:
Cell dimensions:
a = 36.08 A
b = 6.72 A
c = 22.77 A
a = 90.0° β = 125.3°
γ = 90.0°
Space group: C2
Molecules of Example 133/asymmetric unit: 1
Volume/Number of molecules in the unit cell = 564 A3
Density (calculated) = 1.253 g/cm3,
wherein the unit cell parameters of Form N-2 are measured at a temperature of 296 K.
In another embodiment, N-2 form of Example 133 is characterized by a simulated powder x-ray diffraction (PXRD) pattern substantially in accordance with the pattern shown in Figure 2.
In yet an even further embodiment, the N-2 Form of Example 133 is characterized by fractional atomic coordinates substantially as listed in Table 3.
Table 3
Fractional Atomic Coordinates of Example 133, Form N-2 Calculated at 296 K;
Atomic Coordinates (xlO4)
Figure imgf000045_0001
Figure imgf000045_0002
Atom X Y Z Atom X Y Z
N(l l) 1661 1392 7750 C(40) 947 13730 10136
N(6) 862 8714 2813 C(30) 1613 -320 7396
N(5) 1824 20680 1906 C(13) 571 10240 2252
N(12) 1788 -4902 6863 C(27) 2844 2060 8946
C(5) 2021 10760 3742 C(9) 1623 16123 2405
C(26) 2003 5158 8719 C(20) 744 500 4695
C(2) 1619 7670 3846 C(41) 587 13000 10248
C(23) 1572 8313 8831 C(14) 111 10170 2215
C(10) 2127 14036 3267 C(15) 406 8980 1582
C(37) 1380 10080 8937 C(35) 150 5160 7282
C(22) 2046 8038 9257 C(42) 801 15490 9711
C(4) 1549 10770 3270 C(34) 520 5000 7392
C(31) 2073 1935 8208 C(21) 675 3310 5418
C(25) 1542 5270 8276 C(36) 559 5670 6860
C(16) 1367 5835 3877 C(39) 1052 12159 9792
C(l) 2059 7938 4272 F(2) 1227 10440 10251
C(19) 972 2360 5230 N(13) 880 6907 7894
DEFINITIONS
The features and advantages of the invention may be more readily understood by those of ordinary skill in the art upon reading the following detailed description. It is to be appreciated that certain features of the invention that are, for clarity reasons, described above and below in the context of separate embodiments, may also be combined to form a single embodiment. Conversely, various features of the invention that are, for brevity reasons, described in the context of a single embodiment, may also be combined so as to form sub-combinations thereof. Embodiments identified herein as exemplary or preferred are intended to be illustrative and not limiting.
Unless specifically stated otherwise herein, references made in the singular may also include the plural. For example, "a" and "an" may refer to either one, or one or more. As used herein, the phase "compounds" refers to at least one compound. For example, a compound of Formula (I) includes a compound of Formula (I) and two or more compounds of Formula (I).
Unless otherwise indicated, any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
The definitions set forth herein take precedence over definitions set forth in any patent, patent application, and/or patent application publication incorporated herein by reference.
Listed below are definitions of various terms used to describe the present invention. These definitions apply to the terms as they are used throughout the specification (unless they are otherwise limited in specific instances) either individually or as part of a larger group.
Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds.
In accordance with a convention used in the art, ^ is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.
The term "alkyl" as used herein, refers to both branched and straight-chain saturated aliphatic hydrocarbon groups containing, for example, from 1 to 12 carbon atoms, from 1 to 6 carbon atoms, and from 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4- methylpentyl. When numbers appear in a subscript after the symbol "C", the subscript defines with more specificity the number of carbon atoms that a particular group may contain. For example, "Ci_6 alkyl" denotes straight and branched chain alkyl groups with one to six carbon atoms.
The term "cycloalkyl", as used herein, refers to a group derived from a non- aromatic monocyclic or polycyclic hydrocarbon molecule by removal of one hydrogen atom from a saturated ring carbon atom. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When numbers appear in a subscript after the symbol "C", the subscript defines with more specificity the number of carbon atoms that a particular cycloalkyl group may contain. For example, "C3-C6 cycloalkyl" denotes cycloalkyl groups with three to six carbon atoms.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The compounds of Formula (I) can be provided as amorphous solids or crystalline solids. Lyophilization can be employed to provide the compounds of Formula (I) as amorphous solids.
It should further be understood that solvates (e.g., hydrates) of the compounds of Formula (I) are also within the scope of the present invention. The term "solvate" means a physical association of a compound of Formula (I) with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art.
Various forms of prodrugs are well known in the art and are described in:
a) Wermuth, C.G. et al., The Practice of Medicinal Chemistry, Chapter 31, Academic Press (1996);
b) Bundgaard, H. ed., Design of Prodrugs, Elsevier (1985);
c) Bundgaard, H., Chapter 5, "Design and Application of Prodrugs", A Textbook of Drug Design and Development, pp. 113-191, Krogsgaard-Larsen, P. et al, eds., Harwood Academic Publishers (1991); and
d) Testa, B. et al., Hydrolysis in Drug and Prodrug Metabolism, Wiley- VCH
(2003).
In addition, compounds of Formula (I), subsequent to their preparation, can be isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound of Formula (I) ("substantially pure"), which is then used or formulated as described herein. Such "substantially pure" compounds of Formula (I) are also contemplated herein as part of the present invention.
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The present invention is intended to embody stable compounds.
"Therapeutically effective amount" is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to act as an inhibitor to IRAK4, or effective to treat or prevent autoimmune and/or inflammatory disease states, such as multiple sclerosis and rheumatoid arthritis.
As used herein, "treating" or "treatment" cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease- state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e., arresting its development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state.
The compounds of the present invention are intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include 13C and 14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. For example, methyl (- CH3) also includes deuterated methyl groups such as -CD3.
Compounds in accordance with Formula (I) can be administered by any means suitable for the condition to be treated, which can depend on the need for site-specific treatment or quantity of Formula (I) compound to be delivered.
Also embraced within this invention is a class of pharmaceutical compositions comprising a compound of Formula (I) and one or more non-toxic, pharmaceutically- acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of Formula (I) may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compounds and compositions of the present invention may, for example, be administered orally, mucosally, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intrasternally in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. For example, the pharmaceutical carrier may contain a mixture of mannitol or lactose and microcrystalline cellulose. The mixture may contain additional
components such as a lubricating agent, e.g., magnesium stearate and a disintegrating agent such as crospovidone. The carrier mixture may be filled into a gelatin capsule or compressed as a tablet. The pharmaceutical composition may be administered as an oral dosage form or an infusion, for example.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. For example, the pharmaceutical composition may be provided as a tablet or capsule comprising an amount of active ingredient in the range of from about 0.1 to 1000 mg, preferably from about 0.25 to 250 mg, and more preferably from about 0.5 to 100 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, can be determined using routine methods.
Any pharmaceutical composition contemplated herein can, for example, be delivered orally via any acceptable and suitable oral preparations. Exemplary oral preparations, include, but are not limited to, for example, tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration can be prepared according to any methods known in the art for manufacturing pharmaceutical compositions intended for oral administration. In order to provide pharmaceutically palatable preparations, a pharmaceutical composition in accordance with the invention can contain at least one agent selected from sweetening agents, flavoring agents, coloring agents, demulcents, antioxidants, and preserving agents.
A tablet can, for example, be prepared by admixing at least one compound of Formula (I) with at least one non-toxic pharmaceutically acceptable excipient suitable for the manufacture of tablets. Exemplary excipients include, but are not limited to, for example, inert diluents, such as, for example, calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents, such as, for example, microcrystalline cellulose, sodium croscarmellose, corn starch, and alginic acid; binding agents, such as, for example, starch, gelatin, polyvinyl-pyrrolidone, and acacia; and lubricating agents, such as, for example, magnesium stearate, stearic acid, and talc. Additionally, a tablet can either be uncoated, or coated by known techniques to either mask the bad taste of an unpleasant tasting drug, or delay disintegration and absorption of the active ingredient in the gastrointestinal tract thereby sustaining the effects of the active ingredient for a longer period. Exemplary water soluble taste masking materials, include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl-cellulose. Exemplary time delay materials, include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.
Hard gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) with at least one inert solid diluent, such as, for example, calcium carbonate; calcium phosphate; and kaolin.
Soft gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) with at least one water soluble carrier, such as, for example, polyethylene glycol; and at least one oil medium, such as, for example, peanut oil, liquid paraffin, and olive oil.
An aqueous suspension can be prepared, for example, by admixing at least one compound of Formula (I) with at least one excipient suitable for the manufacture of an aqueous suspension. Exemplary excipients suitable for the manufacture of an aqueous suspension, include, but are not limited to, for example, suspending agents, such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl- cellulose, sodium alginate, alginic acid, polyvinyl-pyrrolidone, gum tragacanth, and gum acacia; dispersing or wetting agents, such as, for example, a naturally-occurring phosphatide, e.g., lecithin; condensation products of alkylene oxide with fatty acids, such as, for example, polyoxyethylene stearate; condensation products of ethylene oxide with long chain aliphatic alcohols, such as, for example heptadecaethylene-oxycetanol;
condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, such as, for example, polyoxyethylene sorbitol monooleate; and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, such as, for example, polyethylene sorbitan monooleate. An aqueous suspension can also contain at least one preservative, such as, for example, ethyl and n- propyl p-hydroxybenzoate; at least one coloring agent; at least one flavoring agent; and/or at least one sweetening agent, including but not limited to, for example, sucrose, saccharin, and aspartame.
Oily suspensions can, for example, be prepared by suspending at least one compound of Formula (I) in either a vegetable oil, such as, for example, arachis oil; olive oil; sesame oil; and coconut oil; or in mineral oil, such as, for example, liquid paraffin. An oily suspension can also contain at least one thickening agent, such as, for example, beeswax; hard paraffin; and cetyl alcohol. In order to provide a palatable oily suspension, at least one of the sweetening agents already described hereinabove, and/or at least one flavoring agent can be added to the oily suspension. An oily suspension can further contain at least one preservative, including, but not limited to, for example, an antioxidant, such as, for example, butylated hydroxyanisol, and alpha-tocopherol.
Dispersible powders and granules can, for example, be prepared by admixing at least one compound of Formula (I) with at least one dispersing and/or wetting agent; at least one suspending agent; and/or at least one preservative. Suitable dispersing agents, wetting agents, and suspending agents are as already described above. Exemplary preservatives include, but are not limited to, for example, anti-oxidants, e.g., ascorbic acid. In addition, dispersible powders and granules can also contain at least one excipient, including, but not limited to, for example, sweetening agents; flavoring agents; and coloring agents.
An emulsion of at least one compound of Formula (I) thereof can, for example, be prepared as an oil-in- water emulsion. The oily phase of the emulsions comprising compounds of Formula (I) may be constituted from known ingredients in a known manner. The oil phase can be provided by, but is not limited to, for example, a vegetable oil, such as, for example, olive oil and arachis oil; a mineral oil, such as, for example, liquid paraffin; and mixtures thereof. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Suitable emulsifying agents include, but are not limited to, for example, naturally-occurring phosphatides, e.g., soy bean lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as, for example, sorbitan
monooleate; and condensation products of partial esters with ethylene oxide, such as, for example, polyoxyethylene sorbitan monooleate. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. An emulsion can also contain a sweetening agent, a flavoring agent, a preservative, and/or an antioxidant. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art.
The compounds of Formula (I) can, for example, also be delivered intravenously, subcutaneously, and/or intramuscularly via any pharmaceutically acceptable and suitable injectable form. Exemplary injectable forms include, but are not limited to, for example, sterile aqueous solutions comprising acceptable vehicles and solvents, such as, for example, water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in- water microemulsions; and aqueous or oleaginous suspensions.
Formulations for parenteral administration may be in the form of aqueous or nonaqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (i.e., CAPTISOL®), cosolvent solubilization (i.e., propylene glycol) or micellar solubilization (i.e., Tween 80).
The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
A sterile injectable oil-in-water microemulsion can, for example, be prepared by 1) dissolving at least one compound of Formula (I) in an oily phase, such as, for example, a mixture of soybean oil and lecithin; 2) combining the Formula (I) containing oil phase with a water and glycerol mixture; and 3) processing the combination to form a microemulsion.
A sterile aqueous or oleaginous suspension can be prepared in accordance with methods already known in the art. For example, a sterile aqueous solution or suspension can be prepared with a non-toxic parenterally-acceptable diluent or solvent, such as, for example, 1,3-butane diol; and a sterile oleaginous suspension can be prepared with a sterile non-toxic acceptable solvent or suspending medium, such as, for example, sterile fixed oils, e.g., synthetic mono- or diglycerides; and fatty acids, such as, for example, oleic acid.
Pharmaceutically acceptable carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-alpha-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, polyethoxylated castor oil such as CREMOPHOR® surfactant (BASF), or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as alpha-, beta-, and gamma-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals. The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.
The amounts of compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex, the medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A daily dose of about 0.001 to 100 mg/kg body weight, preferably between about 0.0025 and about 50 mg/kg body weight and most preferably between about 0.005 to 10 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. Other dosing schedules include one dose per week and one dose per two day cycle.
For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered orally, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
Pharmaceutical compositions of this invention comprise at least one compound of Formula (I) and optionally an additional agent selected from any pharmaceutically acceptable carrier, adjuvant, and vehicle. Alternate compositions of this invention comprise a compound of the Formula (I) described herein, or a prodrug thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
The compounds of the invention modulate kinase activity, including the modulation of IRAK-4. Other types of kinase activity that may be modulated by the compounds of the instant invention include, but are not limited to, the Pelle/IRAK family and mutants thereof.
Accordingly, compounds of Formula (I) have utility in treating conditions associated with the modulation of kinase activity, and particularly the selective inhibition of IRAK-4 activity or the inhibition of IRAK and other Pelle family kinases. Such conditions include TLR/IL-1 family receptor associated diseases in which cytokine levels are modulated as a consequence of intracellular signaling. Moreover, the compounds of Formula (I) have advantageous selectivity for IRAK-4 activity, preferably from at least 20 fold to over 1,000 fold more selective.
As used herein, the terms "treating" or "treatment" encompass the treatment of a disease state in a mammal, particularly in a human, and include: (a) preventing or delaying the occurrence of the disease state in a mammal, in particular, when such mammal is predisposed to the disease state but has not yet been diagnosed as having it; (b) inhibiting the disease state, i.e., arresting its development; and/or (c) achieving a full or partial reduction of the symptoms or disease state, and/or alleviating, ameliorating, lessening, or curing the disease or disorder and/or its symptoms.
In view of their activity as selective inhibitors IRAK-4, compounds of Formula (I) are useful in treating TLR/IL-1 family receptor associated diseases, but not limited to, inflammatory diseases such as Crohn's disease, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease; autoimmune diseases such as Graves' disease, rheumatoid arthritis, systemic lupus erythematosis, psoriasis; auto-inflammatory diseases including CAPS, TRAPS, FMF, adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis; metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma- related bone disorder; proliferative disorders such as acute myelogenous leukemia, chronic myelogenous leukemia; angiogenic disorders such as angiogenic disorders including solid tumors, ocular neovasculization, and infantile haemangiomas; infectious diseases such as sepsis, septic shock, and Shigellosis; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury, oncologic and viral diseases such as metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HIV infection and CMV retinitis, AIDS, respectively.
More particularly, the specific conditions or diseases that may be treated with the inventive compounds include, without limitation, pancreatitis (acute or chronic), asthma, allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic β-cell disease; diseases characterized by massive neutrophil infiltration; rheumatoid spondylitis, gouty arthritis and other arthritic conditions, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, keloid formation, scar tissue formation, ulcerative colitis, pyresis, influenza, osteoporosis, osteoarthritis, acute myelogenous leukemia, chronic
myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, sepsis, septic shock, and Shigellosis; Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury; angiogenic disorders including solid tumors, ocular neovasculization, and infantile haemangiomas; viral diseases including acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis, AIDS, ARC or malignancy, and herpes; stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hypoxia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia and/or toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris. Preferred methods of treatment are those wherein the condition is selected from Crohn's disease, ulcerative colitis, allograft rejection, rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and pemphigus vulgaris. Alternatively preferred methods of treatment are those wherein the condition is selected from ischemia reperfusion injury, including cerebral ischemia reperfusions injury arising from stroke and cardiac ischemia reperfusion injury arising from myocardial infarction. Another preferred method of treatment is one in which the condition is multiple myeloma.
In addition, the kinase inhibitors of the present invention inhibit the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also referred to as cyclooxygenase-2 (COX-2), IL-1, IL-6, IL-18, chemokines. Accordingly, additional IRAK-4-associated conditions include edema, analgesia, fever and pain, such as neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain. The inventive compounds also may be used to treat veterinary viral infections, such as lentivirus infections, including, but not limited to equine infectious anemia virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, and canine immunodeficiency virus.
In view of their activity as selective inhibitors of IRAK-4, the compounds of Formula (I) are useful in treating cancers associated with the MyD88 L265P mutation, including but not limited to, activated B cell-like subset of diffuse large B cell lymphoma (ABC-DLBCL); ref: Ngo, V.N. et al, Nature, 470: 115-119 (2011); Waldenstrom's macroglobulinemia (WM); ref: Treon, S.P. et al, N. Engl. J. Med., 367:826-833 (2012); chronic lymphocytic leukemia (CLL); cutaneous diffuse large B cell lymphoma; and primary central nervous system lymphoma; ref: Wang, J.Q. et al., Frontiers Immunol., 5:367-377 (2014).
The compounds of Formula (I) are useful in treating cancers associated the overexpression of TLR2/activated IRAKI including myelodysplastic syndrome (MDS); ref: Rhyasen, G.W. et al, Cancer Cell, 24:90-104 (2013). When the terms "IRAK-4-associated condition" or "IRAK-4 -associated disease or disorder" are used herein, each is intended to encompass all of the conditions identified above as if repeated at length, as well as any other condition that is affected by IRAK-4 kinase activity.
The present invention thus provides methods for treating such conditions, comprising administering to a subject in need thereof a therapeutically-effective amount of at least one compound of Formula (I) or a salt thereof. "Therapeutically effective amount" is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination to inhibit IRAK-4 and/or treat diseases.
The methods of treating IRAK-4 kinase-associated conditions may comprise administering compounds of Formula (I) alone or in combination with each other and/or other suitable therapeutic agents useful in treating such conditions. Accordingly, "therapeutically effective amount" is also intended to include an amount of the combination of compounds claimed that is effective to inhibit IRAK-4 and/or treat diseases associated with IRAK-4.
Exemplary of such other therapeutic agents include corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, PROGRAF®); anti-malarials such as hydroxychloroquine; cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-a inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or RAPAMUNE®) or derivatives thereof.
The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians ' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art. In the methods of the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the
administration of the inventive compounds. The present invention also provides pharmaceutical compositions capable of treating IRAK-4 kinase-associated conditions, including TLR and IL-1 family receptor mediated diseases as described above.
METHODS OF PREPARATION
The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.
The reactions and techniques described in this section are performed in solvents appropriate to the reagents and materials employed and are suitable for the
transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents that are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene et al. {Protective Groups in Organic Synthesis, Third Edition, Wiley and Sons (1999)).
Compounds of the general Formula (I) can be prepared according to the method outlined in Scheme 1. Hydrolysis of ester (1) to the acid 1.1 followed by reaction with an amine using standard amide bond forming conditions can afford the dichloro amide 1.2. Selective displacement of the C4 chloride by reacting with an amine can afford the mono- chloro product 1.3. Reaction of 1.3 with an appropriate heterocyclic nucleophile, in the presence of a catalyst, such as palladium, can afford compounds of the general formula I. heme 1
Figure imgf000061_0001
Alternatively, the order of reactions can be modified to change the overall synthesis to allow for variations at different positions of the molecule at different stages of the preparation. For example, in Scheme 2, the chloride 1 may be reacted with an amine first to form the mono-chlorinated ester 2.1. Subsequent reaction with a heterocyclic nucleophile, may form the disubstituted intermediate 2.2. Hydrolysis of the ester to acid 2.3 followed by amide bond formation can afford the final analog 2.4.
Scheme 2
Figure imgf000062_0001
An additional variation on the order of substitution is shown in Scheme 3. First, reacting the dichloride with an amine may afford compound 3.1. Hydrolysis of the ester with a base, such as NaOH or KOH, may afford the acid 3.2. This acid may be reacted with an amine using standard amide bond forming reaction conditions, such as HOBt, EDC and DIPEA, in an appropriate solvent to form the amide 3.3, similar to amide 1.3 in Scheme 1. Subsequent heterocyclic amine coupling in the presence of a metal catalyst such as palladium, may afford the final compound 3.4.
Scheme 3
Figure imgf000062_0002
Another variation involves the synthesis of a differentially halogenated pyridine core to allow for variation of the HNR3R4 substituent at the last stage of the synthesis. 6- Bromo-4-choronicotinic acid may be reacted with a halogenating reagent, such as oxalyl chloride, to afford the acid chloride 4.1. This may be further reacted with an amine in the presence of a base, such as DIPEA or TEA, in an appropriate solvent, such as DCM, to afford the amide 4.2. Amide 4.2 may be reacted with a heterocyclic amine in the presence of a metal catalyst, such as Pd, in a solvent to afford compound 4.3. Finally, compound 4.3 may be reacted with an amine in the presence of a base at elevated temperature to afford compound 4.4.
Scheme 4
Figure imgf000063_0001
It should be also noted, and obvious to those skilled in the art, that synthetic manipulations of the incorporated R1, R2, and R3 groups is possible. An illustrative example is shown in Scheme 5. The secondary alcohol incorporated in compound 5.1 may be converted to the fluoro analog 5.2 upon treatment with a fluorinating reagent, such as DAST, in an appropriate solvent, such as DCM. Other functionalities than an alcohol may be present for subsequent functionalization. For example, nitro groups can be converted readily to amines and subsequently functionalized, and esters can be readily converted to acids, amides or heterocycles. Additionally, aryl or heteroaryl groups incorporated into compound 5.3 may be converted, through standard chemical manipulations, to analogs of varying degrees of substitution. For example, when Y is nitro, the functionality may be converted to an amine under standard reducing conditions and further functionalized as an amide (Z is NHCOCH3) or sulfonamide (Z is
NHSO2CH3). The order of synthetic manipulations, of course, may be carried out in a fashion that is consistent with the methods outlined in Schemes 1-3 and should not be limited to the final step of the example preparation.
Scheme 5
Figure imgf000064_0001
Additionally, variations to the R1 group can be made via functionalization after incorporating onto the pyridine scaffold. For example, in Scheme 6, an appropriately protected amine, sulfide or ester may be coupled to the pyridine acid 6.1 via standard amide bond forming conditions to form 6.2. Compound 6.2 may be further manipulated (amine deprotection/functionalization; sulfide oxidation; ester hydrolysis/amide or heterocycle formation) to form compounds of the general formula 6.3.
heme 6
Figure imgf000065_0001
Substitution on the heterocyclic substituent may be accomplished via the methods outlined in Scheme 7. Preparation of an appropriately functionalized precursor, such as compound 7.1 (Rx is a functional group such as an amine, ester or halogen), and reaction with a variety of reagents, such as amines, aryl cross coupling partners, cyanide may form compounds of the formula 9.2 (Rx). For example, compound 7.3 may be converted to compound 7.4 via reaction with an aldehyde in the presence of a reducing agent.
Scheme 7
Figure imgf000065_0002
EXAMPLES
Compounds of the current invention, and intermediates used in the preparation of compounds of the current invention, can be prepared using procedures shown in the following examples and related procedures. The methods and conditions used in these examples, and the actual compounds prepared in these examples, are not meant to be limiting, but are meant to demonstrate how the compounds of the current invention can be prepared. Starting materials and reagents used in these examples, when not prepared by a procedure described herein, are generally either commercially available, or are reported in the chemical literature, or may be prepared by using procedures described in the chemical literature. The invention is further defined in the following Examples. It should be understood that the Examples are given by way of illustration only. From the above discussion and the Examples, one skilled in the art can ascertain the essential
characteristics of the invention, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the invention to various uses and conditions. As a result, the invention is not limited by the illustrative examples set forth herein below, but rather defined by the claims appended hereto.
In the Examples given, the phrase "dried and concentrated" generally refers to drying of a solution in an organic solvent over either sodium sulfate or magnesium sulfate, followed by filtration and removal of the solvent from the filtrate (generally under reduced pressure and at a temperature suitable to the stability of the material being prepared).
Column chromatography was performed with pre-packed silica gel cartridges using an Isco medium pressure chromatography apparatus (Teledyne Corporation), eluting with the solvent or solvent mixture indicated. Preparative high performance liquid chromatography (HPLC) was performed using a reverse phase column (Waters SunFire Ci8, Waters XBridge Ci8, PHENOMENEX® Axia Ci8, YMC S5 ODS or the like) of a size appropriate to the quantity of material being separated, generally eluting with a gradient of increasing concentration of methanol or acetonitrile in water, also containing 0.05% or 0.1% trifluoroacetic acid or 10 mM ammonium acetate, at a rate of elution suitable to the column size and separation to be achieved. Chemical names were determined using CHEMDRAW® Ultra, version 9.0.5 (CambridgeSoft). The following abbreviations are used: BrettPhos = 2-(dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropyl-l , -biphenyl BrettPhos precatalyst = [2-(2-aminoethyl)phenyl](chloro)palladium; dicyclohexyl({3,6- dimethoxy-2-[2,4,6-tris(propan-2-yl)phenyl]phenyl})phosphane
Bn = benzyl
(BOC)20 = di(tert-butoxycarbonyl) ether
BOP = benzotriazol-l-yloxytris-(dirnethylamino)-phosphonium hexafluorophosphate brine = saturated aqueous sodium chloride
DAST = (diethylamino)sulfur trifluoride
DCM = dichloromethane
DIPEA = N,N-diisopropylethylamine
DMA = N,N-dimethylacetamide
DMF = N,N-dimethylformamide
DMSO = dimethyl sulfoxide
Et = ethyl
EtOAc = ethyl acetate
EtOH = ethanol
g = gram(s)
h = hour(s)
HATU = 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
LCMS = Liquid Chromatography-Mass Spectroscopy
MeCN = acetonitrile
MeOH = methanol
MTBE = methyl t-butyl ether
NaHC03 (aq) = saturated aqueous sodium bicarbonate
n-BuLi = n-butyl lithium
NH4OAc = ammonium acetate
Pd2(dba)3 = tris-(dibenzylideneacetone)dipalladium
PyBOP = bromotripyrrolidinophosphonium hexafluorophosphate
t-BuOH = tert-butanol
TEA = triethylamine
TFA = trifiuoroacetic acid THF = tetrahydrofuran
Xantphos = 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene HPLC Conditions:
Method A: SunFire C18 (4.6xl50mm), 3.5 μ, Mobile Phase A: 95:5 water/MeCN,
0.05% TFA; Mobile Phase B: 95:5 MeCN/water, 0.05% TFA; 1 mL/min, 12 min gradient.
Method B: XBridge Phenyl (4.6x150mm), 3.5 μ, Mobile Phase A: 95:5 water/MeCN, 0.05% TFA; Mobile Phase B: 95:5 MeCN/water, 0.05% TFA; 1 mL/min, 12 min gradient.
Method C: Ascentis Express C18 (2.1x50mm), 2.7 μ, Mobile Phase A: 95:5 water/MeCN, 10 mM NH4OAc; Mobile Phase B: 5:95 water/MeCN, 10 mM NH4OAc; 1.1 mL/min, 3 min gradient, 50 °C.
Method D: Ascentis Express C18 (2.1x50mm), 2.7 μ, Mobile Phase A: 95:5 water/MeCN, 0.01% TFA; Mobile Phase B: 5:95 water/MeCN, 0.01% TFA; 1.1 mL/min, 3 min gradient, 50 °C.
Method E: Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7 μ; Mobile Phase A: 5:95 MeCN:water with 10 mM ammonium acetate; Mobile Phase B: 95:5
MeCN:water with 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
Method F: Column: Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7 μ; Mobile Phase A: 5:95 MeCN:water with 0.1%> trifluoroacetic acid; Mobile Phase B: 95:5
MeCN:water with 0.1% trifluoroacetic acid; Temperature: 50 °C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.
Method G: Ascentis Express CI 8 (4.6x50mm), 2.7 μ, Mobile Phase A: 95:5 water/MeCN, 10 mM NH4OAc; Mobile Phase B: 5:95 water/MeCN, 10 mM NH4OAc; 4 mL/min, 4 min gradient, 50 °C.
Method H: Ascentis Express C18 (2.1x50mm), 2.7 μ, Mobile Phase A: 95:5 water/MeCN, 0.1% TFA; Mobile Phase B: 5:95 water/MeCN, 0.1% TFA; 1.1 mL/min, 3 min gradient, 50 °C. Method I: Column: Waters Acquity UPLC BEH CI 8, 2.0 x 50 mm, 1.7 μ; Mobile Phase A: 10:90 MeCN:water with 0.1% trifluoroacetic acid; Mobile Phase B: 90: 10 MeCN:water with 0.1 %> trifluoroacetic acid; Temperature: 40 °C; Gradient: 0-100%> B over 1.5 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min; Detection: UV at 220 nm.
Method J: Column: Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, 1.7 μ; Mobile Phase A: 100% water with 0.05% trifluoroacetic acid; Mobile Phase B: 100% MeCN with 0.05%) trifluoroacetic acid; Temperature: 40 °C; Gradient: 20-100%) B over 1.8 minutes, then a 0.2-minute hold at 100% B; Flow: 0.8 mL/min; Detection: UV at 220 nm.
Intermediate 1
Ethyl 6-chloro-4- c clo ro lamino nicotinate
Figure imgf000069_0001
To a solution of ethyl 4,6-dichloronicotinate (50 g, 227 mmol) in DMA (500 mL) were added DIPEA (39.7 mL, 227 mmol) and cyclopropyl amine (17.6 mL, 250 mmol). The mixture was heated at 90 °C for 5 h. The reaction mixture was quenched into crushed ice with stirring. The resulting slurry was stirred and filtered to afford the crude product (42 g, 91%> yield) which was used without further purification. LCMS m/z 241.1 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ 8.54 (s, 1H), 8.09 (s, 1H), 7.03 (s, 1H), 4.29 (q, J= 7.2 Hz, 2H), 2.61 (m, 1H), 1.31 (t, J= 7.2 Hz, 3H), 0.86 (m, 2H), 0.58 (m, 2H).
Intermediate 2
6-Chloro- -(cyclopropylamino)nicotinic acid
Figure imgf000069_0002
To a solution of ethyl 6-chloro-4-(cyclopropylamino)nicotinate (2 g, 8.31 mmol) in EtOH (14 mL), was added LiOH»H20 (1.02 g, 25 mmol) and water (6 mL, 8.31 mmol). The reaction mixture was stirred at room temperature for 1 h. The solvents were removed in vacuo and the pH adjusted to 3-4 with 1.5 N HCl. The resulting solid was filtered and dried to afford 6-chloro-4-(cyclopropylamino)nicotinic acid (1.5 g, 82% yield) as a white solid. LCMS m/z 213.2 (M+H)+.
Intermediate 3
Ethyl 6-chloro-4-(((l S)-3 -hydroxy cyclohexyl)amino)nicotinate
Figure imgf000070_0001
Intermediate 1-3 was prepared according to the general procedure for Example 5, Step 1 using ethyl 4,6-dichloronicotinate and (3S)-3-aminocyclohexanol. LC/MS:
ZORBAX® SB C18, 4.6 x 50mm, 5μιη; Solvent A = 10% MeOH: 90% H20: 0.1% TFA; Solvent B = 90% MeOH: 10% H20: 0.1% TFA; gradient 0-100% B over 2 min (3 min run time); retention time: 1.65 min; LCMS (ES-API), m/z 299.0 (M+H).
Intermediate 4
6-Chloro-4-((l S)-3 -hydroxy eye lohexylamino)nicotinic acid
Figure imgf000070_0002
Intermediate 1-4 was prepared according to the general procedure for Example 5, Step 3 using 6-chloro-4-(3-hydroxycyclohexylamino)nicotinate. LC/MS: ZORBAX® SB C18, 4.6 x 50mm, 5μιη; Solvent A = 10% MeOH: 90% H20: 0.1% TFA; Solvent B = 90% MeOH: 10% H20: 0.1% TFA; gradient 0-100% B over 2 min (3 min run time); retention time: 1.095 min; LCMS (ES-API), m/z 271.0 (M+H).
Intermediate 5
6-Chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((lS)-3- hydroxycyclohexylamino)nicotinamide
Figure imgf000071_0001
Intermediate 1-5 was prepared according to the general procedure for Example 5, Step 4, using (R)-4-amino-3-fluoro-2-methylbutan-2-ol and 6-chloro-4-((lS)-3- hydroxycyclohexylamino)nicotinic acid.
Intermediate 6
Ethyl 6-chlor -4-((l S)-3-fluorocyclohexylamino)nicotinate
Figure imgf000071_0002
A solution of ethyl 6-chloro-4-((3-hydroxycyclohexyl)amino)nicotinate (0.3 g, 1 equiv.) in DCM (10 mL) was cooled to -78 °C and the mixture was stirred for 5 min.
XtalFluor-E (1.2 equiv.) was added to the reaction mixture. After completion of addition the reaction mixture was stirred for 5 min. The reaction mixture was quenched with saturated solution of NH4C1 at -78 °C and extracted with DCM (twice). The organic layers were collected together, dried over anhydrous sodium sulfate and concentrated. The crude material obtained was purified via column chromatography (EtOAc: pet ether) to afford ethyl 6-chloro-4-((lS)-3-fluorocyclohexylamino)nicotinate. LC/MS:
ZORBAX® SB C18, 4.6 x 50mm, 5μιη; Solvent A = 10% MeOH: 90% H20: 0.1% TFA; Solvent B = 90% MeOH: 10% H20: 0.1% TFA; gradient 0-100% B over 2 min (3 min run time); retention time: 1.981 min; LCMS (ES-API), m/z 301 (M+H).
Intermediate 7
6-Chloro-4-((l -3-fluorocyclohexylamino)nicotinic acid
Figure imgf000071_0003
Intermediate 1-7 was prepared according to the general procedure for Example 5, Step 3 using 6-chloro-4-((lS)-3-fluorocyclohexylamino)nicotinate. LC/MS: ZORBAX® SB C18, 4.6 x 50mm, 5μιη; Solvent A = 10% MeOH: 90% H20: 0.1% TFA; Solvent B = 90% MeOH: 10% H20: 0.1% TFA; gradient 0-100% B over 2 min (3 min run time); retention time: 1.393 min; LCMS (ES-API), m/z 273.0 (M+H).
Intermediate 8
6-Chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((lS)-3- fluorocyclohexylamino)nicotinamide
Figure imgf000072_0001
)
Intermediate 8 was prepared according to the general procedure for Example 5, Step 4, using (R)-4-amino-3-fluoro-2-methylbutan-2-ol and 6-chloro-4-((lS)-3- fluorocyclohexylamino)nicotinic acid.
Intermediate 9
Ethyl 6-chloro-4-(( 1 R,2R)-2-hydroxycyclopentylamino)nicotinate
Figure imgf000072_0002
Intermediate 9 was prepared according to the general procedure for Example 5, Step 1 using ethyl 4,6-dichloronicotinate and (lR,2R)-2-aminocyclopentanol. LC/MS: Ascentis Express C18, 5 x 2.1mm, 2.7 μιη; Solvent A = 2% ACN: 98% H20: 10 mM NH4COOH; Solvent B = 98% ACN: 2% H20: 10 mM NH4COOH; gradient 0-100% B over 1.5 min; retention time: 1.786 min; LCMS (ES-API), m/z 285.2 (M+H).
Intermediate 10
6-Chloro-4-((( 1 R,2R)-2-hydroxycyclopentyl)amino)nicotinic acid
Figure imgf000073_0001
Ethyl 6-chloro-4-(((lR,2R)-2-hydroxycyclopentyl)amino)nicotinate (1.3 g, 4.57 mmol) in THF (10 mL), MeOH (4 mL) and water (2 mL) was added LiOH (0.328 g, 13.7 mmol) and the mixture was stirred at room temperature for 18 h. The organic layer was evaporated and the pH of the crude mixture was adjusted to 6 with 1.5N HC1 to precipitate the crude acid. The solids were filtered and dried under vacuum to afford 6- chloro-4-(((lR,2R)-2-hydroxycyclopentyl)amino)nicotinic acid (0.95 mg, 81% yield). LCMS (ES-API), m/z 257 '.4 (M+H).
Intermediate 1 1
6-Chloro-N-((R)-2-fiuoro-3-hydroxy-3-methylbutyl)-4-(((lR,2R)-2- hydroxycyclopentyl)amino)nicotinamide
Figure imgf000073_0002
a solution of 6-chloro-4-(((lR,2R)-2-hydroxycyclopentyl)amino)nicotinic acid (900 mg, 3.51 mmol) in DMF (10 mL) and (R)-4-amino-3-fluoro-2-methylbutan-2-ol (425 mg, 3.51 mmol) were added HATU (1333 mg, 3.51 mmol) and DIPEA (0.612 mL, 3.51 mmol). The reaction mixture was allowed to stir for 18 h at room temperature. The DMF was removed under vacuum and the crude mass was diluted with water and extracted with ethyl acetate. The ethyl acetate layer was washed with NaHCOs, then dried and concentrated to give 1.4 g crude mass which was purified by column chromatography (CHCl3:MeOH:9.5/0.5) to provide the product. LCMS m/z 360.5 (M+H).
Intermediate 12
Ethyl 6-chloro-4-(( 1 R)-2-fluorocyclopentylamino)nicotinate
Figure imgf000074_0001
A solution of ethyl 6-chloro-4-(((2S)-2-hydroxycyclopentyl)amino)nicotinate (1.0 g, 1 equiv.) in DCM (15 mL) was cooled to 0 °C. DAST (0.7 mL, 1.5 equiv.) was added dropwise. The reaction mixture was stirred overnight at room temperature. The reaction mixture was again cooled to 0 °C and quenched with 10% NaHC03 solution. The product was extracted in DCM. The aqueous layer was washed with DCM (twice). The organic extracts were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by flash column chromatography using silica gel and EtOAc: pet ether to obtain the desired product. LC/MS: Ascentis Express CI 8, 5 x 2.1mm, 2.7 μιη; Solvent A = 2% ACN: 98% H20: lOmM NH4COOH; Solvent B = 98% ACN: 2% H20: lOmM NH4COOH; gradient 0-100% B over 1.5min; retention time: 2.013 min; LCMS (ES-API), m/z 287.2 (M+H).
Intermediate 13
(R)-Ethyl 6-chloro-4- 2-oxocyclopentylamino)nicotinate
Figure imgf000074_0002
To a solution of ethyl 6-chloro-4-(((2S)-2-hydroxycyclopentyl)amino)nicotinate (0.5 g, 1 equiv.) in DCM (20 mL) was added Dess-Martin Periodinane (2.98 g, 4 equiv.). The reaction mixture was stirred at room temperature for 10 min. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate and filtered through a bed of CELITE®. The filtrate was concentrated. The crude product was purified by flash column chromatography using silica gel and EtOAc: pet ether to obtain the desired product. LC/MS: Ascentis Express CI 8, 5 x 2.1mm, 2.7 μιη; Solvent A = 2% ACN: 98% H20: lOmM NH4COOH; Solvent B = 98% ACN: 2% H20: lOmM NH4COOH; gradient 0-100% B over 1.5min; retention time: 1.863min; LCMS (ES-API), m/z 283.2 (M+H). Intermediate 14
(R)-Ethyl 6-chloro-4- 2,2-difluorocyclopentylamino)nicotinate
Figure imgf000075_0001
Ethyl 6-chloro-4-((2-oxocyclopentyl)amino)nicotinate (0.57 g, 1 equiv.) in DCM (10 mL) was cooled to 0 °C. DAST (0.67 mL, 2.5 equiv.) was added dropwise to the reaction mixture and allowed to stir overnight at room temperature. The reaction mixture was diluted with DCM, quenched with 10% NaHC03 at 0 °C. The organic layer was collected, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by flash column chromatography using silica gel and EtOAc: pet ether to obtain the desired product. LC/MS: PUROSPHER® Star RP-18, 4 x 55 mm, 3 μιη; Solvent A = 10% ACN: 90% H20: 20mM NH4OAc; Solvent B = 90% ACN: 10% H20: 20 mM NH4COOAc; gradient 0-100% B over 1.5min (3.2min run time); retention time: 2.017min; LCMS (ES-API), m/z 305 (M+H).
Intermediate 15
Ethyl 6-chlor -4-((l S)-3 -hydroxy cyclopentylamino)nicotinate
Figure imgf000075_0002
Intermediate 15 was prepared from 3-aminocyclopentanol and ethyl 4,6- dichloronicotinate following the standard procedures outlined in Example 5. LC/MS: Acquity BEH CI 8 2.1 x 50mm, 1.8 μ; Solvent A = 0.1% TFA in water; Solvent B = 0.1% TFA in ACN; gradient 0-100% B over 2 min; retention time: 0.70 min; LCMS (ES-API), m/z 285.1 (M+H).
Intermediate 16 Ethyl 6-chlo -4-((l S)-3-fluorocyclopentylamino)nicotinate
Figure imgf000076_0001
Intermediate 16 was prepared from the reaction of ethyl 6-chloro-4-(3- hydroxycyclopentylamino)nicotinate and DAST according to the methods outlined for the preparation of ethyl 6-chloro-4-((lR)-2-fluorocyclopentylamino)nicotinate. LC/MS:
XBridge Phenyl, 4.6 x 30mm, 3.5μιη; Solvent A = 2% ACN: 98% H20: 10 mM
NH4COOH; Solvent B = 98% ACN: 2% H20: 10 mM NH4COOH; gradient 0-100% B over 1.5 min (3.2 min run time); retention time: 1.165 min; LCMS (ES-API), m/z 287.0 (M+H).
Intermediate 17
(S)-Ethyl 6-chloro-4-(( 1 -hydroxypropan-2-yl)amino)nicotinate
Figure imgf000076_0002
To a stirred solution of ethyl 4,6-dichloronicotinate (1.0 g, 4.54 mmol) in DMA (5 mL) were added DIPEA (2.381 mL, 13.63 mmol) and (S)-2-aminopropan-l-ol (0.424 mL, 5.45 mmol). The reaction mixture was stirred for 3 h at 100 °C, cooled to room temperature and the solvents removed in vacuo. The residue was added to water and extracted with ethyl acetate. The organic solution was dried over anhydrous Na2S04, filtered, and concentrated. The product was purified via column chromatography to afford (S)-ethyl 6-chloro-4-((l-hydroxypropan-2-yl)amino)nicotinate (1.1 g, 93% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 8.53 (s, 1 H) 8.22 (d, J=8.03 Hz, 1 H) 8.20-8.24 (m, 1 H) 6.87 (s, 1 H) 6.85-6.88 (m, 1 H) 4.97-4.97 (m, 1 H) 4.99 (t, J=5.27 Hz, 1 H) 4.30 (q, J=7.03 Hz, 1 H) 4.26-4.33 (m, 2 H) 3.73-3.82 (m, 1 H) 3.39-3.52 (m, 2 H) 1.29-1.34 (m, 3 H) 1.16 (m, 3 H); LCMS 259.3 (M+H)+.
Intermediate 18 (S)-Ethyl 6-chloro-4-((l -fluoropropan-2-yl)amino)nicotinate
Figure imgf000077_0001
To a stirred solution of (S)-ethyl-6-chloro-4-((l-hydroxypropan-2-yl)amino) nicotinate (2 g, 7.73 mmol) in THF (15 niL) at -78 °C was added DAST (2.55 mL, 19.33 mmol). The reaction mixture was then allowed to warm to room temperature and stirred overnight. The reaction was quenched with 10% aq NaHC03 and extracted with EtOAc. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to afford the crude material which was purified via column chromatography to afford the product (1.2 g, 60% yield). LCMS 261.0 (M+H)+.
Intermediate 19
(S)-6-Chloro-4-((l -fluoropropan-2-yl)amino)nicotinic acid
Figure imgf000077_0002
To a solution of (S)-ethyl 6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinate (1.3 g, 4.99 mmol) in ethanol (10 mL), was added LiOH (0.615 g, 14.96 mmol) and water (3 mL, 4.99 mmol). The reaction mixture was stirred at room temperature for 1 h. TLC showed absence of starting material. The mixture was concentrated and acidified to a pH of 3-4 using 1.5 N HC1. The resulting solid was filtered to afford (S)-6-chloro-4-((l- fluoropropan-2-yl)amino)nicotinic acid (1.0 g, 41% yield) as an off-white solid. LCMS 233.2 (M+H)+.
Intermediate 20
6-Chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((S)-l-fluoropropan-2- yl)amino)nicotinamide
Figure imgf000078_0001
To as solution of (S)-6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinic acid (0.650 g, 2.79 mmol) in DMF (6 mL) were added DIPEA (1.952 mL, 11.18 mmol), (R)- 4-amino-3-fiuoro-2-methylbutan-2-ol (0.406 g, 3.35 mmol) and HATU (1.062 g, 2.79 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate. The combined organic extracts was washed with 10% sodium bicarbonate, dried over sodium sulfate and concentrated. The crude material was purified via column chromatography to afford 6- chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)- 1 -fluoropropan-2-yl)amino) nicotinamide (0.4 g, 42% yield) as a pale yellow oil. LCMS 336.2 (M+H)+.
Intermediate 21
(R)-6-Chloro-N-(2,3-difluoro-3-methylbutyl)-4-(isopropylamino)nicotinamide
Figure imgf000078_0002
To a solution of (R)-6-chloro-N-(2-fluoro-3-hydroxyl-3-methylbutyl)-4-
(isopropylamino)nicotinamide (250 mg, 0.79 mmol) in DCM (10 mL) at -40 °C were added DAST (0.21 mL, 1.57 mmol). The reaction was allowed to warm to room temperature slowly. The reaction was stirred at room temperature for 30 min then quenched with MeOH and concentrated. The crude product was purified by column chromatography using 0-40% EtOAc in hexane to afford (R)-6-chloro-N-(2,3-difluoro-3- methylbutyl)-4-(isopropylamino)nicotinamide (80 mg, 29% yield) as a white solid. 1H NMR (400MHz, DMSO-d6) δ 8.86 (d, J=5.5 Hz, 1H), 8.41 (m, 1H), 6.73 (s, 1H), 4.60 (m, 1H), 3.70 (m, 2H), 3.39 (m, 1H), 1.44 (s, 3H), 1.38 (S, 3H), 1.19 (s, 3H), 1.17 (s, 3H). Intermediate 22
3 -Vinyloxetan-3 -ol
Figure imgf000079_0001
In a dry flask, under a nitrogen atmosphere, a stirring solution of oxetan-3-one (2.1 g, 29.1 mmol) in anhydrous THF (100 mL) was cooled to 0 °C, and treated dropwise with vinylmagnesium bromide (1M in THF) (50 mL, 50.0 mmol) at a rate which maintained an internal temperature below 10 °C. The reaction mixture was stirred for 10 minutes, then allowed to warm to room temperature and stirred for 2 hours. The reaction mixture was poured into saturated ammonium chloride (200 mL). The mixture was stirred for 5 minutes, the layers were separated, and the aqueous phase was extracted 4x with diethyl ether (75 mL). The combined organic phases were dried over sodium sulfate, and concentrated in vacuo to yield 3-vinyloxetan-3-ol (2.66 g, 26.6 mmol, 91% yield) as a pale yellow oil, which was used as-is in the next step. 1H NMR (400MHz, chloroform-d) δ 6.31 (dd, J=17.4, 10.8 Hz, 1H), 5.44 (dd, J=17.4, 0.7 Hz, 1H), 5.29 (dd, J=10.8, 0.7 Hz, 1H), 4.70 (q, J=7.0 Hz, 4H), 2.31 (s, 1H). Intermediate 23
;nzyloxy)-3 -vinyloxetane
Figure imgf000079_0002
A stirring solution of 3-vinyloxetan-3-ol (1.0 g, 9.99 mmol) in anhydrous THF (50 mL) was cooled to 5 °C and treated with sodium hydroxide (60% in mineral oil) (0.799 g, 19.98 mmol). The mixture was stirred at 5 °C for 1 hour, then treated with benzyl bromide (2.495 mL, 20.98 mmol) and tetrabutyl ammonium iodide (0.369 g, 0.999 mmol). The reaction mixture was allowed to slowly come to room temperature, and was stirred for 18 hours, at which point it was judged to be complete by TLC (3 : 1
hexanes/ethyl acetate; UV/KMnC ). About half of the THF was evaporated via rotary evaporator, and the remaining solution was poured into saturated ammonium chloride. The turbid mixture was extracted three times with diethyl ether, then the combined ether phases were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was chromatographed via MPLC over an 80 g silica gel column, eluting at 60 mL/min with 5% to 25% acetone/hexanes over 10 column volumes. Fractions containing the desired product were pooled and concentrated in vacuo to yield 3-(benzyloxy)-3- vinyloxetane (1.58 g, 8.31 mmol, 83% yield. 1H NMR (400MHz, chloroform-d) δ 7.45- 7.29 (m, 5H), 6.14 (dd, J=17.6, 10.8 Hz, 1H), 5.54 (dd, J=17.6, 0.7 Hz, 1H), 5.49 (dd, J=10.9, 0.8 Hz, 1H), 4.81 (d, J=7.0 Hz, 2H), 4.65 (d, J=7.3 Hz, 2H), 4.42 (s, 2H).
Intermediate 24
Lz loxy)-3-(oxiran-2-yl)oxetane
Figure imgf000080_0001
A stirring solution of 3-(benzyloxy)-3-vinyloxetane (3.13 g, 16.45 mmol) in dichloromethane (50 mL) was cooled to 5 °C and treated with m-CPBA (8.11 g, 36.2 mmol). The reaction mixture was allowed to slowly come to room temperature, heated at reflux for 1 hour, then cooled to room temperature and stirred for 42 hours, at which point it was judged to be complete by LCMS. The mixture was cooled to 5 °C and treated with half-saturated sodium bisulfite (150 mL). The mixture was allowed to come to room temperature and stirred for 30 minutes, then most of the DCM was evaporated via rotary evaporator. The resulting heterogeneous mixture was extracted 3x with ethyl acetate (30 mL), then the combined organic phases were washed 3x with saturated sodium
bicarbonate and once with brine, then dried over sodium sulfate and concentrated in vacuo to yield 3-(benzyloxy)-3-(oxiran-2-yl)oxetane (3.32 g, 16.10 mmol, 98%> yield). 1H NMR (400MHz, chloroform-d) δ 7.45-7.30 (m, 5H), 4.75 (d, J=6.6 Hz, 1H), 4.68 (d, J=6.6 Hz, 1H), 4.66 (d, J=2.4 Hz, 1H), 4.60-4.54 (m, 1H), 4.48 (d, J=6.6 Hz, 1H), 4.40 (d, J=7.3 Hz, 1H), 3.35 (dd, J=3.6, 2.8 Hz, 1H), 3.00-2.95 (m, 1H), 2.94-2.90 (m, 1H).
Intermediate 25
2-Azido-l- 3-(benzyloxy)oxetan-3-yl)ethanol
Figure imgf000080_0002
A mixture of 3-(benzyloxy)-3-(oxiran-2-yl)oxetane (3.7 g, 17.94 mmol) and sodium azide (1.749 g, 26.9 mmol) in acetone/water (1 : 1) (40 mL) was stirred at room temperature for 60 hours. Most of the acetone was evaporated, and the remainder of the reaction mixture was treated with saturated ammonium chloride (20 mL). The turbid solution was extracted 3x with dichloromethane (30 mL), and the combined aqueous phases were washed once with water and once with brine, then dried over sodium sulfate and concentrated in vacuo. The residue was chromatographed via MPLC over a 40 g silica gel column, eluting at 40 mL/min with a 5% to 50% methylene chloride/hexanes gradient over 12 column volumes. Fractions containing the desired product were pooled and concentrated in vacuo to yield 2-azido-l-(3-(benzyloxy)oxetan-3-yl)ethanol (2.31 g, 9.27 mmol, 51.7% yield) as an amber oil. 1H NMR (400MHz, chloroform-d) δ 7.45-7.31 (m, 5H), 4.94-4.81 (m, 4H), 4.79 (d, J=7.7 Hz, 1H), 4.68-4.63 (m, 1H), 4.22-4.09 (m, 1H), 3.55-3.50 (m, 2H), 2.38 (d, J=6.6 Hz, 1H).
Intermediate 26
3- 2-Azido- 1 -fluoroethyl)-3-(benzyloxy)oxetane
Figure imgf000081_0001
A stirring solution of 2-azido-l-(3-(benzyloxy)oxetan-3-yl)ethanol (1.2 g, 4.81 mmol) in anhydrous dichloromethane (30 mL) was cooled to -78 °C and treated with diethylaminosulfur trifluoride (1.209 mL, 9.15 mmol). The mixture was stirred at -78 °C for 2 hours, then allowed to come to room temperature and stirred for 42 hours. The reaction mixture was poured into stirring, ice-cold saturated sodium carbonate solution (200 mL), and the mixture was stirred for 30 minutes. The layers were separated, the aqueous phase was extracted twice with dichloromethane (50 mL), and the combined organic phases were dried over sodium sulfate and concentrated in vacuo. The residue was chromatographed via MPLC over a 80 g silica gel column, eluting at 60 mL/min with a 5% to 30% acetone/hexanes gradient over 10 column volumes. Fractions containing the product were pooled and concentrated in vacuo to yield 3-(2-azido-l-fluoroethyl)-3- (benzyloxy)oxetane (0.65 g, 2.59 mmol, 53.7% yield) as a colorless oil. 1H NMR (400MHz, chloroform-d) δ 7.46-7.31 (m, 5H), 5.04-4.82 (m, 5H), 4.81-4.74 (m, 1H), 4.63 (d, J=7.5 Hz, 1H), 3.70 (ddd, J=19.6, 13.6, 7.0 Hz, 1H), 3.58-3.43 (m, 1H). The enantiomers were resolved by supercritical fluid chromatography using the following conditions: Instrument: Thar Preparative SFC-350; Column: CHIRALPAK® AD
(5x25cm, 5μιη); BPR pressure: 100 bars; Temperature: 30 °C; Flow rate: 270 mL/min; Mobile Phase: C02/MeOH (87/13); Detector Wavelength: 212 nm; Separation Program: Sequence injection; Injection: 0.90 mL with cycle time 3.25 min. The separation yielded: First-eluting isomer: 3-(2-azido-l-fluoroethyl)-3-(benzyloxy)oxetane, Isomer 1 (0.25 g, 1.00 mmol, 77% yield); Second-eluting isomer: 3-(2-azido-l-fluoroethyl)-3- (benzyloxy)oxetane, Isomer 2 (0.19 g, 0.73 mmol, 53% yield).
Intermediate 27
fert-Butyl (2-fluoro-2-(3 -hydroxyoxetan-3 -yl)ethyl)carbamate
Figure imgf000082_0001
A Parr bottle was charged with 20% palladium hydroxide on carbon (100 mg, 0.142 mmol) under nitrogen, and the catalyst was wetted with methanol. The vessel was charged with a solution of 3-(2-azido-l-fluoroethyl)-3-(benzyloxy)oxetane, Isomer 2 (122 mg, 0.486 mmol) in methanol (5 mL) and BOC-anhydride (0.135 mL, 0.583 mmol), and the mixture was degassed by thrice evacuating the vessel under vacuum and
repressurizing with nitrogen. The mixture was hydrogenated at 50 psi for 9 hours, at which point the reaction was judged to be complete by LCMS. The catalyst was removed by filtration and thoroughly rinsed with methanol. The combined filtrate and rinsings were concentrated in vacuo to yield tert- vXyl (2-fluoro-2-(3-hydroxyoxetan-3-yl)ethyl) carbamate, Isomer 2 (135 mg, 0.574 mmol, 118%) yield) as a slightly yellow oil, which was used as-is in the next step. 1H NMR (400MHz, chloroform-d) δ 4.96 (bd, J=7.3 Hz, 1H), 4.89 (d, J=5.7 Hz, 1H), 4.76-4.67 (m, 2H), 4.66-4.48 (m, 3H), 3.77-3.58 (m, 1H), 3.45 (tdd, J=15.8, 6.2, 4.2 Hz, 1H), 1.47 (s, 9H).
Intermediate 28
3-(2-Amino-l-fluoroethyl)oxetan-3-ol, TFA salt
Figure imgf000083_0001
(I-28-isomers 1 and 2)
A solution of tert-butyl (2-fluoro-2-(3-hydroxyoxetan-3-yl)ethyl)carbamate, Intermediate 27, isomer 2 (0.6 g, 2.55 mmol) in anhydrous methylene chloride (3 mL) was cooled to 5 °C and treated with TFA (3 mL, 38.9 mmol). The reaction mixture was stirred at 5 °C for 1 hour, at which point it was judged to be complete by TLC. The mixture was concentrated in a vacuum, and the residue was concentrated once from 1 : 1 DCM/toluene (10 mL), then twice from DCM (10 mL) to remove residual TFA. The residue was dried under vacuum for 3 hours to yield 3-(2-amino-l-fluoroethyl)oxetan-3- ol, isomer 2, TFA (0.66 g, 2.65 mmol, 104% yield) as a colorless oil. 1H NMR (400MHz, methanol-d4) δ 5.11-4.94 (m, 1H), 4.75 (d, J=7.0 Hz, 1H), 4.66-4.58 (m, 3H), 3.30-3.23 (m, 1H).
Intermediate 29
l,6-Dioxaspiro[2.5]octane-2-carbonitrile
Figure imgf000083_0002
(1-29)
To a mixture of dihydro-2H-pyran-4(3H)-one (2.5 g, 25 mmol) and 2- chloroacetonitrile (1.89 g, 25 mmol) was added a solution of potassium tert-butoxide in tert-butanol (1.0 M, 25 mL) dropwise. The reaction mixture was stirred overnight and quenched with water (50 mL). The mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with water and brine, then dried over magnesium sulfate, filtered and concentrated. The crude product was purified via column chromatography (10-60% ethyl acetate/pet ether) to afford l,6-dioxaspiro[2.5]octane-2-carbonitrile (2.9 g, 83% yield) as a yellow oil. 1H NMR (400 MHz, CDC13) δ 3.95-3.80 (m, 4H), 3.35 (s, 1H), 2.18-2.01 (m, 1H), 1.96-1.76 (m, 2H), 1.67-1.50 (m, 1H).
Intermediate 30
4-(2-Aminoethyl)tetrahydro-2H-pyran-4-ol
Figure imgf000084_0001
A mixture of l,6-dioxaspiro[2.5]octane-2-carbonitrile (3.0 g, 22 mmol) and 10% Pd on carbon (0.3 g) in methanol (40 mL) was stirred for 2 h under a hydrogen balloon. The mixture was filtered through a pad of CELITE® and the filtrate was concentrated. The residue was dissolved in THF (50 mL). The solution was added dropwise to a mixture of lithium aluminum hydride (1.6 g, 43 mmol) and THF (100 mL), and the mixture was stirred for 2 hours at reflux temperature. After cooling to 0 °C, Na2S04- 10H2O (16 g) and KF (2.5 g) were added and the mixture was stirred overnight. After filtration, the filtrate was concentrated, and the residue was acidified with 4N HCl in 1 ,4- dioxane. The mixture was concentrated and the residue was crystallized from ethanol- ether. The precipitate was filtered to afford 4-(2-aminoethyl)tetrahydro-2H-pyran-4-ol
(2.1 g, 67% yield) as a HCl salt. 1H NMR (400 MHz, CDC13) δ 3.94-3.65 (m, 6H), 2.57 (s, 2H), 1.95-1.51 (m, 6H).
Intermediate 31
6-Chloro-N-(2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethyl)-4- (isopropylamino)nicotinamide
Figure imgf000084_0002
To a solution of 6-chloro-4-(isopropylamino)nicotinic acid (0.1 g, 0.47 mmol) in DMF (1 mL), were added HOBt (0.7 g, 0.51 mmol) and EDC (0.1 g, 0.51 mmol). The mixture was stirred at room temperature for 0.5 h and then 4-(2-aminoethyl)tetrahydro- 2H-pyran-4-ol hydrochloride (0.09 g, 0.49 mmol) and DIPEA (0.17 mL, 0.978 mmol) were added. The mixture was stirred for 2 h, quenched with water, stirred, and filtered to give 6-chloro-N-(2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethyl)-4-(isopropylamino) nicotinamide (67 mg, 42%> yield) as a off-white solid.
Intermediate 32
4-Nitro- 1 -(oxetan-3-yl)- 1 H-pyrazole
Figure imgf000085_0001
To a stirred solution of 4-nitro-lH-pyrazole (4 g, 35 mmol) in THF (80 mL) were added oxetan-3-ol (2.9 g, 39 mmol), triphenylphosphine (11.1 g, 42 mmol), and di-tert- butyl azodicarboxylate (10.6 g, 46 mmol) at 0 °C. The mixture was stirred at room temperature for 16 h. The reaction mixture was then concentrated to give crude product. The product was purified via column chromatography to afford 4-nitro-l-(oxetan-3-yl)- lH-pyrazole (4.4 g, 74% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 1H), 8.41 (s, 1H), 5.65 (m, 1H), 4.91 (m, 4H).
Intermediate 33
1 -(Ox tan-3-yl)- 1 H-pyrazol-4-amine
Figure imgf000085_0002
To a solution of 4-nitro-l-(oxetan-3-yl)-lH-pyrazole (4.4 g, 26 mmol) in MeOH (80 mL) was added Pc/C (2.77 g, 2.6 mmol) and the mixture was degassed by evacuating the vessel under vacuum and repressurizing with hydrogen. The mixture was hydrogenated under balloon pressure. After TLC indicated completion of the reaction, the mixture was degassed, and the reaction mixture was filtered under nitrogen through fiberglass filter paper. The filter cake was thoroughly rinsed with methanol (300 mL total rinse volume), and the combined filtrate and rinsings were concentrated in vacuo to obtain l-(oxetan-3-yl-lH-pyrazole-4-amine (3.4 g, 94% yield). 1H NMR (400 MHz, DMSO-de) δ 7.16 (s, 1H), 7.04 (s, 1H), 5.35 (m, 1H), 4.81 (m, 4H), 3.88 (br s, 2H).
Intermediate 34
(R)-4-Amino-3-fluoro-2-meth lbutan-2-ol
Figure imgf000085_0003
Figure imgf000086_0001
Step 1 : To a solution of K2C03 (34.8 g, 2 equiv.) in DMF (280 niL), L-serine methyl ester hydrochloride (1 equiv.), potassium iodide (10.8 g, 0.5 equiv.) and benzyl bromide (38 mL, 2.5 equiv.) were added. The mixture was stirred for 16 h at room temperature. The reaction mixture was concentrated under reduced pressure to remove excess of DMF and then diluted with EtOAc. The organic layer was washed with brine and water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography through silica gel (EtOAC: pet ether as eluent) to afford methyl 2-(dibenzylamino)-3- hydroxypropanoate. 1H NMR: 400 MHz, DMSO-d6: δ 2.49 (s, 1H), 3.58-3.59 (m, 1H), 3.67-3.70 (m, 2H), 3.73-3.75 (m, 2H), 3.77-3.80 (m, 3H), 3.90-3.94 (m, 2H), 7.24-7.38 (m, 10H).
Figure imgf000086_0002
Step 2: To an ice cool solution of methyl 2-(dibenzylamino)-3- hydroxypropanoate (15 g, 1 equiv.) in THF (95 mL), DAST (13.1 mL, 1.23 equiv.) was added dropwise under N2-atmosphere and the reaction mixture was stirred for 14 h at room temperature. The reaction mixture was quenched with aqueous 10% NaHC03 solution at 0 °C and extracted into ethyl acetate (twice). The organic layers were collected, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by flash column chromatography using silica gel and EtOAc: pet ether to afford (R)-methyl 3-(dibenzylamino)-2-fluoropropanoate. 1H NMR: 400 MHz, CDC13: δ 2.93-3.11 (m, 2H), 3.51-3.55 (m, 2H), 3.70 (s, 3H), 3.82-3.85 (m, 2H), 4.98- 5.13 (m, 1H), 7.22-7.34 (m, 10H).
Figure imgf000086_0003
Step 3: (R)-Ethyl 3-(dibenzylamino)-2-fluoropropanoate was prepared according to the method as described for the synthesis of (R)-methyl 3-(dibenzylamino)-2- fluoropropanoate.
Figure imgf000087_0001
Step 4: To a solution of (R)-ethyl 3-(dibenzylamino)-2-fluoropropanoate (15 g, 1 equiv.) in THF (150 mL), methyl magnesium bromide (3M in diethyl ether) (15 mL, 2.5 equiv.) was added dropwise at 0 °C under N2 atm. The reaction mixture was slowly allowed to attain room temperature and stirred for 1 h. The reaction mixture was quenched with saturated aqueous ammonium chloride at 0 °C and extracted into ethyl acetate (twice). The organic layers were collected, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by flash column
chromatography using silica gel and EtOAc: pet ether to afford (R)-4-(dibenzylamino)-3- fhioro-2-methylbutan-2-ol. 1H NMR: 400 MHz, DMSO-d6: δ 0.92-0.92 (m, 3H), 0.98- 0.98 (m, 3H), 2.53-2.94 (m, 2H), 3.51-3.81 (m, 4H), 4.34-4.46 (m, 1H), 4.80 (s, 1H), 7.22-7.40 (m, 10H).
Figure imgf000087_0002
Step 5: To a solution of (R)-4-(dibenzylamino)-3-fluoro-2-methylbutan-2-ol (44 g, 146 mmol) in MeOH (400 mL) was added Pd/C (3.11 g, 29.2 mmol) and PdOH2 (2.05 g, 14.6 mmol) and the mixture was evacuated and backfilled with H2 gas and stirred for 18 h. The reaction mixture was filtered through CELITE® using 500 mL of methanol and the filterate was concentrated to afford (R)-4-amino-3-fluoro-2-methylbutan-2-ol (16.8 g, 95% yield). 1H NMR: 400 MHz, DMSO-d6: δ 1.06 (s, 3H), 1.10 (s, 3H), 2.64- 2.91 (m, 2H), 3.96-4.16 (m, 1H).
Example 1
(R)-6-(5-Cyano-lH-indol-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide
Figure imgf000088_0001
Figure imgf000088_0002
Step 1 : To a solution of ethyl 4,6-dichloronicotinate (10 g, 45 mmol) in DMA (40 mL) was added propan-2-amine (5.3 g, 91 mmol) and DIPEA (31.7 mL, 182 mmol). The reaction mixture was stirred at room temperature for 48 h. The reaction mixture was diluted with MTBE and washed water (3x). The organic layer was dried over Na2S04, filtered and concentrated to afford the crude product. The product was purified by flash chromatography through silica gel (10% EtOAc:pet ether as eluent) to afford ethyl 6- chloro-4-(isopropylamino)nicotinate (8.3 g, 75% yield) as a crystalline solid. LCMS m/z 243 (M+H); 1H NMR (400 MHz, DMSO-d6) δ 8.54 (s, 1H), 7.98 (d, J = 7.6 Hz, 1H), 6.85 (s, 1H), 4.29 (q, J = 7.2 Hz, 2H), 3.86 (m, 1H), 1.32 (d, J = 6.8 Hz, 3H), 1.20 (s, 3H), 1.19 (s, 3H).
Figure imgf000088_0003
Step 2: To a solution of ethyl 6-chloro-4-(isopropylamino)nicotinate (7 g, 28.8 mmol) in EtOH (70 mL) was added water (30 mL) and LiOH (2. lg, 87 mmol). The mixture was stirred for 3 h, concentrated and acidified with 1.5 N HCl. The resultant solids were collected and dried to afford 6-chloro-4-(isopropylamino)nicotic acid (5.3 g, 85% yield) as a white solid. LCMS 215.3 (M+H)+; 1H NMR (400 MHz, DMSO-d6) δ 13.32 (br s, 1H), 8.51 (s, 1H), 8.19 (d, J=7.6 Hz, 1H), 6.79 (s, 1H), 2.50 (m, 1H), 1.20 (s, 3H), 1.18 (s, 3H).
Figure imgf000089_0001
Step 3: To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (2.9 g, 13.51 mmol) in DMF was added (R)-4-amino-3-fluoro-2-methylbutan-2-ol (1.637 g, 13.51 mmol), HATU (6.16 g, 16.21 mmol), and DIPEA (9.44 mL, 54.0 mmol). The reaction mixture was stirred for 18 h. The reaction mixture was diluted with ethyl acetate and washed with water (3x). The organic layer was dried over Na2S04 and concentrated to provide the crude compound which was purified via column chromatography (10-40% ethyl acetate/pet ether) to afford (R)-6-chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide (2.8 g, 65%> yield) as an off-white solid. LCMS 318.1 (M+H): 1H NMR (400 MHz, DMSO-d6) δ 8.75 (t, J = 7.6 Hz, 1H), 8.44 (br d, J = 10.4 Hz, 1H), 8.38 (s, 1H), 6.71 (s, 1H), 4.24 (m, 1H), 3.64 (m, 2H), 3.42 (m, 1H), 1.16 (m, 12H).
Example 1 :
To a solution of (R)-6-chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-
(isopropylamino)nicotinamide (100 mg, 0.315 mmol) and lH-indole-5-carbonitrile (44.7 mg, 0.315 mmol) in 1,4-dioxane (5 mL) was added Cs2C03 (308 mg, 0.944 mmol) and Xantphos (72.8 mg, 0.126 mmol). The reaction vessel was purged with N2 for 20 mins then added Pd2(dba)3 (115 mg, 0.126 mmol) and again purged for 5 mins. The vessel was heated in a sealed tube at 110 °C for 18 h. The reaction mixture was cooled to room temperature, filtered through CELITE®, and diluted with EtOAc (50 mL). The crude mixture was washed with water (10 mL) and brine (10 mL) then dried over Na2S04. The filtered solution was concentrated to give the crude compound which was purified via silica gel chromatography (50% EtOAc in hexane) to afford (R)-6-(5-cyano-lH-indol-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (20 mg, 15% yield). LCMS 424.2 (M+H)+; 1H-NMR (400 MHz, DMSO-d6) δ 8.75 (t, J= 5.60 Hz, 1H), 8.62 (s, 1H), 8.57 (d, J= 8.00 Hz, 1H), 8.52 (d, J= 8.80 Hz, 1H), 8.26 (d, J= 3.60 Hz, 1H), 8.19 (d, J= 1.20 Hz, 1H), 7.62 (dd, J= 1.60, 8.80 Hz, 1H), 6.87-6.89 (m, 2H), 4.84 (s, 1H), 4.37 (ddd, J= 2.00, 9.20, 49.20 Hz, 1H), 3.95-4.00 (m, 1H), 3.62-3.78 (m, 1H), 3.40-3.45 (m, 1H), 1.23 (d, J = 6.00 Hz, 6H), 1.18 (d, J = 6.80 Hz, 6H); LC/MS: 424.2 (M+H); HPLC rt 9.47 min, Conditions A.
The Examples in Table 4 were prepared using the methods outlined for Example 1 using the appropriate starting material and amine. The absolute stereochemistry of the diastereomers was undetermined.
Table 4
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Example 79
ano- 1 H-indol- 1 -yl)-4-(isopropylamino)-N-((tra/?s)- (methylcarbamoyl)cyclohexyl)nicotinamide
Figure imgf000103_0002
Step 1 : To a stirred solution of (trans)-4-((tert-butoxycarbonyl)amino) cyclohexanecarboxylic acid (250 mg, 1.03 mmol), PyBOP (535 mg, 1.03 mmol) and Hunig's Base (0.538 mL, 3.08 mmol) in DMF (5 mL) at 25 °C was added methanamine, HCl (104 mg, 1.541 mmol). After 2 hours, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (3x). The organic layer was dried over Na2S04 and concentrated to provide tert-butyl ((trans)-4-(methylcarbamoyl)cyclohexyl)carbamate (250 mg, 85% yield) of white solids as product. LCMS (TFA) 201.1 (M+H-t-butyl)+.
Step 2: To a stirred solution of tert-butyl ((trans)-4-(methylcarbamoyl) cyclohexyl)carbamate (250 mg, 0.975 mmol) in dioxane (5 mL) at 25 °C was added 4N HCl in dioxane (2.438 mL, 9.75 mmol). The reaction mixture was stirred for 3 hours then was concentrated from methylene chloride (5x) to provide (trans)-4-amino-N- methylcyclohexanecarboxamide, HCl (150 mg, 71.8% yield) as a tan solid.
Figure imgf000104_0001
Step 3 : To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (100 mg, 0.466 mmol), PyBOP (242 mg, 0.466 mmol) and Hunig's Base (0.244 mL, 1.398 mmol) in DMF (3 mL) at 25 °C was added (trans)-4-amino-N- methylcyclohexanecarboxamide, HCl (90 mg, 0.466 mmol). After 1 hour, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (3x). The organic layer was dried over Na2S04 and concentrated to provide 6-chloro-4-(isopropylamino)-N- ((tra/75)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (130 mg, 71.2% yield) of off- white solids.
Step 4: To a stirred solution of 6-chloro-4-(isopropylamino)-N-((tra/?s)-4- (methylcarbamoyl)cyclohexyl)nicotinamide (20 mg, 0.057 mmol) in 6: 1 tert-butanol/ DMA (1 mL) at room temperature was added lH-indole-5-carbonitrile (8.06 mg, 0.057 mmol), and K2CO3 (23.50 mg, 0.170 mmol). The reaction vessel was purged with N2 for 5 mins then added BrettPhos precatalyst (2.264 mg, 2.83 μιηοΐ) and again purged for 5 mins. The vessel was heated in a microwave tube at 150 °C for 40 min. The reaction mixture was cooled to room temperature. The reaction mixture was filtered, then the filtrate was concentrated and purified via preparative HPLC to provide 6-(5-cyano-lH- indol-l-yl)-4-(isopropylamino)-N-((tran5)-4-(methylcarbamoyl)cyclohexyl)nicotinamide, 2 TFA (11 mg, 28%) of white solids. 1H NMR (400 MHz, DMSO-d6) δ 1H NMR
(500MHz, methanol-d4) δ 8.25 (s, 1H), 7.84-7.79 (m, 2H), 7.54 (d, J=3.5 Hz, 1H), 7.38 (s, 1H), 7.30 (d, J=9.9 Hz, 1H), 6.61 (d, J=3.5 Hz, 1H), 6.47 (s, 1H), 3.70-3.55 (m, 2H), 3.09 (dt, J=3.3, 1.5 Hz, 3H), 1.98-1.89 (m, 1H), 1.89-1.82 (m, 2H), 1.71 (d, J=12.4 Hz, 2H), 1.40 (qd, J=13.0, 3.0 Hz, 2H), 1.18 (qd, J=12.6, 3.2 Hz, 2H), 1.10 (d, J=6.4 Hz, 6H). LCMS 458.55 (M+H)+. HPLC rt 1.72 min, Conditions E. The Examples in Table 5 were prepared using the general method outlined for
Example 79 using the appropriate starting material and amine.
Table 5
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Example 101
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4- (methylthio)cyclohexyl)nicotinamide
Figure imgf000109_0001
Step 1 : To a stirred solution of tert-butyl ((ls,4s)-4-hydroxycyclohexyl) carbamate (1.00 g, 4.64 mmol) and triethylamine (3.24 mL, 23.22 mmol) in CH2CI2 (10 mL) at 0 °C were added methanesulfonyl chloride (0.543 mL, 6.97 mmol) dropwise. The mixture was stirred at 0 °C for 15 min then diluted with water. The layers were separated and the organic layer was rinsed with saturated sodium bicarbonate (lx) followed by brine (lx). The organic layer was dried over Na2S04 and concentrated to provide (ls,4s)- 4-((tert-butoxycarbonyl)amino)cyclohexyl methanesulfonate (3.20 g, 89% yield) as a light amber solid. LCMS (TFA) 238.0 (M+H-t-butyl)+.
Figure imgf000109_0002
Step 2: To a stirred solution of (ls,4s)-4-((tert-butoxycarbonyl)amino)cyclohexyl methanesulfonate (3.20 g, 10.91 mmol) in DMF (40 mL) at room temperature was added potassium thioacetate (1.869 g, 16.36 mmol). The reaction mixture was heated at 80 °C behind a safety shield for 7 hours, then at room temperature for 48 hours. The reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (2x), saturated ammonium chloride (lx), saturated sodium bicarbonate (lx), and brine (2x). The organic layer was dried over Na2S04 and concentrated to provide a dark oil as crude product. Purification via column chromatography provided S-((tra/?s)-4-((tert-butoxycarbonyl) amino)cyclohexyl)ethanethioate (820 mg, 27.5% yield). LCMS (TFA) 218.0 (M+H-t- butyl)+.
Figure imgf000110_0001
Step 3: To a stirred solution of S-((trans)-4-((tert-butoxycarbonyl)amino) cyclohexyl)ethanethioate (820 mg, 3.00 mmol) in MeOH (5 mL) at room temperature was added sodium methoxide (648 mg, 12.00 mmol) followed by iodomethane (0.281 mL, 4.50 mmol). The flask was then stoppered and stirred for 16 hours. The reaction mixture was diluted with water then extracted with ethyl acetate (3x). The combined organic layer was rinsed with saturated ammonium chloride (lx), saturated sodium bicarbonate (lx), and brine (lx). The organic layer was dried over Na2S04 and concentrated to provide tert-butyl ((trans)-4-(methylthio)cyclohexyl)carbamate (650 mg, 79% yield) of amber solids. LCMS (TFA) 190.0 (M+H)+.
Figure imgf000110_0002
Step 4: To a stirred solution of tert-butyl ((trans)-4-(methylthio)cyclohexyl) carbamate (650 mg, 2.65 mmol) in dioxane (5 mL) and methanol (1 mL) at room temperature was added 4N HC1 in dioxane (3.31 mL, 13.24 mmol). After 20 hours, the reaction mixture was concentrated from methylene chloride (5x) to provide (trans)-4- (methylthio)cyclohexanamine, HC1 (490 mg, 92% yield) of tan solids as product.
Figure imgf000110_0003
Step 5: To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (236 mg, 1.101 mmol), BOP (487 mg, 1.101 mmol) and TEA (0.307 mL, 2.201 mmol) in DMF (0.5 mL) at 25 °C was added (trans)-4-(methylthio)cyclohexanamine, HC1 (200 mg, 1.101 mmol). After 2 hours, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (2x), saturated sodium bicarbonate (lx) and finally 10% LiCl (lx). The organic layer was dried over Na2S04 and concentrated to provide tert-butyl ((trans)- 4-(methylcarbamoyl)cyclohexyl)carbamate (320 mg, 77% yield) of an amber oil as product. LCMS 342.2 (M+H)+.
Step 6: A mixture of 6-chloro-4-(isopropylamino)-N-((tra/?5)-4-(methylthio) cyclohexyl) nicotinamide (100 mg, 0.292 mmol), lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (41.9 mg, 0.292 mmol), potassium carbonate (29.4 mg, 0.213 mmol), and 6:1 t-BuOH/DMA (2 mL) were mixed in a 5 mL microwave vial containing a magnetic stir bar and degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (23.36 mg, 0.029 mmol) and degassed for another 5 minutes. The vial was sealed and the reaction heated in the microwave with stirring at 145 °C for 15 minutes. The reaction mixture was evaporated, diluted with DMF, filtered, purified via preparative HPLC to afford the product (16.8 mg, 12% yield). 1H NMR (500MHz, DMSO-de) δ 8.80 (d, J=1.8 Hz, IH), 8.66 (d, J=1.8 Hz, IH), 8.60-8.53 (m, 2H), 8.51 (d, J=3.7 Hz, IH), 8.34 (d, J=7.9 Hz, IH), 8.07 (s, IH), 6.87 (d, J=4.3 Hz, IH), 3.82-3.71 (m, 2H), 2.06 (s, 3H), 2.02 (d, J=12.2 Hz, 2H), 1.90 (d, J=13.4 Hz, 2H), 1.47-1.30 (m, 5H), 1.28 (d, J=6.7 Hz, 6H). LCMS 449.20 (M+H)+; HPLC rt 2.31 min, Conditions E.
Example 102
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4- methylsulfonyl)cyclohexyl)nicotinamide
Figure imgf000111_0001
To a stirred solution of 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (isopropylamino)-N-((tra/75)-4-(methylthio)cyclohexyl)nicotinamide (40 mg, 0.089 mmol) in methanol (3.5 mL) at 0 °C was added a solution of OXONE® (110 mg, 0.178 mmol) in water (1.5 mL). The reaction mixture was stirred for 1 h at 0 °C then allowed to stir at room temperature overnight. Solids present were filtered off and rinsed well with methanol. The filtrate was concentrated to remove the methanol, then extracted with methylene chloride (2x). The organic layer was dried over Na2S04 and concentrated to provide an amber oil as crude product. Purified via preparative HPLC to afford the product (29 mg, 65% yield). 1H NMR (500MHz, DMSO-d6) δ 8.80 (d, J=1.8 Hz, IH), 8.66 (d, J=1.8 Hz, IH), 8.59-8.54 (m, 2H), 8.51 (d, J=3.7 Hz, IH), 8.40 (d, J=7.9 Hz, IH), 8.07 (s, IH), 6.88 (d, J=3.7 Hz, IH), 3.76 (dq, J=13.1, 6.6 Hz, 2H), 3.13-3.01 (m, IH), 2.94 (s, 3H), 2.15 (d, J=12.2 Hz, 2H), 2.01 (d, J=9.8 Hz, 2H), 1.58-1.46 (m, 2H), 1.46-1.36 (m, 2H), 1.28 (d, J=6.1 Hz, 6H). LCMS 481.3 (M+H)+. HPLC rt 1.70 min, Conditions E.
Example 103
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide
Figure imgf000112_0001
(103) Example 103 was prepared according to the general procedure described for Example 102 substituting, where appropriate the requisite amines in the synthesis. LCMS 523.4 (M+H)+. HPLC rt 1.51 min, Conditions E.
Example 104
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(cyclopropylamino)-N-((tra/75)-4- methylsulfonyl)cyclohexyl)nicotinamide
Figure imgf000112_0002
Example 104 was prepared according to the general procedure described for Example 102 substituting, where appropriate the requisite amines in the synthesis. LCMS 479.2 (M+H)+. HPLC rt 1.72 min, Conditions E. Example 105
4-((3-Carbamoylphenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/75)-4- methylsulfonyl)cyclohexyl)nicotinamide
Figure imgf000113_0001
Example 106 was prepared in according to the general procedure described for
Example 102 substituting, where appropriate the requisite amines in the synthesis. LCMS 558.2 (M+H)+. HPLC rt 1.36 min, Conditions E.
Example 106
6-(5-Cyano- lH-pyrrolo[2,3-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-
((3-fl rotetrahydro-2H-pyran-4-yl)amino)nicotinamide
Figure imgf000113_0002
To solution of 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorotetrahydro-2H-pyran-4-yl)amino)nicotinamide (0.1 g, 0.265 mmol) in dioxane (5 mL):water (1 mL), lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (0.049 g, 0.344 mmol), Cs2C03 (0.259 g, 0.794 mmol) and Xantphos (0.077 g, 0.132 mmol) were added and degassed for 10 min. The reaction mixture was added Pd2(dba)3 (0.121 g, 0.132 mmol) and degassed again for 10 min. It was then heated for 18 h at 110 °C. The reaction mass was cooled and filtered through small pad of CELITE®. The filtrate obtained was concentrated to provide crude material. The crude material was purified by flash column chromatography through silica gel and MeOH: CHC13 as eluent. Further purification via chiral HPLC afforded two isomers, the latter being the desired product 6-(5-cyano-lH- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -
- I l l - fluorotetrahydro-2H-pyran-4-yl)amino)nicotinamide (2.5 mg, 4.85 μηιοΐ, 1.8% yield). LCMS 483.2 (M-H)+. HPLC rt 7.68 min, Conditions B.
Examples 107 and 108
Diastereomers 1 and 2)
Figure imgf000114_0001
Step 1 : To a solution of 3-aminotetrahydro-2H-pyran-4-ol hydrochloride (1.26 g, 8.20 mmol) and ethyl 4,6-dichloronicotinate (1.805 g, 8.20 mmol) in DMA (20 mL) was added DIPEA (7.16 mL, 41.0 mmol) and the reaction mixture was heated at 100 °C for 4 h. Water (20 mL) was added and the product was extracted with ethyl acetate (2 x 50 mL). The extracts were washed with cold water (30 mL) and brine (20 mL) then dried over Na2S04. The concentrated extracts were purified over silica gel eluting 50% EtOAc in hexane to afford ethyl 6-chloro-4-((4-hydroxytetrahydro-2H-pyran-3-yl)amino) nicotinate (1.67 g, 5.55 mmol, 68% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.54-8.57 (m, 1 H) 8.29 (d, J=8.53 Hz, 1 H) 6.94-7.00 (m, 1 H) 5.19-5.24 (m, 1 H) 4.28-4.36 (m, 2 H) 3.87-3.97 (m, 1 H) 3.72-3.82 (m, 1 H) 3.45-3.69 (m, 4 H) 1.72-1.92 (m, 1 H) 1.47- 1.58 (m, 1 H) 1.30-1.36 (m, 3 H) LCMS (M+H) 301.0.
Figure imgf000114_0002
Step 2: To a solution of ethyl 6-chloro-4-((4-hydroxytetrahydro-2H-pyran-3- yl)amino) nicotinate (1.0 g, 3.33 mmol) in DCM (20 mL) was added DAST (0.879 mL, 6.65 mmol) at -20 °C and stirred for 1 h at the same temp. The reaction was quenched with aqueous NaHC03 and extracted with DCM (50 mL). The extracts were washed with water (30 mL) and brine (20 mL) then dried over Na2S04 and concentrated. The compound was purified over silica gel eluting 1 :9 EtOAc and hexane to give ethyl 6- chloro-4-((4-fluorotetrahydro-2H-pyran-3-yl) amino) nicotinate (0.38 g, 1.25 mmol, 38% yield) as colorless syrup, which was taken for the next step without chiral separation. 1H
NMR (400 MHz, chloroform-d) δ 8.69-8.72 (m, 1 H) 8.57 (d, J=8.28 Hz, 1 H) 6.66 (s, 1 H) 4.59-4.77 (m, 1 H) 4.36 (q, J=7.03 Hz, 2 H) 4.07 (dt, J=l 1.92, 3.83 Hz, 1 H) 3.89-3.96 (m, 1 H) 3.62-3.71 (m, 2 H) 3.51 (dd, J=11.92, 5.90 Hz, 1 H) 2.10-2.25 (m, 1 H) 1.92 (dddd, J=14.30, 10.79, 7.15, 3.89 Hz, 1 H) 1.72 (d, J=0.50 Hz, 1 H) 1.36-1.42 (m, 3 H) 1.06-1.17 (m, 2 H) LCMS(M+H) 303.0.
Figure imgf000115_0001
Step 3: To a solution of ethyl 6-chloro-4-((4-fluorotetrahydro-2H-pyran-3- yl)amino)nicotinate (0.38 g, 1.25 mmol) in MeOH (5 mL) was added LiOH (0.090 g, 3.77 mmol) as 2N aq solution at 0 °C, then stirred for 1 h at 60 °C. After cooling the MeOH was removed and water (2 mL) was added and acidified to pH 4 with 1.5N HC1. The precipitated solids (0.26g, 75% yield) were collected and used directly in the next step. 1H
NMR (300 MHz, DMSO-d6) δ 13.48 (br s., 1 H) 8.44-8.56 (m, 2 H) 7.03 (s, 1 H) 4.67- 4.94 (m, 1 H) 3.76-4.04 (m, 3 H) 3.39-3.60 (m, 2 H) 2.04 (d, J=15.30 Hz, 1 H) 1.81 (d, J=9.82 Hz, 1 H) LCMS (M+H) 275.0.
Figure imgf000115_0002
Step 4: To a solution of 6-chloro-4-((4-fluorotetrahydro-2H-pyran-3-yl)amino) nicotinic acid (0.26 g, 0.947 mmol) and 4-amino-3-fluoro-2-methylbutan-2-ol (0.115 g, 0.947 mmol) in DMF (10 mL) was added DIPEA (0.496 mL, 2.84 mmol) and HATU (0.720 g, 1.893 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. EtOAc (50mL) was added and the organic layer was washed with cold water (3 x 20mL), brine (15mL) then dried over Na2SC"4 and concentrated. The crude product was purified over silica gel eluting 50% EtOAc in hexane to afford 6- chloro-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-fluorotetrahydro-2H-pyran-3 -yl) amino)nicotinamide (0.2 lg, 59% yield) which was taken for the next step without chiral separation. 1H NMR (300 MHz, chloroform-d) δ 8.74 (d, J=8.31 Hz, 1 H) 8.25-8.28 (m, 1 H) 6.85 (br. s., 1 H) 6.67 (s, 1 H) 4.73-4.81 (m, 1 H) 4.50-4.65 (m, 2 H) 3.89-4.19 (m, 3 H) 3.41-3.71 (m, 4 H) 2.11-2.31 (m, 1 H) 2.05 (d, J=6.52 Hz, 1 H) 1.84-1.98 (m, 1 H) 1.31-1.39 (m, 6 H); LCMS (M+H) 378.2.
Step 5: To a solution of 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((4-fluorotetrahydro-2H-pyran-3-yl)amino)nicotinamide (300 mg, 0.794 mmol) and 1H- pyrrolo[2,3-b]pyridine-5-carbonitrile (114 mg, 0.794 mmol) in 1,4-dioxane (6 mL) was added Cs2C03 (776 mg, 2.382 mmol) and Xantphos (184 mg, 0.318 mmol). The mixture was degassed with nitrogen for 15 mins, then Pd2dba3 (291 mg, 0.318 mmol) was added to the reaction mixture and again degassed for 5 mins. The reaction vessel was sealed and heated at 110 °C for 16 h. The reaction mixture was cooled and filtered through small pad of CELITE®. The filtrate was concentrated and purified by column chromatography through silica gel eluting 10% MeOH in DCM to afford diastereomeric mixture of 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-((4-fluorotetrahydro-2H-pyran-3-yl)amino)nicotinamide. The two diastereomers were separated by SFC.
Diastereomer 1 : 1H NMR (400 MHz, DMSO-d6) δ 8.99 (d, J=8.53 Hz, 1 H) 8.81- 8.85 (m, 2 H) 8.64-8.70 (m, 2 H) 8.53 (d, J=3.51 Hz, 1 H) 8.21 (s, 1 H) 6.90 (d, J=4.02 Hz, 1 H) 4.85 (s, 2 H) 4.29-4.46 (m, 1 H) 4.00-4.07 (m, 1 H) 3.66-3.90 (m, 3 H) 3.58 (br. s., 1 H) 3.35-3.49 (m, 2 H) 2.07-2.20 (m, 1 H) 1.77-1.89 (m, 1 H) 1.18 (dd, J=5.77, 1.25 Hz, 6 H); LC/MS 485.0(M+H); 15mg, 5%yield.
Diastereomer 2: 1H NMR (400 MHz, DMSO-d6) δ 9.01 (d, J=8.03 Hz, 1 H) 8.89 (t, J=5.52 Hz, 1 H) 8.81 (d, J=2.01 Hz, 1 H) 8.65-8.69 (m, 2 H) 8.53 (d, J=4.02 Hz, 1 H) 8.20 (s, 1 H) 6.90 (s, 1 H) 4.80-4.99 (m, 2 H) 4.30-4.47 (m, 1 H) 4.04 (dt, J=11.55, 4.52 Hz, 1 H) 3.66-3.89 (m, 3 H) 3.55-3.62 (m, 1 H) 3.40-3.50 (m, 2 H) 2.06-2.18 (m, 1 H) 1.78-1.90 (m, 1 H) 1.18 (dd, J=6.02, 1.51 Hz, 6 H); LC/MS 485.0(M+H); 25mg, 6.5% yield.
Examples 109 and 110
(Diastereomers 1 and 2)
Step 1 : To a solution of 3-aminocyclopentanol hydrochloride (1.05 g, 7.63 mmol) and ethyl 4,6-dichloronicotinate (1.679 g, 7.63 mmol) in DMA (10 mL) was added
DIPEA (6.66 mL, 38.2 mmol), then reaction mixture was heated at 100 °C for 4 h. Water (50mL) was added and the mixture was extracted with ethyl acetate (2 x 150 mL). The combined organic layers were washed with cold water (2 x 50 mL) and brine solution (40 mL) then dried over Na2S04. The filtrate was concentrated and the product was purified using silica gel eluting 40% ethyl acetate in hexane to afford ethyl 6-chloro-4-((3- hydroxycyclopentyl)amino)nicotinate (1.5 g, 5.27 mmol, 69% yield), which was taken for the next step without chiral separation. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.54 (br. s., 1 H) 8.03-8.42 (m, 1 H) 6.78 (d, J=9.54 Hz, 1 H) 4.62-4.77 (m, 1 H) 3.99-4.33 (m, 4 H) 1.86-2.29 (m, 3 H) 1.38-1.78 (m, 3 H) 1.31 (td, J=7.03, 1.00 Hz, 3 H); LCMS(M+H) 285.0.
Figure imgf000117_0002
Step 2: To a solution of ethyl 6-chloro-4-((3 -hydroxy cyclopentyl)amino) nicotinate (1.5 g, 5.27 mmol) in DCM (20 mL) was added DAST (1.392 mL, 10.54 mmol) slowly at -20 °C. The reaction mixture was stirred at room temperature for 2 h. After the reaction was complete, the mixture was quenched with aqueous NaHC03 solution and extracted with DCM (50 mL). The organic layer was washed with water (30 mL) and brine (20 mL) then dried over Na2S04. The crude compound was purified over silica gel eluting 1 :9 EtOAc and hexane to get two diastereomers of desired product separately. Yield: Diastereomer 1 : 540 mg, Diastereomer 2: 320 mg.
Diastereomer 1 : 1H NMR (400 MHz, chloroform-d) δ ppm 8.67 (s, 1 H) 8.22 (br. s., 1 H) 6.58 (s, 1 H) 5.16-5.34 (m, 1 H) 4.33 (q, J=7.03 Hz, 2 H) 4.06-4.15 (m, 1 H) 2.47-2.60 (m, 1 H) 2.35 (dq, J=13.18, 7.99 Hz, 1 H) 2.00-2.16 (m, 2 H) 1.59-1.84 (m, 2 H) 1.36-1.41 (m, 3 H) LC/MS 287.0(M+H).
Diastereomer 2: 1H NMR (400 MHz, chloroform-d) δ ppm 8.67 (s, 1 H) 8.42 (br. s., 1 H) 6.52 (s, 1 H) 5.16-5.33 (m, 1 H) 4.30-4.38 (m, 2 H) 3.93-4.00 (m, 1 H) 1.81-2.35 (m, 6 H) 1.37 (t, J=7.03 Hz, 3 H) LC/MS 287.0(M+H).
Figure imgf000118_0001
Step 3: To a solution of ethyl 6-chloro-4-((3-fluorocyclopentyl)amino)nicotinate (1.0 g, 3.49 mmol) in EtOH (10 mL) was added LiOH (0.167 g, 6.98 mmol) as 2N aq solution at 0 °C, then stirred for 3 h at room temperature. When the reaction was complete, the EtOH was removed and water (1 mL) was added and acidified to pH 4 with 1.5N HC1. The precipitated solid was collected on a filter and used in the next step without chiral separation. Yield: 88% (0.79 g). 1H NMR (400 MHz, DMSO-d6) δ ppm 13.37 (br. s., 1 H) 8.52 (d, J=9.04 Hz, 1 H) 8.32 (d, J=7.03 Hz, 1 H) 6.83 (s, 1 H) 5.17- 5.35 (m, 1 H) 4.19 (dq, J=13.68, 6.99 Hz, 1 H) 2.21-2.47 (m, 2 H) 1.73-2.17 (m, 3 H) 1.47-1.57 (m, 1 H) LCMS (M+H) 259.0.
Figure imgf000118_0002
Step 4: To a solution of 6-chloro-4-((3-fluorocyclopentyl)amino)nicotinic acid
(0.91 g, 3.52 mmol) and (R)-4-amino-3-fluoro-2-methylbutan-2-ol (0.511 g, 4.22 mmol) in DMF (10 mL) was added DIPEA (1.843 mL, 10.55 mmol) and HATU (2.68 g, 7.04 mmol). The reaction mixture was stirred for 2 hrs at room temperature. Then reaction mixture was diluted with EtOAc (50 mL) and the organic layer was washed with cold water (3 x 20 mL) and brine (15 mL). The extracts were dried over Na2S04 and concentrated to give the crude compound which was purified over silica gel eluting 60% EtOAc in hexane to afford 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorocyclopentyl) amino)nicotinamide (0.98 g, 2.71 mmol, 77% yield) as off-white solid, which was taken for the next step without chiral separation. 1H NMR 400 MHz, DMSO- d6: δ 8.71 (t, J = 7.20 Hz, 2H), 8.38 (s, 1H), 6.71 (s, 1H), 5.14-5.27 (m, 1H), 4.83 (s, 1H), 4.24-4.39 (m, 1H), 4.03 (d, J = 2.80 Hz, 1H), 3.60-3.69 (m, 1H), 3.31-3.37 (m, 1H), 2.25- 2.42 (m, 1H), 2.14-2.18 (m, 1H), 1.59-1.97 (m, 4H), 1.15 (dd, J = 0.80, 6.00 Hz, 6H), LCMS(M+H) 362.2
Figure imgf000119_0001
Step 5: To a solution of 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4- ((3-fluorocyclopentyl)amino)nicotinamide (120 mg, 0.332 mmol) and lH-pyrrolo[2,3-b] pyridine-5-carbonitrile (47.5 mg, 0.332 mmol) in 1,4-dioxane (6 mL) was added Cs2C03 (324 mg, 0.995 mmol) and Xantphos (77 mg, 0.133 mmol). The mixture was degassed with nitrogen for 15 mins, then Pd2(dba)3 (121 mg, 0.133 mmol) was added and again degassed for 5 mins. The vessel was sealed and the reaction mixture was heated at 110 °C for 16 h. The reaction mixture was cooled and filtered through small pad of
CELITE®. The filtrate was concentrated and the crude material was purified by column chromatography through silica gel eluting 10% MeOH in DCM to afford a diastereomeric mixture of 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-((4-fluorotetrahydro-2H-pyran-3-yl)amino)nicotinamide. The two diastereomers were separated by SFC.
Diastereomer 1 : 1H NMR (400 MHz, DMSO-d6) δ 8.82-8.87 (m, 2 H) 8.74 (t, J=5.52 Hz, 1 H) 8.68 (s, 1 H) 8.61 (s, 1 H) 8.56 (d, J=4.02 Hz, 1 H) 8.16 (s, 1 H) 6.90 (d, J=4.02 Hz, 1 H) 5.18-5.37 (m, 1 H) 4.28-4.45 (m, 1 H) 4.06 (br. s., 1 H) 3.63-3.80 (m, 1 H) 3.35-3.48 (m, 1 H) 2.43 (dd, J=8.03, 5.02 Hz, 1 H) 2.28-2.37 (m, 1 H) 1.72-2.11 (m, 4 H) 1.17 (dd, J=5.77, 1.25 Hz, 6 H); LC/MS 469.2(M+H); HPLC Condition A, RT 8.015min; 20mg, 13% yield.
Diastereomer 2: 1H NMR (400 MHz, DMSO-d6) δ 8.82-8.87 (m, 2 H) 8.74 (t, J=5.52 Hz, 1 H) 8.68 (d, J=2.01 Hz, 1 H) 8.62 (s, 1 H) 8.56 (d, J=4.02 Hz, 1 H) 8.16 (s, 1 H) 6.90 (d, J=3.51 Hz, 1 H) 5.19-5.37 (m, 1 H) 4.83 (s, 1 H) 4.28-4.45 (m, 1 H) 4.02-4.11 (m, 1 H) 3.64-3.81 (m, 1 H) 3.34-3.46 (m, 1 H) 2.53-2.59 (m, 1 H) 2.28-2.37 (m, 1 H) 1.72-2.10 (m, 4 H) 1.17 (dd, J=6.27, 1.25 Hz, 6 H); LC/MS 469.2(M+H); HPLC
Condition A, RT 7.993min; 20mg, 14% yield.
Examples 111 and 112
Diastereomers 1 and 2
Figure imgf000120_0001
Step 1 : To a stirred solution of ethyl 4,6-dichloronicotinate (650 mg, 2.95 mmol) in DMA (10 mL) was added (lS,6R)-6-amino-2,2-difluorocyclohexanol (491 mg, 3.25 mmol) and DIPEA (2.064 mL, 11.82 mmol). The reaction mixture was heated at 130 °C for 2 hours and cooled to room temperature. DMA was removed in vacuo and the residue was partitioned between ethyl acetate and water. The layers were separated and the organic layer was dried over Na2S04, filtered, and evaporated. The product was purified by silica gel column using 10%> ethyl acetate/pet ether to provide the desired product. LCMS m/z 335.3 (M+H).
Figure imgf000121_0001
Step 2: To a stirred solution of ethyl 6-chloro-4-(((lS,2R)-3,3-difluoro-2- hydroxycyclohexyl)amino)nicotinate (700 mg, 2.091 mmol) in ethanol (5 mL), THF (10 mL) and water (5 mL), was added lithium hydroxide monohydrate (263 mg, 6.27 mmol) and stirred at 25 °C for 2 h. The reaction mixture was evaporated to dryness, and neutralized with 1.5 N HCl to obtain a white solid which was filtered and dried to afford the desired compound. LCMS m/z 307.3 (M+H).
Figure imgf000121_0002
Step 3: To a stirred solution of 6-chloro-4-(((lS,2R)-3,3-difluoro-2- hydroxycyclohexyl)amino)nicotinic acid (500 mg, 1.630 mmol) in DMF (10 mL) was added (R)-4-amino-3-fluoro-2-methylbutan-2-ol (198 mg, 1.630 mmol), DIPEA (0.712 mL, 4.08 mmol) and HATU (620 mg, 1.630 mmol). The mixture was stirred at 25 °C for 14 h. The reaction mixture was concentrated to dryness, and extracted with ethyl acetate (3 times). The combined organic layers were dried over Na2S04, filtered, and concentrated. The residue was purified by column chromatography using 2%
MeOF DCM to isolate desired product (550 mg, 82% yield); LCMS m/z 410.4 (M+H).
Figure imgf000121_0003
Step 4: A stirred solution of 6-chloro-4-((3,3-difluoro-2-hydroxycyclohexyl) amino)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (100 mg, 0.244 mmol), lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (34.9 mg, 0.244 mmol), Xantphos (85 mg, 0.146 mmol) and Cs2C03 (159 mg, 0.488 mmol) in 1,4-dioxane (10 mL) was degassed for 5 min. Pd2(dba)3 (67.0 mg, 0.073 mmol) was added and the mixture was degassed for additional 5 mins then heated at 110 °C for 12 hours. The reaction mixture was filtered, evaporated, and the residue was purified by silica gel chromatography using 3%
MeOH:DCM to isolate expected diastereomeric mixture product (55 mg), which was subjected chiral separation to give the desired chiral compounds.
Diastereomer 1 : 1H NMR (400 MHz, methanol-d4) δ 8.71 (d, J=2.01 Hz, 1 H),
8.52 (s, 1 H), 8.47-8.50 (m, 2 H), 8.28 (s, 1 H), 6.86 (d, J=4.02 Hz, 1 H), 4.36-4.54 (m, 1 H), 3.79-3.99 (m, 3 H), 3.43-3.57 (m, 2 H), 2.15-2.40 (m, 2 H), 1.67-1.99 (m, 3 H), 1.48- 1.63 (m, 1 H), 1.32 (d, J=1.51 Hz, 6 H); LCMS m/z 517.4 (M+H), 26mg (20% yield).
Diastereomer 2: 1H NMR (400 MHz, methanol-d4) δ 8.71 (d, J = 2.00 Hz, 1H), 8.52 (s, 1H), 8.48-8.49 (m, 2H), 8.28 (s, 1H), 6.86 (d, J = 4.00 Hz, 1H), 4.45 (ddd, J =
2.40, 9.20, 48.80 Hz, 1H), 3.82-3.98 (m, 3H), 3.45-3.55 (m, 1H), 2.18-2.39 (m, 2H), 1.82- 1.99 (m, 2H), 1.74-1.81 (m, 1H), 1.54-1.69 (m, 1H), 1.31-1.32 (m, 6H); LCMS m/z 517.4 (M+H); 25mg (19% yield). Example 113
N-((R)-2-Fluoro-3-hydroxy-3-methylbutyl)-4-((l-fluoropropan-2-yl)amino)-6-(7H- rrolo[2,3-d]pyrimidin-7-yl)nicotinamide
Figure imgf000122_0001
Figure imgf000122_0002
Step 1 : To a sealed vial, ethyl 4,6-dichloronicotinate (270 mg, 1.227 mmol), 1- aminopropan-2-ol (111 mg, 1.472 mmol) and DIPEA (0.262 mL, 1.472 mmol) in 2- propanol (1 mL) were stirred and heated at 100 °C for 3 h. The mixture was cooled to room temperature, concentrated and purified by a flash column, using 20-40% EtOAc in hexanes as an eluent. Ethyl 6-chloro-4-((2-hydroxypropyl)amino)nicotinate (269 mg, 1.040 mmol, 85% yield) was obtained as a white solid. 1H NMR (400MHz, chloroform-d) δ 9.34 (s, 1H), 9.14 (br. s., 1H), 7.97 (s, 1H), 5.04 (q, J=7.2 Hz, 2H), 4.81 (dt, J=6.5, 3.4 Hz, 1H), 4.04-3.94 (m, 1H), 3.91-3.82 (m, 1H), 3.11 (d, J=4.2 Hz, 1H), 2.57 (s, 1H), 2.08 (t, J=7.2 Hz, 3H), 2.02 (d, J=6.4 Hz, 3H). LCMS 259.0 (M+H)+.
Figure imgf000123_0001
Step 2: To a solution of ethyl 6-chloro-4-((l-hydroxypropan-2-yl)amino) nicotinate (270 mg, 1.044 mmol) in DCM (10 mL) at -40 °C, was added DAST (0.276 mL, 2.087 mmol), the mixture was stirred at room temperature for 1 h, warmed to room temperature and stirred overnight. The reaction was quenched with aqueous sodium bicarbonate (aq). The mixture was extracted with DCM (50 mL), concentrated to give a yellow solid. The ester was hydrolyzed in sodium hydroxide (IN, 4.17 mL, 4.17 mmol) in a mixed solvent of THF (2 mL) and MeOH (2 mL) at room temperature overnight, the reaction mixture was neutralized with IN HC1. The product precipitated from the mixture. The solid was collected by filtration, washed with water and ether, dried under vacuum to give 6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinic acid (189 mg, 0.812 mmol, 78% yield). 1H NMR (400MHz, DMSO-d6) δ 13.40 (br. s, 1H), 8.52 (s, 1H), 8.40 (d, J=7.2 Hz, 1H), 7.92 (s, 1H), 4.59-4.36 (m, 2H), 4.19 - 4.11 (m, 1H), 2.21 (d, J=6.4 Hz, 3H). LCMS 233.0 (M+H)+.
Figure imgf000123_0002
Step 3: To a solution of 6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinic acid (189 mg, 0.812 mmol) in DMF (1 mL), was added (R)-4-amino-3-fluoro-2-methylbutan- 2-ol (103 mg, 0.853 mmol), BOP (396 mg, 0.894 mmol) and DIPEA (0.301 mL, 1.706 mmol). The mixture was stirred at room temperature for 1 h, then added water, extracted by EtOAc, washed with aqueous NaHC03 and brine, concentrated. The product was purified by flash chromatography through silica gel (30% EtOAc in hexanes as eluent) to afford 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((l-fluoropropan-2- yl)amino) nicotinamide (221 mg, 0.658 mmol, 81% yield). LCMS 336.1 (M+H)+.
Step 4: To a solution of 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((l-fluoropropan-2-yl)amino)nicotinamide (20 mg, 0.060 mmol) in t-BuOH (0.6 mL) and DMA (0.1 mL), was added 7H-pyrrolo[2,3-d]pyrimidine (7.80 mg, 0.066 mmol), BrettPhos (0.960 mg, 1.787 μπιοΐ), BrettPhos precatalyst (1.428 mg, 1.787 μπιοΐ) and K2C03 (24.66 mg, 0.179 mmol). The mixture vial was purged with N2, sealed and heated at 135 °C for one hour, cooled to room temperature. The residue was purified via preparative HPLC to afford residue was purified via preparative HPLC to afford the diastereomeric mixture of N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -fluoropropan- 2-yl)amino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (7.3 mg, 0.016 mmol, 27.5% yield). 1H NMR (500MHz, DMSO-d6) δ 9.17 (s, 1H), 9.01 (s, 1H), 8.90 (br. s., 1H), 8.81 (t, J=5.4 Hz, 1H), 8.61 (s, 1H), 8.44 (d, J=4.0 Hz, 1H), 8.13 (s, 1H), 6.91 (s, 1H), 5.10-4.91 (m, 1H), 4.45-4.28 (m, 1H), 3.83-3.49 (m, 2H), 2.88 (s, 1H), 2.73 (s, 1H), 1.47-1.36 (m, 3H), 1.18 (d, J=6.4 Hz, 6H). LCMS 419.2 (M+H)+. HPLC rt 1.39 min, Conditions E.
Example 114
6-(5-Cyano-lH-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-
4- R)- 1 -fluoropropan-2-yl)amino)nicotinamide
Figure imgf000124_0001
Figure imgf000125_0001
Step 1 : In a sealed vial, a stirring mixture of ethyl 4,6-dichloronicotinate (400 mg, 1.818 mmol), (R)-2-aminopropan-l-ol (150 mg, 2.000 mmol) and DIPEA (0.678 mL, 3.82 mmol) in isopropanol (2 mL) was heated at 100 °C over night. The mixture was concentrated. The residue was purified by a flash column using 30-60% EtOAc in hexanes to give (R)-ethyl 6-chloro-4-((l-hydroxypropan-2-yl)amino)nicotinate (418 mg, 1.616 mmol, 89% yield). 1H NMR (400MHz, chloroform-d) δ 9.34 (s, 1H), 9.14 (br. s., 1H), 7.97 (s, 1H), 5.04 (q, J=7.2 Hz, 2H), 4.81 (dt, J=6.5, 3.4 Hz, 1H), 4.04-3.94 (m, 1H), 3.91-3.82 (m, 1H), 3.11 (d, J=4.2 Hz, 1H), 2.57 (s, 1H), 2.08 (t, J=7.2 Hz, 3H), 2.02 (d, J=6.4 Hz, 3H). LCMS 259.0 (M+H)+.
Figure imgf000125_0002
Step 2: To a solution of (R)-ethyl 6-chloro-4-((l-hydroxypropan-2-yl)amino) nicotinate (0.39 g, 1.508 mmol) in DCM (10 mL) at -78 °C, was added DAST (0.398 mL, 3.02 mmol). The mixture was stirred and warmed to room temperature over night. The reaction was quenched with NaHC03, extracted by DCM (30 mL), washed with aqueous NaHC03 and brine, concentrated. The residue was added THF (2 mL), MeOH (2 mL) and IN NaOH (6.03 mL, 6.03 mmol). The mixture was stirred at room temperature for 3 h, then neutralized with IN HC1. The precipitated solid was filtered and dried to afford (R)-6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinic acid (200 mg, 0.860 mmol, 57.0% yield) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ 13.40 (br. s, 1H), 8.52 (s, 1H), 8.40 (d, J=7.2 Hz, 1H), 7.92 (s, 1H), 4.59-4.36 (m, 2H), 4.19 - 4.11 (m, 1H), 2.21 (d, j=6.4 Hz, 3H). LCMS (ESI) = 233.2 (M+H).
Figure imgf000126_0001
Step 3: To a solution of (R)-6-chloro-4-((l-fluoropropan-2-yl)amino)nicotinic acid (40 mg, 0.172 mmol) in THF (2 mL), was added (R)-4-amino-3-fluoro-2- methylbutan-2-ol (20.83 mg, 0.172 mmol), BOP (84 mg, 0.189 mmol), DIPEA (0.063 mL, 0.361 mmol), the mixture was stirred at room temperature for 2 hours and concentrated. The residue was purified by a flash column using 30-60% EtOAc in hexanes to give 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)-l- fluoropropan-2-yl)amino)nicotinamide (43 mg, 0.128 mmol, 74.5% yield). LCMS (ESI) = 416.2 (M+H); HPLC rt 1.25 min, Conditions E.
Step 4: In a sealed vial, a mixture of 6-chloro-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(((R)-l-fluoropropan-2-yl)amino)nicotinamide (20 mg, 0.060 mmol), 1H- pyrazolo[3,4-b]pyridine-5-carbonitrile (9.01 mg, 0.063 mmol), di-tert-butyl(2',4',6'- triisopropyl-3,4,5,6-tetramethyl-[l,l '-biphenyl]-2-yl)phosphine oxide (8.88 mg, 0.018 mmol), Pd2(dba)3 (8.18 mg, 8.93 μπιοΐ), K2C03 (24.70 mg, 0.179 mmol) in dioxane (1 mL) was purged with nitrogen, stirred and heated at 100 °C over night. The mixture was cooled and concentrated. The residue was purified via preparative HPLC to afford 6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((R)-l-fluoropropan-2-yl)amino)nicotinamide (5.1 mg, 10.93 μιηοΐ, 18.34% yield). 1H NMR (500MHz, DMSO-d6) δ 9.03 (s, 1H), 8.99 (s, 1H), 8.86 (br. s., 1H), 8.83-8.78 (m, 1H), 8.63 (m, 2H), 7.40-7.34 (m, 1H), 5.02-4.85 (m, 2H), 4.47-4.27 (m, 1H), 3.83-3.63 (m, 1H), 1.38 (d, J=6.1 Hz, 1H), 1.33 (d, J=6.4 Hz, 1H), 1.25 (d, J=6.1 Hz, 1H), 1.17 (d, J=5.7 Hz, 9H). LCMS (ESI) = 443.2 (M+H); HPLC rt 1.27 min, Conditions E.
The Examples in Table 6 were prepared using the general methods for Examples 115-122 using the appropriate starting material and amine. Table 6
Figure imgf000127_0001
Figure imgf000128_0001
Example 123
(R)-l-(4-(Ethylamino)-5-((2-fluoro-3-hydroxy-3-methylbutyl)carbamoyl)pyridin-2-yl)-
1 H-pyrrolo [2,3 -b]pyridine-5 -carboxamide
Figure imgf000128_0002
To a stirred solution of (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (ethylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (25 mg, 0.061 mmol) in DMSO (ImL) at room temperature was added 5M KOH (0.061 mL, 0.305 mmol), then 35% hydrogen peroxide (69.1 mg, 0.609 mmol). After 1 hour, the reaction mixture was filtered, then the filtrate was concentrated and purified via preparative HPLC to afford the product (Pv)- 1 -(4-(ethylamino)-5 -((2-fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)pyridin- 2-yl)-lH-pyrrolo[2,3-b]pyridine-5-carboxamide (3.3 mg, 12% yield). 1H NMR
(500MHz, DMSO-d6) δ 8.94 (d, J=1.8 Hz, IH), 8.73 (t, J=5.8 Hz, IH), 8.60-8.51 (m, 3H), 8.47 (d, J=4.3 Hz, IH), 8.29 (s, IH), 8.14 (br. s., IH), 7.95 (s, IH), 7.48 (br. s., IH), 6.84 (d, J=3.7 Hz, IH), 6.60-6.58 (m, IH), 4.85 (s, IH), 4.44-4.28 (m, IH), 3.81-3.63 (m, IH), 3.45-3.36 (m, IH), 1.30 (t, J=7.0 Hz, 3H), 1.17 (d, J=6.1 Hz, 6H). LCMS (M+H)+ = 429.1. HPLC rt 1.22 min, Conditions E. Example 124
(R)- 1 -(4-(Cyclobutylamino)-5 -((2-fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)pyridin-2- -lH-pyrrolo[2,3-b]pyridine-5-carboxamide
Figure imgf000129_0001
Example 124 was prepared according to the general procedure for Example 123 substituting, where appropriate, the requisite amines in the synthesis. LCMS 455.1 (M+H)+. HPLC rt 1.41 min, Conditions E.
Example 125
l-((2-(6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)nicotinamido) eth l)amino)-2-methyl- 1 -oxopropan-2-yl acetate
Figure imgf000129_0002
Step 1 : A mixture of l-chloro-2-methyl-l-oxopropan-2-yl acetate (2.0 g, 12.15 mmol) in DCM (20 mL) and TEA (3.39 mL, 24.30 mmol) was added tert-butyl (2- aminoethyl)carbamate (1.95 g, 12.15 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h then diluted with DCM and washed with water. The organic layer was dried (Na2S04), filtered and concentrated to afford 1 -((2-((tert-butoxycarbonyl) amino)ethyl)amino)-2-methyl-l-oxopropan-2-yl acetate (2.7 g, 9.36 mmol, 77% yield) as a brown oil. 1H NMR (400MHz, CDC13) δ 6.85 (br s, 1H), 4.91 (br s, 1H), 3.36 (m, 4H), 2.10 (s, 3H), 1.60 (s, 6H), 1.44 (s, 9H); LCMS 289.4 (M+H)+.
Figure imgf000130_0001
Step 2 : 1 -((2-((tert-Butoxycarbonyl)amino)ethyl)amino)-2-methyl- 1 -oxopropan- 2-yl acetate (2.5 g, 8.67 mmol) was dissolved in 1,4-dioxane (10 mL), cooled to -10 °C and HC1 (0.132 mL, 4.34 mmol, 4N in dioxane) was added dropwise. The reaction mixture was then allowed to stir at room temperature for 1 h. The reaction mixture was concentrated and dried to afford ((2-aminoethyl)amino)-2-methyl-l-oxopropan-2-yl acetate (1.5 g, 7.97 mmol, 92% yield) which was used without further purification.
Figure imgf000130_0002
Step 3: 6-Chloro-4-(isopropylamino)nicotinic acid (0.5 g, 2.329 mmol) and l-((2- aminoethyl)amino)-2-methyl-l-oxopropan-2-yl acetate (0.438 g, 2.329 mmol) were dissolved in DMF (10 mL), added DIPEA (2.034 mL, 11.65 mmol) and HATU (0.886 g, 2.329 mmol) and the reaction mixture was stirred at room temperature overnight. From the reaction mixture, all solvent was removed and the crude product was purified by ISCO (24g silica column, MeOH/CHCl3) to obtain l-((2-(6-chloro-4-(isopropylamino) nicotinamido)ethyl)amino)-2-methyl-l-oxopropan-2-yl acetate (0.73 g, 81% yield) as a colorless gel. 1H NMR (400MHz, CDC13) δ 8.29 (s, 1H), 6.71 (s, 1H), 3.77-3.71 (m, 1H), 3.49-3.32 (m, 4H), 2.02 (s, 3H), 1.55 (s, 6H), 1.41 (d, 6H, J = 8Hz); LCMS 385.4
(M+H)+.
Step 4 : 1 -((2-(6-Chloro-4-(isopropylamino)nicotinamido)ethyl)amino)-2-methyl- l-oxopropan-2-yl acetate (0.07 g, 0.182 mmol) and lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (0.026 g, 0.182 mmol) was dissolved in 1,4-dioxane (10 mL). To this mixture was added Na2C03 (0.019 g, 0.182 mmol) and water (1 mL). The vessel was purged with N2 and added Xantphos (0.105 g, 0.182 mmol) followed by Pd2(dba)3 (0.167 g, 0.182 mmol). The reaction mixture was heated at 110 °C for 18 h then cooled to room temperature. The product was isolated via column chromatography and repurified via preparative HPLC to afford the product (27 mg, 30%> yield) as a white solid. 1H NMR (400MHz, MeOD4) δ 8.7 (s, 1H), 8.49-8.47 (m, 3H), 8.18 (s, 1H), 6.85 (6, lH, J= 4Hz), 3.91-3.88 (m, 1H), 3.54-3.50 (m, 2H),3.46-3.43 (m, 2H), 2.08 (s, 3H), 1.57 (s, 6H), 1.38 (d, 6H, J= 8Hz); LCMS 490.2 (M+H)+.
Example 126
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-(2-hydroxy-2- meth lpropanamido)ethyl)-4-(isopropylamino)nicotinamide
Figure imgf000131_0001
To a solution of l-((2-(6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-
(isopropylamino)nicotinamido)ethyl) amino)-2-methyl-l-oxopropan-2-yl acetate (0.1 g, 0.203 mmol) in MeCN (10 mL) was added K2C03 (0.056 g, 0.407 mmol). The mixture was stirred at room temperature for 30 mins. The mixture was filtered and the concentrated residue was purified via preparative TLC to afford the product (11 mg, 12% yield) as a white solid. 1H NMR (400MHz, MeOD4) δ 1H NMR (400MHz, CD3OD) δ 8.7 (s, 1H), 8.47-8.44 (m, 3H), 8.15 (s, 1H), 6.83 (d, 1H, J= 4Hz), 3.90-3.85 (m, 1H), 3.52- 3.44 (m, 4H), 1.37-1.35 (m, 12H); LCMS 450.2 (M+H)+.
Example 127
(R)-6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-methoxypropyl)-4- isopropylamino)nicotinamide
Figure imgf000131_0002
Figure imgf000132_0001
Step 1 : To a stirred solution of (R)-methyl 3-(dibenzylamino)-2-fluoropropanoate (1.00 g, 3.32 mmol) in anhydrous THF (15 mL) at 0 °C was added 2N lithium
tetrahydroborate in THF (1.659 mL, 3.32 mmol). The reaction mixture was stirred at room temperature for 48 hours and was then added saturated aqueous NH4C1 solution to quench. The product was extracted with ethyl acetate and the organic layer was dried over Na2S04 and concentrated to provide (R)-3-(dibenzylamino)-2-fluoropropan-l-ol (800 mg, 79% yield) of a colorless oil. LCMS (M+H)+ = 274.3.
Figure imgf000132_0002
Step 2: To a stirred solution of (R)-3-(dibenzylamino)-2-fluoropropan-l-ol (400 mg, 1.463 mmol) in THF (10 mL) and DMF (10 mL) at 0 °C under nitrogen was added NaH (70.2 mg, 1.756 mmol). After 10 min iodomethane (0.092 mL, 1.463 mmol) was added. After an additional 30 min additional NaH (70.2 mg, 1.756 mmol) was added. After an additional 10 min iodomethane (0.092 mL, 1.463 mmol) was added again. The mixture was carefully quenched with the dropwise addition of water. The mixture was diluted with ethyl acetate and rinsed with 10% LiCl (2x), saturated sodium bicarbonate (lx), and finally 10% LiCl (lx). The organic layer was dried over Na2S04 and concentrated to provide (R)-N,N-dibenzyl-2-fluoro-3-methoxypropan-l -amine (400 mg, 86%) as a colorless oil. LCMS (M+H)+ = 287.7.
Figure imgf000132_0003
Step 3 : Under a nitrogen atmosphere, a Parr bottle was carefully charged with 10% Pd/C (74.1 mg, 0.070 mmol), and the catalyst was carefully wetted with methanol (10 mL). The vessel was charged with a methanol (10 mL) solution of (R)-N,N-dibenzyl- 2-fluoro-3-methoxypropan-l -amine (400 mg, 1.392 mmol) and the mixture was degassed by evacuating the vessel under vacuum and depressurizing with nitrogen. The mixture was shaken under 50 psi hydrogen for 4 hours. The mixture was degassed as previously described, and the reaction mixture was filtered under nitrogen through fiberglass filter paper. The filter cake was thoroughly rinsed with methanol (25 mL), and the filtrate was concentrated in vacuo to provide (R)-2-fluoro-3-methoxypropan-l -amine (125 mg, 75% yield) as a colorless oil as product.
Figure imgf000133_0001
Step 4: To a stirred solution of 6-chloro-4-(isopropylamino)nicotinic acid (250 mg, 1.167 mmol), BOP (516 mg, 1.167 mmol) and TEA (0.325 mL, 2.334 mmol) in DMF (5 mL) at 25 °C was added (R)-2-fluoro-3-methoxypropan-l -amine (125 mg, 1.167 mmol). After 20 hours, the reaction mixture was diluted with ethyl acetate and rinsed with 10% LiCl (2x), saturated sodium bicarbonate (lx) and finally 10% LiCl (lx). The organic layer was dried over Na2S04 and concentrated to provide (R)-6-chloro-N-(2- fluoro-3-methoxypropyl)-4-(isopropylamino)nicotinamide (300 mg, 71% yield) as tan solid. LCMS (M+H)+ = 304.2.
Step 5: A mixture of (R)-6-chloro-N-(2-fluoro-3-methoxypropyl)-4- (isopropylamino)nicotinamide (35 mg, 0.115 mmol), lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (16.49 mg, 0.115 mmol), potassium carbonate (31.8 mg, 0.230 mmol), and 6: 1 t-BuOH/DMA (2 mL) in a 5 mL microwave vial containing a magnetic stir bar was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (4.6 mg, 0.115 mmol), and degassed for another 5 minutes. The vial was sealed and the reaction mixture was heated in the microwave with stirring at 145 °C for 15 minutes. The reaction mixture was evaporated, diluted with DMF, filtered, and purified via preparative HPLC to afford the product (12 mg, 24% yield). 1H NMR (500MHz, DMSO-de) δ 8.80 (d, J=l .8 Hz, 2H), 8.66 (d, J=l .8 Hz, 1H), 8.58 (s, 1H), 8.52 (d, J=3.7 Hz, 2H), 8.09 (s, 1H), 6.88 (d, J=3.7 Hz, 1H), 4.87-4.69 (m, 1H), 3.77 (dq, J=13.0, 6.4 Hz, 1H), 3.65-3.45 (m, 4H), 3.31 (s, 3H), 1.29 (d, J=6.1 Hz, 6H). LCMS (M+H)+ = 411.3 for product. HPLC rt 1.88 min, Conditions E. Example 128
(R)-6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fiuoro-3-methoxypropyl)-4- isopropylamino)nicotinamide
Figure imgf000134_0001
Example 128 was prepared according to the general procedure for Example 127 utilizing lH-pyrazolo[3,4-b]pyridine-5-carbonitrile in the final step. LCMS 412.2 (M+) HPLC rt 1.47 min, Conditions E.
Example 129
6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3-(isopropylamino)butyl)-4- isopropylamino)nicotinamide
Figure imgf000134_0002
Figure imgf000134_0003
Step 1 : To a solution of 4-(dibenzylamino)-3-fluorobutan-2-one (1.0 g, 3.50 mmol) in DCM (4 mL) at 0 °C was added TEA (2.442 mL, 17.52 mmol). After 5 minutes, propan-2-amine (1.036 g, 17.52 mmol) and TiCl4 (1.159 mL, 10.51 mmol) were added and stirred continued at room temperature overnight. NaCNBH4 (1.10 g, 17.52 mmol) was added to the reaction mixture at 0 °C and again stirred at room temperature for 1 hr. The reaction mixture was filtered through CELITE® using 1 : 1 methanol and dichloromethane and was concentrated to obtain brown solid. Sodium bicarbonate was added to the mixture and extracted with ethylacetate (3 times). The combined organic extracts were washed with water and brine then dried over anhydrous Na2S04, filtered and concentrated to obtain brown color liquid. This crude product was purified via column chromatography to afford ΝΙ,ΝΙ -dibenzyl-2-fluoro-N3-isopropylbutane- 1,3- diamine (1.06 g, 92% yield). LCMS 329.0 (M+H)+.
Figure imgf000135_0001
Step 2: A solution of (2S)-Nl,Nl-dibenzyl-2-fluoro-N3-isopropylbutane-l,3- diamine (1.0 g, 3.04 mmol) in MeOH (30 mL) was added Pd/C (0.2 g, 1.879 mmol) and PdOH2 (0.2 g, 1.424 mmol). The vessel was charged with H2 gas and stirred overnight. The reaction mixture was filtered through CELITE® using 500 mL of methanol and the filtrate was concentrated to afford the product (0.42 g, 93% yield) as a brown solid. 1H NMR (400MHz, DMSO-d6) δ 5.40-5.20 (m, 1H), 3.72-3.40 (m, 1H), 3.55-3.45 (m, 3H), 1.31- 1.21 (m, 9H).
Figure imgf000135_0002
Step 3: 6-Chloro-4-(isopropylamino)nicotinic acid (0.22 g, 1.025 mmol) in DMF
(5 mL), was added HATU (0.585 g, 1.537 mmol), DIPEA (0.895 mL, 5.12 mmol) and (2S)-2-fluoro-N3-isopropylbutane-l,3-diamine (0.182 g, 1.230 mmol). The reaction mixture was stirred at room temperature for 4 hrs. Sodium bicarbonate was added to the reaction mixture and it was extracted with ethylacetate (3 times). The combined organic extracts were washed with water, brine, then dried over anhydrous Na2S04. The organic layer was filtered and concentrated to afford the crude product which was purified via column chromatography to afford 6-chloro-N-((2R)-2-fluoro-3-(isopropylamino)butyl)-4- (isopropylamino)nicotinamide (0.34 g, 96% yield). 1H NMR (400MHz, DMSO-d6) δ 8.79-8.76 (m, 1H), 8.41-8.32 (m, 2H), 6.70 (s, 1Η),4.65-4.40 (m, 1H), 3.78-3.73 (m, 1H), 3.55-3.45 (m, 2H), 2.92-2.85 (m, 3H), 1.16 (d, 6H, J= 8.0 Hz), 1.07-0.93 (m, 9H); LCMS 345.4 (M+H)+.
Step 4: A solution of 6-chloro-N-((2R)-2-fluoro-3-(isopropylamino)butyl)-4- (isopropylamino)nicotinamide (0.2 g, 0.580 mmol) and lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (0.125 g, 0.870 mmol) in 1,4 dioxane (5 mL) was added Xantphos (0.168 g, 0.290 mmol) and 3 eq of K2C03 (0.240 g, 1.740 mmol). The mixture was purged with N2 and then added Pd2dba3 (0.266 g, 0.290 mmol) and again purged for 10 minutes. The vessel was then heated at 110 °C for 18 h. The mixture was cooled and filtered through CELITE® using 1 : 1 methanol and dichloromethane and extracted using 1.5N HC1 and ethyl acetate. The water layer was neutralized with sodium carbonate and extracted with ethylacetate (3 times). The combined organic extracts were washed with water, brine then dried over anhydrous Na2S04. The organics were filtered and concentrated to obtain a brown solid which was purified via column chromatography and then preparative HPLC to afford 12 mg of the diastereomeric mixture. This material was separated via SFC chiral chromatography to furnish Example 129 (5 mg) as an off-white solid. 1H NMR (400MHz, DMSO-de) δ 8.81-8.77 (m, 3H), 8.67 (d, 1H; J= 2.0Hz), 8.58-8.52 (m, 3H), 8.31 (s, 1H), 8.10 (s, 1H), 6.87 (d, 1H, J= 4Hz),4.55-4.39 (m, 1H), 3.79-3.76 (m, 1H), 3.70-3.40 (m, 3H), 2.90-2.85 (m, 2H), 1.27 (d, 6H), j= 8.0 Hz), 1.08-0.94 (m, 9H); LCMS 452.0 (M+H)+.
The second diastereomer (3 mg) was isolated as Example 130.
Example 130
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3-(isopropylamino)butyl)-
4-(isopropylamino)nicotinamide
Figure imgf000136_0001
1H NMR (400MHz, DMSO-d6) δ 8.81-8.80 (m, 2H), 8.67(d, 1H, j= 2.0Hz), 8.59- 8.57 (m, 2H), 8.53-8.52 (m, 1H), 8.31 (s, 1H), 8.10 (s, 1H), 6.87 (d, 1H, J= 4Hz),4.61- 4.46 (m, 1H), 3.80-3.76 (m, 1H), 3.55-3.45 (m, 2H), 2.95-2.80 (m, 3H), 1.29 (d, 6H, J= 8.0 Hz), 1.07 (d, 3H, J=8.0 Hz), 1.01 (d, 3H, J =8.0 Hz), 0.95 (d, 3H, J = 8.0 Hz); LCMS 452.0 (M+H)+.
Example 131
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4- (( 1 -fluoro-3 -h droxypropan-2-yl)amino)nicotinamide
Figure imgf000137_0001
Figure imgf000137_0002
Step 1 : To a stirred solution of ethyl 4,6-dichloronicotinate (6.0 g, 27.3 mmol) in DMA (lOOmL), DIPEA (23.81 mL, 136 mmol) and 2-aminopropane-l,3-diol (2.98 g, 32.7 mmol) were added and heated at 60 °C in a round bottom flask for 4 h. Reaction mixture was cooled to room temperature, added water and extracted with ethyl acetate (3 times). The organic extracts were combined together, dried over Na2S04, filtered and concentrated to get the brown color liquid as the required crude product. The crude material obtained was purified by column chromatography through silica gel and EtOAC: pet. Ether (70%) as eluent to obtain the ethyl 6-chloro-4-((l,3-dihydroxypropan-2- yl)amino)nicotinate (7.1 g, 95% yield). LC/MS: 275.4 (M+H)+.
Figure imgf000137_0003
Step 2: Ethyl 6-chloro-4-((l,3-dihydroxypropan-2-yl)amino)nicotinate (0.1 g, 0.364 mmol) in DCM (3 mL) at -78 °C was added DAST (0.096 mL, 0.728 mmol) and then allowed to stir at room temperature for 10 min. Sodium bicarbonate in ice water was added the reaction mixture slowly and then extracted 3 times with DCM. The combined organic extracts were dried Na2S04, filtered, and concentrated to obtain the crude product which was purified via column chromatography to afford ethyl 6-chloro-4-((l-fluoro-3- hydroxypropan-2-yl)amino)nicotinate (0.090 g, 89% yield). LCMS 277.0 (M+H)+.
Figure imgf000138_0001
Step 3: To a solution of ethyl 6-chloro-4-((l-fluoro-3-hydroxypropan-2-yl)amino) nicotinate (0.12 g, 0.434 mmol) in EtOH (4 mL) and water (1 mL) was added LiOH (0.052 g, 2.168 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated and the residue was acidified with 1.5N HC1 to precipitate the product. The white solids were filtered and washed to afford 6-chloro-4- ((l-fluoro-3-hydroxypropan-2-yl)amino)nicotinic acid (0.1 g, 93% yield) as a white solid. LCMS 249.4 (M+H)+.
Figure imgf000138_0002
Step 4: A solution of 6-chloro-4-((l-fluoro-3-hydroxypropan-2-yl)amino) nicotinic acid (0.1 g, 0.40 mmol) in DMF (3 mL) was added HATU (0.23 g, 0.60 mmol), DIPEA (0.35 mL, 2.01 mmol) and (R)-4-amino-3-fiuoro-2-methylbutan-2-ol (0.058 g, 0.48 mmol). The reaction mixture was stirred at room temperature overnight. Sodium bicarbonate was added and the reaction mixture was extracted with ethylacetate (3 times). The combined organic extracts were washed with water and brine then dried over Na2S04. The solution was filtered and concentrated to obtain brown liquid which was purified via column chromatography to afford 6-chloro-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-((l-fluoro-3-hydroxypropan-2-yl)amino Nicotinamide (0.13 g, 92% yield). LCMS 352.3 (M+H).
Step 5: A solution of 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((l- fluoro-3-hydroxypropan-2-yl)amino)nicotinamide (0.15 g, 0.426 mmol) and 1H- pyrrolo[2,3-b]pyridine-5-carbonitrile (0.092 g, 0.640 mmol) in 1,4 dioxane (3 mL) was added Xantphos (0.123 g, 0.213 mmol) and K2CO3 (0.177 g, 1.279 mmol). The mixture was evacuated and backfilled with N2 then added Pd2(dba)3 (0.195 g, 0.213 mmol). The mixture was evacuated and backfilled with N2 again and then heated at 110 °C for 18 h. The mixture was cooled to room temperature and filtered through CELITE® using 1 : 1 methanol and dichloromethane. The crude product was purified via column
chromatography and preparative HPLC to afford 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -fluoro-3 -hydroxypropan-2- yl)amino)nicotinamide (3 mg, 1.5% yield). LCMS 459.2 (M+H)+; 1H NMR (400MHz, DMSO-de) δ 8.82-8.80 (m, 1 H), 8.70-8.64 (m, 2 H), 8.54-8.53 (m, 1 H), 8.33-8.32 (m, 1 H), 8.18-8.16 (m, 1 H), 6.91-6.90 (m, 1 H), 5.23-5.19 (m, 1 H), 4.74-4.58 (m, 3 H), 3.45- 3.37 (m, 4 H), 1.20-1.17 (m, 6 H).
Example 132
(R)-6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(cyclopropylamino)-N-(2-fluoro-3- (methylamino)-3 -oxopropyl)nicotinamide
Figure imgf000139_0001
Step 1 : (R)-Ethyl 3-(dibenzylamino)-2-fluoropropanoate (5 g, 15.85 mmol) was taken in ethanol (15 mL),water (3 mL) and to this LiOH (1.139 g, 47.6 mmol) was added and allowed to stir overnight. Ethanol and water were removed under vacuum and the crude reaction mixture was acidified using 1.5N HCl. The aqueous layer was extracted with ethylacetate and the ethylacetate layer was washed with water, dried and evaporated. The crude material was purified by combiflash using 5% MeOH in CHCI3 to afford a brown oily product (3.5 g, 77% yield). LCMS 288.1 (M+H)+.
Figure imgf000140_0001
Step 2: (R)-3-(Dibenzylamino)-2-fluoropropanoic acid (0.5 g, 1.740 mmol) was taken in DMF (2 mL) and to this solution, methanamine (0.054 g, 1.740 mmol) was added along with HATU (0.662 g, 1.740 mmol) and DIPEA (1.216 mL, 6.96 mmol). The reaction mixture was allowed to stir for 4 hrs. DMF removed under vacuum and the crude was diluted with water and extracted with ethylacetate. The ethyl acetate layer was washed with 10%> NaHC03, dried and evaporated. The crude brown solid was purified by combiflash (12g column) using 5% MeOH in CHC13 and used directly in the next reaction (some starting material remained in the product).
Figure imgf000140_0002
Step 3: To a solution of (R)-3-(dibenzylamino)-2-fluoro-N-methylpropanamide (800 mg, 2.66 mmol) in MeOH (5 mL) was added Pd/C (142 mg, 1.332 mmol) and Pd(OH)2 (187 mg, 1.332 mmol). The solution was hydrogenated at 1 atm pressure for 6 hrs. The reaction mixture was diluted with ethyl acetate and passed through a small plug of CELITE®. The filtrate was concentrated and the crude product (150 mg, 47% yield) was used without further purification.
Figure imgf000140_0003
Step 4: 6-Chloro-4-(cyclopropylamino)nicotinic acid (500 mg, 2.351 mmol) was taken in DMF (3 mL) and to this solution, (R)-3-amino-2-f uoro-N-methylpropanamide (282 mg, 2.351 mmol) was added along with HATU (894 mg, 2.351 mmol) and DIPEA (0.411 mL, 2.351 mmol). The reaction mixture was stirred at room temperature for 4 hrs TLC indicated the absence of starting material. The reaction mixture was diluted with 10% NaHC03 and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried and evaporated to afford the crude product which was purified by column chromatography (12 g, 5% MeOH in CHC13). The compound (340 mg, 46%> yield) was used without further purification.
Step 5: To solution of lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (54.6 mg, 0.381 mmol) in dioxane (5 mL):water (1 mL), lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (54.6 mg, 0.381 mmol), K2C03 (132 mg, 0.953 mmol) and Xantphos (92 mg, 0.159 mmol) were added and degassed for 10 min. To the reaction mixture Pd2(dba)3 (116 mg, 0.127 mmol) was added and degassed again for 10 min and then heated at 110 °C overnight in a pressure tube. The reaction mixture was cooled and filtered through small pad of CELITE®. The filtrate obtained was concentrated to provide crude material. The crude product was purified via preparative HPLC to afford (R)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -(methylamino)-3 -oxopropyl) nicotinamide (8 mg, 0.018 mmol, 5.56% yield). 1H NMR (400MHz, DMSO-d6) δ 8.86- 8.81 (m, 1 H), 8.69 (d, J= 2.0 Hz, 1 H), 8.61-8.56 (m, 4 H), 8.24 (br. s., 1 H), 6.91 (d, J = 4.0 Hz, 1 H), 5.11-4.93 (m, 1 H), 3.88-3.72 (m, 1 H), 3.61-3.48 (m, 1 H), 2.69-2.59 (m, 4 H), 0.98-0.92 (m, 2 H), 0.63-0.58 (m, 2 H); LCMS (M+H)+ = 422.2; HPLC rt 7.49 min, Conditions B.
Example 133
(R)-6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-
4-(isopropylamino)nicotinamide
Figure imgf000141_0001
Figure imgf000142_0001
Step 1 : Ethyl 6-chloro-4-(isopropylamino)nicotinate (1 g, 4.12 mmol) and 1H- pyrazolo[3,4-b]pyridine-5-carbonitrile (0.594 g, 4.12 mmol) was dissolved in 1,4-dioxane (10 mL) in a pressure tube at room temperature. The reaction mixture was degassed by bubbling nitrogen into the reaction mixture. 2-Di-tert-butylphosphino-2',4',6'- triisopropylbiphenyl (0.525 g, 1.236 mmol) and potassium phosphate dibasic (2.153 g, 12.36 mmol) was added and the mixture was degassed for another 20 min. Pd2(dba)3 (0.755 g, 0.824 mmol) was added and the nitrogen purging continued for 5 min. The reaction mixture was then heated at 110 °C for 18 h. Reaction mixture was cooled to room temperature and diluted with EtOAc (150 mL), filtered through CELITE®, and washed with 100 mL of EtOAc. The filtrate was concentrated and the crude material was purified by flash column chromatography using silica gel as stationary phase and EtOAc: pet ether (1 : 1) as eluent to afford the compound. The material was further purified by reverse phase HPLC to get ethyl 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4- (isopropylamino)nicotinate (100 mg, 6.44% Yield). 1H NMR (400MHz,DMSO-d6) δ 9.08 (d, J= 1.5 Hz, 2 H), 9.03 (d, J= 2.0 Hz, 2 H), 8.82 (s, 2 H), 8.68 (s, 1 H), 8.10 (d, J= 7.5 Hz, 1 H), 7.48 (s, 1 H), 4.36 (q, J= 7.0 Hz, 2 H), 4.12-4.07 (m, 1 H), 3.92-3.83 (m, 2 H), 1.36 (t, J= 7.0 Hz, 3 H), 1.32-1.29 (m, 6 H).
Figure imgf000142_0002
Step 2: To the solution of ethyl 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4- (isopropylamino)nicotinate (0.7 g, 1.998 mmol) in ethanol (2 mL) and THF (10 mL) was added lithium hydroxide (0.5 g) in water (0.500 mL) at room temperature in 2 portions (at an interval of 4 h). The reaction mixture was stirred at room temperature for 1 h.
Temperature of the reaction mixture was raised to 65 °C and stirred for 18 hrs. Excess solvent was removed under reduced pressure, diluted with water 10 mL, cooled to 0 °C. The pH of the reaction mixture was adjusted using a saturated solution of citric acid (dropwise addition) at 0 °C to pH 7. The product precipitated from solution to afford 6- (5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)nicotinic acid (0.6 g, 1.861 mmol, 93% yield) after filtration. LC/MS 321 (M-H).
Step 3: To a stirred solution of 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4- (isopropylamino)nicotinic acid (0.6 g, 1.861 mmol) in DMF (2 mL) was added DIPEA (0.975 mL, 5.58 mmol) and HATU (1.416 g, 3.72 mmol) and stirred for 20 min at room temperature. (R)-4-Amino-3-fluoro-2-methylbutan-2-ol (0.226 g, 1.861 mmol) in DMF (2 mL) was added to the reaction mixture and stirred at room temperature for 1 h. Excess DMF was removed under reduced pressure. The residue was diluted with ethyl acetate (100 mL), washed with 10% NaHC03 solution (20 mL) followed by brine (20 mL). The organic layer was collected, dried over Na2S04, filtered and concentrated to get the crude material which was purified by RP-HPLC to obtain (R)-6-(5-cyano-lH-pyrazolo[3,4-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (0.3015 g, 37.7% yield). HPLC: 99%, Condition A. LC/MS: 426 (M+H). 1H NMR (400MHz,DMSO-d6) δ = 9.05 (dd, J= 2.0, 13.6 Hz, 1 H), 8.85-8.79 (m, 1 H), 8.66-8.64 (m, 1 H), 8.60-8.55 (m, 1 H), 7.34 (s, 1 H), 4.85 (s, 1 H), 4.47-4.29 (m, 1 H), 3.82-3.74 (m, 1 H), 1.29-1.17 (m, 6 H).
Alternatively, the penultimate carboxylic acid was prepared according to the following procedures:
Figure imgf000143_0001
Step 1 : A suspension of 6-chloro-4-(isopropylamino)nicotinic acid (240 g, 1118 mmol) in toluene (1800 mL) in a 1L round bottom flask was heated to 90 °C. N,N- dimethylformamide di-tert-butyl acetal (1609 mL, 6709 mmol) in toluene (1800 mL) was added slowly over 8-9 hrs. The reaction mixture was heated at 90 °C for 12 hrs. After completion of 12 hrs, the reaction mixture was cooled and concentrated under reduced pressure to remove excess of solvent and obtain the crude material. The crude material was purified by flash column chromatography using silica gel as stationary phase and EtOAc: pet ether (2:8) as eluent to afford the title compound, tert-butyl 6-chloro-4- (isopropylamino)nicotinate (275g, 91% yield). LC/MS 271.0 (M+H). 1H NMR
(400MHz, CDC13) δ = 8.59 (s, 1 H), 8.14-8.08 (m, 1 H), 6.51 (s, 1 H), 3.71-3.61 (m, 1 H), 1.57 (s, 9 H), 1.28 (d, J= 6.5 Hz, 6 H).
Figure imgf000144_0001
Step 2: A solution of lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (69.2 g, 480 mmol) and tert-butyl 6-chloro-4-(isopropylamino)nicotinate (130 g, 480 mmol) in 1,4- dioxane (4200 mL) in 10L autoclave was degassed by purging nitrogen gas into the reaction mixture for 10 min. Xantphos (111 g, 192 mmol) and potassium carbonate (199 g, 1440 mmol) were added to the autoclave and degassing was continued for another 10 min. Bis(dibenzylidineacetone)palladium (110 g, 192 mmol) was added to the reaction mixture. The reaction mixture was purged with nitrogen gas for additional 10 min. The autoclave was then heated under 10 kg pressure at 120 °C for 12 hrs. After the completion of 12 hrs, the autoclave was cooled to room temperature and reaction mass was unloaded. The solvent was removed under vacuum. Ethyl acetate (2.5 L) and water (2.5 L) was added to the residue and the resulting mixture was filtered through a
CELITE® bed. The CELITE® was washed with 1x1000 mL ethyl acetate. The organic layer was separated, washed with water (1 L) followed by brine (0.5 L). The organic layer was collected, dried over sodium sulfate, filtered and concentrated to get a dark green crude material. The crude material was purified by column chromatography using silica gel as stationary phase and EtOAc: pet ether (2:8) as eluent to get the desired compound. The material obtained after purification was treated with MTBE to precipitate the product tert-butyl 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-
(isopropylamino)nicotinate (50g, 27.5%). LC/MS 379.2 (M+H). 1H NMR (400MHz, CDCI3) δ = 8.97-8.93 (m, 2 H), 8.48 (d, J= 2.0 Hz, 1 H), 8.36 (s, 1 H), 8.27-8.22 (m, 1 H), 7.49 (s, 1 H), 3.91-3.82 (m, 1 H), 1.61-1.52 (m, 9 H), 1.37 (d, J= 6.5 Hz, 6 H).
Figure imgf000145_0001
Step 3: A solution of tert-butyl 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4- (isopropylamino)nicotinate (42 g, 111 mmol) in DCE (277 mL) in a 1 L pressure tube at room temperature was added TFA (86 mL, 1110 mmol). The reaction mixture was heated at 80 °C for 2 hrs. After completion of 2 hrs, the reaction mixture was cooled to room temperature and concentrated under reduced pressure to remove excess solvent. The residue obtained was diluted with 350 mL of water and the pH of the reaction mixture was adjusted to 5 with saturated Na2C03 solution (21 mL). The solids were stirred for 10 min at room temperature, filtered, and washed with 200 mL of water and air dried. The crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase and MeOH: DCM (1 :9) as eluent to afford 6-(5- cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)nicotinic acid (31.05g, 81% yield). LC/MS 323.4 (M+H). 1H NMR (400MHz, DMSO-d6) δ = 13.39-13.19 (bs, 1 H), 9.05 (d, J= 19.1 Hz, 2 H), 8.80-8.64 (m, 2 H), 8.32 (d, J= 7.5 Hz, 1 H), 7.44 (s, 1 H), 3.86-3.81 (m, 1 H), 1.30 (d, J= 6.0 Hz, 6 H).
Step 4: To a solution of (R)-4-amino-3-fluoro-2-methylbutan-2-ol (27.8 g, 229 mmol) in DMF (579 mL) was added 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4- (isopropylamino)nicotinic acid (61.63 g, 191 mmol) followed by DIPEA (100 mL, 574 mmol) and HATU (109 g, 287 mmol). The reaction mixture was stirred for a total of 60 min then added water (20 mL) slowly via dropping funnel. After the addition, the mixture slowly became cloudy and was allowed to stir for ~1 h and then another 20 mL of water was added and stirred for 0.5 h then filtered. The solids were washed with water (2 x 20 mL) and dried on the filter to give (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (76 g, 172 mmol, 90% yield).
Figure imgf000146_0001
In a 5 mL microwave vial, a mixture of (R)-6-chloro-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)nicotinamide (33 mg, 0.104 mmol), lH-pyrazolo[3,4-b] pyridine-5-carbonitrile (17.96 mg, 0.125 mmol), and potassium phosphate, tribasic (66.1 mg, 0.312 mmol) in dioxane (1 mL) was degassed with bubbling nitrogen for 5 minutes. In a separate sealed vial, a degassed, stirring mixture of Pd2(dba)3 (4.75 mg, 5.19 μιηοΐ) and tetramethyl t-Bu XPhos (5.99 mg, 0.012 mmol) in 5: 1 toluene/dioxane (0.1 mL) was heated at 120 °C for 5 minutes. After cooling to room temperature, this solution was transferred to the vial containing the reaction mixture. The vial was sealed, and the reaction mixture was heated at 80 °C for 3 hours, then cooled to room temperature and stirred for 18 hours. LCMS detects a 3.5: 1 ratio of the desired product and starting material chloropyridine. The reaction mixture was heated at 80 °C for an additional 4 hours, at which point it was judged to be essentially complete by LCMS. The solvent was evaporated, and the residue was taken up in DMF (5 mL). Solids were removed by filtration and rinsed 3 times with DMF (1 mL), and the combined filtrate and rinses were concentrated in vacuo. The residue was chromatographed via MPLC over a 12 g silica gel column, eluting at 30 mL/min with 0-5% methanol/methylene chloride. Fractions containing the desired product were pooled and concentrated in vacuo to yield (R)-6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-
(isopropylamino) nicotinamide (27 mg, 0.063 mmol, 61.1% yield) as a slightly yellow film. LCMS 426.3 (M+H)+. 1H NMR (400MHz, MeOH-d4) δ 8.98 (d, J=2.0 Hz, IH), 8.83 (d, J=2.0 Hz, IH), 8.53 (s, IH), 8.52 (s, IH), 7.75 (s, IH), 4.45 (ddd, J=49.1, 9.3, 2.4 Hz, IH), 3.99-3.83 (m, 2H), 3.51 (ddd, J=16.4, 14.5, 9.1 Hz, IH), 1.37 (d, J=6.4 Hz, 6H), 1.32 (d, J=1.5 Hz, 6H).
Preparations of Crystalline Form N-l
To a slurry of 1.15 grams of (R)-6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide in water (18 mL) was added acetone (2 mL). The mixture was stirred at room temperature for 18 h. A fine white solid was collected by filtration and rinsed with water. After drying, 1.10 g (96% recovery) of Example 133 was obtained as a white crystalline solid.
A solution of Example 133 (50 mg) was prepared in DMF (1 ml) at room temperature (~22 to 25 °C). The solution was evaporated to dryness at room temperature to afford needle-like crystals.
Preparation of Crystalline Form N-2
Example 133 (25 mg) was dissolved in 2-propanol (2.5 ml) at 60-70 °C. The saturated solution was allowed to cool to afford needle shaped crystals.
The Examples in Table 7 were prepared according to the general procedure for Example 133 using the appropriate starting material and amine.
Table 7
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Example 158
(R)-6-(5-Bromo-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-
4- isopropylamino)nicotinamide
Figure imgf000151_0002
Step 1 : (R)-6-Chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino) nicotinamide (100 mg, 0.315 mmol) and hydrazine hydrate (3 mL, 0.315 mmol) were heated at 120 °C for 2 hours in a round bottom flask. TLC indicated complete consumption of the starting material and the mixture was concentrated with toluene (2x). The crude material was used directly in the next step.
Step 2: To a stirred solution of (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-6- hydrazinyl-4-(isopropylamino Nicotinamide (50 mg, 0.160 mmol) in 1 ,4-dioxane (1 mL) was added 5-bromo-2-fluoronicotinaldehyde (32.5 mg, 0.160 mmol), K2CO3 (44.1 mg, 0.319 mmol) and Cul (3.04 mg, 0.016 mmol). The mixture was heated at 1 10 °C for 13 hours in a sealed tube, cooled to room temperature and filtered. The filtrate was concentrated and the product purified via preparative HPLC to afford the desired product (10 mg, 13% yield). LCMS 479.0 (M+).
The Examples in Table 8 were prepared according to the general procedure for Example 133 using the appropriate starting material and amine.
Table 8
Figure imgf000152_0001
Figure imgf000153_0001
Example 167
-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2,2-difluoro-3-hydroxy-3-methylbutyl)-
4-(isopropylamino)nicotinamide
Figure imgf000154_0001
Figure imgf000154_0002
Step 1 : To a stirred solution of lH-benzo[d][l,2,3]triazole (2 g, 16.79 mmol) in MeOH (28 mL) was added dibenzylamine (17.6 mL, 16.79 mmol) and formaldehyde (8.1 mL, 16.79 mmol). The reaction mixture was made homogenous by adding Et20 (10 mL) to the reaction mixture and refluxed for 18 h. After cooling, the reaction mixture was diluted with H20 (100 mL) followed by brine solution. A white solid was formed during the wash with brine which was filtered. The residue was washed with Et20 and dried under high vacuum to obtain the desired product, N-((1H benzo[d][l,2,3]triazol-l- yl)methyl)-N-benzyl-l-phenylmethanamine (4.9g, 90% yield). 1H NMR
(400MHz,CDCl3-d) δ = 8.11 (td, J= 1.1, 8.1 Hz, 1 H), 7.46-7.36 (m, 10 H), 7.34-7.25 (m, 2 H), 7.24-7.20 (m, 1 H), 5.49 (s, 2 H), 3.82 (s, 4 H).
Figure imgf000154_0003
Step 2: To a stirred suspension of zinc dust (0.795 g, 12.18 mmol) in THF (20 mL) was added TMSC1 (0.662 g, 6.09 mmol), followed by ethyl 2-bromo-2,2- difluoroacetate (1.360 g, 6.70 mmol). The reaction mixture was stirred for 15 min and a solution of N-(( 1 H-benzo [d] [ 1 ,2,3 jtriazol- 1 -yl)methyl)-N-benzyl- 1 -phenylmethanamine (2 g, 6.09 mmol) in THF (20 mL) was added dropwise. The reaction mixture was allowed to stir for 2 h at room temperature. The reaction mixture was diluted with aqueous NaHC03 and EtOAC. The aqueous layer was extracted with EtOAc (twice). The organic extracts were combined, dried over Na2S04 and concentrated. The crude material was purified by flash column chromatography using silica gel as stationary phase and EtOAc: pet ether (0-10%) as eluent to get ethyl 3-(dibenzylamino)-2,2- difluoropropanoate (1.8 g, 94.6% yield). LC/MS: 334.6 (M+H).
Figure imgf000155_0001
Step 3: To a solution of ethyl 3-(dibenzylamino)-2,2-difluoropropanoate (5.5 g,
16.50 mmol) in THF (50 mL) at 0 °C was added methyl magnesium bromide (3M in diethyl ether) (16.50 mL, 49.5 mmol) dropwise. After completion of the addition the reaction mixture was allowed to stir at room temperature for 2 h. The mixture was cooled to 0 °C and quenched with saturated ammonium chloride solution. The aqueous layer was extracted with ethyl acetate, dried over Na2SC"4 and concentrated to afford 4-
(dibenzylamino)-3,3-difluoro-2-methylbutan-2-ol (5 g, 90% yield). LC/MS: 320.2 (M+H).
Figure imgf000155_0002
Step 4: A solution of 4-(dibenzylamino)-3,3-difluoro-2-methylbutan-2-ol (5 g,
15.65 mmol) in MeOH (50 mL) was added Pd/C ((2.5 g, 23.49 mmol) and PdOH2 (2.5 g, 15.65 mmol) and then hydrogenated at 1 atm pressure for 4 hrs. The reaction mixture was diluted with ethyl acetate and passed through a small plug of CELITE®. The filtrate was concentrated to afford 4-amino-3,3-difluoro-2-methylbutan-2-ol (2 g, 91% yield). The product was used without further purification. 1H NMR (400MHz, methanol^) δ = 3.14 (t, J= 16.3 Hz, 2 H), 1.30 (t, J= 1.1 Hz, 6 H).
Figure imgf000155_0003
Step 5: To a solution of 6-chloro-4-(isopropylamino)nicotinic acid (1 g, 4.66 mmol) in DMF (10 mL), DIPEA (2.441 mL, 13.98 mmol), was added HATU (1.771 g, 4.66 mmol) and 4-amino-3,3-difluoro-2-methylbutan-2-ol (0.778 g, 5.59 mmol). The reaction mixture was stirred for 2 h, diluted with water and extracted with EtOAc (3x75 mL). The organic layers were combined, washed with 10% NaHC03 and dried over Na2S04. The filtrate was concentrated to afford 6-chloro-N-(2,2-difluoro-3-hydroxy-3- ethylbutyl)-4-(isopropylamino)nicotinamide (1 g, 60% yield). LC/MS 336.2 (M+H).
Step 6: 6-Chloro-N-(2,2-difluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino) nicotinamide (0.15 g, 0.447 mmol) and lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (0.064 g, 0.447 mmol) were dissolved in 1,4-dioxane (10 mL) in a pressure tube at room temperature. Xantphos (0.258 g, 0.447 mmol) and Na2C03 (0.142 g, 1.340 mmol) were added and the mixture was purged with nitrogen for 20 min. Pd2(dba)3 (0.205 g, 0.223 mmol) was added to the reaction mixture and purging was continued for another 5 min. The reaction vessel was sealed and heated at 100 °C for 18 h. The reaction mixture was cooled to room temperature and diluted with 15% MeOH:DCM (150 mL) and filtered through CELITE®. The CELITE® was washed with 15% MeOH:DCM (50 mL) and the filtrate was concentrated to get the crude material. The crude material was purified by flash column chromatography using silica gel as stationary phase and 5-6%
MeOH/CHCl3 as eluent to afford the compound. The material obtained was further purified by reverse phase HPLC. LC/MS 444.4 (M+H)+. HPLC 7.322min, Condition A. 1H NMR (400MHz DMSO-d6) δ 9.09-9.03 (m, 2 H), 8.89-8.85 (m, 1 H), 8.67 (d, J= 10.5 Hz, 2 H), 8.58-8.53 (m, 1 H), 7.42 (s, 1 H), 5.41 (bs, 1 H), 3.92 (d, J= 6.5 Hz, 3 H), 1.29- 1.22 (m, 12 H)
Example 168
(R)-N-(2-Fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)-6-(3-(pyridazin-4-yl)-lH- razol- 1 -yl)nicotinamide
Figure imgf000156_0001
Step 1 : In a heavy- walled glass vial, a mixture of 4-bromopyridazine hydrobromide (156 mg, 0.650 mmol), 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l- ((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrazole (422 mg, 1.301 mmol) (prepared via the method of Rault et al, Tetrahedron Letters, 47:4665-4669 (2006)), degassed 0.5 M potassium phosphate (aq) (5.20 mL, 2.60 mmol), and THF (5 mL) was degassed with bubbling nitrogen for 5 minutes. XPhos precatalyst, second generation (CAS #
[1310584-14-5]) (51.2 mg, 0.065 mmol) was added, and the mixture was degassed for another 5 minutes. The vial was sealed, and the reaction mixture was stirred at room temperature for 96 hours, at which point it was judged to be complete by LCMS. The THF was evaporated with a stream of nitrogen, and the remaining aqueous mixture was extracted three times with diethyl ether (5 mL). The combined ether phases were washed once with saturated sodium carbonate and once with brine, then dried over sodium sulfate and concentrated in vacuo. The residue was chromatographed via MPLC over a 24 g silica gel column, eluting at 40 mL/min with 15-95% ethyl acetate/hexanes. Fractions containing the product were pooled and concentrated in vacuum to yield 4-(l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrazol-5-yl)pyridazine (123 mg, 0.445 mmol, 68.4% yield) as a colorless oil. LCMS = 276.5 (M+H)+.
Step 2: A solution of 4-(l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrazol-5- yl)pyridazine (123mg, 0.445 mmol) in dichloromethane (1 mL) was stirred at room temperature for 2 hours, at which point the reaction mixture was judged to be complete by LCMS based on the complete consumption of starting material, and a single product peak with m/z = 111. The mixture was concentrated in vacuo, and the residue was
concentrated twice from dichloromethane to remove residual TFA. The residue was stirred in saturated sodium bicarbonate (1.5 mL) for 5 minutes, then the turbid mixture was extracted 4 x with ethyl acetate (3 mL). The combined organic phases were dried over sodium sulfate and concentrated in vacuo. The residue was triturated with diethyl ether (3 mL), and the resulting amber powder was collected by filtration, rinsed twice with diethyl ether (0.5 mL), and dried under vacuum to yield 42 mg of amber powder. LCMS of this material detects m/z = 177.0, which was consistent with (3-(pyridazin-4- yl)-lH-pyrazol-l-yl)methanol, resulting from partial decomposition of the SEM protecting group. In a 2-dram vial, the powder was suspended in ethanol (1 mL), and the mixture was treated with 5 M HCl in water (0.445 mL, 2.225 mmol) (5 eq). The vial was capped, and the reaction mixture was stirred at 60 °C for 18 hours. The mixture was concentrated in vacuo, and the residue was treated carefully with saturated sodium bicarbonate (1 mL). The turbid mixture was stirred for 10 minutes, then extracted 4 x with ethyl acetate (2 mL). The combined organic phases were dried over sodium sulfate and concentrated in vacuo to yield 4-(lH-pyrazol-3-yl)pyridazine (29 mg, 0.198 mmol, 44.6% yield). LCMS = 147.3 (M+H)+.
Step 3 : In a 2 mL microwave vial, a mixture of ethyl 6-chloro-4-(isopropylamino) nicotinate (46.8 mg, 0.193 mmol), 4-(lH-pyrazol-3-yl)pyridazine (31 mg, 0.212 mmol), and NaOtBu (37.1 mg, 0.386 mmol) in toluene (1 mL) was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with tBu XPhos precatalyst, first generation (CAS # [1142811-12-8]) (13.24 mg, 0.019 mmol) and degassed for another 5 minutes. The vial was sealed, and the reaction mixture was heated with stirring at 150 °C for 20 minutes, at which point it was judged to be complete by LCMS. The toluene was evaporated, and the residue was taken up in 1 : 1 methanol/water (2 mL). The mixture was treated with LiOH (6.93 mg, 0.289 mmol), and the reaction mixture was stirred for 2 hours, with occasional gentle heating via heat gun. LCMS shows that the reaction was essentially complete. The mixture was concentrated in vacuo, and the residue was concentrated twice from isopropanol and dried under vacuum to yield lithium 4- (isopropylamino)-6-(3-(pyridazin-4-yl)-lH-pyrazol-l-yl)nicotinate as a brown solid which was used as-is in the next step. LCMS = 325.2 (M+H)+ of the protonated carboxylic acid.
Step 4: A stirring mixture of (R)-4-amino-3-fluoro-2-methylbutan-2-ol (46.0 mg, 0.380 mmol), sodium 4-(isopropylamino)-6-(3-(pyridazin-4-yl)-lH-pyrazol-l- yl)nicotinate (65.8 mg, 0.19 mmol), and TEA (0.053 mL, 0.380 mmol) was treated with BOP (126 mg, 0.285 mmol). The reaction mixture was stirred at room temperature for 2 hours, at which point it was judged to be complete by LCMS based on the complete consumption of the starting nicotinate. The reaction mixture was concentrated in vacuo. The crude material was purified via preparative LC/MS with the following conditions: Column: 19 x 200 mm, 5-um particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1%
trifluoroacetic acid; Gradient: 0-100% B over 20 minutes, then a 0-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)-6-(3-(pyridazin-4-yl)-lH-pyrazol-l-yl)nicotinamide (21mg, 0.045 mmol, 23.53% yield), 98264-072-01. LCMS = 428.2 (M+H)+. HPLC rt = 1.32 min, Conditions E. 1H NMR (500MHz, DMSO-d6) δ 9.88 (s, 1H), 9.35 (d, J=4.9 Hz, 1H), 8.85-8.76 (m, 2H), 8.69 (d, J=7.9 Hz, 1H), 8.56 (s, 1H), 8.23 (dd, J=5.5, 1.8 Hz, 1H), 7.40 (d, J=2.4 Hz, 1H), 7.30 (s, 1H), 4.45-4.28 (m, 1H), 3.99-3.88 (m, 1H), 3.81-3.66 (m, 1H), 1.27 (d, J=6.1 Hz, 6H), 1.18 (d, J=6.7 Hz, 6H). Note that one proton from the fluoro-alkyl side-chain and the isopropyl methyl proton are obscured by the water signal at 3.7-3.3 ppm in this spectrum.
Example 169
(R)-6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-((2,2-difluoro-3-hydroxy-3- methylbutyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide
Figure imgf000159_0001
Figure imgf000159_0002
Step 1 : To a stirred solution of ethyl 4,6-dichloronicotinate (0.5 g, 2.272 mmol) and 4-amino-3,3-difluoro-2-methylbutan-2-ol (0.379 g, 2.73 mmol) in DMA (2mL) was added DIPEA (1.191 mL, 6.82 mmol). The reaction mixture was stirred for 18 h then diluted with water and extracted with ethyl acetate (3 x 75 mL). The extracts were dried over Na2S04, filtered and concentrated to get the crude material which was purified by column chromatography (12 g, 40% EtOAc: pet ether). Ethyl 6-chloro-4-((2,2-difluoro- 3-hydroxy-3-methylbutyl)amino)nicotinate (0.7 g, 95% yield) was obtained. LC/MS 323.2 (M+H).
Figure imgf000160_0001
Step 2: To a solution of ethyl 6-chloro-4-((2,2-difluoro-3-hydroxy-3-methylbutyl) amino)nicotinate (0.3 g, 0.930 mmol) in ethanol (5 mL) and water (2 mL) was added lithium hydroxide (0.067 g, 2.79 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated completely to dryness and the residue was acidified with 1.5N HC1 solution to pH 4-5. The resulting solid was filtered to afford 6-chloro-4-((2,2-difluoro-3-hydroxy-3-methylbutyl)amino)nicotinic acid (0.25 g, 90% yield) as off-white solid. LC/MS 295 (M+H).
Figure imgf000160_0002
Step 3: To a solution of 6-chloro-4-((2,2-difluoro-3-hydroxy-3-methylbutyl) amino)nicotinic acid (0.4 g, 1.357 mmol) in DMF (5 mL)was added DIPEA (0.711 mL, 4.07 mmol), HATU (0.516 g, 1.357 mmol) and (R)-4-amino-3-fluoro-2-methylbutan-2-ol (0.197 g, 1.629 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water (80 mL) and extracted with ethyl acetate
(3x80 mL). The extracts were dried over Na2S04, filtered and concentrated to afford the crude material which was purified by column chromatography (24 g, 80% EtOAc: pet ether). The compound, (R)-6-chloro-4-((2,2-difluoro-3-hydroxy-3-methylbutyl)amino)- N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (180 mg, 32.7% yield) was isolated as a light brown oil. LC/MS 398.2 (M+H).
Step 4: A mixture of lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (36.2 mg, 0.251 mmol) in dioxane (10 mL) in a pressure tube at room temperature was degassed by bubbling nitrogen gas into the reaction mixture for 5 min. Xantphos (29.1 mg, 0.050 mmol) and K2CO3 (104 mg, 0.754 mmol) was added into the reaction mixture and degassed for another 5 min. (R)-6-Chloro-4-((2,2-difluoro-3-hydroxy-3-methylbutyl) amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (100 mg, 0.251 mmol) was added into the reaction mixture and degassed for another 5 min. Pd2(dba)3 (46.0 mg, 0.050 mmol) was added to the reaction mixture and purging was continued for another 5 min. The reaction mixture temperature was raised to 100 °C and stirred for 18 h in a closed condition. The reaction mixture was cooled to room temperature, diluted with 15% MeOH:DCM (150 mL) and filtered through CELITE®. The CELITE® was washed with 15% MeOH: DCM (50 mL) and the filtrate was concentrated to afford the crude material. The crude material was purified by reverse phase HPLC. LC/MS 506.2
(M+H)+. HPLC 7.322 min, Condition F. 1H NMR (400MHz, MeOH-d4) δ = 8.98 (d, J = 2.0 Hz, 1 H), 8.84 (d, J= 2.0 Hz, 1 H), 8.61-8.54 (m, 2 H), 7.92 (s, 1 H), 4.55-4.38 (m, 1 H), 4.03 (t, J= 16.1 Hz, 4 H), 3.51 (d, J= 1.5 Hz, 2 H), 1.42-1.38 (m, 6 H), 1.32 (d, J = 2.0 Hz, 6 H).
Example 170
(R)-N-(2-Fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)-6-(9H-purin-9-yl) nicotinamide
Figure imgf000161_0001
The title compound was prepared from (R)-6-chloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide and purine via the conditions used in Example 1. LCMS detects m/z = 401.6 (M+). HPLC rt = 1.17, method F. 1H NMR (500MHz, DMSO-de) δ 9.32 (s, 1H), 9.30 (s, 1H), 9.12 (s, 1H), 8.85 (t, j=5.4 Hz, 1H), 8.72 (d, J=6.4 Hz, 1H), 8.63 (s, 1H), 7.92 (s, 1H), 4.89 (br. s., 1H), 4.50-4.27 (ddd, J=1.5, 9.9, 49.4 Hz, 1H), 3.89-3.64 (m, 2H), 1.31 (d, J=5.9 Hz, 6H), 1.18 (d, J=6.4 Hz, 6H).
Example 171
(R)-6-(2-Amino-9H-purin-9-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide
Figure imgf000162_0001
In a 5 mL microwave vial, a mixture of (R)-6-chloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide (35 mg, 0.110 mmol), 7H-purin-2-amine (22.32 mg, 0.165 mmol), and powdered phosphoric acid, potassium salt (58.4 mg, 0.275 mmol) in toluene (1 mL) was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[l,l '- biphenyl]-2-yl)phosphine (21.18 mg, 0.044 mmol) and Pd2(dba)3 (10.09 mg, 0.011 mmol), and degassed for another 5 minutes. The vial was sealed, and the reaction mixture was heated with stirring at 100 °C for 18 hours, at which point the reaction mixture was judged to be complete by LCMS. The toluene was evaporated, and the residue was taken up in DMF (2 mL). The solution was filtered and purified via preparative LC/MS with the following conditions: Column: Waters XBridge CI 8, 19 x 100 mm, 5-μιη particles; Guard Column: Waters XBridge CI 8, 19 x 10 mm, 5-μιη particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 0- 100% B over 10 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield (R)-6-(2-amino-9H-purin-9-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide (14 mg, 29% yield). LCMS = 417.2 (M+H)+. HPLC rt =
1.13 min, Conditions E. 1H NMR (500MHz, DMSO-d6) δ 8.82-8.75 (m, 2H), 8.71 (s, 1H), 8.64 (d, J=7.4 Hz, 1H), 8.57 (s, 1H), 7.97 (s, 1H), 6.79 (br. s., 2H), 4.87 (s, 1H), 4.44-4.29 (m, 1H), 3.90 (dq, J=12.9, 6.4 Hz, 1H), 3.79-3.65 (m, 2H), 1.28 (d, J=6.4 Hz, 6H), 1.18 (d, J=6.9 Hz, 6H).
Example 172
(R)-N-(2-Fluoro-3-hydroxy-3-methylbutyl)-6-(2-((2-hydroxyethyl)amino)-9H-purin-9- yl)-4-(isopropylamino)nicotinamide
Figure imgf000163_0001
Step 1 : In a sealed vial, a stirring mixture of 2-chloro-9H-purine (69 mg, 0.446 mmol) and 2-aminoethanol (0.243 mL, 4.02 mmol) in ethanol (0.75 mL) was heated at 160 °C for 1 hour, at which point the reaction mixture was judged to be complete by LCMS. The ethanol was evaporated, and the residue was chromatographed via MPLC over a 12 g silica gel column, eluting at 30 mL/min with a 5% to 15%
methanol/methylene chloride gradient over 12 column volumes, then with 15%
methanol/methylene chloride to complete the elution of the major product. Fractions containing the product were pooled and concentrated in vacuo to yield 2-((9H-purin-2- yl)amino)ethanol (43 mg, 0.240 mmol, 53.8% yield). LCMS m/z = 180 (M+H)+.
Step 2: In a 5 mL microwave vial, a mixture of (R)-6-chloro-N-(2-fluoro-3- hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (30 mg, 0.094 mmol), 2-((9H- purin-2-yl)amino)ethanol (20.30 mg, 0.113 mmol), and powdered phosphoric acid, potassium salt (40.1 mg, 0.189 mmol) in toluene (0.5 mL) was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with di-tert-butyl(2',4',6'-triisopropyl- 3,4,5, 6-tetramethyl-[l,l '-biphenyl]-2-yl)phosphine (9.08 mg, 0.019 mmol) and Pd2(dba)3 (4.32 mg, 4.72 μιηοΐ), and degassed for another 5 minutes. The vial was sealed, and the reaction mixture was heated with stirring at 110 °C for 6 hours, at which point it was judged to be complete by LCMS. The solvents were evaporated, and the residue was taken up in DMF (2 mL). The product was isolated from the solution via preparative LC/MS with the following conditions: Column: Waters XBridge C18, 19 x 200 mm, 5- μιη particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 5- 50% B over 25 minutes, then a 10-minute hold at 50% B; Flow: 25 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(2-((2 -hydroxy ethyl)amino)-9H-purin- 9-yl)-4-(isopropylamino)nicotinamide (24 mg, 0.052 mmol, 55.2% yield). LCMS m/z = 461.2 (M+H)+. HPLC rt = 1.18 min, Conditions E. 1H NMR (500MHz, DMSO-d6) δ 8.82 (s, 1H), 8.78 (t, J=5.5 Hz, 1H), 8.74 (s, 1H), 8.66 (d, J=7.3 Hz, 1H), 8.57 (s, 1H), 8.04 (br. s., 1H), 7.33 (br. s., 1H), 4.89 (s, 1H), 4.77 (t, J=5.2 Hz, 1H), 4.44-4.28 (m, 1H), 3.84 (d, J=7.3 Hz, 1H), 3.78-3.64 (m, 1H), 3.61 (q, J=5.7 Hz, 2H), 3.51-3.45 (m, 3H, peaks partially obscured by water peak), 1.28 (d, J=6.1 Hz, 6H), 1.17 (d, J=6.7 Hz, 6H).
Example 173
6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4-(l-methyl-lH- pyrazol-5- l)cyclohexyl)-4-(isopropylamino)nicotinamide
Figure imgf000164_0001
Step 1 : A solution of 1 -methyl- lH-pyrazole (1.012 mL, 12.18 mmol) in THF (50 mL) was cooled to -78 °C and n-BuLi (4.87 mL, 12.18 mmol) was added. The mixture was allowed to stir at room temperature for 1 hr. Next, a solution of tert-butyl (4- oxocyclohexyl)carbamate (1.299 g, 6.09 mmol) in THF (10 mL) was added and the mixture stirred at room temperature overnight. The reaction mixture was worked up by quenching with water, evaporating the THF, adding EtOAc, and washing the product with water (2x). The organic layer was dried (sodium sulfate) and the solvent removed in vacuo to yield 1.061 g of a viscous yellow oil which was purified via column
chromatography to afford a mixture of cis and trans isomers (0.85g, 46% yield). 1H NMR (400 MHz, CDCl3-d) δ 7.40-7.33 (m, 1H), 6.24-6.00 (m, 1H), 5.31 (s, 1H), 4.48 (br. s., 1H), 4.12-4.00 (m, 3H), 2.23-1.80 (m, 6H), 1.73-1.59 (m, 2H), 1.50-1.43 (m, 9H). Note that there are two sets of vinyl peaks in a ration of 3 : 1 designating the ratio of trans/cis products.
Figure imgf000165_0001
Step 2: tert-Butyl (4-hydroxy-4-(l -methyl- lH-pyrazol-5-yl)cyclohexyl) carbamate (0.85 g, 2.88 mmol) was dissolved in DCM (20 mL) and to this solution was added HC1 (4N in dioxane) (7.19 mL, 28.8 mmol). The contents were stirred at room temperature. The reaction appeared to be precipitating and additional MeOH was added to help make the product more soluble. The reaction mixture was evaporated and the residue evaporated from methylene chloride 3x to remove traces of HC1. The solid thus obtained was dried under house vacuum to afford 0.75 g of a light yellow solid which was used without further purification: 1H NMR (400 MHz, DMSO-d6) δ 8.31-8.14 (m, 3H), 7.39 (d, J=2.0 Hz, IH), 6.14 (d, J=2.0 Hz, IH), 3.98 (s, 3H), 3.08-2.95 (m, IH), 2.08-1.96 (m, 2H), 1.82 (br. s., 5H).
Figure imgf000165_0002
Step 3: A 4-amino-l-(l -methyl- lH-pyrazol-5-yl)cyclohexanol, HC1 (200 mg, 0.863 mmol), 6-chloro-4-(isopropylamino)nicotinic acid (185 mg, 0.863 mmol), Hunig's Base (0.754 mL, 4.32 mmol), and PyBOP (898 mg, 1.726 mmol) were mixed and stirred in DMF (3 mL) at room temperature. The reaction mixture was quenched with IN NaOH, and EtOAc was added. The layers were separated and the organic layer rinsed with IN NaOH (2x), brine (lx), dried (sodium sulfate) and the solvent removed in vacuo to yield 1.25 g of a brown oily solid. The residue was purified via column
chromatography to afford 245 mg (69% yield) of a mixture of 4-5 : 1 ratio of trans to cis isomers. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J=7.7 Hz, IH), 8.42-8.25 (m, 2H), 7.33-7.19 (m, IH), 6.74-6.61 (m, IH), 6.25-6.02 (m, IH), 5.22-5.08 (m, IH), 4.01-3.91 (m, 3H), 3.88-3.69 (m, 2H), 2.11-1.60 (m, 7H), 1.20 (d, J=6.6 Hz, IH), 1.16 (d, J=6.4 Hz, 5H), 1.09-1.09 (m, IH).
Step 4: A mixture of 6-chloro-N-(4-hydroxy-4-(l -methyl- lH-pyrazol-5- yl)cyclohexyl)-4-(isopropylamino)nicotinamide (40 mg, 0.102 mmol), lH-pyrrolo[2,3-b] pyridine-5-carbonitrile (29.2 mg, 0.204 mmol), potassium carbonate (56.4 mg, 0.408 mmol), and 6: 1 t-BuOH/DMA (1.5 mL) were mixed in a 5 mL microwave vial containing a magnetic stir bar and degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (4.08 mg, 5.10 μιηοΐ) and degassed for another 5 minutes. The vial was sealed and the reaction heated in the microwave with stirring at 145 °C for 15 minutes. The reaction mixture was evaporated, diluted with DMF, filtered, purified via preparative HPLC to afford the trans isomer product (17.5 mg, 33% yield). 1H NMR (500MHz, DMSO-d6) δ 8.81 (d, J=1.7 Hz, 1H), 8.68 (d, J=1.7 Hz, 1H), 8.65- 8.59 (m, 2H), 8.53 (d, J=4.0 Hz, 1H), 8.42 (d, J=7.7 Hz, 1H), 8.08 (s, 1H), 7.26 (s, 1H), 6.89 (d, J=4.0 Hz, 1H), 6.11 (d, J=1.3 Hz, 1H), 3.97 (s, 3H), 3.88-3.71 (m, 2H), 2.05 (d, J=12.1 Hz, 2H), 1.95-1.82 (m, 2H), 1.78-1.65 (m, 4H), 1.29 (d, J=6.4 Hz, 7H); LCMS 499.3 (M+H) ; HPLC rt 2.10 min, Conditions E. The minor cis isomer product was obtained in 8% yield.
Example 174
6-(5 -Cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(( 1 s,4s)-4-fluoro-4-( 1 -methyl- 1 H-pyrazol-
5- l)cyclohexyl)-4-(isopropylamino)nicotinamide
Figure imgf000166_0001
To a suspension of 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4- hydroxy-4-( 1 -methyl- 1 H-pyrazol-5 -yl)cyclohexyl)-4-(isopropylamino)nicotinamide (8.3 mg, 0.017 mmol) in dry DCM (0.5 mL) at -0 °C under N2 was added DAST (4.40 μΐ, 0.033 mmol). The mixture was kept at 0 °C for 0.5 h. Additional DAST (4.40 μΐ, 0.033 mmol) was added and stirred for 30 min. The reaction mixture was quenched by adding 1M aqueous NaOH. The mixture was diluted with EtOAc, the layers separated and the organic layer washed with brine, dried over Na2S04, and concentrated to yield 10.6 mg of a light yellow solid. The crude material was purified via preparative HPLC to afford 2.1 mg (23% yield) of the desired product. 1H NMR (500MHz, DMSO-d6) δ 8.80 (s, 1H), 8.66 (s, 1H), 8.60-8.55 (m, 2H), 8.52 (d, J=3.7 Hz, 1H), 8.47 (d, J=7.7 Hz, 1H), 8.08 (s, 1H), 7.35 (s, 1H), 6.89 (d, J=4.0 Hz, 1H), 6.27 (s, 1H), 3.99-3.87 (m, 4H), 3.83-3.72 (m, 1H), 2.30 (br. s., 2H), 2.08-1.71 (m, 6H), 1.28 (d, J=6.1 Hz, 6H); LCMS 501.4 (M+H) ; HPLC rt 1.71 min, Conditions E.
Separate HPLC fractions contained the cis isomer which was also isolated in 20% yield.
The Examples in Table 9 were prepared using the methods outlined for Examples 173 and 174 using the appropriate starting material and amine.
Table 9
Figure imgf000167_0001
Figure imgf000168_0001
Example 183
-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2,4-dioxo-l,3-diazaspiro[4.5]decan-8-yl)-
4- isopropylamino)nicotinamide
Figure imgf000168_0002
Figure imgf000169_0001
Step 1 : 4-Aminocyclohexanone, HC1 (200 mg, 1.337 mmol), 6-chloro-4- (isopropylamino)nicotinic acid (287 mg, 1.337 mmol), Hunig's Base (2.335 mL, 13.37 mmol), and PyBOP (1391 mg, 2.67 mmol) were added to DMF (5 mL). The mixture was stirred at room temperature overnight. The reaction mixture was quenched with IN NaOH, and EtOAc was added. The layers were separated and the organic layer rinsed with IN NaOH (2x), brine (lx), dried (sodium sulfate) and the solvent removed in vacuo to yield 1.10 g of an amber oil which was purified via column chromatography to afford the desired product (0.314 g, 76% yield) as an off-white solid. 1H NMR (400MHz, DMSO-de) δ 8.47-8.41 (m, 1H), 8.37 (s, 2H), 6.69 (s, 1H), 4.40-4.12 (m, 1H), 3.76 (dd, J=13.8, 6.5 Hz, 1H), 2.49-2.42 (m, 2H), 2.36-2.23 (m, 2H), 2.13-1.97 (m, 2H), 1.86-1.70 (m, 2H), 1.17 (d, J=6.4 Hz, 6H); LCMS 310.1 (M+H)+.
Figure imgf000169_0002
Step 2: A mixture of 6-chloro-4-(isopropylamino)-N-(4-oxocyclohexyl) nicotinamide (40 mg, 0.129 mmol), lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (37.0 mg, 0.258 mmol), potassium carbonate (71.4 mg, 0.516 mmol), and 6: 1 t-BuOH/DMA (1.5 mL) were mixed in a 5 mL microwave vial containing a magnetic stir bar and degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (5.16 mg, 6.46 μιηοΐ) and degassed for another 5 minutes. The vial was sealed and the reaction heated in the microwave with stirring for 145 °C for 15 minutes. The reaction mixture was worked up by adding water and EtOAc, filtering off the solids, separating the layers, and washing the organic layer with water (2x), brine (lx), drying (sodium sulfate) and removing the solvent in vacuo to yield 0.0800 g of a brown glass. The product was used without further purification. LCMS 417.3 (M+H)+. Step 3: 6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-(4- oxocyclohexyl)nicotinamide (0.080 g, 0.192 mmol) was dissolved in EtOH (0.4 mL). Ammonium carbonate (0.240 g, 2.497 mmol) and KCN (0.031 g, 0.480 mmol) were dissolved in water (0.4 mL). The two mixtures were mixed and stirred in a 20 mL septum capped vial equipped with a magnetic stir bar at 80 °C for 3 hours. Water and EtOAc were added to the mixture. The layers were separated and the organic layer washed with water (2x), brine (lx), dried (sodium sulfate), and the solvent removed in vacuo to yield a tan glass. The residue was dissolved in DMF and purified via preparative HPLC to afford the desired product (12.7 mg, 13% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.66 (br. s., 1H), 8.81 (s, 1H), 8.67 (s, 1H), 8.63-8.55 (m, 1H), 8.54-8.46 (m, 3H), 8.38 (d, J=6.4 Hz, 1H), 8.08 (s, 1H), 6.89 (d, J=4.0 Hz, 1H), 3.83-3.65 (m, 2H), 3.36-3.32 (m, 1H), 2.07- 1.49 (m, 7H), 1.29 (d, J=6.4 Hz, 6H). LCMS 487.1 (M+H)+; HPLC rt 1.23 min,
Conditions F. Example 184
(S)-6-(5-Cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-(4-(pyridin-4- yl)cyclohex-3-en- 1 -yl)nicotinamide
Figure imgf000170_0001
(184)
To a solution of 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy- 4-(pyridin-4-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (7.77 mg, 0.016 mmol) in dry DCM (0.5 mL) at 0 °C under N2 was added DAST (4.14 μί, 0.031 mmol). The mixture was kept at 0 °C for 1.5 h. The reaction mixture was then quenched by adding 1M aqueous NaOH. The mixture was diluted with EtOAc, the layers separated and the organic layer washed with brine, dried over Na2S04, and concentrated to yield 8.6 mg of a pink solid. The crude solid was purified via preparative HPLC to afford the desired product (6.2 mg, 79% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.81 (s, 1H), 8.76 (d, J=5.7 Hz, 2H), 8.68 (s, 1H), 8.60 (s, 1H), 8.52 (d, J=4.0 Hz, 2H), 8.10 (s, 1H), 7.96 (d, J=5.7 Hz, 2H), 6.94-6.81 (m, 2H), 4.12 (br. s., 1H), 3.84-3.73 (m, 1H), 3.51 (br. s., 1H), 2.72-2.58 (m, 3H), 2.43 (d, J=l l .l Hz, 1H), 2.07 (br. s., 1H), 1.81 (d, J=l l .l Hz, 1H), 1.30 (d, J=6.1 Hz, 6H). LCMS 478.3 (M+H)+; HPLC rt 2.05 min, Conditions E.
Example 185
(R)-6-(2-(Dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide
Figure imgf000171_0001
In a 5 mL microwave vial, a mixture of (R)-6-chloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide (24 mg, 0.076 mmol), N,N-dimethyl-7H- pyrrolo[2,3-d]pyrimidin-2-amine (14.70 mg, 0.091 mmol), and K2C03 (41.8 mg, 0.302 mmol) in 3: 1 tert-butanol/dioxane (0.6 mL) was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (3.02 mg, 3.78 μιηοΐ), degassed for another 5 minutes, and the vial was sealed. The reaction mixture was heated with stirring at 120 °C for 18 hours, at which point the reaction mixture was judged to be complete by LCMS. The solvent was evaporated, and the residue was taken up in DMF (2 mL). The solution was filtered, and purified via preparative HPLC to afford (R)-6-(2- (dimethylamino)-7H-pyrrolo [2,3 -d]pyrimidin-7-yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)nicotinamide (20 mg, 0.044 mmol, 57.9% yield). LCMS (ESI) = 444.3 (M+H). 1H NMR (500MHz, DMSO-d6) δ 8.74-8.68 (m, 2H), 8.63 (d, J=7.3 Hz, 1H), 8.56 (s, 1H), 8.28 (s, 1H), 8.06 (d, J=3.7 Hz, 1H), 6.60 (d, J=3.7 Hz, 1H), 4.85 (br. s., 1H), 4.46-4.27 (m, 1H), 3.87-3.79 (m, 1H), 3.78-3.64 (m, 1H), 3.23 (s, 6H), 1.28 (d, J=6.1 Hz, 6H), 1.18 (d, J=6.7 Hz, 6H). LCMS (ESI) = 444.3 (M+H); HPLC rt 1.82 min, Conditions E.
Example 186
(R)-6-(2-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide
Figure imgf000172_0001
Figure imgf000172_0002
Step 1 : In a sealed vial, a stirring mixture of 2-chloro-7H-pyrrolo[2,3-d] pyrimidine (167 mg, 1.087 mmol), and (4-methoxyphenyl)methanamine (0.563 mL, 4.35 mmol) in ethanol (2 mL) was heated at 120 °C for 38 hours. LCMS of the mixture detects both starting materials and a new peak with m/z = 255, consistent with the expected product. Upon cooling, the product precipitated from the mixture. The solids were collected by filtration, washed twice with ethanol (0.5 mL), and dried under vacuum to yield N-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (87 mg, 0.342 mmol, 31.5% yield) as an off-white powder. The combined filtrate and rinses were returned to the reaction vial, which was then capped. The contents of the vial were stirred at 130 °C for 7 hours, then allowed to cool to room temperature. The volume of the solution was reduced to ~1 mL. The resulting precipitate was collected by filtration, rinsed twice with ethanol, and dried under vacuum to yield a second crop of 55 mg as a colorless powder. The two crops were combined to yield N-(4-methoxybenzyl)-7H-pyrrolo[2,3-d] pyrimidin-2-amine (142 mg, 0.558 mmol, 51.4% yield). LCMS 255.0 (M+H)+.
Step 2: In a 5 mL microwave vial, a mixture of (R)-6-chloro-N-(2-fluoro-3- hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (35 mg, 0.110 mmol), N-(4- methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (33.6 mg, 0.132 mmol), and
K2CO3 (60.9 mg, 0.441 mmol) in 3: 1 tert-butanol/dioxane (0.6 mL) was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (4.40 mg, 5.51 μιηοΐ), degassed for another 5 minutes, and the vial was sealed. The reaction mixture was heated with stirring at 120 °C for 3 hours, at which point it was judged to be complete by LCMS. The mixture was cooled to room temperature, diluted with DMF (5 mL), and filtered, and the filtrate was concentrated in vacuo. The residue was chromatographed via MPLC over a 12 g silica gel column, eluting at 30 mL/min with 3% methanol/methylene chloride. Fractions containing the desired product were pooled and concentrated in vacuo to yield (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)-6-(2-((4-methoxybenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl) nicotinamide (34 mg, 0.063 mmol, 57.6% yield). 24 mg was suspended in methylene chloride and treated with TFA (0.2 mL, 2.60 mmol), and the reaction mixture was stirred at room temperature for 3 hours. LCMS detects no conversion to the deprotected compound. A 50 aliquot was withdrawn and the DCM was evaporated with a stream of nitrogen. The residue was taken up in TFA (100 μί), and the mixture was stirred at 80 °C in a sealed vial for 20 minutes. LCMS shows clean conversion to the deprotected material. The DCM was evaporated from the bulk reaction mixture, and the residue was treated with TFA (1 mL). The reaction mixture was stirred at reflux for 20 minutes, at which point it was judged to be complete by LCMS. The reaction mixture was concentrated in vacuo, and the residue was concentrated twice from DCM and once from IPA to remove residual TFA. The residue was purified via preparative HPLC to afford (R)-6-(2-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino) nicotinamide (11 mg, 0.026 mmol, 24% yield). 1H NMR (500MHz, DMSO-d6) δ 8.69 (t, J=5.5 Hz, 1H), 8.59 (s, 1H), 8.56-8.49 (m, 2H), 8.23 (s, 1H), 7.97 (d, J=3.7 Hz, 1H), 6.56 (d, J=3.7 Hz, 1H), 6.51 (br. s., 2H), 4.86 (s, 1H), 4.45-4.27 (m, 1H), 3.99-3.87 (m, 1H), 3.81-3.61 (m, 1H), 1.28 (d, J=6.1 Hz, 6H), 1.17 (d, J=6.7 Hz, 6H). LCMS (ESI) = 416.2 (M+H); HPLC rt 1.25 min, Conditions E.
Example 187
(R)-N-(2-Fluoro-3-hydroxy-3-methylbutyl)-6-(2-((2-hydroxy-2-methylpropyl)amino)- 7H-pyrr lo[2,3-d]pyrimidin-7-yl)-4-(isopropylamino)nicotinamide
Figure imgf000173_0001
In a 5 mL microwave vial, a mixture of (R)-6-chloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide (25 mg, 0.079 mmol), l-((7H-pyrrolo [2,3-d]pyrimidin-2-yl)amino)-2-methylpropan-2-ol (19.5 mg, 0.094 mmol), and K2CO3 (43.5 mg, 0.315 mmol) in 3: 1 tert-butanol/dioxane (0.6 mL) was degassed with bubbling nitrogen for 5 minutes. The mixture was treated with BrettPhos precatalyst (3.14 mg, 3.93 μιηοΐ), degassed for another 5 minutes, and the vial was sealed. The reaction mixture was heated with stirring at 130 °C for 2 hours, at which point it was judged to be complete by LCMS. The solvents were evaporated, and the residue was taken up in DMF (2 mL). The solution was filtered, and purified via preparative HPLC to afford (R)-N-(2- fluoro-3-hydroxy-3-methylbutyl)-6-(2-((2-hydroxy-2-methylpropyl)amino)-7H-pyrrolo [2,3-d]pyrimidin-7-yl)-4-(isopropylamino)nicotinamide (25 mg, 0.050 mmol, 63.9% yield). 1H NMR (500MHz, DMSO-d6) δ 8.71 (t, J=5.2 Hz, 1H), 8.65-8.58 (m, 2H), 8.55 (s, 1H), 8.26 (s, 1H), 8.01 (d, J=4.3 Hz, 1H), 6.67-6.54 (m, 2H), 4.87 (s, 1H), 4.67 (s, 1H), 4.48-4.28 (m, 1H), 3.98-3.85 (m, 1H), 3.79-3.61 (m, 1H), 1.29 (d, J=6.1 Hz, 6H), 1.22-1.10 (m, 12H). LCMS (ESI) = 488.2 (M+H); HPLC rt 1.50 min, Conditions E.
The Examples in Table 10 were prepared using the methods outlined for
Examples 186 and 187 using the appropriate starting material and amine.
Table 10
Figure imgf000174_0001
Figure imgf000175_0001
Example 191
(R)-4-(6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)nicotinamido)-3- fl ro-2-methylbutan-2-yl dihydrogen phosphate
Figure imgf000175_0002
Step 1 : To a solution of (R)-4-amino-3-fluoro-2-methylbutan-2-ol (10 g, 83 mmol) in DCM (100 mL) was added TEA (23.01 mL, 165 mmol) and (BOC)20 (21.08 mL, 91 mmol). The reaction mixture was allowed to stir at room temperature overnight. The mixture was partitioned between water and DCM and the organic layer was washed consecutively with water, 1.5N HCl and brine. The organic layer was dried over Na2S04 and concentrated to afford (R)-tert-butyl (2-fluoro-3-hydroxy-3-methylbutyl)carbamate (16.2 g, 73.2 mmol, 89% yield). 1H NMR (DMSO-d6, 400 MHz) δ 6.93 (m, 1H), 4.71 (m, 1H), 4.14 (m, 1H), 3.26 (m, 1H), 3.05 (M, 1H), 1.38 (s, 9H), 1.10 (m, 6H).
Figure imgf000175_0003
Step 2: To a solution of (R)-tert-butyl (2-fluoro-3-hydroxy-3-methylbutyl) carbamate (13.0 g, 58.8 mmol) in DCM (130 mL) was added dibenzyl
diisopropylphosphoramidite (29.6 mL, 88 mmol) and lH-tetrazole (261 mL, 118 mmol). The resulting mixture was stirred at room temperature for 1 h. The mixture was cooled to 0 °C and H202 (4.87 mL, 58.8 mmol) was added. The mixture was stirred for 1 h. The mixture was then diluted with DCM (100 mL) and washed with brine. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified via column chromatography on silica gel (10% EtOAc in DCM) to afford (R)-tert-butyl (3- ((bis(benzyloxy)phosphoryl) oxy)-2-fluoro-3-methylbutyl)carbamate (18 g, 37.4 mmol, 64% yield) as colorless oil. 1H NMR (DMSO-d6, 400 MHz) δ 7.35 (m, 10H), 7.08 (m, 1H), 5.00 dd, J = 3.2, 8.0 Hz, 4H), 4.42 (m, 1H), 3.07 (m, 1H), 1.46 (s, 3H), 1.43 (s, 3H), 1.38 (s, 9H); LCMS 482.5 (M+H)+.
Figure imgf000176_0001
Step 3: To a solution of (R)-tert-butyl (3-((bis(benzyloxy)phosphoryl)oxy)-2- fluoro-3-methylbutyl)carbamate (3.2 g, 6.65 mmol) in DCM (5 mL) was added HC1 (20 mL, 80 mmol) as 4M solution in dioxane and then stirred for 30 min at 0 °C. The mixture was concentrated and the residue was dissolved in DCM and basified with aqueous ammonia solution. The layers were separated and the organic layer was dried over Na2S04, filtered and concentrated to afford (R)-4-amino-3-fluoro-2-methylbutan-2-yl dibenzyl phosphate (2.2 g, 5.77 mmol, 87% yield). LCMS 382.1 (M+H)+.
Figure imgf000176_0002
Step 4: To a solution of 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4- (isopropylamino)nicotinic acid (1.1 g, 3.41 mmol) in DCM (20 mL) was added DIPEA (2.98 mL, 17.06 mmol) and HATU (2.60 g, 6.83 mmol). The mixture was stirred for 10 mins and (R)-4-amino-3-fluoro-2-methylbutan-2-yl dibenzyl phosphate (1.665 g, 3.75 mmol) was added. The reaction mixture was stirred for 3 h at room temperature. The mixture was then partitioned between water and DCM and the organic layer was washed with water and brine. The organic extracts were dried over Na2S04, filtered and concentrated. The product was isolated via column chromatography (5% MeOH in DCM) to afford (R)-dibenzyl (4-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-
(isopropylamino)nicotinamido)-3-fluoro-2-methylbutan-2-yl) phosphate (1.65 g, 2.406 mmol, 70.5% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.06 (d, J=2.01 Hz, 1 H) 9.02 (d, J=2.01 Hz, 1 H) 8.92 (t, J=5.52 Hz, 1 H) 8.65-8.66 (m, 2 H) 8.57 (d, J=7.53 Hz, 1 H) 7.34-7.41 (m, 11 H) 5.05 (dd, J=7.53, 5.02 Hz, 4 H) 4.58-4.74 (m, 1 H) 3.69-3.84 (m, 2 H) 3.36-3.52 (m, 1 H) 1.54 (d, J=9.04 Hz, 6 H) 1.23-1.26 (m, 6 H); LCMS 686.2 (M+H).
Step 5: To a solution of (R)-dibenzyl (4-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin- l-yl)-4-(isopropylamino)nicotinamido)-3-fluoro-2-methylbutan-2-yl) phosphate (2.55 g, 3.72 mmol) in 1 ,2-dichloroethane was added a solution of TFA (57.3 mL, 744 mmol) in 15 mL of 1 ,2-dichloroethane and the resulting mixture was stirred at 35 °C for 18 h. The mixture was concentrated under vacuum at 35 °C, and co-distilled with toluene (two times) and with CHC13 (two times). The product was isolated via prep HPLC to afford (R)-4-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)nicotinamido)-3- fhioro-2-methylbutan-2-yl dihydrogen phosphate (1.36 g, 72% yield). 1H NMR (DMSO- d6/D20, 400 MHz) δ 9.02 (d, J = 2.0 Hz, 1H), 8.95 (d, J = 2.0 Hz, 1H), 8.62 (m, 2H), 7.36 (s, 1H), 4.57 (m, 1H), 3.78 (m, 3H), 1.46 (s, 3H), 1.40 (s, 3H), 1.29 (s, 3H), 1.26 (s, 3H); LCMS 504.0 (M-H)+.
Example 192
(R)-6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)- 4-(isopropylamino)nicotinamide, hydrochloride
A solution of Example 133, (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N- (2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide, (45 mg, 0.106 mmol) in acetonitrile (5 mL) was cooled to -20 °C. HC1 in diethyl ether (0.106 mL, 0.106 mmol) was added. The mixture was stirred for 2 mins and then cooled to -50 °C. Water (5 mL) was added and the mixture was frozen. The solvents were removed on a lyophilizer to provide (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide hydrochloride (40
yield) as an off-white powder.
Example 193
-Butylamino)-6-(5-cyano-lH-pyrazolo [3, 4-b]pyridin-l-yl)-N-(3 -hydroxy-3 methylbutyl)nicotinamide
Figure imgf000178_0001
Intermediate 193 A: (R)-4-(sec-Butylamino)-6-chloronicotinic acid
Figure imgf000178_0002
A mixture of ethyl 4,6-dichloronicotinate (0.6 g, 2.73 mmol), (R)-butan-2-amine (0.219 g, 3 mmol) and DIPEA (0.521 mL, 3 mmol) in i-PrOH (2 mL) was heated at 85 °C for 18 h. The mixture was cooled and the solvents were removed in vacuo. MeOH (2 mL), THF (2 mL) and 1 N NaOH (5.45 mL, 5.45 mmol) was added and the mixture was stirred at room temperature for 3 h. The reaction mixture was neutralized with IN HCl and the precipitated solids were collected via filtration. LCMS 229.2 (M+H); 1H NMR (500MHz, DMSO-de) δ 8.16 (m, 2H), 7.69 (s, 1H), 5.09 (s, 1H), 4.32 (s, 1H), 3.36 (br. s., 1H), 3.25-3.16 (m, 2H), 1.61-1.53 (m, 2H), 1.52-1.41 (m, 2H), 1.13-1.05 (m, 9H), 0.88 (t, J=7.2 Hz, 3H).
Intermediate 193B : (R)-4-(sec-Butylamino)-6-chloro-N-(3 -hydroxy-3 -methylbutyl) nicotinamide
Figure imgf000179_0001
To as solution of (R)-4-(sec-butylamino)-6-chloronicotinic acid (98 mg, 0.43 mmol) in DMF (0.5 mL) were added DIPEA (0.16 mL, 0.9 mmol), 4-amino-2- methylbutan-2-ol (49 mg, 0.47 mmol) and BOP (209 mg, 0.47 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate and concentrated. The crude material was purified via column
chromatography to afford (R)-4-(sec-butylamino)-6-chloro-N-(3 -hydroxy-3 -methylbutyl) nicotinamide (105 mg, 78% yield) as a pale yellow oil.
Example 193:
A mixture of di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[l, -biphenyl]- 2-yl)phosphine (9.2 mg) and Pd2(dba)3 (7.3 mg) in toluene/dioxane (5: 1, 0.5 mL) was purged with N2, sealed and heated at 120 °C for 5 mins and then cooled to room temperature. A separate mixture of (R)-4-(sec-butylamino)-6-chloro-N-(3 -hydroxy-3 - methylbutyl)nicotinamide, 1 H-pyrazolo [3, 4-b]pyridine-5-carbonitrile and K3PO4 in 1,4- dioxane (0.5 mL) was purged with N2. The preformed catalyst was added and the mixture was purged with N2 and heated at 110 °C for 4 h. The reaction mixture was cooled and the product was purified directly by preparative HPLC to afford (R)-4-(sec- butylamino)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(3 -hydroxy-3 -methylbutyl) nicotinamide (7.6 mg, 11% yield). LCMS 422.22, Rt 1.56 min, Conditions E; 1H NMR (500MHz, DMSO-de) δ 9.02 (d, J=14.8 Hz, 2H), 8.68-8.48 (m, 4H), 7.31 (s, 1H), 4.39 (s, 1H), 3.64-3.50 (m, 2H), 3.36 (m, 1H), 1.74-1.50 (m, 4H), 1.20 (d, J=6.4 Hz, 3H), 1.15 (s, 6H), 0.93 (t, J=7.4 Hz, 3H).
The Examples in Table 11 were prepared using the general methods for Example 193 using the appropriate starting material and amine. Table 1 1
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Enantiomer 2
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Racemic
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Example 333
(R)-6-(6-Cyano-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)- -(oxetan-3-ylamino)nicotinamide
Figure imgf000204_0001
Intermediate 333A: Ethyl 6-chloro-4-(oxetan-3-ylamino)nicotinate
Figure imgf000204_0002
Ethyl 4,6-dichloronicotinate (3.91 g, 17.79 mmol) was taken in a seal tube in DMA (10 mL) and oxetan-3 -amine (1.3 g, 17.79 mmol) and DIPEA (12.43 mL, 71.1 mmol) were added. The reaction mixture was stirred for 16 hrs at 25 °C and then diluted with ethyl acetate, washed with water (100 ml). The organic layer was dried over anhydrous Na2S04, filtered, and concentrated. The residue was dissolved in minimum volume of DCM (20 ml), charged with silica gel 60-120, purified through ISCO, eluting at 15%EtOAc/Pet.ether. Ethyl 6-chloro-4-(oxetan-3-ylamino)nicotinate (2.4 g, 7.74 mmol, 43.5% yield) was isolated as a colorless liquid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56-8.60 (m, 1 H) 8.45 (d, J=5.52 Hz, 1 H) 6.63 (s, 1 H) 4.87-4.93 (m, 2 H) 4.77- 4.87 (m, 1 H) 4.46-4.52 (m, 2 H) 4.34 (q, J=7.03 Hz, 2 H) 1.30-1.37 (m, 3 H).
Intermediate 333B: 6-Chloro-4-(oxetan-3-ylamino)nicotinic acid
Figure imgf000204_0003
(333B)
To a stirred solution of ethyl 6-chloro-4-(oxetan-3-ylamino)nicotinate (2.35 g, 9.16 mmol) in a mixture of THF (10 mL), ethanol (4 mL) and water (4 mL), LiOH (0.658 g, 27.5 mmol) was added. The reaction mixture was stirred for 2 hrs and concentrated completely. The resulting residue was dissolved in water (5 ml) and acidified to pH 4 using saturated aqueous citric acid solution. The solids were filtered, washed with water (2 x 30 ml) and dried to afford 6-chloro-4-(oxetan-3-ylamino)nicotinic acid (1.9 g, 79% yield) as off-white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.92 (br. s., 1 H) 8.53 (s, 1 H) 6.56 (s, 1 H) 4.87-4.93 (m, 2 H) 4.75-4.84 (m, 1 H) 4.43-4.49 (m, 2 H).
Intermediate 333C: (R)-6-Chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(oxetan-3- ylamino)nicotinamide
Figure imgf000205_0001
To a stirred solution of 6-chloro-4-(oxetan-3-ylamino)nicotinic acid (0.6 g, 2.62 mmol) in DMF (10 mL) at 0 °C were added DIPEA (2.292 mL, 13.12 mmol) and HATU (1.996 g, 5.25 mmol) followed by the addition of (R)-4-amino-3-fluoro-2-methylbutan-2- ol (0.318 g, 2.62 mmol). The reaction mixture was stirred for 16 hrs at 25 °C. The mixture was diluted with ethyl acetate and washed with water and brine. The organic solution was dried over anhydrous Na2S04, filtered, concentrated and then purified on silica gel using 3.5% MeOH/chloroform to afford (R)-6-chloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(oxetan-3-ylamino)nicotinamide (0.6 g, 65.3% yield) as an off- white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.91 (d, J=6.53 Hz, 1 H) 8.83 (t, J=5.52 Hz, 1 H) 8.43 (s, 1 H) 6.52 (s, 1 H) 4.86-4.92 (m, 2 H) 4.83 (s, 1 H) 4.71-4.77 (m, 1 H) 4.27- 4.46 (m, 3 H) 3.63-3.79 (m, 1 H) 3.34-3.45 (m, 1 H) 1.17 (dd, J=5.52, 1.51 Hz, 6 H). LCMS m/z 332 (M+H).
Example 333:
In a vial suitable for heating, a mixture of a mixture of (R)-6-chloro-N-(2-fluoro- 3-hydroxy-3-methylbutyl)-4-(oxetan-3-ylamino)nicotinamide (34.5 mg, 0.104 mmol),
3H-imidazo[4,5-b]pyridine-6-carbonitrile (15 mg, 0.104 mmol) and powdered phosphoric acid, potassium salt, tribasic (66.3 mg, 0.312 mmol) in dioxane (2 mL) was degassed with bubbling nitrogen for 5 minutes. In a separate sealed vial, a degassed, stirring mixture of Pd2(dba)3 (4.76 mg, 5.20 μιηοΐ) and tetramethyl t-Bu XPhos (6.00 mg, 0.012 mmol) in 5: 1 toluene/dioxane (0.2 mL) was heated at 120 °C for 5 minutes. After cooling to room temperature, this solution was transferred to the vial containing the reaction mixture. The vial was sealed, and the reaction mixture was heated at 80 °C for 4 hours, at which point it was judged to be complete by LCMS. The reaction mixture was diluted with ethyl acetate (2 mL), filtered, and concentrated in vacuo. The product was purified by HPLC to afford (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(oxetan-3-ylamino)nicotinamide (13 mg, 26% yield). LCMS 440.3 (M+H)+. HPLC Rt 1.24 min, Conditions E. 1H NMR (500MHz, DMSO-d6) δ 9.38 (s, IH), 9.07 (d, J=4.7 Hz, IH), 9.00 (d, J=1.7 Hz, IH), 8.91 (t, J=5.2 Hz, IH), 8.87 (d, J=1.3 Hz, IH), 8.66 (s, IH), 7.64 (s, IH), 5.00 (t, J=6.7 Hz, 2H), 4.81-4.73 (m, IH), 4.57 (t,
J=6.2 Hz, 2H), 4.44 (d, J=8.1 Hz, IH), 4.35 (d, J=7.7 Hz, IH), 3.84-3.66 (m, IH), 1.19 (d, J=6.4 Hz, 7H).
The Examples in Table 12 were prepared using the general methods for Example 333 using the appropriate starting material and amine.
Table 12
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Example 347
(R)-6-(5 -Cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4- yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide
Figure imgf000209_0001
Figure imgf000209_0002
added K2CO3 (12.22 g, 88 mmol) over a period of 5 minutes. The reaction mixture was stirred at ambient temperature for 10 minutes. Next, l,l-difluoro-2-iodoethane (11.03 g, 57.5 mmol) was added and the reaction mixture was stirred for 12 h at 90 °C. The reaction mixture was then partitioned between water (150 mL) and EtOAc (150 mL) and the aqueous layer was extracted with EtOAc (2 x 100 mL). The combined EtOAc layer was washed with water (2 x 100 mL) and brine (100 mL), dried over sodium sulfate, filtered and concentrated to give crude product. The product was purified via column chromatography to afford l-(2,2-difluoroethyl)-4-nitro-lH-pyrazole (5.2 g, 60% yield) as a tan solid. 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H), 8.35 (s, 1H), 6.45 (m, 1H), 4.75 (td, J=15, 3.5 Hz, 2H).
Intermediate 347B: l-(2,2-Difluoroeth l)-4-amino-lH-pyrazole
Figure imgf000209_0003
Under a nitrogen atmosphere, a Parr bottle was carefully charged with 10% Pd on carbon (1.56 g, 1.47 mmol) and the catalyst was carefully wetted with MeOH (50 mL). The vessel was charged with a solution of l-(2,2-difluoroethyl)-4-nitro-lH-pyrazole (5.2 g, 29.4 mmol) and the mixture was degassed by evacuating the vessel under vacuum and repressurizing with hydrogen. The mixture was hydrogenated at 15 psi for 6 hours. The mixture was degassed, and the reaction mixture was filtered under nitrogen through fiberglass filter paper. The filter cake was thoroughly rinsed with methanol (200 mL total rinse volume), and the combined filtrate and rinsings were concentrated in vacuo to obtain l-(2,2-difluoroethyl)-4-amino-lH-pyrazole (5.2 g, 62% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.07 (s, 1H), 6.99 (d, J=0.9 Hz, 1H), 6.38-6.10 (m, 1H), 4.40 (td, J=15.1, 4.0 Hz, 2H), 3.18 (m, 2H).
Intermediate 347C: Ethyl 6-chloro-4-((l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)amino) nicotinate
Figure imgf000210_0001
A solution of ethyl 4,6-dichloronicotinate (0.6 g, 2.73 mmol), l-(2,2- difluoroethyl)-lH-pyrazol-4-amine (0.401 g, 2.73 mmol), and DIPEA (2.381 mL, 13.63 mmol) in DMA (12 mL) was heated at 100 °C overnight. The reaction mixture was concentrated to remove DMA and water was added. The product was extracted with ethylacetate (3 times) and the combined extracts were washed with water and brine. The extracts were dried over anhydrous Na2S04, filtered, and concentrated to obtain a brown liquid. This crude product was purified via column chromatography to afford ethyl 6- chloro-4-((l-(2,2-difiuoroethyl)-lH-pyrazol-4-yl)amino)nicotinate (0.78 g, 86% yield). 1H NMR (300MHz, DMSO-d6) δ 9.29 (s, 1H), 8.63 (s, 1H), 8.02 (s, 1H), 7.66 (s, 1H), 6.67 (s, 1H), 6.61-6.19 (m, 1H), 4.64 (td, J=15.2, 3.6 Hz, 2H), 4.36 (q, J=7.2 Hz, 2H), 1.41-1.29 (m, 3H).; LCMS m/z 331.0 (M+H).
Intermediate 347D: 6-Chloro-4-((l-(2,2-difiuoroethyl)-lH-pyrazol-4-yl)amino)nicotinic acid
Figure imgf000210_0002
To a solution of ethyl 6-chloro-4-((l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)amino) nicotinate (0.4 g, 1.21 mmol) in ethanol (10 mL) and water (4 mL) was added LiOH (0.09 g, 3.6 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated to remove ethanol and the residue was acidified with 1.5N HC1. The white solid formed was collected and used without further purification (0.35 g, 96% yield). LCMS m/z 303.0 (M+H).
Intermediate 347E: (R)-6-Chloro-4-((l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)amino)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide
Figure imgf000211_0001
To a solution of 6-chloro-4-((l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)amino) nicotinic acid (0.4 g, 1.322 mmol) in DMF (8 mL), were added HATU (0.75 g, 2 mmol), DIPEA (1.15 mL, 6.6 mmol), and (R)-4-amino-3-fluoro-2-methylbutan-2-ol (0.19 g, 1.6 mmol). The reaction mixture was stirred at room temperature overnight. Sodium bicarbonate was added and the reaction mixture was extracted with ethyl acetate (3 times). The combined organic extracts were washed with water and brine then dried over anhydrous Na2S04. The filtrate was concentrated to a brown liquid which was purified via column chromatography to afford (R)-6-chloro-4-((l-(2,2-difluoroethyl)-lH-pyrazol- 4-yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (0.51 g, 95% yield). 1H NMR (300MHz, DMSO-d6) δ 9.83 (s, 1H), 8.95 (t, J=5.5 Hz, 1H), 8.49 (s, 1H), 8.00 (s, 1H), 7.63 (d, J=0.8 Hz, 1H), 6.66 (s, 1H), 6.60-6.18 (m, 1H), 4.85 (s, 1H), 4.62 (td, J=15.1, 3.8 Hz, 2H), 4.48-4.25 (m, 1H), 3.85-3.61 (m, 1H), 3.50-3.36 (m, 1H), 1.20-1.12 (m, 6H); LCMS m/z 406.0 (M+H).
Example 347:
To a solution of (R)-6-chloro-4-((l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)amino)- N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (0.1 g, 0.25 mmol) and 1H- pyrazolo[3,4-b]pyridine-5-carbonitrile (0.043 g, 0.3 mmol) in 1,4 dioxane were added Xantphos (0.057 g, 0.1 mmol), K2C03 (0.102 g, 0.74 mmol), LiCl (10.45 mg, 0.246 5 mmol), and ZnCl2 (6.72 mg, 0.05 mmol). The reaction mixture was purged with nitrogen and tris(dibenzylidene)dipalladium (0.090 g, 0.1 mmol) was added. The reaction mixture was purged again with nitrogen for 10 minutes. The reaction vessel was sealed and heated at 110 °C. The reaction mixture was filtered through CELITE® using 1 : 1 methanol and dichloromethane and extracted with 1.5N HCl and ethyl acetate. The water layer was neutralized with sodium carbonate and extracted with ethyl acetate (3 times). The combined organic extracts were washed with water and brine then dried over anhydrous Na2S04, filtered, and concentrated to obtain a brown solid. The product was purified via column chromatography to afford (R)-6-(5-cyano-lH-pyrazolo[3,4-b] pyridin- 1 -yl)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)amino)-N-(2-fluoro-3-hydroxy-3- methylbutyl) nicotinamide (10 mg, 8% yield). 1H NMR (400 MHz, DMSO-d6) δ = 10.04 (s, 1H), 9.09-8.95 (m, 3H), 8.75 (s, 1H), 8.64 (s, 1H), 8.02 (s, 1H), 7.69 (s, 1H), 7.65 (s, 1H), 6.55-6.13 (m, 1H), 4.87 (s, 1H), 4.67 (td, J=15.2, 3.8 Hz, 2H), 4.52-4.30 (m, 1H), 3.89-3.66 (m, 1H), 3.51-3.39 (m, 1H), 1.19 (dd, J=5.3, 1.3 Hz, 6H). LCMS m/z 514.2 (M+H).
The Examples in Table 13 were prepared using the general methods for Example 347 using the appropriate starting material and amine.
Table 13
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Diastereomeric Mixture
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Example 414
6-(5 -Cyano- 1 H-indol- 1 -yl)-N-(( 1 R,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-
(isopropylamino)nicotinamide
Figure imgf000225_0002
Intermediate 414A: (1R,4R)-Ethyl 4-(6-chloro-4-(isopropylamino)nicotinamido) cyclohexanecarboxylate
Figure imgf000226_0001
To a solution of 6-chloro-4-(isopropylamino)nicotinic acid (0.4 g, 1.86 mmol) in DMF (10 mL), were added HATU (1.06 g, 2.8 mmol), DIPEA (1.63 mL, 9.3 mmol) and (lR,4R)-ethyl 4-aminocyclohexanecarboxylate (0.38 g, 2.24 mmol). The reaction mixture was stirred at room temperature overnight. Sodium bicarbonate was added and the reaction mixture was extracted with ethyl acetate (3 times). The combined organic extracts were washed with water and brine then dried over anhydrous Na2S04. The extracts were filtered and concentrated to afford the crude product which was purified via column chromatography to afford (lR,4R)-ethyl 4-(6-chloro-4-(isopropylamino) nicotinamido)cyclohexanecarboxylate (0.6 g, 88% yield). This product was used directly in the next step.
Intermediate 414B : 6-Chloro-N-(( 1 R,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide
Figure imgf000226_0002
To a solution of (lR,4R)-ethyl 4-(6-chloro-4-(isopropylamino)nicotinamido) cyclohexane carboxylate (0.3 g, 0.816 mmol) in THF (8 mL) was added MeMgBr (0.816 mL, 2.45 mmol) at -78 °C. The reaction mixture was allowed to stir at room temperature overnight. The mixture was cooled in an ice bath and sodium bicarbonate was added. The mixture was extracted with ethyl acetate (3 times). The combined organic extracts were washed with water and brine then dried over anhydrous Na2S04. The extracts were filtered and concentrated to afford the crude product which was purified via column chromatography to afford 6-chloro-N-((lR,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (0.26 g, 90% yield). LCMS m/zl 354.4 (M+H). Example 414:
A solution of 6-chloro-N-((lR,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (100 mg, 0.283 mmol), lH-indole-5-carbonitrile (60.3 mg, 0.424 mmol) in dioxane (10 mL) and water (1 mL) was purged with nitrogen for 2 min. Xantphos (65.4 mg, 0.113 mmol), Cs2C03 (368 mg, 1.130 mmol) and Pd2(dba)3 (104 mg, 0.113 mmol) was added and the vessel was purged with nitrogen for 5 min. The reaction was sealed and heated at 110 °C for 16 h. The mixture was cooled, concentrated and dissolved in 10% MeOH/CHCl3. The material was filtered through CELITE® and concentrated. The product was purified by preparative tic (50% EtOAc:PE) to obtain the desired product (20 mg, 14% yield). HPLC Rt 9.33 min, Conditions B; LCMS m/z 458.2 (M+H); 1H NMR (400MHz, DMSO-d6) δ 8.64-8.47 (m, 3H), 8.29 (d, J=7.5 Hz, IH), 8.25 (d, J=3.5 Hz, IH), 8.19 (d, J=1.0 Hz, IH), 7.61 (dd, J=8.8, 1.8 Hz, IH), 6.91-6.81 (m, 2H), 4.03 (s, IH), 3.96 (d, J=7.5 Hz, IH), 3.76-3.62 (m, IH), 1.96-1.79 (m, 4H), 1.40- 1.01 (m, 17H).
The Examples in Table 14 were prepared using the general methods for Example 414 using the appropriate starting material and amine.
Table 14
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Enantiomer 1
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Diastereomeric Mixture
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Diastereomer 2
Figure imgf000241_0001
Diastereomer 1
Figure imgf000242_0001
Enantiomer 2
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Figure imgf000247_0001
Example 521
(R)-6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)- -((5-(2-hydroxypropan-2-yl)thiazol-2-yl)amino)nicotinamide
Figure imgf000247_0002
Intermediate 521 A: 4,6-Dichloronicotinic acid
Figure imgf000247_0003
To a solution of ethyl 4,6-dichloronicotinate (8 g, 36.4 mmol) in THF (50 mL), ethanol (25 mL) and water (25 mL) was added LiOH (2.61 g, 109 mmol). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was concentrated to remove solvent. The residue was dissolved in water and acidified to neutral pH with 1.5 N HCl The precipitated solid was filtered and washed with water (2 x 30 mL). The solid was dried to afford 4,6-dichloronicotinic acid (6.5 g, 83% yield). LCMS 194.1 (M+2); 1H NMR (400 MHz, DMSO-d6) δ 8.80 (s, 1H), 7.93 (s, 1H).
Intermediate 52 IB: (R)-4,6-Dichloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)
nicotinamide
Figure imgf000248_0001
To a solution of 4,6-dichloronicotinic acid (5 g, 26.0 mmol) in dichloromethane (30 mL) were added (R)-4-amino-3-fluoro-2-methylbutan-2-ol (3.16 g, 26.0 mmol) and TEA (18.15 mL, 130 mmol) at 0 °C followed by the addition of 1-propanephosphonic acid cyclic anhydride (50% in ethyl acetate) (24.86 g, 78 mmol) at the same temperature. The reaction mixture was stirred at 25 °C for 16 h. The mixture was then diluted with dichloromethane and the organic layer was washed with water and brine solution. The organic layer was dried over anhydrous Na2S04, filtered and concentrated. The residue was purified via column chromatography (40% EtO Ac/pet ether) to afford (R)-4,6- dichloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (3.6 g, 46%> yield). 1H
NMR (400MHz, DMSO) δ = 8.98-8.81 (m, 1H), 8.48 (s, 1H), 7.92 (s, 1H), 4.85 (s, 1H), 4.46-4.33 (m, 1H), 4.30-4.20 (m, 1H), 3.89-3.66 (m, 2H), 1.17 (dd, J=7.5, 1.5 Hz, 9H); LCMS 297.2 (M+2).
Intermediate 521C: (R)-6-Chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((5-(2- hydroxypropan-2-yl)thiazol-2- l)amino)nicotinamide
Figure imgf000248_0002
To a solution of (R)-4,6-dichloro-N-(2-fluoro-3-hydroxy-3-methylbutyl) nicotinamide (1 g, 3.39 mmol) in DMF (15 mL) were added 2-(2-aminothiazol-5-yl) propan-2-ol (0.643 g, 4.07 mmol) and CS2CO3 (2.208 g, 6.78 mmol). The reaction mixture was stirred at 60 °C for 2 h. The reaction mixture was then concentrated and partitioned between EtO AC and water. The layers were separated the organic layer was dried over anhydrous Na2S04, filtered and concentrated. The crude was purified via column chromatography to afford (R)-6-chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- ((5-(2-hydroxypropan-2-yl)thiazol-2-yl)amino)nicotinamide (0.45 g, 31% yield). LCMS 417.0 (M+H). Example 521 :
To a solution of (R)-6-chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((5-(2- hydroxypropan-2-yl)thiazol-2-yl)amino)nicotinamide (0.1 g, 0.240 mmol) in 1,4-dioxane (10 mL) were added 3a,7a-dihydro-lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (0.035 g, 0.240 mmol) and Xantphos (0.056 g, 0.096 mmol). The mixture was degassed for 10 min. K2C03 (0.133 g, 0.959 mmol) and Pd2(dba)3 (0.088 g, 0.096 mmol) were added. The mixture was degassed for 15 min and then heated at 110 °C for 16 hours. The reaction mixture was cooled and filtered through CELITE® and concentrated to remove solvent. The crude material was purified through combiflash (silica gel) and then purified by preparative HPLC to afford (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((5 -(2-hydroxypropan-2-yl)thiazol-2-yl)amino) nicotinamide (8 mg, 6% yield) as a white solid. HPLC Rt 7.10, Conditions B; LCMS 525.2 (M+H); 1H NMR (400MHz, DMSO) δ = 12.10-11.80 (m, 1H), 9.29-9.14 (m, 1H), 9.11-9.06 (m, 1H), 9.06-9.02 (m, 1H), 8.92-8.87 (m, 1H), 8.73-8.68 (m, 1H), 7.66-7.62 (m, 1H), 7.32-7.19 (m, 1H), 7.08-6.94 (m, 1H), 5.64-5.52 (m, 1H), 4.92-4.85 (m, 1H),
4.54-4.32 (m, 1H), 3.93-3.72 (m, 1H), 3.57-3.42 (m, 1H), 1.53 (s, 6H), 1.24-1.16 (m, 6H).
The Examples in Table 15 were prepared using the general methods for Example 521 using the appropriate starting material and amine.
Table 15
Figure imgf000249_0001
Figure imgf000250_0001
Figure imgf000251_0001
Example 532
ano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)- 4-(((R)- 1 -(5 -fluoropyrimidin-2-yl)pyrrolidin-3 -yl)amino)nicotinamide
Figure imgf000252_0001
Intermediate 532A: 6-Chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)-l-(5- fluoropyrimidin-2-yl)pyrrolidin-3-yl)amino)nicotinamide
Figure imgf000252_0002
To a stirred solution of (R)-4,6-dichloro-N-(2-fluoro-3-hydroxy-3-methylbutyl) nicotinamide (300 mg, 1.02 mmol) in DMA (5 mL) were added (R)-l-(5- fluoropyrimidin-2-yl)pyrrolidin-3-amine (222 mg, 1.22 mmol) and DIPEA (0.178 mL, 1.02 mmol). The reaction mixture was heated at 130 °C for 2 hours. The mixture was then cooled and concentrated. The residue was partitioned between EtOAc and water. The layers were separated and the organic layer was dried over Na2S04, filtered and concentrated to afford crude 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)- l-(5-fluoropyrimidin-2-yl)pyrrolidin-3-yl)amino)nicotinamide (200 mg, 45% yield). LCMS 441.4 (M+H).
Example 532:
A stirred solution of 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)- l-(5-fluoropyrimidin-2-yl)pyrrolidin-3-yl)amino)nicotinamide (65 mg, 0.147 mmol), 1H- pyrazolo[3,4-b]pyridine-5-carbonitrile (21.25 mg, 0.147 mmol), Xantphos (85 mg, 0.147 mmol) and Na2C03 (46.9 mg, 0.442 mmol) in 1,4-dioxane (8 mL) was degassed with nitrogen for 5 mins then Pd2(dba)3 (67.5 mg, 0.074 mmol) was added. The mixture was further degassed with nitrogen for 5 mins and then the reaction mixture was heated at 110 °C for 12 hours in a sealed tube. The mixture was cooled to room temperature, filtered and purified directly via preparative HPLC to afford 6-(5-cyano-lH-pyrazolo[3,4-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)- 1 -(5 -fluoropyrimidin-2- yl)pyrrolidin-3-yl)amino)nicotinamide (9 mg, 11% yield). HPLC Rt 1.14 min,
Conditions D; LCMS 549.2 (M+H); 1H NMR (400MHz, DMSO-d6) δ 9.08-9.02 (m, 2H), 8.90-8.82 (m, 2H), 8.70-8.64 (m, 2H), 8.46 (s, 2H), 7.47 (s, 1H), 4.83 (s, 1H), 4.47-4.25 (m, 2H), 3.93 (dd, J=11.5, 6.0 Hz, 1H), 3.81-3.56 (m, 3H), 3.54-3.35 (m, 2H), 2.48-2.36 (m, 1H), 2.10 (dd, J=12.3, 7.3 Hz, 1H), 1.16 (dd, J=6.3, 1.3 Hz, 6H).
The Examples in Table 16 were prepared using the general methods for Example 532 using the appropriate starting material and amine.
Table 16
Figure imgf000253_0001
Figure imgf000254_0001
Figure imgf000255_0001
Example 544
6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)- 4-(((R -tetrahydrofuran-3-yl)amino)nicotinamide, TFA salt
Figure imgf000256_0001
Intermediate 544A: 6-Chloro-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)- tetrahydrofuran-3 -yl)amino) nicotinamide
Figure imgf000256_0002
(544A)
In a vial suitable for heating, (R)-4,6-dichloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (150 mg, 0.51 mmol), (R)-tetrahydrofuran-3 -amine, CI (62.8 mg, 0.51 mmol) and Hunig's Base (0.266 mL, 1.53 mmol) were dissolved in DMF (5 mL) at room temperature with stirring and then heated at 120 °C for 18 h. The reaction mixture was concentrated and purified directly via preparative HPLC to afford 6-chloro- N-((R)-2-fluoro-3 -hydroxy-3 -methylbuty l)-4-(((R)-tetrahydrofuran-3 -yl)amino) nicotinamide (127 mg, 69% yield) as a tan solid. 1H NMR (400MHz, DMSO-d6) δ 8.77 (t, J=5.5 Hz, 1H), 8.67 (d, J=7.0 Hz, 1H), 8.40 (s, 1H), 6.76 (s, 1H), 4.81 (s, 1H), 4.38 (dd, J=9.5, 2.0 Hz, 0.5H), 4.28-4.16 (m, 1.5H), 3.87-3.77 (m, 2H), 3.77-3.67 (m, 1.5H), 3.66-3.58 (m, 0.5H), 3.56 (dd, J=9.0, 2.9 Hz, 1H), 3.45-3.32 (m, 1H), 2.32-2.20 (m, 1H), 1.79-1.69 (m, 1H), 1.14 (dd, J=6.2, 1.1 Hz, 6H).
Example 544:
In a vial suitable for heating, a mixture of 6-chloro-N-((R)-2-fluoro-3 -hydro xy-3- methylbutyl)-4-(((R)-tetrahydrofuran-3-yl)amino)nicotinamide (30 mg, 0.087 mmol), 1H- pyrazolo[3,4-b]pyridine-5-carbonitrile (15.01 mg, 0.104 mmol),and potassium phosphate, tribasic (55.3 mg, 0.260 mmol) in dioxane (2 mL) was degassed with bubbling nitrogen for 5 minutes. In a separate sealed vial, a degassed, stirring mixture of Pd2(dba)3 (3.97 mg, 4.34 μιηοΐ) and tetramethyl t-Bu XPhos (5.00 mg, 10.41 μιηοΐ) in 5: 1
toluene/dioxane (0.2 mL) was heated at 120 °C for 5 minutes. After cooling to room temperature, this solution was transferred to the vial containing the reaction mixture. The vial was sealed, and the reaction mixture was heated at 80 °C for 4 hours and then stirred at room temperature overnight. The mixture was filtered, and the filtrate was
concentrated under high vacuum. The residue was purified directly via preparative HPLC to afford 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-(((R)-tetrahydrofuran-3-yl)amino)nicotinamide, TFA salt (37 mg, 76% yield). HPLC Rt 1.11 min, Conditions E; LCMS 454.3 (M+H); LCMS 346.1 (M+H); 1H NMR (500MHz, DMSO-d6) δ 9.09 (s, 1H), 9.04 (s, 1H), 8.93 (m, 1H), 8.70 (s, 1H), 8.67 (s, 1H), 7.48 (s, 1H), 4.43 (d, J=8.1 Hz, 1H), 4.33 (d, J=8.1 Hz, 1H), 4.26 (br. s., 1H), 3.94 (dd, J=9.1, 5.4 Hz, 1H), 3.88 (q, J=7.5 Hz, 1H), 3.82-3.74 (m, 2H), 3.69 (d, J=6.4 Hz, 1H), 3.48-3.35 (m, 1H), 2.41-2.31 (m, 1H), 1.94-1.82 (m, 1H), 1.18 (d, J=7.1 Hz,
6H).
Example 545
6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)- 4-(((S -tetrahydrofuran-3-yl)amino)nicotinamide, TFA salt
Figure imgf000257_0001
Intermediate 545A: 6-Chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((S)- tetrahydrofuran-3-yl)amino)nicotinamide
Figure imgf000257_0002
(545A)
In a vial suitable for heating, (R)-4,6-dichloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (150 mg, 0.508 mmol), (S)-tetrahydrofuran-3 -amine, HC1 (62.8 mg, 0.508 mmol) and Hunig's Base (0.266 mL, 1.525 mmol) were dissolved in DMF (5 mL) at room temperature with stirring and then heated at 120 °C overnight. The reaction mixture was cooled and the DMF removed under vacuum to afford the crude solid which was purified via column chromatography to afford 6-chloro-N-((R)-2-fluoro-3-hydroxy- 3-methylbutyl)-4-(((S)-tetrahydrofuran-3-yl)amino)nicotinamide (112 mg, 61% yield) as a tan solid. LCMS 346.1 (M+H); 1H NMR (400MHz, DMSO-d6) δ 8.77 (t, J=5.6 Hz, 1H), 8.67 (d, J=7.0 Hz, 1H), 8.40 (s, 1H), 6.75 (s, 1H), 4.81 (s, 1H), 4.37 (dd, J=9.4, 1.9 Hz, 0.5H), 4.28-4.16 (m, 1.5H), 3.88-3.77 (m, 2H), 3.76-3.67 (m, 2H), 3.62 (dd, J=14.5, 3.3 Hz, 1H), 3.55 (dd, J=9.2, 2.9 Hz, 1H), 3.42-3.32 (m, 1H), 2.30-2.20 (m, 1H), 1.79- 1.69 (m, 1H), 1.14 (dd, J=5.9, 1.1 Hz, 6H).
Example 545:
In a vial suitable for heating, a mixture of 6-chloro-N-((R)-2-fluoro-3 -hydro xy-3 - methylbutyl)-4-(((S)-tetrahydrofuran-3-yl)amino)nicotinamide (99645-090-01) (30 mg, 0.087 mmol), lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (12.50 mg, 0.087 mmol), and potassium phosphate, tribasic (55.3 mg, 0.260 mmol) in dioxane (2 mL) was degassed with bubbling nitrogen for 5 minutes. In a separate sealed vial, a degassed, stirring mixture of Pd2(dba)3 (3.97 mg, 4.34 μιηοΐ) and tetramethyl t-Bu XPhos (5.00 mg, 10.41 μιηοΐ) in 5: 1 toluene/dioxane (0.2 mL) was heated at 120 °C for 5 minutes. After cooling to room temperature, this solution was transferred to the vial containing the reaction mixture. The vial was sealed and heated at 80 °C for 4 hours and maintained at room temperature overnight. The mixture was filtered, and the filtrate was concentrated under high vacuum. The product was purified directly via preparative HPLC to afford 6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((S)-tetrahydrofuran-3-yl)amino)nicotinamide, TFA salt (49 mg, 85% yield). HPLC Rt 1.12 min, Conditions E; LCMS 454.3 (M+H); 1H NMR (500MHz, DMSO-d6) δ 9.10 (s, 1H), 9.04 (s, 1H), 9.01-8.91 (m, 1H), 8.71 (s, 1H), 8.66 (s, 1H), 7.52 (s, 1H), 4.42 (d, J=9.1 Hz, 1H), 4.32 (d, J=9.1 Hz, 1H), 4.26 (br. s., 1H), 3.94 (dd, J=9.1, 5.4 Hz, 1H), 3.88 (q, J=7.4 Hz, 1H), 3.82-3.74 (m, 2H), 3.73-3.65 (m, 1H), 3.48-3.35 (m, 1H), 2.41- 2.32 (m, 1H), 1.89 (dd, J=7.9, 4.5 Hz, 1H), 1.18 (d, J=7.1 Hz, 7H). The Examples in Table 17 were prepared using the general methods for Examples 544 and 545 using the appropriate starting material and amine.
Table 17
Figure imgf000259_0001
Figure imgf000260_0001
Figure imgf000261_0001
Example 563 (R)-6-(5-Cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)- -((3,3,3-trifluoropropyl)amino)nicotinamide
Figure imgf000262_0001
Intermediate 563A: Ethyl -chloro-4-((3,3,3-trifluoropropyl)amino)nicotinate
Figure imgf000262_0002
To a solution of ethyl 4,6-dichloronicotinate (2 g, 9.09 mmol) in DMA (4 mL) were added 3,3,3-trifluoropropan-l-amine (1.028 g, 9.09 mmol) and DIPEA (1.587 mL, 9.09 mmol). The mixture was stirred at room temperature for 24 h. DMA and DIPEA were removed under vacuum and the crude material was diluted with ice cold water. The off-white solid formed was collected on a filter and dried to afford ethyl 6-chloro-4- ((3,3,3-trifluoropropyl)amino)nicotinate (1.8 g, 67% yield) which was used without further purification. LCMS 297.0 (M+H).
Intermediate 563B: 6-Chloro-4-((3,3,3-trifluoropropyl)amino)nicotinic acid
Figure imgf000262_0003
To a solution of ethyl 6-chloro-4-((3,3,3-trifluoropropyl)amino)nicotinate (2 g, 6.74 mmol) in EtOH (4 mL) were added water (1 mL) and LiOH (0.484 g, 20.22 mmol). The mixture was stirred at room temperature overnight and then concentrated to remove the EtOH. The residue was acidified with 1.5N HC1 and the precipitated product was filtered, washed with water and dried to afford 6-chloro-4-((3,3,3-trifluoropropyl)amino) nicotinic acid (1.5 g, 83% yield) which was used without further purification. LCMS 269.1 (M+H); 1H NMR (300 MHz, DMSO-d6) δ 8.52 (s, 1H), 6.84 (s, 1H); 3.55 (M, 2H), 2.63 (m, 2H).
Intermediate 563 C: (R)-6-Chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3,3,3- trifluoropropyl)amino)nicotinamide
Figure imgf000263_0001
To a solution of 6-chloro-4-((3,3,3-trifluoropropyl)amino)nicotinic acid (1.1 g, 4.10 mmol) in DMF (3 mL) were added HATU (1.557 g, 4.10 mmol) and DIPEA (0.715 mL, 4.10 mmol). To this stirred solution was added (R)-4-amino-3-fluoro-2- methylbutan-2-ol (0.496 g, 4.10 mmol) and the mixture was stirred at room temperature for 4 hrs. DMF was removed under vacuum and the crude mixture was diluted with water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried and concentrated. The crude product was purified by column chromatography using 2% MeOH in chloroform to afford (R)-6-chloro-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-((3,3,3-trifluoropropyl)amino)nicotinamide (0.7 g, 46% yield) as an off- white solid. 1H NMR (400MHz, DMSO-d6) δ = 8.82-8.72 (m, 1H), 8.63-8.54 (m, 1H), 8.39 (s, 1H), 6.78 (s, 1H), 4.82 (s, 1H), 4.44-4.22 (m, 1H), 3.79-3.59 (m, 1H), 3.50 (d, J=6.0 Hz, 2H), 3.43-3.34 (m, 1H), 2.61 (d, J=11.5 Hz, 2H), 1.16 (dd, J=4.5, 1.5 Hz, 6H). Example 563:
To solution of (R)-6-chloro-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3,3,3- trifluoropropyl)amino)nicotinamide (100 mg, 0.269 mmol) in dioxane (5 mL) were added lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (46.5 mg, 0.323 mmol), Xantphos (93 mg, 0.161 mmol) and Na2C03 (86 mg, 0.807 mmol). The mixture was degassed for 10 min and Pd2(dba)3 (99 mg, 0.108 mmol) was added. The mixture was degassed again for 10 min. The reaction mixture was then heated at 100 °C in a microwave vial for 2 h. The reaction mixture was cooled and filtered through small pad of CELITE®. The filtrate was concentrated and the crude material was purified by flash column chromatography through 24 g silica gel column using (1-6%) MeOH:CHCl3 as eluent. The product was further purified via preparative HPLC to afford (R)-6-(5-cyano-lH-pyrazolo[3,4-b] pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3,3,3-trifluoropropyl)amino) nicotinamide (30 mg, 21% yield). HPLC Rt 7.05 min, Conditions A; LCMS 480.2 (M+H); 1H NMR (400 MHz, DMSO-d6) δ 9.04-9.02 (m, 2H), 8.84 (t, J = 5.60 Hz, 1H), 8.71 (t, J = 5.60 Hz, 1H), 8.66 (d, J = 3.20 Hz, 2H), 7.40 (s, 1H), 4.85 (s, 1H), 4.38 (ddd, J = 2.00, 9.20, 49.20 Hz, 1H), 3.85-3.67 (m, 1H), 3.57 (q, J = 6.80 Hz, 2H), 3.50-3.39 (m, 1H), 2.74-2.66 (m, 2H), 1.19-1.15 (m, 6H).
The Examples in Table 18 were prepared using the general methods for Example 563 using the appropriate starting material and amine.
Table 18
Figure imgf000264_0001
Figure imgf000265_0001
Diastereomer 1
Figure imgf000266_0001
Figure imgf000267_0001
Figure imgf000268_0001
Figure imgf000269_0001
Diastereomer 2
Figure imgf000270_0001
Figure imgf000271_0001
Example 606
ano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)- 4-(((lr,4R)- -(2-hydroxypropan-2-yl)cyclohexyl)amino)nicotinamide
Figure imgf000271_0002
Figure imgf000272_0001
A solution of ethyl 4,6-dichloronicotinate (3 g, 13.6 mmol), 2-(4- aminocyclohexyl)propan-2-ol (2.144 g, 13.63 mmol), and DIPEA (7.14 mL, 41 mmol) in DMA (30 mL) was heated at 100 °C overnight. The reaction mixture was concentrated to remove DMA and water was added. The product was extracted with ethylacetate (3 times) and the combined extracts were washed with water and brine. The extracts were dried over anhydrous Na2S04, filtered, and concentrated. This crude product was purified via column chromatography to afford ethyl 6-chloro-4-(((lr,4r)-4-(2-hydroxypropan-2- yl)cyclohexyl)amino)nicotinate (3.5 g, 75% yield). 1H NMR (300MHz, DMSO-d6) δ 8.53 (s, 1H), 7.98 (d, J+8.4 Hz, 1H), 6.92 (s, 1H), 4.29 (q, J=6.9 Hz, 2H), 4.08 (s, 1H), 3.40 (br s, lH), 2.10 (br m, 2H), 1.83 (br m, 2H), 1.31 (t, J=6.9 Hz, 3H), 1.21 (m, 5H), 1.05 (s, 3H).
Intermediate 606B : 6-Chloro-4-(((lr,4r)-4-(2-hydroxypropan-2-yl)cyclohexyl)amino) nicotinic acid
Figure imgf000272_0002
To a solution of ethyl 6-chloro-4-(((lr,4r)-4-(2-hydroxypropan-2-yl)cyclohexyl) amino)nicotinate (1.31 g, 3.8 mmol) in EtOH (13 mL) was added water (7 mL) and LiOH (0.27 g, 11.44 mmol). The mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated and acidified with 1.5 N HC1 to pH 4. The resulting solids were filtered, rinsed with water and dried to afford 6-chloro-4-(((lr,4r)-4-(2- hydroxypropan-2-yl)cyclohexyl)amino) nicotinic acid (1.0 g, 83% yield) as a white solid.
LCMS 313.1 (M+H); 1H NMR (400MHz, DMSO-d6) δ 13.30 (br s, 1H), 8.49 (s, 1H), 8.19 (d, J=8.1 Hz, 1H), 6.68 (s, 1H), 4.08 (s, 1H), 3.44 (br s, 1H), 2.02 (m, 2H), 1.82 (M, 2H), 1.20 (m, 5H), 1.05 (s, 6H).
Intermediate 606C : 6-Chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((lr,4R)-4- (2 -hydroxypropan-2-yl)cyclohexyl)amino Nicotinamide
Figure imgf000273_0001
To a stirred solution of 6-chloro-4-(((lr,4r)-4-(2-hydroxypropan-2-yl)cyclohexyl) amino)nicotinic acid (800 mg, 2.56 mmol) in DMF (8 mL) were added HATU (1.95 g, 5.1 mmol), DIPEA (1.34 mL, 7.7 mmol) and (R)-4-amino-3-fluoro-2-methylbutan-2-ol (340 mg, 2.8 mmoL). The reaction mixture was stirred at room temperature for 1 h. The mixture was concentrated, water was added, and the product was extracted with EtOAc. The organic extracts were washed with saturated aqueous sodium bicarbonate, washed with brine and collectively dried over Na2SC"4. The solution was filtered and the filtrate concentrated to afford the crude product which was purified via column chromatography to afford 6-chloro-N-((R)-2-fiuoro-3-hydroxy-3-methylbutyl)-4-(((lr,4R)-4-(2- hydroxypropan-2-yl)cyclohexyl)amino)nicotinamide (800 mg, 75% yield) which was used in the next step. LCMS 416.1 (M+H).
Example 606:
To a stirred solution of 6-chloro-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4- (((lS,4S)-4-(2-hydroxypropan-2-yl)cyclohexyl)amino)nicotinamide (50 mg, 0.120 mmol) in dioxane (10 mL) were added lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (17.33 mg, 0.120 mmol), Xantphos (27.8 mg, 0.048 mmol), and Na2C03 (51.0 mg, 0.481 mmol). The mixture was degassed for 3 minutes with nitrogen. Next, Pd2(dba)3 (44.0 mg, 0.048 mmol) was added and the mixture was degassed with nitrogen for 5 min. The reaction vessel was sealed and the mixture was heated at 110 °C for 24 h. The reaction mixture was cooled to room temperature, filtered through CELITE® with 10% MeOH/CHCl3 and concentrated. The residue was purified via preparative HPLC to afford 6-(5-cyano-lH- pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fiuoro-3-hydroxy-3-methylbutyl)-4-(((lS,4S)-4-(2- hydroxypropan-2-yl)cyclohexyl)amino)nicotinamide (5 mg, 8% yield) as a pale yellow solid. HPLC Rt 1.34 min, Conditions C; LCMS 524.2 (M+H). 1H NMR (400MHz,
MeOD4) δ 8.99 (d, J=2Hz, 1H), 8.84 (d, J=2Hz, 1H), 8.53 (m, 1H), 7.78 (s, 1H), 4.39 (dd, J=9.2, 2.0 Hz, 1H), 3.87 (m, 1H), 3.51 (m, 2H), 2.31 (m, 2H), 2.02 (m, 2H), 1.40 (m, 5H), 1.35 (s, 6H), 1.31 (s, 6H).
The Examples in Table 19 were prepared using the general methods for Example using the appropriate starting material and amine.
Table 19
Figure imgf000274_0001
Figure imgf000275_0001
Diastereomer 1
Figure imgf000276_0001
Diastereomer 2
Figure imgf000277_0001
Figure imgf000278_0001
Figure imgf000279_0001
Figure imgf000280_0001
Diastereomer 3
Figure imgf000281_0001
Figure imgf000282_0001
BIOLOGICAL ASSAYS
The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays. The exemplified biological assays, which follow, have been carried out with compounds of the invention.
IRAK4 Inhibition Assay
The assays were performed in U-bottom 384-well plates. The final assay volume was 30 prepared from 15 additions of enzyme and substrates (fluoresceinated peptide and ATP) and test compounds in assay buffer (20 mM HEPES pH 7.2, 10 mM MgCl2, 0.015% Brij 35 and 4 mM DTT). The reaction was initiated by the combination of IRAK4 with substrates and test compounds. The reaction mixture was incubated at room temperature for 60 min. and terminated by adding 45 of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assays are ATP, 500 μΜ; FL- IPTSPITTTYFFFKK peptide 1.5 μΜ; IRAK4, 0.6 nM; and DMSO, 1.6%.
PBMC TLR2 Induced IL-6 Assay
Peripheral blood mononuclear cells (PBMCs) were isolated from human blood containing the anti-coagulant EDTA (2.5 mM) by centrifugation over a FICOLL® gradient. PBMCs (250000 cells/well) were cultured in assay media (RPMI with 10% heat inactivated FCS) with compounds for 30 minutes at 37 °C in a 5% C02 incubator.
Following pretreatment with compounds, cells were stimulated for 5 hours with 10 μg/ml lipoteichoic acid (Invivogen, San Diego, CA), a TLR2 agonist. At the end of the culture, plates were centrifuged at 1800 rpm for 10 minutes to pellet the cells. Supernatants were harvested and analyzed for IL-6 levels by ELISA (BD Biosciences, San Jose, CA).
The table below lists the IRAK4 IC50 values and Cell IC50 or EC50 values for the following Examples of this invention measured in the IRAK4 Inhibition Assay and the PBMC TLR2 Induced IL-6 Assay. The compounds of the present invention, as exemplified by the following examples, showed IRAK IC50 inhibition values of less than 0.025 μΜ.
Table 11
IRAK4 Inhibition Data
Figure imgf000283_0001
Figure imgf000283_0002
Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
11 0.0017 0.050 - 336 0.0038 0.168 0.556
12 0.0017 0.122 - 337 0.0071 0.572 0.765
13 0.0120 0.346 - 338 0.0045 - 0.147
14 0.0148 0.286 - 339 0.0040 - 0.332
15 0.0055 0.171 - 340 0.0100 0.536 -
16 0.0012 0.015 - 341 0.0019 0.161 -
17 0.0012 0.042 - 342 0.0087 - 0.423
18 0.0021 0.062 - 343 0.0035 - 0.428
19 0.0032 0.252 - 344 0.0135 - 0.144
20 0.0057 0.497 - 345 0.0074 - 0.180
21 0.0023 0.051 - 346 0.0036 - 0.306
22 0.0018 0.047 - 347 0.0013 - 0.146
23 0.0026 0.110 - 348 0.0018 - 0.489
24 0.0014 0.030 - 349 0.0033 - 0.180
25 0.0015 0.022 - 350 0.0022 - 0.424
26 0.0025 0.168 - 351 0.0023 - 0.027
27 0.0016 0.044 - 352 0.0065 - 0.170
28 0.0028 0.080 - 353 0.0017 - 0.018
29 0.0037 0.141 - 354 0.0019 - 0.115
30 0.0022 0.101 0.184 355 0.0024 - 0.122
31 0.0034 0.367 1.085 356 0.0024 - 0.154
32 0.0019 0.075 0.562 357 0.0017 - 0.067
33 0.0071 0.661 0.403 358 0.0035 - 0.257
34 0.0053 0.180 0.407 359 0.0013 - 0.084
35 0.0021 0.117 0.452 360 0.0015 - 0.376
36 0.0031 0.133 - 361 0.0029 - 0.206
37 0.0118 1.231 - 362 0.0043 - 0.486
38 0.0016 0.084 - 363 0.0032 - 0.459
39 0.0011 0.151 0.151 364 0.0026 - 0.083 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
40 0.0020 0.175 0.175 365 0.0017 - 0.066
41 0.0019 0.220 0.220 366 0.0079 - 0.205
42 0.0136 0.612 0.940 367 0.0013 - 0.041
43 0.0060 0.316 - 368 0.0024 - 0.061
44 0.0042 0.098 - 369 0.0019 - 0.032
45 0.0232 0.148 - 370 0.0026 - 0.084
46 0.0022 0.023 - 371 0.0021 - 0.045
47 0.0056 0.173 - 372 0.0012 - 0.002
48 0.0014 0.024 - 373 0.0024 - 0.071
49 0.0032 0.071 - 374 0.0033 - 0.085
50 0.0019 0.058 - 375 0.0018 - 0.156
51 0.0044 0.065 - 376 0.0021 - 0.349
52 0.0024 0.066 - 377 0.0027 - 0.440
53 0.0019 0.271 - 378 0.0026 - 0.655
54 0.0018 0.254 - 379 0.0025 - 0.188
55 0.0036 0.513 - 380 0.0029 - 0.228
56 0.0025 0.102 - 381 0.0025 - 0.041
57 0.0015 0.173 - 382 0.0025 - 0.482
58 0.0027 0.049 - 383 0.0014 - 0.113
59 0.0016 0.153 - 384 0.0023 - 0.024
60 0.0018 0.024 - 385 0.0009 - 0.040
61 0.0013 0.034 - 386 0.0015 0.079 1.078
62 0.0036 0.143 - 387 0.0033 - 0.198
63 0.0041 0.012 - 388 0.0112 - 0.245
64 0.0017 0.093 - 389 0.0040 - 0.241
65 0.0015 0.100 - 390 0.0170 - 0.199
66 0.0017 0.201 - 391 0.0062 - 0.241
67 0.0017 0.102 - 392 0.0071 - 0.016
68 0.0021 0.030 - 393 0.0035 - 0.250 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
69 0.0013 0.050 - 394 0.0028 - 0.188
70 0.0028 0.210 - 395 0.0022 - 0.085
71 0.0015 0.028 - 396 0.0086 - 0.157
72 0.0020 0.072 - 397 0.0066 - 0.210
73 0.0131 0.189 - 398 0.0049 - 0.277
74 0.0043 - 0.531 399 0.0013 - 0.024
75 0.0076 - 0.022 400 0.0078 - 0.156
76 0.0015 - 0.395 401 0.0057 - 0.485
77 0.0026 - 0.161 402 0.0025 - 0.412
78 0.0029 - 0.063 403 0.0025 - 0.147
79 0.0116 0.436 0.436 404 0.0011 - 0.164
80 0.0011 0.167 0.079 405 0.0062 - 0.561
81 0.0142 0.121 0.565 406 0.0048 - 0.066
82 0.0044 0.166 0.578 407 0.0031 - 0.287
83 0.0049 0.443 0.777 408 0.0018 - 0.073
84 0.0093 1.996 2.006 409 0.0175 0.463 -
85 0.0133 0.523 - 410 0.0015 0.092 -
86 0.0071 0.110 - 411 0.0016 0.051 -
87 0.0019 0.063 - 412 0.0036 - 0.053
88 0.0071 0.345 - 413 0.0070 - 0.382
89 0.0033 0.090 - 414 0.0100 0.188 -
90 0.0019 0.041 - 415 0.0148 0.286 -
91 0.0020 0.032 - 416 0.0019 0.058 -
92 0.0017 0.079 - 417 0.0055 0.171 -
93 0.0084 0.562 - 418 0.0044 0.065 -
94 0.0017 0.062 - 419 0.0048 0.107 -
95 0.0051 0.408 - 420 0.0044 0.186 -
96 0.0014 0.038 - 421 0.0019 - 0.167
97 0.0049 0.108 - 422 0.0023 0.004 - Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
98 0.0033 0.176 - 423 0.0184 0.346 1.303
99 0.0046 0.223 - 424 0.0060 0.338 -
100 0.0025 0.095 - 425 0.0018 0.154 -
101 0.0078 0.112 - 426 0.0016 0.051 -
102 0.0036 0.047 - 427 0.0028 0.089 -
103 0.0035 0.125 - 428 0.0046 0.361 -
104 0.0017 0.067 - 429 0.0015 0.092 -
105 0.0039 0.437 - 430 0.0021 0.208 -
106 0.0019 0.896 0.896 431 0.0021 0.106 -
107 0.0018 0.057 - 432 0.0021 0.080 -
108 0.0035 0.172 - 433 0.0041 0.164 0.499
109 0.0010 0.045 - 434 0.0016 0.057 -
110 0.0013 0.047 - 435 0.0099 0.291 -
111 0.0050 0.238 - 436 0.0018 0.165 -
112 0.0044 0.159 - 437 0.0010 0.042 -
113 0.0019 0.222 - 438 0.0025 0.033 -
114 0.0046 - - 439 0.0026 0.073 -
115 0.0033 0.082 - 440 0.0019 0.072 -
116 0.0062 0.133 - 441 0.0030 0.109 -
117 0.0024 0.028 - 442 0.0015 0.042 -
118 0.0018 0.018 - 443 0.0016 0.031 -
119 0.0044 0.091 - 444 0.0046 0.186 -
120 0.0051 0.105 - 445 0.0053 0.108 -
121 0.0052 0.112 - 446 0.0039 0.051 -
122 0.0160 0.501 - 447 0.0053 0.092 -
123 0.0045 0.128 - 448 0.0024 0.175 -
124 0.0048 0.119 - 449 0.0015 0.082 0.059
125 0.0067 0.202 - 450 0.0028 0.268 0.438
126 0.0075 0.150 - 451 0.0044 0.429 - Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
127 0.0028 0.089 - 452 0.0052 0.700 0.252
128 0.0089 0.248 - 453 0.0044 0.213 0.326
129 0.0041 0.451 - 454 0.0059 0.757 0.289
130 0.0023 0.099 - 455 0.0022 0.072 -
131 0.0068 0.410 - 456 0.0048 0.241 -
132 0.0047 0.092 - 457 0.0103 0.458 1.239
133 0.0026 0.120 - 458 0.0071 0.261 0.260
134 0.0069 0.282 - 459 0.0049 0.095 0.343
135 0.0045 0.168 - 460 0.0033 0.088 0.113
136 0.0031 0.133 - 461 0.0025 0.074 0.122
137 0.0027 0.084 - 462 0.0029 0.066 0.398
138 0.0064 0.152 - 463 0.0017 0.023 -
139 0.0029 0.118 - 464 0.0031 0.257 -
140 0.0083 0.226 - 465 0.0013 0.007 0.023
141 0.0022 0.087 - 466 0.0139 0.792 0.130
142 0.0114 0.354 - 467 0.0023 0.026 0.100
143 0.0065 0.185 - 468 0.0058 0.128 1.010
144 0.0062 0.148 - 469 0.0029 0.084 0.207
145 0.0045 0.061 - 470 0.0080 0.240 -
146 0.0065 0.267 - 471 0.0101 0.194 -
147 0.0119 0.338 - 472 0.0020 0.070 0.123
148 0.0014 0.064 - 473 0.0041 0.238 0.483
149 0.0093 0.239 - 474 0.0012 0.077 0.315
150 0.0090 0.593 - 475 0.0067 0.305 1.183
151 0.0148 0.443 - 476 0.0030 0.198 -
152 0.0056 0.294 - 477 0.0029 0.301 1.302
153 0.0031 0.160 - 478 0.0047 0.462 0.805
154 0.0120 0.584 - 479 0.0057 0.144 0.835
155 0.0070 0.164 - 480 0.0040 0.170 0.270 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
156 0.0095 0.231 - 481 0.0019 0.053 0.595
157 0.0053 0.097 - 482 0.0174 0.433 -
158 0.0042 0.127 - 483 0.0108 0.199 -
159 0.0024 0.112 - 484 0.0035 - 0.282
160 0.0058 0.176 - 485 0.0087 0.198 1.077
161 0.0068 0.253 - 486 0.0012 - 0.177
162 0.0038 0.129 - 487 0.0020 0.034 0.111
163 0.0030 0.081 - 488 0.0068 0.208 0.379
164 0.0035 0.299 - 489 0.0043 0.318 1.700
165 0.0091 0.172 - 490 0.0043 0.121 0.225
166 0.0046 0.192 - 491 0.0034 0.116 0.102
167 0.0105 0.171 - 492 0.0070 0.250 0.547
168 0.0131 0.305 - 493 0.0030 0.185 0.209
169 0.0033 0.204 - 494 0.0030 - 0.289
170 0.0151 0.423 - 495 0.0018 - 0.215
171 0.0037 0.208 0.587 496 0.0109 - 0.197
172 0.0025 - 10.000 497 0.0037 - 0.098
173 0.0023 0.081 0.242 498 0.0057 - 0.248
174 0.0033 0.182 - 499 0.0061 - 0.213
175 0.0050 0.113 - 500 0.0132 - 0.546
176 0.0064 0.476 - 501 0.0054 - 0.332
177 0.0036 0.352 - 502 0.0048 - 0.366
178 0.0037 0.100 - 503 0.0023 - 0.099
179 0.0028 0.135 - 504 0.0043 - 0.262
180 0.0053 0.208 - 505 0.0135 - 0.559
181 0.0043 0.152 - 506 0.0015 - 0.065
182 0.0018 0.074 - 507 0.0014 - 0.374
183 0.0041 0.179 - 508 0.0028 - 0.224
184 0.0055 0.436 - 509 0.0016 - 0.128 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
185 0.0034 0.350 - 510 0.0032 - 0.250
186 0.0013 0.044 - 511 0.0054 - 0.047
187 0.0019 0.086 - 512 0.0035 - 0.541
188 0.0017 0.057 - 513 0.0059 - 0.389
189 0.0048 0.075 - 514 0.0082 - 0.047
190 0.0047 0.120 - 515 0.0022 - 0.542
191 0.0147 10.000 - 516 0.0086 - 0.414
192 0.0026 0.120 - 517 0.0012 - 0.113
193 0.0034 - 0.287 518 0.0140 - 0.094
194 0.0031 0.160 - 519 0.0027 - 0.126
195 0.0194 0.340 0.647 520 0.0105 - 0.347
196 0.0104 0.304 0.328 521 0.0035 0.460 -
197 0.0081 0.297 - 522 0.0026 0.177 -
198 0.0034 0.134 - 523 0.0026 0.024 -
199 0.0063 0.281 - 524 0.0026 0.132 -
200 0.0028 0.079 - 525 0.0016 0.253 -
201 0.0163 0.583 - 526 0.0037 0.113 -
202 0.0106 0.131 - 527 0.0030 0.228 -
203 0.0039 0.124 - 528 0.0033 0.091 0.326
204 0.0049 0.174 - 529 0.0048 - 0.163
205 0.0070 0.240 - 530 0.0114 0.329 0.163
206 0.0144 0.086 - 531 0.0022 - 0.067
207 0.0103 0.227 - 532 0.0055 0.127 -
208 0.0160 0.238 - 533 0.0103 0.194 -
209 0.0153 0.322 - 534 0.0015 0.059 0.824
210 0.0031 0.206 - 535 0.0040 0.185 -
211 0.0081 0.087 - 536 0.0081 0.189 -
212 0.0124 0.192 - 537 0.0068 0.159 -
213 0.0148 0.428 - 538 0.0096 - 0.698 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
214 0.0136 0.209 - 539 0.0063 0.256 -
215 0.0037 0.144 - 540 0.0030 - 0.158
216 0.0045 0.253 - 541 0.0144 - 0.149
217 0.0155 0.503 - 542 0.0073 - 0.973
218 0.0195 0.111 - 543 0.0068 - 0.404
219 0.0149 0.502 0.678 544 0.0041 0.239 -
220 0.0065 0.168 - 545 0.0087 0.476 -
221 0.0084 0.230 - 546 0.0037 0.257 -
222 0.0051 0.305 - 547 0.0166 0.065 0.591
223 0.0040 - 0.178 548 0.0106 0.708 0.763
224 0.0067 0.303 0.159 549 0.0168 0.413 0.757
225 0.0092 0.098 - 550 0.0103 0.416 -
226 0.0068 0.248 - 551 0.0126 - 0.212
227 0.0053 0.055 - 552 0.0134 - 0.213
228 0.0069 0.163 - 553 0.0112 - 0.298
229 0.0096 0.137 1.417 554 0.0055 - 0.370
230 0.0134 0.410 0.459 555 0.0070 - 0.047
231 0.0142 0.237 0.544 556 0.0062 - 0.305
232 0.0023 0.033 0.211 557 0.0051 - 0.475
233 0.0036 0.038 0.176 558 0.0061 - 0.615
234 0.0047 0.128 1.363 559 0.0053 - 0.018
235 0.0061 0.184 - 560 0.0034 - 0.254
236 0.0116 0.323 - 561 0.0078 - 0.321
237 0.0067 0.102 0.364 562 0.0125 0.255 -
238 0.0081 0.357 1.808 563 0.0050 0.159 -
239 0.0053 0.211 0.775 564 0.0201 0.659 -
240 0.0157 0.305 - 565 0.0157 0.757 -
241 0.0073 0.292 - 566 0.0172 0.637 -
242 0.0062 0.089 - 567 0.0099 0.164 0.264 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
243 0.0053 0.298 1.990 568 0.0089 0.661 1.367
244 0.0063 0.259 - 569 0.0130 0.242 -
245 0.0157 0.233 - 570 0.0107 0.425 -
246 0.0198 0.353 - 571 0.0152 - 0.101
247 0.0068 0.173 - 572 0.0091 - 0.303
248 0.0036 - 0.554 573 0.0088 0.729 0.270
249 0.0061 - 0.355 574 0.0153 - 0.258
250 0.0083 0.497 - 575 0.0118 - 0.587
251 0.0031 0.311 - 576 0.0058 - 0.153
252 0.0036 - 0.197 577 0.0032 - 0.175
253 0.0085 - 0.363 578 0.0026 - 0.218
254 0.0100 - 0.496 579 0.0039 - 0.269
255 0.0075 0.329 - 580 0.0107 - 0.487
256 0.0147 - 0.148 581 0.0084 - 0.227
257 0.0089 0.136 - 582 0.0038 - 0.109
258 0.0063 - 0.042 583 0.0041 - 0.188
259 0.0025 - 0.102 584 0.0100 0.209 0.508
260 0.0033 - 0.159 585 0.0085 - 0.147
261 0.0034 - 0.154 586 0.0097 - 0.259
262 0.0013 - 0.048 587 0.0138 - 0.298
263 0.0135 - 0.401 588 0.0044 - 0.506
264 0.0065 - 0.338 589 0.0041 - 0.361
265 0.0024 - 0.241 590 0.0019 - 0.129
266 0.0026 - 0.073 591 0.0027 - 0.160
267 0.0045 - 0.516 592 0.0028 - 0.271
268 0.0106 - 0.171 593 0.0196 - 0.408
269 0.0036 - 0.171 594 0.0175 - 0.319
270 0.0016 - 0.348 595 0.0053 - 0.129
271 0.0159 - 0.176 596 0.0182 - 0.578 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
272 0.0051 - 0.737 597 0.0156 - 0.307
273 0.0186 - 0.094 598 0.0166 - 0.054
274 0.0062 - 0.204 599 0.0048 - 0.275
275 0.0080 - 0.1 15 600 0.0053 - 0.477
276 0.0047 - 0.380 601 0.0142 - 0.490
277 0.0059 - 0.251 602 0.0093 - 0.233
278 0.0100 - 0.203 603 0.0067 - 0.321
279 0.0065 - 0.247 604 0.0061 - 0.104
280 0.0169 - 0.692 605 0.0075 - 0.165
281 0.0078 - 0.255 606 0.0040 0.127 -
282 0.0041 - 0.541 607 0.0040 0.332 -
283 0.0028 - 0.135 608 0.0126 0.318 -
284 0.0019 - 0.258 609 0.0227 0.485 1.441
285 0.0100 - 0.200 610 0.0089 0.166 0.217
286 0.0017 - 0.158 611 0.0174 0.536 1.854
287 0.0082 - 0.489 612 0.0056 0.163 0.262
288 0.0034 - 0.234 613 0.0028 0.157 0.130
289 0.0047 - 0.275 614 0.0077 0.481 0.491
290 0.0059 - 0.364 615 0.0023 - 0.190
291 0.0035 - 0.349 616 0.0109 0.305 0.425
292 0.0027 - 0.456 617 0.0028 - 0.485
293 0.0010 - 0.032 618 0.0058 0.127 -
294 0.0134 - 0.292 619 0.0040 0.119 -
295 0.0019 - 0.240 620 0.0034 0.114 -
296 0.0071 - 0.412 621 0.0040 0.139 -
297 0.0041 - 0.219 622 0.0052 - 0.132
298 0.0045 - 0.142 623 0.0052 - 0.484
299 0.0063 - 0.252 624 0.0021 - 0.068
300 0.0016 - 0.083 625 0.0022 - 0.210 Ex. IRAK4 Cell EC50 Cell IC50 Ex. IRAK4 Cell EC50 Cell IC50
No. IC50 (μΜ) (μΜ) (μΜ) No. IC50 (μΜ) (μΜ) (μΜ)
301 0.0024 - 0.063 626 0.0011 - 0.076
302 0.0041 - 0.148 627 0.0023 - 0.007
303 0.0035 - 0.176 628 0.0033 - 0.148
304 0.0107 - 0.408 629 0.0033 - 0.135
305 0.0092 - 0.207 630 0.0022 - 0.030
306 0.0048 - 0.800 631 0.0034 - 0.066
307 0.0020 - 0.127 632 0.0026 - 0.149
308 0.0030 - 0.073 633 0.0033 - 0.257
309 0.0184 - 0.207 634 0.0039 - 0.277
310 0.0045 - 0.023 635 0.0018 - 0.375
311 0.0047 - 0.347 636 0.0030 - 0.293
312 0.0092 - 0.375 637 0.0015 - 0.165
313 0.0147 - 0.289 638 0.0117 - 0.554
314 0.0137 - 0.420 639 0.0085 - 0.055
315 0.0107 - 0.267 640 0.0032 - 0.033
316 0.0017 - 0.046 641 0.0064 - 0.718
317 0.0038 - 0.172 642 0.0048 - 0.197
318 0.0079 - 0.188 643 0.0054 - 0.320
319 0.0065 - 0.191 644 0.0043 - 0.089
320 0.0056 - 0.261 645 0.0069 - 0.154
321 0.0031 - 0.053 646 0.0105 - 0.393
322 0.0067 - 0.159
323 0.0173 - 0.612
324 0.0066 - 0.278
325 0.0060 - 0.227
Single Crystal X-Ray Diffractometry
The single crystal x-ray diffraction data was obtained using Bruker APEX II system (Bruker-AXS, Germany) with sealed tube X-ray source (Mo target). The source is mounted on the 3-axis D8 goniometer in the standard, compact D8 safety enclosure. The data was collected on instrument with X-ray source operating at voltage (50 kV) and current (35 mA). The single crystal obtained using crystallization studies is mounted on nylon wire loop and analyzed at temperature of 296 K. The crystal was exposed to monochromatic x-ray beam. The scattered beams were analyzed using 4 K CCD detector. Indexing and processing of the measured intensity data were carried out with the APEX2 software package/program suite (APEX2 Data collection and processing user interface: APEX2 User Manual, vl .27; Bruker AXS, Inc., 5465 East Cheryl Parkway Madison, WI 53711 USA). The structures were solved by direct methods and refined on the basis of observed reflections using the crystallographic package SHELXTL (Bruker AXS, 5465 East Cheryl Parkway, Madison, WI, 53711, USA).
The derived atomic parameters (coordinates and temperature factors) were refined through full matrix least-squares. The function minimized in the refinements was∑W(|F0| - |FC|)2. R is defined as∑||F0| - |FC||/∑|F0| while Rw = [∑w(|F0| - |FC|)2/∑W |F0|2]1/2 where w is an appropriate weighting function based on errors in the observed intensities. Difference maps were examined at all stages of refinement. Hydrogen atoms were introduced in idealized positions with isotropic temperature factors, but no hydrogen parameters were varied. X-Ray Powder Diffractometry
The powder diffraction data were obtained with a Bruker D8 Advance system (Bruker AXS, Germany) which was equipped with a sealed tube Cu source, operating at a tube load of 40kV and 40mA. The source was mounted on the 3-axis D8 goniometer in the standard, compact D8 safety enclosure. Powder samples were placed in a thin uniform layer on Silicon low background sample holders (51.5mm, with 20mm x 0.5mm sample cavity); the sample holder was rotated during data collection. The sample- detector distance was 280 mm. Data were collected with a step size of 0.03 degrees 2theta in the range of 2 to 32 degrees 2theta, with a sample exposure time of at least 1000 seconds. The scattered beams were analyzed using Lynx eye 1 dimensional position sensitive (PSD) detector.

Claims

What is claimed is:
1. A compound of Formula I)
Figure imgf000296_0001
or a salt thereof, wherein:
HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl,
pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb;
Ra is H, F, CI, Br, -CN, -OH, Ci_4 alkyl, Ci_4 fluoroalkyl, Ci_4 hydroxyalkyl, Ci_4 alkoxy, -NH2, -NH(Ci_4 alkyl), -N(CM alkyl)2, -NH(Ci_4 hydroxyalkyl), -NH(Ci_4
fluoroalkyl), -NH(Ci_6 hydroxy-fiuoroalkyl), -C(0)NH2, -CH2NHC(0)(Ci_6 alkyl), -CH2NHC(0)(Ci_6 hydroxyalkyl), -CH2NHC(0)NH(Ci_6 alkyl),
-CH2NHC(0)NHCH2(phenyl), -CH2NHC(0)N(Ci_4 alkyl)2, -CH2NHC(0)0(Ci_4 alkyl), -CH2NHC(0)(C3-6 cycloalkyl), -CH2NHC(0)(tetrahydrofuranyl),
-CH2NHC(0)CH2(C3_6 cycloalkyl), -CH2NHC(0)CH2(tetrahydropyranyl),
-CH2NHC(0)CH2(phenyl), -NHC(0)(Ci_4 alkyl), pyrrolidinyl, hydroxypyrrolidinyl, or pyridazinyl;
Rb is H or -NH2;
Ri is:
(i) Ci_6 alkyl, Ci_6 fluoroalkyl, Ci_6 hydroxyalkyl, Ci_g hydroxy-fiuoroalkyl, -(Ci_6 alkylenyl)0(Ci_4 alkyl), -(Ci_6 alkylenyl)0(Ci_4 fluoroalkyl), -(Ci_6
fiuoroalkylenyl)0(Ci_4 alkyl), -(Ci_6 f uoroalkylenyl)0(Ci_4 deuteroalkyl), -(Ci_6 fiuoroalkylenyl)0(Ci_4 fluoroalkyl), -(Ci_4 fluoroalkylenyl)C(C3_6
cycloalkyl)2(OH), -(CM alkylenyl)NHC(0)(Ci_4 alkylenyl)OC(0)(Ci_3 alkyl), -(Ci_6 alkylenyl)NHS(0)2(Ci_4 alkyl), -(Ci_6 alkylenyl)P(0)(Ci_4 alkoxy)2, -(Ci_6 f uoroalkylenyl)NH(Ci_4 alkyl), -(Ci_6 alkylenyl)C(0)NH(Ci_4 alkyl), -(Ci_6 fluoroalkylenyl)C(0)NH(Ci_4 alkyl), -(Ci_6 fluoroalkylenyl)C(0)NH(Ci_4 hydroxyalkyl), or -(Ci_6 fluoroalkylenyl)OP(0)(OH)2;
(ii) -(Ci-3 alkylenyl)Rx, -(Ci_3 fluoroalkylenyl)Rx, -(Ci_3 alkylenyl)C(0)Rx, -(Ci_3 alkylenyl)C(0)NHRx, -(Ci_3 fluoroalkylenyl)C(0)Rx, or
-CH2CF=(tetrahydropyranyl), wherein Rx is a cyclic group selected from C3_6 cycloalkyl, tetrazolyl, 1,1-dioxidotetrahydrothiophenyl,
1,1-dioxidothiomorpholinyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -C(CH2)2OH, -OCH3, -C(0)CH2CN, -S(0)2CH3, -S(0)2NH2, -NHC(0)CH3, -N(S(0)2CH3)2, -CH2CH2(acetamidophenyl), -CH2CH2(methoxyphenyl),
-CH2CH2(sulfamoylphenyl), oxetanyl, benzyl, and morpholinyl;
(iii) C3_6 cycloalkyl or C4-6 cycloalkenyl, each substituted with zero to 3 substituents independently selected from F, -OH, -CN, Ci_3 alkyl, Ci_3 alkoxy, -S(Ci_3 alkyl), -N02, -S(0)2(Ci_3 alkyl), Ci_4 hydroxyalkyl, -C(Ci_3 alkyl)(OH)(C3_6 cycloalkyl), -CH2C(0)NH(Ci_3 alkyl), -NHC(0)(Ci_3 alkyl), -NHC(0)(Ci_4 hydroxyalkyl), -C(0)NH(Ci_3 alkyl), -C(0)NH(Ci_3 deuteroalkyl), -C(0)NH(C3_6 cycloalkyl), -NHC(0)0(Ci_3 alkyl), -NHS(0)2(Ci_3 alkyl), pyridinyl, imidazolyl, pyrazolyl, methylimidazolyl, methylpyrazolyl, and thiazolyl;
(iv) tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from -OH, Ci_3 alkyl, Ci_3 fluoroalkyl, Ci_4 hydroxyalkyl, Ci_3 alkoxy, -C(0)(Ci_4 alkyl), -S(0)2(Ci_4 alkyl), -S(0)2NH(Ci_4 alkyl), -NH(Ci_3 alkyl), -N(Ci_3 alkyl)2, -0(Ci_3 alkylenyl)N(Ci_3 alkyl)2, -CH2(morpholinyl), azetidinyl, oxetanyl, tetrahydropyranyl,
morpholinyl, piperazinyl, piperidinyl, methylpiperazinyl, methoxypiperidinyl, pyridinyl, pyrimidinyl, methylsulfonyl azetidinyl, and -C(0)(methylsulfonyl azetidinyl); or
(v) pyrrolo[2,3-c]pyridinyl, bicyclo[2.2.1]heptan-l-ol,
tetrahydrobenzo[d]thiazol-2-amine, or l,3-diazaspiro[4.5]decane-2,4-dione; and
R2 is: (i) Ci_7 alkyl or C2_6 alkenyl, each substituted with zero to three substituents independently selected from F, -OH, and -CN; -(C1-4 alkylenyl)0(Ci_4 alkyl), -(CM alkylenyl)0(Ci_4 fiuoroalkyl), -(Ci_6 alkylenyl)NH2, -(Ci_6
alkylenyl)S(0)2(Ci_3 alkyl), -(Ci_6 fhioroalkylenyl)NH(Ci_3 alkyl), or -(Ci_6 alkylenyl)NHC(0)(C M fiuoroalkyl);
(ii) -(Ci_4 alkylenyl)Ry wherein Ry is C3_6 cycloalkyl, azetidinyl, oxetanyl, oxazolyl, pyridinyl, tetrahydropyranyl, or morpholinyl, each substituted with zero to 2 substituents independently selected from F, -OH, and Ci_3 alkyl;
(iii) C3_6 cycloalkyl, azetidinyl, oxetanyl, furanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, or tetrahydropyranyl, each substituted with zero to 3 substituents independently selected from F, -OH, Ci_3 alkyl, Ci_3 hydroxyalkyl, -C(0)(Ci_3 alkyl), -C(0)(Ci_3 fiuoroalkyl), -C(0)(Ci_3 cyanoalkyl), -C(0)0(Ci_3 alkyl), -C(0)NH2, -C(0)NH(Ci_3 alkyl), -C(0)(difiuorophenyl), -NH2, -NH(Ci_3 alkyl), -NH(Ci_3 fiuoroalkyl), -NH(oxetanyl), -NHC(0)(Ci_3 alkyl), -NHC(0)(Ci_3 fiuoroalkyl), -NHC(0)(C3_6 cycloalkyl), -NHC(0)(fiuorophenyl), -S(0)2(Ci_3 alkyl), imidazolyl, phenyl, pyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, and methoxypyrimidinyl;
(iv) adamantanyl, hydroxyadamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, bicyclo[l . l .l]pentanyl, or hydroxy- bicyclo[2.2.1]heptanyl; or
(v) phenyl, pyrazolyl, thiazolyl, thiadiazolyl, or indazolyl, each substituted with 0 to 2 substituents independently selected from F, CI, -OH, -CN, Ci_4 alkyl, Ci_4 hydroxyalkyl, Ci_4 fiuoroalkyl, Ci_4 cyanoalkyl, Ci_3 alkoxy, C3_6 cycloalkyl, -(Ci-3 alkylenyl)0(Ci_3 alkyl), -(Ci_3 alkylenyl)0(Ci_3 fiuoroalkyl), -C(0)NH2, -C(0)NH(Ci_3 alkyl), -NHC(0)(Ci_3 alkyl), -NHC(0)S(0)2(Ci_3 alkyl),
-S(0)2NH2, -S(0)2(Ci_3 alkyl), pyrazolyl, methyl pyrazolyl, imidazolyl, triazolyl, methyl tetrazolyl, ethyl tetrazolyl, phenyl, pyrimidinyl,
fluoropyrimidinyl, and tetrahydropyranyl.
The compound according to claim 1 or a salt thereof, wherein:
is a heteroaryl selected from:
Figure imgf000299_0001
wherein each of said heteroaryl is substituted with Ra and Rb. 3. The compound according to claim 1 or a salt thereof, wherein:
HET i a heteroaryl selected from:
Figure imgf000299_0002
Ra is H, F, CI, Br, -CN, -OH, -CH3, -CHF2, -OCH3, -NH2, -N(CH3)2, -NHCH2CH2OH, -NHCH2C(CH3)2OH, -NHCH2CHFC(CH3)2OH, -C(0)NH2,
-CH2NHC(0)CH2CH2CH3, -CH2NHC(0)CH(CH3)2, -CH2NHC(0)CH2CH(CH3)2, -CH2NHC(0)CH2C(CH3)3, -CH2NHC(0)CH2CH2CH(CH3)2,
-CH2NHC(0)CH2C(CH3)2OH, -CH2NHC(0)NHCH2CH2CH3,
-CH2NHC(0)NHCH2CH2CH2CH3, -CH2NHC(0)NHCH2(phenyl),
-CH2NHC(0)N(CH2CH3)2, -CH2NHC(0)OCH2CH3, -CH2NHC(0)OCH2CH(CH3)2,
-CH2NHC(0)(cyclopropyl), -CH2NHC(0)(tetrahydrofuranyl),
-CH2NHC(0)CH2(cyclopentyl), -CH2NHC(0)CH2(cyclohexyl),
-CH2NHC(0)CH2(tetrahydropyranyl), -CH2NHC(0)CH2(phenyl), -NHC(0)CH3, hydroxypyrrolidinyl, or pyridazinyl;
Rb is H or -NH2;
Ri is:
(i) -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2CH2CH(CH3)2, -CH2CHFCH3, -CH2CH2CF2CH3,
-CH2CHFCH(CH3)2, -CH2CH2C(CH3)2F, -CH2CHFC(CH3)2F,
-CH2CH2CH(OH)CH3, -CH2CH2C(CH3)2OH, -CH2CHFCH(CH3)OH, -CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH, -CH2CHFC(CH2CH3)2OH, -CH2CHFC(cyclopropyl)2(OH), -CH2CHFCH(OH)CH(CH3)2,
-CH2CH2OCH2CH3, -(CH2)3OCH(CH3)2, -(CH2)3OC(CH3)3,
-CH2CHFCH2OCH3, -CH2CHFC(CH3)2OCH3, -CH2CHFC(CH3)2OCD3, -CH2CHFC(CH3)2OCHF2, -CH2CHFC(CH3)2OCH2CH3, -CH2CH2C(0)OCH3, -CH2CH2NHC(0)C(CH3)2OC(0)CH3, -CH2CH2NHS(0)2CH3,
-CH2CH2CH(CH3)NHS(0)2CH3, -CH2CH2C(CH3)2NHS(0)2CH3,
-CH2CH2P(0)(OCH2CH3)2, -CH2CHFCH(CH3)NHCH(CH3)2,
-CH2CHFC(0)NHCH3, -CH2CH2C(0)NHCH2CH3,
-CH2CHFC(0)NHCH(CH3)2, -CH2CHFC(0)NHCH(CH3)CH2OH, or
-CH2CHFC(CH3)2OP(0)(OH)2;
(ii) -(Ci_3 alkylenyl)Rx, -(Ci_2 fluoroalkylenyl)Rx, -(Ci_2 alkylenyl)C(0)Rx,
-CH2C(0)NHRx, -CH2CHFC(0)Rx, or -CH2CF=(tetrahydropyranyl), wherein Rx is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl, 1 , 1 -dioxidotetrahydrothiophenyl, 1 , 1 -dioxidothiomorpholinyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents
independently selected from F, -OH, -CH3, -C(CH2)2OH, -OCH3, -C(0)CH2CN, -S(0)2CH3, -S(0)2NH2, -NHC(0)CH3, -N(S(0)2CH3)2,
-CH2CH2(acetamidophenyl), -CH2CH2(methoxyphenyl),
-CH2CH2(sulfamoylphenyl), oxetanyl, benzyl, and morpholinyl;
(iii) cyclopropyl, cyclopentyl, cyclopentenyl, or cyclohexyl, each substituted with zero to 2 substituents independently selected from F, -OH, -CN, -CH3, -OCH3, -SCH3, -N02, -S(0)2CH3, -C(CH3)2OH, -C(CH3)(OH)(cyclopropyl),
-CH2C(0)NHCH3, -NHC(0)CH(OH)CH3, -C(0)NHCD3, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(cyclopropyl), -NHC(0)CH3, -NHC(0)OCH3, -NHS(0)2CH3, pyridinyl, methylimidazolyl, methylpyrazolyl, and thiazolyl;
(iv) tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from -OH, -OCH3,
-CH2CHF2, -C(CH3)2OH, -CH2C(CH3)2OH, -C(0)CH(CH3)2, -S(0)2CH3, -S(0)2CH2CH3, -S(0)2CH(CH3)2, -S(0)2NHCH3, -S(0)2NHCH(CH3)2, -N(CH3)2, -OCH2CH2N(CH3)2, -CH2(morpholinyl), oxetanyl, tetrahydropyranyl, morpholinyl, piperazinyl, methylpiperazinyl, methoxypiperidinyl, pyrimidinyl, methylsulfonyl azetidinyl, and -C(0)(methylsulfonyl azetidinyl); or
pyrrolo[2,3-c]pyridinyl, bicyclo[2.2. l]heptan-l-ol, tetrahydrobenzo[d]thiazol-2- amine, or l,3-diazaspiro[4.5]decane-2,4-dione; and
-CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3,
-CH(CH3)CH2CH3, -CH2CH2CH(CH3)2, -CH(CH3)CH2CH(CH3)2,
-CH(CH3)CH2OH, -CH2CH2CH(CH3)OH, -CH(CH3)CH2CH2OH,
-CH2C(CH3)2OH, -C(CH3)2CH2OH, -CH(CH3)CH(OH)CH2CH(CH3)2,
-CH2CH(OH)CH(CH3)2, -CH(CH2OH)CH2CH3, -CH(CH2OH)CH(CH3)2, -CH=CHC(CH3)2OH, -CH2CH2CN, -CH2CHF2, -CH2CF3, -CH2CHFCH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2F, -CH2CH2CH2F,
-CH2CHFCH2CH3, -CH2CH2CHFCH3, -CH(CH3)CHFCH3,
-CH(CH3)CH2CH2F, -CH2CH2C(CH3)2F, -CH2CHFC(CH3)2OH,
-CH2CF2C(CH3)2OH, -CH2C(CH3)FCH2OH, -CH(CH2F)CH2OH,
-CH2CH2OCHF2, -CH2C(CH3)OCHF2, -CH2C(CH3)2OCHF2,
-CH2C(CH3)2OCH3, -CH2C(CH3)2CH2NH2, -CH2CHFC(0)NHCH(CH3)2, -CH2CH2NHS(0)2CH3, or -CH2CH2NHC(0)OC(CH3)2CF3;
-CH2(azetidinyl), -CH2(cyclopropyl), -CH2(fluorocyclobutyl),
-CH2(hydroxycyclobutyl), -CH2(oxetanyl), -CH2(methyloxetanyl),
-CH2(oxazolyl), -CH2(methylpyridinyl), -CH2(tetrahydropyranyl),
-CH2CH2(methylmorpholinyl) -CH(CH3)(cyclopropyl), -CH2CH2(morpholinyl), -CH2CH(CH3)(morpholinyl), or -CH2C(CH3)2(morpholinyl);
C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -CH2OH, -C(CH3)2OH, -C(0)NH2, -C(0)NHCH(CH3)2, -NH2, -NHCH2CF3, -NH(oxetanyl), -NHC(0)CHF2, -NHC(0)(cyclopropyl), -NHC(0)(fiuorophenyl), and imidazolyl; azetidinyl substituted with -C(0)CH3, -C(0)OCH3, -C(0)OCH2CH3, -C(0)OC(CH3)3, -S(0)2CH3, fluoropyrimidinyl, or chloropyrimidinyl; tetrahydrofuranyl substituted with zero to 2 substituents independently selected from F and -OH; pyrrolidinyl substituted with zero to 1 substituent selected from -C(0)CH3, -C(0)CH2CF3, -C(0)CH2CN, -C(0)OCH3, -S(0)2CH3, -C(0)(difluorophenyl), pyrimidinyl, fluoropyrimidinyl, and methoxypyrimidinyl; piperidinyl substituted with -S(0)2CH3, phenyl, or fluoropyrimidinyl; tetrahydropyranyl, fluorotetrahydropyranyl, or oxetanyl;
(iv) adamantanyl, hydroxyadamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, bicyclo[l . l .l]pentanyl, or hydroxy- bicyclo[2.2.1]heptanyl; or
(v) phenyl substituted with 1 to 2 substituents independently selected from F, -OH, -CN, -CH2OH, -C(CH3)2OH, -OCH3, -C(0)NH2, -C(0)NHCH3, -NHC(0)CH3, -NHC(0)S(0)2CH3, -S(0)2NH2, pyrazolyl, methyl pyrazolyl, imidazolyl, triazolyl, methyl tetrazolyl, and ethyl tetrazolyl; pyrazolyl substituted with 1 to 2 substituents independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CHF2, -CH2CHF2, -CH2CF3, -CH2CHFCH3, -CH2CH2CH2F, -CH2C(CH3)2F, -CH2CF2CH3, -CH2C(CH3)2OH, -CH2CH2OCH3,
-CH2CH(CH3)OCHF2, -CH2CH2CN, -C(0)NHCH2CH3, -S(0)2CH3, cyclopropyl, oxetanyl, phenyl, pyrimidinyl, fluoropyrimidinyl, and
tetrahydropyranyl; methyl thiadiazolyl, hydroxypropyl thiazolyl, or indazolyl.
4. The com ound according to claim 1 or a salt thereof, wherein:
Figure imgf000302_0001
Ra is F, CI, Br, -CN, -OH, -CH3, -CHF2, -OCH3, -C(0)NH2, or
-CH2NHC(0)CH2CH(CH3)2;
Rb is H or -NH2;
Ri is:
(i) -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2CH2CH(CH3)2, -CH2CHFCH3, -CH2CH2CF2CH3,
-CH2CHFCH(CH3)2, -CH2CH2C(CH3)2F, -CH2CHFC(CH3)2F,
-CH2CH2CH(OH)CH3, -CH2CH2C(CH3)2OH, -CH2CHFC(CH3)2OH,
-CH2CF2C(CH3)2OH, -CH2CHFC(cyclopropyl)2(OH),
-CH2CHFCH(OH)CH(CH3)2, -CH2CH2OCH2CH3, -CH2CHFCH2OCH3, -CH2CHFC(CH3)2OCH3, -CH2CHFC(CH3)2OCD3, -CH2CHFC(CH3)20CH2CH3, -CH2CH2C(0)OCH3, -CH2CH2NHS(0)2CH3, -CH2CH2CH(CH3)NHS(0)2CH3, -CH2CH2C(CH3)2NHS(0)2CH3,
-CH2CH2P(0)(OCH2CH3)2, -CH2CHFC(0)NHCH3, -CH2CH2C(0)NHCH2CH3, -CH2CHFC(0)NHCH(CH3)2, -CH2CHFC(0)NHCH(CH3)CH2OH, or
-CH2CHFC(CH3)2OP(0)(OH)2;
-(Ci-3 alkylenyl)Rx, -(Ci_2 fhioroalkylenyl)Rx, -(Ci_2 alkylenyl)C(0)Rx,
-CH2CHFC(0)Rx, or -CH2CF=(tetrahydropyranyl), wherein Rx is a cyclic group selected from cyclopropyl, cyclopentyl, cyclohexyl, tetrazolyl,
1 , 1 -dioxidotetrahydrothiophenyl, 1 , 1 -dioxidothiomorpholinyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl,
tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents
independently selected from F, -OH, -CH3, -C(CH2)2OH, -OCH3, -C(0)CH2CN, -S(0)2CH3, -S(0)2NH2, -NHC(0)CH3, -N(S(0)2CH3)2, oxetanyl, and benzyl; cyclopropyl, cyclopentyl, cyclopentenyl, or cyclohexyl, each substituted with zero to 1 substituent independently selected from -CN, -CH3, -OCH3,
-S(0)2CH3, -C(CH3)2OH, -CH2C(0)NHCH3, -NHC(0)CH(OH)CH3,
-C(0)NHCD3, -C(0)NHCH3, -NHC(0)CH3, and -NHS(0)2CH3;
tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with a substituent selected from -OH, -OCH3, -CH2CHF2, -C(CH3)2OH, -CH2C(CH3)2OH, -C(0)CH(CH3)2, -S(0)2CH3, -S(0)2CH2CH3, -S(0)2CH(CH3)2, -S(0)2NHCH3, -S(0)2NHCH(CH3)2, -N(CH3)2,
-OCH2CH2N(CH3)2, -CH2(morpholinyl), oxetanyl, tetrahydropyranyl, morpholinyl, piperazinyl, methylpiperazinyl, methoxypiperidinyl, pyrimidinyl, methylsulfonyl azetidinyl, and -C(0)(methylsulfonyl azetidinyl); or
pyrrolo[2,3-c]pyridinyl or tetrahydrobenzo[d]thiazol-2-amine; and
-CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3,
-CH(CH3)CH2CH3, -CH(CH3)CH2OH, -CH2CH2CH(CH3)OH,
-C(CH3)2CH2OH, -CH2CH(OH)CH(CH3)2, -CH(CH2OH)CH2CH3,
-CH(CH2OH)CH(CH3)2, -CH2CHF2, -CH2CF3, -CH2CHFCH3, -CH(CH3)CF3, -CH2CH2CF3, -CH(CH3)CH2F, -CH2CH2CH2F, -CH2CHFCH2CH3, -CH2CH2CHFCH3, -CH(CH3)CHFCH3, -CH(CH3)CH2CH2F, -CH2CH2C(CH3)2F, -CH2CF2C(CH3)2OH, -CH2C(CH3)FCH2OH,
-CH2CH2OCHF2, -CH2C(CH3)OCHF2, -CH2C(CH3)2OCHF2,
-CH2C(CH3)2OCH3, -CH2C(CH3)2CH2NH2, -CH2CH2NHS(0)2CH3, or
-CH2CH2NHC(0)OC(CH3)2CF3;
(ii) -CH2(cyclopropyl), -CH2(fluorocyclobutyl), -CH2(oxazolyl), or
-CH2C(CH3)2(morpholinyl);
(iii) C3_6 cycloalkyl substituted with zero to 3 substituents independently selected from F, -OH, -CH3, -CH2OH, -C(CH3)2OH, -C(0)NHCH(CH3)2, -NH2,
-NH(oxetanyl), -NHC(0)CHF2, -NHC(0)(cyclopropyl), and
-NHC(0)(fluorophenyl); azetidinyl substituted with -C(0)OCH3,
-C(0)OCH2CH3, fluoropyrimidinyl, or chloropyrimidinyl; tetrahydrofuranyl substituted with zero to 2 substituents selected from F; pyrrolidinyl substituted with -C(0)(difiuorophenyl), pyrimidinyl, fluoropyrimidinyl, or
methoxypyrimidinyl; piperidinyl substituted with phenyl or fluoropyrimidinyl; tetrahydropyranyl, or oxetanyl;
(iv) hydroxyadamantanyl, benzo[d]oxazolyl, benzothiazolyl, bicyclo[l . l .l]pentanyl, or hydroxy-bicyclo[2.2.1]heptanyl; or
(v) phenyl substituted with 1 to 2 substituents independently selected from F, -CN, triazolyl, and methyl tetrazolyl,; pyrazolyl substituted with 1 to 2 substituents independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CHF2, -CH2CHF2, -CH2CH2CH2F, -CH2C(CH3)2F, -CH2CF2CH3, -CH2C(CH3)2OH, -CH2CH2OCH3, -CH2CH(CH3)OCHF2, -CH2CH2CN, -C(0)NHCH2CH3, -S(0)2CH3, cyclopropyl, oxetanyl, phenyl, pyrimidinyl, fluoropyrimidinyl, and tetrahydropyranyl; methyl thiadiazolyl, or hydroxypropyl thiazolyl.
5. The compound according to claim 1 or a salt thereof, wherein:
Figure imgf000304_0001
Ra is F, CI, Br, -OH, -CN, or -CH3;
Ri is -CH2CHFCH(CH3)OH, -CH2CHFC(CH3)2OH, -CH2CF2C(CH3)2OH,
-CH2CHFC(CH2CH3)2OH, or -CH2CHFC(CH3)2OP(0)(OH)2; and -CH2CH3, -CH2CH2CH3, -CH(CH3)2, or -CH2CH2CH(CH3)2. The com ound according to claim 1 or a salt thereof, wherein:
Figure imgf000305_0001
Ra is CI or -CN;
Rb is H;
Ri is -CH2CH2C(CH3)2OH, -CH2CHFC(CH3)2OH, or -CH2CHFC(CH3)2OP(0)(OH)2; and
R2 is -CH(CH3)2.
7. The compound according to claim 1 or a salt thereof, wherein said compound is:
Figure imgf000305_0002
8. The compound according to claim 1 or a salt thereof, wherein said compound is selected from: (R)-6-(5-cyano-lH-indol-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide (1); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (2); (R)-6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (3); (R)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(ethylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (4);
(R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((2,2,2-trifluoroethyl)amino)nicotinamide (5); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin- 1 -yl)-4-(cyclobutylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (6); 6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((tetrahydro-2H-pyran-3-yl)amino)nicotinamide (7); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((S)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-3 - yl)amino)nicotinamide (8); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-(((S)- 1 -hydroxypropan-2-yl)amino)nicotinamide (9); (R)-6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-4-(cyclopentylamino)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (10); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(3 - hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (11); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino) nicotinamide (12); 4-((ls,3S)-adamantan-l-ylamino)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (13); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin- 1 -yl)-N-(4-hydroxybicyclo[2.2.1 Jheptan- 1 -yl)-4- (isopropylamino)nicotinamide (14); N-(3-(tert-butoxy)propyl)-6-(5 -cyano- 1 H-pyrrolo [2,3-b]pyridin- 1 -yl)-4-(isopropylamino)nicotinamide (15); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-hydroxybicyclo
[2.2.1 Jheptan- l-yl)amino)nicotinamide (16); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -methylcyclopropyl)amino)nicotinamide (17); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(( 1 -methylcyclopropyl)amino)nicotinamide (18); (R)-6-(5 -cyano- 1 H- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopentylamino) nicotinamide (19); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(((3 -methyloxetan-3 -yl)methyl)amino)nicotinamide (20); 6-(5 - cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((4- hydroxybutan-2-yl)amino)nicotinamide (21); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)- N-((S)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((4-hydroxybutan-2-yl)amino)nicotinamide (22); (S)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(isopropylamino)nicotinamide (23); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxy cyclopentyl) amino)nicotinamide (24); diastereomer 1; 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxy cyclopentyl)amino)nicotinamide (25); diastereomer 2; 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-hydroxycyclopentyl)amino)nicotinamide (26);
diastereomer 3; 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-((3-hydroxycyclopentyl)amino)nicotinamide (27); diastereomer 4; (R)-6- (5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((( 1 - hydroxycyclobutyl)methyl)amino)nicotinamide (28); (R)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((oxetan-3 -ylmethyl)amino) nicotinamide (29); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-(((lR,2R)-2-hydroxycyclopentyl)amino)nicotinamide (30); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(cyclobutylamino)-N-(2-fluoro-3- hydroxy-3-methylbutyl)nicotinamide (31); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino) nicotinamide (32); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(ethylamino)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (33); (R)-6-(5 -chloro- 1 H-pyrrolo [2,3 -b] pyridin- 1 -yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (34); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-((2-hydroxy-2-methylpropyl)amino)nicotinamide (35); 6-(5 -chloro- 1H- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-4- yl)amino)nicotinamide (36); (R)-6-(5 -chloro- lH-indol-1 -yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)nicotinamide (37); (R)-6-(5-fluoro-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (38); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)-6-(7H-pyrrolo
[2,3-d]pyrimidin-7-yl)nicotinamide (39); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-6- (7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (40); (R)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(7H-pyrrolo [2,3-d]pyrimidin-7-yl)nicotinamide (41); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- ((2-hydroxy-2-methylpropyl)amino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (42); N-(3-hydroxy-3-methylbutyl)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tetrahydro- 2H-pyran-4-yl)amino)nicotinamide (43); N-(3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (44); (R)-6-(5- acetamido- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)nicotinamide (45); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxyphenyl)amino)nicotinamide (46); 6-(5 - cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(3-isopropoxypropyl)-4-(isopropylamino) nicotinamide (47); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3- hydroxybutyl)-4-(isopropylamino)nicotinamide (48); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((2S)-2-fluoro-3-hydroxybutyl)-4-(isopropylamino)nicotinamide (49); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- ((3 -sulfamoylphenyl)amino)nicotinamide (50); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -methoxyphenyl)amino)nicotinamide (51); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-(((R)-2-fluoro-3-hydroxy-3-methylbutyl)amino)nicotinamide (52); (R)-6- (5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((3,3-difluorocyclobutyl)amino)-N-(2-fluoro-
3 - hydroxy-3 -methylbutyl)nicotinamide (53); (R)-4-((3-acetamidophenyl)amino)-6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)
nicotinamide (54); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-(methylcarbamoyl)phenyl)amino)nicotinamide (55); (R)-4- ((3-carbamoylphenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (56); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 - yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -(methylsulfonamido)phenyl)amino) nicotinamide (57); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-(4- sulfamoylphenethyl)nicotinamide (58); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-(2-hydroxypropan-2-yl)phenyl)amino) nicotinamide (59); (R)-4-((4-carbamoylphenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methy lbutyl)nicotinamide (60); 6-(5 -cyano- 1 H- pyrrolo[2,3-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((l s,4S)-4- hydroxy-4-methylcyclohexyl)amino)nicotinamide (61); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((tra/?5)-4-hydroxy-4- methylcyclohexyl)amino)nicotinamide (62); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-
4- (isopropylamino)-N-(2-(methylsulfonamido)ethyl)nicotinamide (63); (R)-4-(benzo[d] thiazol-6-ylamino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (64); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((( 1 -fluorocyclobutyl)methy l)amino)nicotinamide (65); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((3-cyanophenyl)amino)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (66); (R)-4-((4-( 1 H- 1 ,2,4-triazol- 1 - yl)phenyl)amino)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (67); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-( 1 -methyl- 1 H-tetrazol-5 -yl)phenyl)amino) nicotinamide (68); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-((4-( 1 -methyl- 1 H-tetrazol-5 -yl)phenyl)amino)nicotinamide (69); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-((l,l-dioxidotetrahydrothiophen-3- yl)amino)-2-oxoethyl)-4-(isopropylamino)nicotinamide (70); (R)-6-(5-cyano-lH-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -(hydroxymethyl) phenyl)amino)nicotinamide (71); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2- fluoro-3-hydroxy-3-methylbutyl)-4-(((2S)-3-fluorobutan-2-yl)amino)nicotinamide (72); N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin-l-yl)-4-(isopropylamino)nicotinamide (73); (R)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)-6-(lH-pyrrolo[2,3-b]pyridin-l-yl)nicotinamide (74); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide (75); (R)-6-(5-chloro-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (76); (R)-6-(5 - cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((2- hydroxy-2-methylpropyl)amino)nicotinamide (77); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin- l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((l-fluoropropan-2-yl)amino) nicotinamide (78); 6-(5 -cyano- lH-indol-1 -yl)-4-(isopropylamino)-N-((tra/?5)-4- (methylcarbamoyl)cyclohexyl)nicotinamide (79); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-4-(isopropylamino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (80); 4- (isopropylamino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)-6-(7H-pyrrolo[2,3-d] pyrimidin-7-yl)nicotinamide (81); N-((trans)-4-(methylcarbamoyl)cyclohexyl)-6-(7H- pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (82); N- ((tra/75)-4-acetamidocyclohexyl)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-((tetrahydro-2H- pyran-4-yl)amino)nicotinamide (83); N-((tra/?5)-4-acetamidocyclohexyl)-4- (isopropylamino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (84); 6-(5 -cyano- 1H- pyrrolo[2,3-b]pyridin- 1 -yl)-4-(cyclopropylamino)-N-((tra/?5)-4-(methylcarbamoyl) cyclohexyl)nicotinamide (85); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/?5)-4- (methylcarbamoyl)cyclohexyl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (86); N-((tra/75)-4-acetamidocyclohexyl)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (cyclopropylamino)nicotinamide (87); N-((tra/?5)-4-acetamidocyclohexyl)-6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (88); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(((S)-l-hydroxypropan-2-yl)amino)-N- ((lr,4S)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (89); 6-(5 -cyano- 1 H-pyrrolo [2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4-(isopropylcarbamoyl)cyclohexyl) nicotinamide (90); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/?5)-4- (cyclopropylcarbamoyl)cyclohexyl)-4-(isopropylamino)nicotinamide (91); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/75)-4-(ethylcarbamoyl)cyclohexyl)-4- (isopropylamino)nicotinamide (92); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((2- hydroxy-2-methylpropyl)amino)-N-((tra/75)-4-(methylcarbamoyl)cyclohexyl)
nicotinamide (93); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((2-hydroxy-2- methylpropyl)amino)-N-((tra/75)-4-((2H3)methylcarbamoyl)cyclohexyl)nicotinamide (94); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-((tra/75)-4- nitrocyclohexyl)nicotinamide (95); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((tra/75)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (96); methyl((tra/75)-4-(6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino) nicotinamido)cyclohexyl)carbamate (97); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((tra/75)-4-hydroxycyclohexyl)-4-(isopropylamino)nicotinamide (98); 6-(5-cyano-lH- pyrrolo[2,3-b]pyridin- 1 -yl)-N-((trans)-4-hydroxy-4-methylcyclohexyl)-4-
(isopropylamino)nicotinamide (99); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (ethylamino)-N-((tra/75)-4-(2-hydroxypropan-2-yl)cyclohexyl)nicotinamide (100); 6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-4-(isopropylamino)-N-((tra/75)-4-(methylthio) cyclohexyl)nicotinamide (101); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (isopropylamino)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl)nicotinamide (102); 6-(5- cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (103); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin-l-yl)-4-(cyclopropylamino)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl) nicotinamide (104); 4-((3-carbamoylphenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin-l-yl)-N-((tra/75)-4-(methylsulfonyl)cyclohexyl)nicotinamide (105); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorotetrahydro-2H-pyran-4-yl)amino)nicotinamide (106); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -fluorotetrahydro-2H- pyran-4-yl)amino)nicotinamide (107); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((S)- 2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -fluorotetrahydro-2H-pyran-4-yl)amino) nicotinamide (108); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (109); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((S)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorocyclopentyl)amino)nicotinamide( 110); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)- 4-((3 ,3 -difluoro-2-hydroxycyclohexyl)amino)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (111); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((3,3-difluoro-2- hydroxy cyclohexyl)amino)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide
(112); N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((l-fluoropropan-2-yl)amino)-6-(7H- pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (113); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)- 1 -fluoropropan-2-yl)amino) nicotinamide (114); N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)-l-fluoropropan-2- yl)amino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinamide (115); N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-(((S)-l-fluoropropan-2-yl)amino)-6-(7H-pyrrolo[2,3-d] pyrimidin-7-yl)nicotinamide (116); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)- 1 -fluoropropan-2-yl)amino)nicotinamide (117); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((R)-l-fluoropropan-2-yl)amino)nicotinamide (118); (S)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(( 1 -fluoropropan-2-yl)amino)-N-(3 -hydroxy-3 -methylbutyl)nicotinamide (119); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-4-((l -fluoropropan-2-yl)amino)-N- (3 -hydroxy-3 -methylbutyl)nicotinamide (120); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)-l-fluoropropan-2-yl)amino) nicotinamide (121); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(((S)-l -fluoropropan- 2-yl)amino)-N-((lr,4S)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (122); (R)-l-(4- (ethylamino)-5-((2-fluoro-3-hydroxy-3-methylbutyl)carbamoyl)pyridin-2-yl)-lH-pyrrolo [2,3-b]pyridine-5-carboxamide (123); (R)-l-(4-(cyclobutylamino)-5-((2-fluoro-3- hydroxy-3 -methylbutyl)carbamoyl)pyridin-2-yl)- 1 H-pyrrolo [2,3 -b]pyridine-5 - carboxamide (124); l-((2-(6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino) nicotinamido)ethyl)amino)-2-methyl-l-oxopropan-2-yl acetate (125); 6-(5 -cyano- 1 H- pyrrolo[2,3-b]pyridin-l-yl)-N-(2-(2-hydroxy-2-methylpropanamido)ethyl)-4- (isopropylamino)nicotinamide (126); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- (2-fluoro-3-methoxypropyl)-4-(isopropylamino)nicotinamide (127); (R)-6-(5 -cyano- 1H- pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-methoxypropyl)-4-(isopropylamino) nicotinamide (128); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3- (isopropylamino)butyl)-4-(isopropylamino)nicotinamide (129); 6-(5 -cyano- 1H- pyrrolo[2,3-b]pyridin-l-yl)-N-((2R)-2-fluoro-3-(isopropylamino)butyl)-4- (isopropylamino)nicotinamide (130); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-
2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -fluoro-3 -hydroxypropan-2-yl)amino) nicotinamide (131); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (cyclopropylamino)-N-(2-fluoro-3-(methylamino)-3-oxopropyl)nicotinamide (132); (R)- 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)nicotinamide (133); (R)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-
3 - methylbutyl)-6-( 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 -yl)nicotinamide (134); (R)-6-(5 - chloro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (135); (R)-6-(5 -chloro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (136); (R)-6-(5 -chloro- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3 - hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (137); (R)-6-(5 -cyano- 1 H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(ethylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (138); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-
(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide ( 139); 6-(5 - cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(cyclopropylamino)-N-((tra/?s)-4- (methylcarbamoyl)cyclohexyl)nicotinamide (140); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methy lbutyl)-4-((tetrahydro-2H-pyran-4- yl)amino)nicotinamide (141); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-3 -yl)amino)nicotinamide, diastereomer 1 (142); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((S)-2-fluoro-3 - hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-3 -yl)amino)nicotinamide, diastereomer 2 (143); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)-6-(l H-pyrazolo [3,4-d]pyrimidin-l-yl)nicotinamide (144); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-4-(cyclobutylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (145); 6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(3 -hydroxy-3 -methylbutyl)-4-(isopropylamino) nicotinamide (146); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 - hydroxy-3-methylbutyl)-4-((2,2,2-trifluoroethyl)amino)nicotinamide (147); 6-(5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((tra/?5)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (148); (R)-N-(3-ethyl-2-fluoro-3-hydroxypentyl)-4- (isopropylamino)-6-(l H-pyrazolo [3, 4-d]pyrimidin-l-yl)nicotinamide (149); 6-(5-chloro- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((tra/?5)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (150); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(3 - hydroxy-3 -methylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (151); 6-(5- chloro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-((tra/?s)-4- (methylcarbamoyl)cyclohexyl)nicotinamide (152); (R)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-6-(5 -hydroxy- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino) nicotinamide (153); 6-(5-chloro-l H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N- (2-morpholinoethyl)nicotinamide (154); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(5 -methyl- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)nicotinamide (155); (R)-4- (cyclopropylamino)-6-(5-fluoro-l H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3-hydroxy-
3 - methylbutyl)nicotinamide (156); (R)-6-(5 -fluoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (157); (R)-6-(5 - bromo- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)nicotinamide (158); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((tra/?s)-4-hydroxy eye lohexyl)amino) nicotinamide (159); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N- ((tra/75)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (160); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-((tra/?5)-4-(methylsulfonyl)cyclohexyl) nicotinamide (161); 6-(5-cyano- 1 H-pyrazolo[3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N- ((tra/75)-4-((2H3)methylcarbamoyl)cyclohexyl)nicotinamide (162); (R)-6-(5 -cyano- 1 H- pyrazo lo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4- fluorocyclohexyl)amino)nicotinamide (163); N-((trafts)-4-acetamidocyclohexyl)-6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)nicotinamide ( 164); N-(2- amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l- yl)-4-(isopropylamino)nicotinamide (165); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-
4- (isopropylamino)-N-((tra/75)-4-(methylsulfonamido)cyclohexyl)nicotinamide ( 166); 6- (5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2,2-difluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide (167); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(3-(pyridazin-4-yl)-lH-pyrazol-l-yl)nicotinamide (168); (R)-6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-((2,2-difluoro-3 -hydroxy-3 -methylbutyl) amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (169); (R)-N-(2-fluoro-3 - hydroxy-3-methylbutyl)-4-(isopropylamino)-6-(9H-purin-9-yl)nicotinamide (170); (R)-6- (2-amino-9H-purin-9-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino) nicotinamide (171); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(2-((2-hydroxy ethyl) amino)-9H-purin-9-yl)-4-(isopropylamino)nicotinamide ( 172); 6-(5 -cyano- 1 H- pyrrolo[2,3-b]pyridin- 1 -yl)-N-(( 1 s,4s)-4-hydroxy-4-( 1 -methyl- 1 H-pyrazol-5- yl)cyclohexyl)-4-(isopropylamino)nicotinamide (173); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(( 1 s,4s)-4-fluoro-4-( 1 -methyl- 1 H-pyrazol-5 -yl)cyclohexyl)-4- (isopropylamino)nicotinamide (174); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((ls,4s)-4-hydroxy-4-(thiazol-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (175); 6- (5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4-(l -methyl- lH-imidazol- 2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (176); 6-(5-cyano-lH-pyrrolo[2,3- b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4-(pyridin-3-yl)cyclohexyl)-4-(isopropylamino) nicotinamide (177); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4- (pyridin-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (178); 6-(5 -cyano- lH-pyrrolo [2,3-b]pyridin-l-yl)-N-((ls,4s)-4-hydroxy-4-(pyridin-4-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (179); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-
((1 s,4s)-4-fluoro-4-(thiazol-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (180); 6- (5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(( 1 s,4s)-4-fluoro-4-( 1 -methyl- 1 H-imidazol-2- yl)cyclohexyl)-4-(isopropylamino)nicotinamide (181); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((trans)-4-fluoro-4-( 1 -methyl- 1 H-imidazol-2-yl)cyclohexyl)-4- (isopropylamino)nicotinamide (182); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2,4- dioxo-l,3-diazaspiro[4.5]decan-8-yl)-4-(isopropylamino)nicotinamide (183); (S)-6-(5- cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-(4-(pyridin-4-yl)cyclohex-3- en-l-yl)nicotinamide (184); (R)-6-(2-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)- N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (185); (R)-6-(2- amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-
(isopropylamino)nicotinamide (186); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-6-(2-((2- hydroxy-2-methylpropyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4- (isopropylamino)nicotinamide (187); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-6-(2-((2- hydroxyethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(isopropylamino) nicotinamide (188); N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-6-(2-((S)-3-hydroxypyrrolidin-l-yl)- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-(isopropylamino) nicotinamide (189); N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-6-(2-((R)-3 -hydroxypyrrolidin- 1 -yl)-7H-pyrrolo [2,3 - d]pyrimidin-7-yl)-4-(isopropylamino) nicotinamide (190); (R)-4-(6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)nicotinamido)-3 -fluoro-2-methylbutan-2- yl dihydrogen phosphate (191); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin-l-yl)-N-(2- fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide, hydrochloride (192); (R)-4-(sec-butylamino)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(3-hydroxy-3- methylbutyl) nicotinamide (193); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-6-(5- hydroxy- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)nicotinamide ( 194); (R)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)-6-(5 -methoxy- 1 H-pyrazolo [3 ,4- b]pyridin- 1 -yl)nicotinamide ( 195); (S)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2- fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (196); (R)-6-(5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3-(isopropylamino)-3-oxopropyl)-4- (isopropylamino)nicotinamide (197); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (isopropylamino)-N-(4-methoxycyclohexyl)nicotinamide (198); N-butyl-6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)nicotinamide (199); (R)-6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -methoxy-3 -methylbutyl)-4-(isopropylamino) nicotinamide (200); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N- (3 -morpholinopropyl)nicotinamide (201); 6-(5-cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N- ((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((2S)-3-fluorobutan-2-yl)amino)nicotinamide (202); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(((2S)-3-fluorobutan-2-yl)amino)nicotinamide (203); 6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-(2-morpholinoethyl)nicotinamide (204); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)-4-((4-fluorobutan-2-yl)amino)nicotinamide (205); 6-(5-cyano-lH-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-(2-morpholino-2-oxoethyl)nicotinamide (206); methyl 3-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino) nicotinamido)propanoate (207); diethyl (2-(6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)- 4-(isopropylamino)nicotinamido)ethyl)phosphonate (208); 6-(5 -cyano- 1 H-pyrazolo [3,4- b]pyridin- 1 -yl)-N-(( 1 , 1 -dioxidotetrahydrothiophen-3 -yl)methyl)-4-(isopropylamino) nicotinamide (209); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3- trideuteromethoxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (210); 6-(5-cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-( 1 , 1 -dioxidothiomorpholino)ethyl)-4- (isopropylamino)nicotinamide (211); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(3- (ethylamino)-3-oxopropyl)-4-(isopropylamino)nicotinamide (212); Ν-(3-(1Η- 1,2,4- triazol-5-yl)propyl)-6-(5-cyano-l H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(isopropylamino) nicotinamide (213); N-((lR,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4- (isopropylamino)-6-(5 -methyl- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)nicotinamide (214); (R)-6- (5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(3-ethoxy-2-fluoro-3-methylbutyl)-4- (isopropylamino)nicotinamide (215); 6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (isopropylamino)-N-(6-morpholinopyridin-3-yl)nicotinamide (216); 6-(5 -cyano-1 H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(5 -hydroxypyridin-2-yl)-4-(isopropylamino)nicotinamide (217); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-(( 1 R,4R)-4-(2- (methylamino)-2-oxoethyl)cyclohexyl)nicotinamide (218); 6-(5 -cyano-1 H-pyrazolo
[3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-(2-(methylsulfonamido)ethyl)nicotinamide (219); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-(2-(tetrahydro- 2H-pyran-2-yl)ethyl)nicotinamide (220); 6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (isopropylamino)-N-(5-morpholinopyridin-2-yl)nicotinamide (221); 6-(5 -cyano- 1H- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-(4-morpholinophenyl)nicotinamide (222); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-( 1 H-pyrrolo [2,3-c]pyridin-5-yl)nicotinamide (223); 6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (isopropylamino)-N-(2-morpholinopyrimidin-5-yl)nicotinamide (224); 6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-N-(5-(2-(dimethylamino)ethoxy)pyridin-2-yl)-4- (isopropylamino)nicotinamide (225); 6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (isopropylamino)-N-(4-(morpholinomethyl)phenyl)nicotinamide (226); 6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-(6-(piperazin- 1 -yl)pyridin-3- yl)nicotinamide (227); 6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(6- (dimethylamino)pyridin-3-yl)-4-(isopropylamino)nicotinamide (228); (R)-6-(5 -cyano- 1H- pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-(methylamino)-3-oxopropyl)-4-
(isopropylamino)nicotinamide (229); 6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- ((R)-2-fluoro-3-(((S)-l-hydroxypropan-2-yl)amino)-3-oxopropyl)-4-(isopropylamino) nicotinamide (230); (R)-6-(5-(difluoromethyl)-l H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2- fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (231); 6-(5 -cyano- 1H- pyrazolo[3,4-b]pyridin-l-yl)-N-((2R)-2-fluoro-3-hydroxy-4-methylpentyl)-4-
(isopropylamino)nicotinamide (232); 6-(5 -cyano-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- ((2R)-2-fluoro-3-hydroxy-4-methylpentyl)-4-(isopropylamino)nicotinamide (233); (R)-6- (5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l- hydroxy-2-methylpropan-2-yl)amino)nicotinamide (234); 6-(5-cyano-lH-pyrazolo
[3 ,4-b]pyridin- 1 -yl)-N-(2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethyl)-4-(isopropylamino) nicotinamide (235); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(5-(2-hydroxypropan- 2-yl)pyridin-2-yl)-4-(isopropylamino)nicotinamide (236); 6-(5-cyano-lH-pyrazolo
[3 ,4-b]pyridin- 1 -yl)-N-(2-(3 -hydroxytetrahydrofuran-3 -yl)ethyl)-4-(isopropylamino) nicotinamide (237); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(3-hydroxybutyl)-4- (isopropylamino)nicotinamide (238); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(3- hydroxybutyl)-4-(isopropylamino)nicotinamide (239); 6-(5-cyano-lH-pyrazolo[3,4-b] pyridin- 1 -yl)-4-(isopropylamino)-N-( 1 -(pyrimidin-2-y l)piperidin-4-yl)nicotinamide (240); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-(5-(4- methylpiperazin- 1 -yl)pyridin-2-yl)nicotinamide (241 ); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin- 1 -yl)-4-(isopropylamino)-N-(3 -(4-methylpiperazin- 1 -yl)-3 -oxopropyl) nicotinamide (242); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-2-(3 - hydroxyoxetan-3-yl)ethyl)-4-(isopropylamino)nicotinamide, racemic (243); 6-(5-cyano- lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((lS,3S)-3-(2-hydroxypropan-2-yl)cyclopentyl)-4- (isopropylamino Nicotinamide (244); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- (isopropylamino)-N-(l-(methylsulfonyl)piperidin-3-yl)nicotinamide (245); (S)-6-(5- cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(isopropylamino)-N-(l-(methylsulfonyl) piperidin-3-yl)nicotinamide (246); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-
(isopropylamino)-N-(6-(4-methoxypiperidin- 1 -yl)pyridin-3-yl)nicotinamide (247); 6-(5- cyano-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-2-(3-hydroxyoxetan-3-yl)ethyl)-4- (isopropylamino)nicotinamide (248); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2- fluoro-2-(3-hydroxyoxetan-3-yl)ethyl)-4-(isopropylamino)nicotinamide (249); 6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-(4-hydroxy- 1 -methylpiperidin-4-yl)ethyl)-4- (isopropylamino)nicotinamide (250); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- (isopropylamino)-N-(4-sulfamoylphenethyl)nicotinamide (251); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-( 1 -hydroxy cyclopentyl)ethyl)-4-(isopropylamino)nicotinamide (252); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-(4-hydroxy-l-(oxetan-3- yl)piperidin-4-yl)ethyl)-4-(isopropylamino)nicotinamide (253); 6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-(5 -(4-methoxypiperidin- 1 -yl)pyridin- 2-yl)nicotinamide (254); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-(3- hydroxypyrrolidin-3-yl)ethyl)-4-(isopropylamino)nicotinamide (255); (R)-6-(5-cyano- lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-morpholino-3-oxopropyl)-4- (isopropylamino Nicotinamide (256); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N- (2-fluoro-3-(4-(methylsulfonyl)piperazin-l-yl)-3-oxopropyl)-4-(isopropylamino) nicotinamide (257); 6-(5-chloro-l H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-2-(3- hydroxyoxetan-3-yl)ethyl)-4-(isopropylamino)nicotinamide (258); 6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-(2-(pyridin-4-yl)ethyl)nicotinamide (259); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(4-fluorophenethyl)-4- (isopropylamino)nicotinamide (260); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- (isopropylamino)-N-(4-methoxyphenethyl)nicotinamide (261); (R)-6-(6-amino-5-cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)nicotinamide (262); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l - yl)-N-((2-(2-hydroxypropan-2-yl)cyclopropyl)methyl)-4-(isopropylamino)nicotinamide (263); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N-(3- (methylsulfonamido)butyl)nicotinamide (264); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-4-(isopropylamino)-N-(3-(methylsulfonamido)butyl)nicotinamide (265); 6-(5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N-(2-(l-methylpiperidin-4- yl)ethyl)nicotinamide (266); N-((3-benzyl-l,2,4-oxadiazol-5-yl)methyl)-6-(5-cyano-lH- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)nicotinamide (267); 6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-( 1 -(oxetan-3 -yl)- 1 H-pyrazol-4- yl)nicotinamide (268); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)- N-(4-(N-(methylsulfonyl)methylsulfonamido)phenethyl)nicotinamide (269); N-(4- acetamidophenethyl)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(isopropylamino) nicotinamide (270); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N- (l-(tetrahydro-2H-pyran-4-yl)-lH-pyrazol-4-yl)nicotinamide (271); 6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-(l-(isopropylsulfonyl)piperidin-4- yl)nicotinamide (272); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-( 1 - isobutyrylpiperidin-4-yl)-4-(isopropylamino)nicotinamide (273); 6-(5 -cyano- 1H- pyrazolo[3,4-b]pyridin-l-yl)-N-((lS,4R)-4-((S)-2-hydroxypropanamido)cyclohexyl)-4- (isopropylamino)nicotinamide (274); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2- (l-(2-cyanoacetyl)piperidin-4-yl)ethyl)-4-(isopropylamino)nicotinamide (275); 6-(5- cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(isopropylamino)-N-(2-(pyridin-3-yl)ethyl) nicotinamide (276); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-(l, 4-dihydroxy-4- methylcyclohexyl)ethyl)-4-(isopropylamino)nicotinamide (277); 6-(5 -cyano- 1 H-pyrazolo [3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-(l-(l-(methylsulfonyl)azetidine-3-carbonyl) piperidin-4-yl)nicotinamide (278); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2- (4,4-difluoro-l-hydroxycyclohexyl)ethyl)-4-(isopropylamino)nicotinamide (279); (R)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)-6-(5 -((3 -methylbutanamido) methyl)- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)nicotinamide (280); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-( 1 -(1 -(methylsulfonyl)azetidin-3 -yl)- 1 H- pyrazol-4-yl)nicotinamide (281); (R)-6-(6-amino-5-chloro-l H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (282); 4-((R)- sec-butylamino)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3-hydroxy-
3 - methylbutyl)nicotinamide (283); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-
4- ((S)-sec-butylamino)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (284); 6- (5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)-4- (isopropylamino Nicotinamide (285); (R)-4-(tert-butylamino)-6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (286); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((lR,4R)-4-((R)-2-hydroxypropanamido) cyclohexyl)-4-(isopropylamino)nicotinamide (287); 4-(tert-butylamino)-6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-N-(3-fluoro-3-methylbutyl)nicotinamide (288); 4-((S)-sec- butylamino)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (289); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-( 1 - (ethylsulfonyl)piperidin-4-yl)-4-(isopropylamino)nicotinamide (290); 6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-( 1 -hydroxy-4-methoxycyclohexyl)ethyl)-4- (isopropylamino Nicotinamide (291); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -methylcyclopropyl)amino)nicotinamide (292); (R)-6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(tert-butylamino)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (293); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin-l-yl)-N-(2-(dihydro-2H-pyran-4(3H)-ylidene)-2-fluoroethyl)-4-(isopropylamino) nicotinamide (294); (R)-6-(6-amino-5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2,3- difluoro-3-methylbutyl)-4-(isopropylamino)nicotinamide (295); 6-(5 -cyano- 1 H-pyrazolo [3,4-b]pyridin-l-yl)-N-((3R,6S)-6-(2-hydroxypropan-2-yl)tetrahydro-2H-pyran-3-yl)-4- (isopropylamino)nicotinamide (296); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1,1,1 -trifluoropropan-2-yl)amino) nicotinamide (297); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-isopentyl-4- (isopropylamino)nicotinamide (298); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-cyclopropylethyl)-4-(isopropylamino)nicotinamide (299); 6-(6-amino-5-cyano- lH-pyrazolo [3, 4-b]pyridin-l-yl)-4-((R)-sec-butylamino)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (300); 6-(6-amino-5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1,1,1 -trifluoropropan-2-yl)amino) nicotinamide (301); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-cyclopropylethyl)- 4-(isopropylamino)nicotinamide (302); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin- l-yl)-N-isopentyl-4-(isopropylamino)nicotinamide (303); 6-(5-cyano-lH-pyrazolo[3,4-b] pyridin- 1 -yl)-N-( 1 -(2-hydroxy-2-methylpropyl)- 1 H-pyrazol-4-yl)-4-(isopropylamino) nicotinamide (304); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (isopropylamino)-N-methylnicotinamide (305); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-4-(isopropylamino)-N-(3-methyl-3-(methylsulfonamido)butyl)nicotinamide (306); 6- (6-amino-5-cyano- lH-pyrazolo[3,4-b]pyridin- 1 -yl)-N-(3-fluoro-3-methylbutyl)-4-
(isopropylamino Nicotinamide (307); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N- (2,3-difluoro-3-methylbutyl)-4-(isopropylamino)nicotinamide (308); 6-(5-cyano-lH- pyrazolo[3,4-b]pyridin-l-yl)-4-(isopropylamino)-N-(l-(N-isopropylsulfamoyl)piperidin- 4-yl)nicotinamide (309); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (isopropylamino)-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)nicotinamide (310); N-(2-( 1 H- imidazol-4-yl)ethyl)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino) nicotinamide (311); (S)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3- methylbutyl)-4-(isopropylamino)nicotinamide (312); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-4-(isopropylamino)-N-( 1 -(N-methylsulfamoyl)piperidin-4-yl)nicotinamide (313); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(3 -(difluoromethoxy)-2-fluoro- 3-methylbutyl)-4-(isopropylamino)nicotinamide (314); (R)-6-(5 -cyano- 1 H-pyrazolo
[3,4-b]pyridin-l-yl)-N-(3,3-dicyclopropyl-2-fluoro-3-hydroxypropyl)-4-(isopropylamino) nicotinamide (315); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N- ((lR,4R)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (316); N-((lR,4R)-4- acetamidocyclohexyl)-6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-
(isopropylamino Nicotinamide (317); (S)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- (2-cyclopropylethyl)-4-((l -hydroxypropan-2-yl)amino)nicotinamide (318); (S)-N-butyl- 6-(5-cyano- 1 H-pyrazolo [3, 4-b]pyridin- 1 -yl)-4-((l -hydroxypropan-2-yl)amino) nicotinamide (319); (S)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-((l- hydroxypropan-2-yl)amino)-N-isopentylnicotinamide (320); (R)-6-(6-amino-5 -cyano- 1 H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -methoxy-3 -methylbutyl)-4-(isopropylamino) nicotinamide (321); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-
(isopropylamino)-N-(l-methylcyclopropyl)nicotinamide (322); (R)-6-(6-amino-5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(l-cyclopropylethyl)-4-(isopropylamino)nicotinamide (323); 6-(6-amino-5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-cyclohexyl-4- (isopropylamino)nicotinamide (324); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(l-cyanocyclopropyl)-4-(isopropylamino)nicotinamide (325); 6-(6-amino-5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(isopropylamino)-N-propylnicotinamide (326); 6-(6- amino-5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(cyclopent-2-en- 1 -yl)-4- (isopropylamino)nicotinamide (327); (R)-6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin-l-yl)-N-(2-fluoropropyl)-4-(isopropylamino)nicotinamide (328); 6-(5 -cyano- 1H- pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-2-(tetrahydro-2H-pyran-4-yl)ethyl)-4-
(isopropylamino)nicotinamide (329); (R)-6-(5 -chloro-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- (2,3 -difluoro-3 -methylbutyl)-4-(isopropylamino)nicotinamide (330); 6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-N-(2-(l -hydroxy cyclopropyl)ethyl)-4-(isopropylamino) nicotinamide (331); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(3,3-difluorobutyl)-4- (isopropylamino Nicotinamide (332); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(oxetan-3 -ylamino)nicotinamide (333); N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-6-(2-(((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)amino)- 9H-purin-9-yl)-4-(isopropylamino)nicotinamide (334); (R)-6-(6-cyano-3H-imidazo
[4,5 -b]pyridin-3 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino) nicotinamide (335); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-4-
(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (336); (R)-6-(6- cyano-3H-imidazo [4,5 -b]pyridin-3 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (propylamino)nicotinamide (337); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-4- (cyclobutylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (338); (R)-6-(6- chloro-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-
(isopropylamino)nicotinamide (339); (R)-6-(6-chloro-3H-imidazo[4,5-b]pyridin-3-yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(oxetan-3 -ylamino)nicotinamide (340); (R)-6-(5 - amino-6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4- (isopropylamino)nicotinamide (341); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-N- (2,3-difiuoro-3-methylbutyl)-4-(isopropylamino)nicotinamide (342); (R)-6-(6-cyano-3H- imidazo [4,5 -b]pyridin-3 -yl)-N-(2-fiuoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 - methylcyclopropyl)amino)nicotinamide (343); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin- 3-yl)-N-(2,3-difiuoro-3-methylbutyl)-4-(oxetan-3-ylamino)nicotinamide (344); (R)-6-(6- cyano-3H-imidazo [4,5 -b]pyridin-3 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (345); (R)-6-(2-amino-9H-purin-9-yl)-N- (2,3-difiuoro-3-methylbutyl)-4-(isopropylamino)nicotinamide (346); (R)-6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)amino)-N-(2- fiuoro-3 -hydroxy-3 -methylbutyl)nicotinamide (347); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin-l-yl)-N-(2-fiuoro-3 -hydroxy-3 -methylbutyl)-4-((l-(oxetan-3-yl)-lH-pyrazol-4- yl)amino)nicotinamide (348); (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2- fiuoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(tetrahydro-2H-pyran-4-yl)- 1 H-pyrazol-4- yl)amino)nicotinamide (349); (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2- fiuoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(2-hydroxy-2-methylpropyl)- 1 H-pyrazol-4- yl)amino)nicotinamide (350); (R)-6-(5-chloro-l H-pyrazolo [3, 4-b]pyridin-l -yl)-4-((l- (2,2-difluoroethyl)-lH-pyrazol-4-yl)amino)-N-(2-fiuoro-3-hydroxy-3-methylbutyl) nicotinamide (351); (R)-6-(5-chloro-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fiuoro-3- hydroxy-3 -methylbutyl)-4-(( 1 -(tetrahydro-2H-pyran-4-yl)- 1 H-pyrazol-4-yl)amino) nicotinamide (352); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fiuoro-3 - hydroxy-3-methylbutyl)-4-((l-(2,2,2-trifiuoroethyl)-lH-pyrazol-4-yl)amino)nicotinamide (353); (R)-6-(5-chloro-l H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-((l-(2,2,2-trifluoroethyl)-lH-pyrazol-4-yl)amino)nicotinamide (354); (R)- 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -ethyl- 1 H-pyrazol-4-yl)amino)-N-(2- fiuoro-3 -hydroxy-3 -methylbutyl)nicotinamide (355); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin- 1 -yl)-4-(( 1 -(2-fluoro-2-methylpropyl)- 1 H-pyrazol-4-yl)amino)-N-(2-fluoro-3 - hydroxy-3 -methylbutyl)nicotinamide (356); (R)-6-(5 -chloro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -ethyl- 1 H-pyrazol-4-yl)amino)-N-(2-fiuoro-3 -hydroxy-3 -methylbutyl) nicotinamide (357); (R)-6-(5 -chloro- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fiuoro-3 - hydroxy-3 -methylbutyl)-4-(( 1 -isopropyl- 1 H-pyrazol-4-yl)amino)nicotinamide (358); (R)- 6-(6-chloro-3H-imidazo[4,5-b]pyridin-3-yl)-4-((l-(2,2-difiuoroethyl)-lH-pyrazol-4- yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (359); (R)-6-(6-chloro-3H- imidazo[4,5-b]pyridin-3-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l-(2,2,2- trifluoroethyl)-lH-pyrazol-4-yl)amino)nicotinamide (360); (R)-6-(6-chloro-3H- imidazo[4,5-b]pyridin-3-yl)-4-((l-ethyl-lH-pyrazol-4-yl)amino)-N-(2-fluoro-3-hydroxy- 3-methylbutyl)nicotinamide (361); (R)-6-(6-chloro-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -isopropyl- 1 H-pyrazol-4-yl)amino)nicotinamide (362); (R)-6-(5-cyano-lH-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(( 1 -(2-methoxyethyl)- 1 H-pyrazol-4-yl)amino)nicotinamide (363); (R)-6- (5 -chloro-lH-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((l- (2-methoxyethyl)- lH-pyrazol-4-yl)amino)nicotinamide (364); (R)-6-(5-cyano-lH- pyrazolo[3,4-b]pyridin-l-yl)-4-((l-(2,2-difluoropropyl)-lH-pyrazol-4-yl)amino)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (365); (R)-6-(6-chloro-3H-imidazo[4,5-b] pyridin-3 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(2-methoxyethyl)- 1 H-pyrazol- 4-yl)amino)nicotinamide (366); (R)-6-(5-chloro-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(3 -fluoropropyl)- 1 H-pyrazol-4-yl)amino) nicotinamide (367); (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(( 1 -(3 -fluoropropyl)- 1 H-pyrazol-4-yl)amino)nicotinamide (368); (R)-6-(5-chloro-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-((l-(2,2-difluoropropyl)-lH- pyrazol-4-yl)amino)-N-(2-f uoro-3-hydroxy-3-methylbutyl)nicotinamide (369); (R)-6-(6- chloro-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-f uoro-3-hydroxy-3-methylbutyl)-4-((l-(3- f uoropropyl)-lH-pyrazol-4-yl)amino)nicotinamide (370); (R)-6-(5-cyano-lH-pyrrolo [2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l-(2,2,2-trif uoroethyl)- lH-pyrazol-4-yl)amino)nicotinamide (371); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-4-(( 1 -ethyl- 1 H-pyrazol-4-yl)amino)-N-(2-f uoro-3 -hydroxy-3 -methylbutyl) nicotinamide (372); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-f uoro-3- hydroxy-3 -methylbutyl)-4-(( 1 -(tetrahydro-2H-pyran-4-yl)- 1 H-pyrazol-4-yl)amino) nicotinamide (373); (R)-6-(6-chloro-3H-imidazo[4,5-b]pyridin-3-yl)-4-((l-(2- cyanoethyl)- 1 H-pyrazol-4-yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (374); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-4-((l-(2,2-difluoroethyl)-lH- pyrazol-4-yl)amino)-N-(2-f uoro-3-hydroxy-3-methylbutyl)nicotinamide (375); (R)-6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -(2-cyanoethyl)- 1 H-pyrazol-4-yl)amino)-N- (2-f uoro-3 -hydroxy-3 -methylbutyl)nicotinamide (376); (R)-6-(5 -chloro- 1 H-pyrazolo [3,4-b]pyridin-l-yl)-4-((l-(2-cyanoethyl)-lH-pyrazol-4-yl)amino)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (377); 6-(6-cyano-3H-imidazo [4,5 -b]pyridin-3 -yl)- N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((l-(2-fluoropropyl)-lH-pyrazol-4- yl)amino Nicotinamide, racemic (378); 6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-4-((l- (2-(difluoromethoxy)propyl)-lH-pyrazol-4-yl)amino)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (379); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -propyl- 1 H-pyrazol-4-yl)amino)nicotinamide (380); (R)-6-(5-chloro-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)-4-(( 1 -propyl- 1 H-pyrazol-4-yl)amino)nicotinamide (381); (R)-6-(6-chloro- 3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l-propyl-lH- pyrazol-4-yl)amino)nicotinamide (382); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -propyl- 1 H-pyrazol-4-yl)amino)nicotinamide (383); (R)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)amino)-6-(5 -fluoro- 1 H-pyrazolo [3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (384); (R)-6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 - (methylsulfonyl)- 1 H-pyrazol-4-yl)amino)nicotinamide (385); (R)-6-(5 -cyano- 1 H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -(ethylcarbamoyl)- 1 H-pyrazol-4-yl)amino)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (386); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methy lbutyl)-4-(( 1 -methyl- 1 H-pyrazol-4- yl)amino)nicotinamide (387); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-((l-(2,2- difluoroethyl)-lH-pyrazol-4-yl)amino)-N-isopropylnicotinamide (388); 6-(5 -cyano- 1 H- pyrazolo [3, 4-b]pyridin-l-yl)-4-((l -(2,2-difluoroethyl)- lH-pyrazol-4-yl)amino)-N- propylnicotinamide (389); N-(tert-butyl)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- ((l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)amino)nicotinamide (390); 6-(5 -cyano- 1H- pyrazolo [3, 4-b]pyridin-l-yl)-4-((l -(2,2-difluoroethyl)- lH-pyrazol-4-yl)amino)-N- isobutylnicotinamide (391); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -(2,2- difluoroethyl)- lH-pyrazol-4-yl)amino)-N-(2-ethoxyethyl)nicotinamide (392); 6-(5-cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)amino)-N- ethylnicotinamide (393); (R)-6-(5-chloro- 1 H-pyrazolo [3, 4-b]pyridin- 1 -yl)-4-((l - (difluoromethyl)- 1 H-pyrazol-4-yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (394); (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2,3-difluoro-3- methylbutyl)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)amino)nicotinamide (395); 6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4- yl)amino)-N-((lR,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)nicotinamide (396); 6-(5- cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2,2-difluoro-3-hydroxy-3-methylbutyl)-4-((l- (2,2-difluoroethyl)- lH-pyrazol-4-yl)amino)nicotinamide (397); (R)-6-(6-chloro-3H- imidazo[4,5-b]pyridin-3-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l -methyl- 1H- pyrazol-4-yl)amino)nicotinamide (398); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l -methyl- lH-pyrazol-4-yl)amino)
nicotinamide (399); (R)-6-(6-chloro-3H-imidazo[4,5-b]pyridin-3-yl)-4-((l- (difluoromethyl)- 1 H-pyrazol-4-yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (400); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-4-((l-
(difluoromethyl)- 1 H-pyrazol-4-yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (401); (R)-6-(6-chloro-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2,3-difluoro-3- methylbutyl)-4-(( 1 -(2,2-difluoroethyl)- 1 H-pyrazol-4-yl)amino)nicotinamide (402); (R)-6- (6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2,3-dif uoro-3-methylbutyl)-4-((l-(2,2- dif uoroethyl)-lH-pyrazol-4-yl)amino)nicotinamide (403); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-((3 -eye lopropyl-1 H-pyrazol-5 -yl)amino)-N-(2-f uoro-3 -hydroxy-3 - methylbutyl)nicotinamide (404); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2- f uoro-3 -hydroxy-3 -methylbutyl)-4-((3 -methyl- 1 H-pyrazol-5 -yl)amino)nicotinamide (405); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-f uoro-3 -hydroxy-3 - methylbutyl)-4-((3-isopropyl-l H-pyrazol-5 -yl)amino)nicotinamide (406); (R)-6-(5- cyano- 1 H-pyrazolo[3 ,4-b]pyridin- 1 -yl)-4-((l -(2,2-difluoroethyl)- 1 H-pyrazol-3- yl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (407); (R)-6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l-(2,2,2- trifluoroethyl)-lH-pyrazol-3-yl)amino)nicotinamide (408); (R)-6-(5-cyano-lH-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((l -methyl- 1 H-pyrazol-5 - yl)amino)nicotinamide (409); (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2- f uoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(pyrimidin-2-yl)- 1 H-pyrazol-4-yl)amino) nicotinamide (410); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3 - hydroxy-3 -methylbutyl)-4-(( 1 -(5 -fluoropyrimidin-2-yl)- 1 H-pyrazol-4-yl)amino) nicotinamide (411); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3 - hydroxy-3 -methylbutyl)-4-((3 -phenyl- 1 H-pyrazol-5 -yl)amino)nicotinamide (412); (R)-6- (5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -y l)-4-(( 1 ,3 -dimethyl- 1 H-pyrazol-5 -yl)amino)-N- (2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (413); 6-(5-cyano- lH-indol- 1 -yl)-N- ((lR,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (414); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l -yl)-N-(4-hydroxybicyclo[2.2.1 Jheptan- 1 -yl)-4- (isopropylamino Nicotinamide (415); (R)-6-(5-cyano- lH-pyrrolo[2,3-b]pyridin- 1 -yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3-sulfamoylphenyl)amino)nicotinamide (416); N-(3-(tert-butoxy)propyl)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino) nicotinamide (417); (R)-6-(5-cyano- lH-pyrrolo[2,3-b]pyridin- 1 -yl)-N-(2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-methoxyphenyl)amino)nicotinamide (418); (R,E)-6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 - hydroxy-3 -methylbut-1 -en- l-yl)amino)nicotinamide (419); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(( 1 R,4R)-4-fluoro-4-( 1 -methyl- 1 H-imidazol-2-yl)cyclohexyl)-4- (isopropylamino Nicotinamide (420); (R)-4-(benzo[d]oxazol-6-ylamino)-6-(5-cyano-lH- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (421 ); 6- (5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((3-hydroxybutyl)amino)nicotinamide (422); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((6-methylpyridin-3 -yl)methyl)amino) nicotinamide (423); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)-4-(( 1 -methyl- 1 H-pyrazol-5 -yl)amino)nicotinamide (424); (R)-6- (5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((3,3,3-trifluoropropyl)amino)nicotinamide (425); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-fluorobutan-2-yl)amino) nicotinamide (426); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3 -methylbutyl)-4-((4-fluorobutan-2-yl)amino)nicotinamide (427); 4- (cyclopropylamino)-6-(5-fluoro-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((lR,4R)-4-(2- hydroxypropan-2-yl)cyclohexyl)nicotinamide (428); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- l-yl)-4-(cyclopropylamino)-N-((lR,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl) nicotinamide (429); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((3-cyano-2- fluorophenyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (430); (R)-4- ((3-(lH-imidazol-2-yl)phenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (431); 6-(5-fluoro-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-4-(((S)- 1 -hydroxypropan-2-yl)amino)-N-(( 1 R,4S)-4-(2-hydroxypropan-2- yl)cyclohexyl)nicotinamide (432); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((4- ( 1 -ethyl- 1 H-tetrazol-5 -yl)phenyl)amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (433); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- methoxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (434); 6-(5-cyano-lH- pyrrolo[2,3-b]pyridin-l-yl)-4-(((R)-2-fluoro-3-(isopropylamino)-3-oxopropyl)amino)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (435); (R)-4-((lH-benzo[d][l,2,3] triazol-6-yl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (436); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(oxetan-3 -ylamino)nicotinamide (437); (R)-4-(( 1 H- indazol-5-yl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy- 3-methylbutyl)nicotinamide (438); (R)-4-((lH-benzo[d]imidazol-6-yl)amino)-6-(5-cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (439); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-(((R)-tetrahydrofuran-3-yl)amino)nicotinamide (440); 6-(5-cyano-lH- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)- tetrahydrofuran-3-yl)amino)nicotinamide (441); (R)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -trideuteromethoxy-3 -methylbutyl)-4-(isopropylamino) nicotinamide (442); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- trideuteromethoxy-3-methylbutyl)-4-((3-(hydroxymethyl)cyclohexyl)amino)nicotinamide (443); 6-(5-cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(4-(l -cyclopropyl-1 -hydroxy ethyl) cyclohexyl)-4-(isopropylamino)nicotinamide (444); 6-(5-cyano-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -(hydroxymethyl) cyclohexyl)amino)nicotinamide (445); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(4- (1 -cyclopropyl-1 -hydroxy ethyl)cyclohexyl)-4-(isopropylamino)nicotinamide (446); 6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-4-(isopropylamino)-N-(l -(methylsulfonyl) piperidin-4-yl)nicotinamide (447); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(3- ethoxy-2-fluoro-3-methylbutyl)-4-(isopropylamino)nicotinamide (448); 6-(5-cyano-lH- pyrrolo[2,3-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)- 1 -(5- fluoropyrimidin-2-yl)pyrrolidin-3 -yl)amino)nicotinamide (449); 6-(5 -cyano- 1 H-pyrrolo [2,3-b]pyridin-l-yl)-4-(((R)-l-cyclopropylethyl)amino)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (450); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(((S)-l- cyclopropylethyl)amino)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (451); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino)-N-(2-(morpholine-4- sulfonamido)ethyl)nicotinamide (452); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (cyclopropylamino)-N-(2-(methylsulfonamido)ethyl)nicotinamide (453); 6-(5 -cyano- 1H- pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4- methylpentan-2-yl)amino)nicotinamide (454); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((3R,4S)-4-hydroxytetrahydrofuran-3- yl)amino)nicotinamide (455); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2- fluoro-3-hydroxy-3-methylbutyl)-4-(((3R,4S)-4-hydroxytetrahydrofuran-3-yl)amino) nicotinamide (456); (R)-tert-butyl 3-((2-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-5-((2- fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)pyridin-4-y l)amino)azetidine- 1 -carboxylate (457); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-(((3R,4S)-4-fluorotetrahydrofuran-3-yl)amino)nicotinamide (458); 6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((3R,4S)-4-fluorotetrahydrofuran-3-yl)amino)nicotinamide (459); 4-((2-(lH-imidazol-4- yl)cyclopropyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)nicotinamide (460); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxybutyl)amino)nicotinamide (461); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-((3-hydroxybutyl)amino)nicotinamide (462); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(methylsulfonyl) piperidin-4-yl)amino)nicotinamide (463); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((l-phenylpiperidin-4-yl)amino)nicotinamide (464); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-(((R)- 1 -(methylsulfonyl)pyrrolidin-3-yl)amino)nicotinamide (465); 6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((R)- pyrrolidin-3-ylamino)nicotinamide (466); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-4- (isopropylamino)-N-(2-(4-methylpiperazin- 1 -yl)-2-oxoethyl)nicotinamide (467); (R)-4- ((l-acetylazetidin-3-yl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3-methylbutyl)nicotinamide (468); 4-(((R)-l-acetylpyrrolidin-3-yl)amino)-6-(5- cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (469); (R)-4-((l-acetylpiperidin-4-yl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b] pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (470); (R)-4-((4-(lH- imidazol-l-yl)phenyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3-methylbutyl)nicotinamide (471); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(5 -fluoropyrimidin-2-yl)azetidin-3 - yl)amino)nicotinamide (472); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)- 1 -(3 ,3 ,3 -trifluoropropanoyl)pyrrolidin-3 - yl)amino)nicotinamide (473); (R)-methyl 3-((2-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)- 5-(((R)-2-fluoro-3-hydroxy-3-methylbutyl)carbamoyl)pyridin-4-yl)amino)pyrrolidine-l- carboxylate (474); (R)- 1 -(4-((azetidin-3 -ylmethyl)amino)-5-((2-fluoro-3 -hydroxy-3 - methylbutyl)carbamoyl)pyridin-2-yl)-lH-pyrrolo[2,3-b]pyridine-5-carboxamide (475); (R)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((l-(methylsulfonyl)azetidin-3-yl)amino)nicotinamide (476); 6-(5 -cyano- 1 H-pyrrolo
[2,3-b]pyridin- 1 -yl)-4-(((R)- 1 -(2-cyanoacetyl)pyrrolidin-3-yl)amino)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)nicotinamide (477); (S)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-4-((l-hydroxypropan-2-yl)amino)-N-(2-(methylsulfonamido)ethyl)nicotinamide (478); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-(methylsulfonamido)ethyl)-4- ((tetrahydro-2H-pyran-4-yl)amino)nicotinamide (479); (R)-6-(5 -cyano- 1 H-pyrrolo
[2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((2-morpholinoethyl) amino)nicotinamide (480); (R)-methyl 3-((2-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-5- ((2-fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)pyridin-4-yl)amino)azetidine- 1 - carboxylate (481); (R)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2-fluoro-3- hydroxy-3-methylbutyl)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)nicotinamide (482); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)-4-((2-(3-methylmorpholino)ethyl)amino)nicotinamide (483); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-4-((4,4-difluorotetrahydrofuran-3-yl)amino)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (484); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b] pyridin- 1 -yl)-4-((4,4-difluorotetrahydrofuran-3-yl)amino)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (485); 4-(((lR,4R)-4-carbamoylcyclohexyl)amino)-6-(5-cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl) nicotinamide (486); 6-(5-cyano- lH-pyrrolo[2,3-b]pyridin- 1 -yl)-N-(2-(l -hydroxy eye lopentyl)ethyl)-4- (isopropylamino)nicotinamide (487); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)- 2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-((2,2,2- trifluoroethyl)amino)cyclopentyl)amino)nicotinamide (488); 6-(5 -cyano- 1 H-pyrrolo
[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-((2,2,2- trifluoroethyl)amino)cyclopentyl)amino)nicotinamide (489); 4-((3-aminocyclopentyl) amino)-6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (490); 4-((3-aminocyclopentyl)amino)-6-(5 -cyano- 1 H-pyrrolo [2,3-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (491); 4-((3- aminocyclopentyl)amino)-6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (492); 4-((3 -aminocyclopentyl)amino)-6-(5 -cyano- lH-pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (493); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin-l -yl)-N-(2-fluoro-2-(3-hydroxyoxetan-3- yl)ethyl)-4-(isopropylamino)nicotinamide (494); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-2-(3-hydroxyoxetan-3-yl)ethyl)-4-(isopropylamino)nicotinamide (495); 6-(5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((2S)-3-hydroxy-5-methylhexan-2-yl)amino)nicotinamide (496); 6-(5 -cyano- 1 H-pyrrolo [2,3-b]pyridin-l-yl)-N-((lS,3S)-3-(2-hydroxypropan-2-yl)cyclopentyl)-4- (isopropylamino)nicotinamide (497); (R)-isobutyl (( 1 -(5 -((2-fluoro-3 -hydroxy-3 - methylbutyl)carbamoyl)-4-(isopropylamino)pyridin-2-yl)-lH-pyrrolo[2,3-b]pyridin-5- yl)methyl)carbamate (498); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-6-(5-((3-hydroxy- 3-methylbutanamido)methyl)-lH-pyrrolo[2,3-b]pyridin-l-yl)-4-(isopropylamino) nicotinamide (499); (R)-6-(5-((3 ,3-diethylureido)methyl)- lH-pyrrolo[2,3-b]pyridin- 1 -yl)- N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (500); (R)-ethyl (( 1 -(5 -((2-fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)-4-(isopropylamino)pyridin-2-yl)- lH-pyrrolo[2,3-b]pyridin-5-yl)methyl)carbamate (501); (R)-isopropyl ((l-(5-((2-fluoro-3- hydroxy-3 -methylbutyl)carbamoyl)-4-(isopropylamino)pyridin-2-yl)- 1 H-pyrrolo [2,3 -b] pyridin-5 -yl)methyl)carbamate (502); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(5 -((3 -methylbutanamido)methyl)- 1 H-pyrrolo [2,3 -b]pyridin- 1 - yl)nicotinamide (503); (R)-6-(5-((2-cyclopentylacetamido)methyl)-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (504); (R)-6-(5-(cyclopropanecarboxamidomethyl)-lH-pyrrolo[2,3-b]pyridin-l-yl)-N-(2- fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (505); 6-(5 -cyano- 1H- pyrrolo[2,3-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)-2- fluoropropyl)amino)nicotinamide (506); 6-(5-cyano-lH-pyrrolo[2,3-b]pyridin-l-yl)-N- ((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((S)-2-fluoropropyl)amino)nicotinamide (507); (R)-propyl ((l-(5-((2-fluoro-3-hydroxy-3-methylbutyl)carbamoyl)-4- (isopropylamino)pyridin-2-yl)-lH-pyrrolo[2,3-b]pyridin-5-yl)methyl)carbamate (508); 6- (5 -cyano- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((lR,3R)-3-(2-hydroxypropan-2-yl)cyclobutyl)amino)nicotinamide (509); (R)-6-(5- (butyramidomethyl)- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)nicotinamide (510); (R)-6-(5-((2-cyclohexylacetamido) methyl)- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)nicotinamide (511); (R)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(5 -((4-methylpentanamido)methyl)- 1 H-pyrrolo [2,3 -b]pyridin- 1 - yl)nicotinamide (512); (R)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)-6- (5-((3-propylureido)methyl)-lH-pyrrolo[2,3-b]pyridin-l-yl)nicotinamide (513); (R)-6-(5- ((3 -benzylureido)methyl)- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)nicotinamide (514); (R)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)-6-(5-((2-phenylacetamido)methyl)-lH-pyrrolo[2,3-b] pyridin-l-yl)nicotinamide (515); (R)-6-(5-((3-butylureido)methyl)-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (516); (R)-6-(5 -cyano- lH-pyrrolo[2,3-b]pyridin- 1 -yl)-N-(2,3-difluoro-3-methylbutyl)-4- ((3-hydroxyphenyl)amino)nicotinamide (517); (R)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)-4-(isopropylamino)-6-(5-((2-(tetrahydro-2H-pyran-4-yl)acetamido)methyl)- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)nicotinamide (518); (R)-6-(5 -((3 ,3 -dimethylbutanamido) methyl)- 1 H-pyrrolo [2,3 -b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)nicotinamide (519); N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino)-6-(5 -((tetrahydrofuran-3 -carboxamido)methyl)- 1 H-pyrrolo [2,3 -b] pyridin- 1 -yl)nicotinamide (520); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((5 -(2-hydroxypropan-2-yl)thiazol-2-yl)amino) nicotinamide (521); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-((3-cyanophenyl) amino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (522); (R)-6-(5 -cyano- 1 H- pyrazo lo [3, 4-b]pyridin-l-yl)-4-((4-cyanophenyl)amino)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (523); (R)-4-(benzo [d]thiazol-6-ylamino)-6-(5 -cyano- 1H- pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (524); (R)-l-(4-(benzo[d]oxazol-6-ylamino)-5-((2-fluoro-3-hydroxy-3-methylbutyl)carbamoyl) pyridin-2-yl)-l H-pyrazolo [3, 4-b]pyridine-5-carboxamide (525); (R)-4-((4-(lH-l,2,4- triazol-l-yl)phenyl)amino)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3 - hydroxy-3-methylbutyl)nicotinamide (526); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-( 1 -methyl- 1 H-tetrazol-5 -yl)phenyl) amino)nicotinamide (527); (R)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-((3-cyano-
2- fluorophenyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (528); (R)-6- (5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2,3-difluoro-3-methylbutyl)-4-((4-(l- methyl-1 H-tetrazol-5 -yl)phenyl)amino)nicotinamide (529); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((5 -methyl- 1,3,4- thiadiazol-2-yl)amino)nicotinamide (530); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((4-( 1 -methyl- 1 H-pyrazol-4-yl)phenyl) amino)nicotinamide (531); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro- 3 -hydroxy-3 -methylbutyl)-4-(((R)- 1 -(5 -fluoropyrimidin-2-yl)pyrrolidin-3 -yl)amino) nicotinamide (532); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3 - hydroxy-3 -methylbutyl)-4-(((S)- 1 -(5 -fluoropyrimidin-2-yl)pyrrolidin-3 -yl)amino) nicotinamide (533); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3- hydroxy-3 -methylbutyl)-4-(((R)- 1 -(5 -fluoropyrimidin-2-yl)pyrrolidin-3 -yl)amino) nicotinamide (534); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3 - hydroxy-3 -methylbutyl)-4-(( 1 -phenylpiperidin-4-yl)amino)nicotinamide (535); 6-(5 - cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((R)- 1 -(5-methoxypyrimidin-2-yl)pyrrolidin-3-yl)amino)nicotinamide (536); 6-(5-cyano- lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)-l- (pyrimidin-2-yl)pyrrolidin-3 -yl)amino)nicotinamide (537); 6-(5 -cyano- 1 H-pyrazolo
[3 ,4-b]pyridin- 1 -yl)-4-(((R)- 1 -(2,4-difluorobenzoyl)pyrrolidin-3-yl)amino)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (538); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methy lbutyl)-4-(( 1 -(5 -fluoropyrimidin-2- yl)azetidin-3-yl)amino)nicotinamide (539); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(( 1 -(5 -fluoropyrimidin-2-yl)piperidin-4- yl)amino)nicotinamide (540); (R)-4-((l-(5-chloropyrimidin-2-yl)azetidin-3-yl)amino)-6- (5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (541); (R)-methyl 3 -((2-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-5 -((2- fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)pyridin-4-y l)amino)azetidine- 1 -carboxylate (542); (R)-ethyl 3-((2-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-5-((2-fluoro-3-hydroxy-
3- methylbutyl)carbamoyl)pyridin-4-yl)amino)azetidine- 1 -carboxylate (543); 6-(5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)- tetrahydrofuran-3-yl)amino)nicotinamide, TFA salt (544); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((S)-tetrahydrofuran-3 - yl)amino)nicotinamide, TFA salt (545); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)- N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(oxetan-3-ylamino)nicotinamide (546); 6-(5- fluoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((tetrahydro-2H-pyran-3-yl)amino)nicotinamide (547); 6-(6-cyano-3H-imidazo[4,5-b] pyridin-3 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)-tetrahydrofuran-3 - yl)amino)nicotinamide (548); (R)-6-(5-cyano-2,3-dihydro-lH-pyrrolo[2,3-b]pyridin-l- yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(oxetan-3-ylamino)nicotinamide (549); (R)- 6-(5 -fluoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (oxetan-3-ylamino)nicotinamide (550); (R)-6-(5 -chloro-1 H-pyrazolo [3, 4-b]pyridin-l -yl)- N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(oxetan-3-ylamino)nicotinamide (551); 6-(5- cyano-1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((l R,4R)-4-methoxycyclohexyl)-4-(oxetan-3- ylamino)nicotinamide (552); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(3 -hydro xy- 3 -methylbutyl)-4-(oxetan-3 -ylamino)nicotinamide (553); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin- 1 -yl)-4-((4,4-difluorotetrahydrofuran-3 -yl)amino)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (554); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N- ((lR,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(oxetan-3-ylamino)nicotinamide (555); 6-(5 -chloro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(( 1 R,4R)-4-(2-hydroxypropan-2- yl)cyclohexyl)-4-(oxetan-3-ylamino)nicotinamide (556); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-N-isopentyl-4-(oxetan-3-ylamino)nicotinamide (557); 6-(6-amino-5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-cyclopropylethyl)-4-(oxetan-3-ylamino) nicotinamide (558); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-butyl-4- (oxetan-3-ylamino)nicotinamide (559); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin- l-yl)-N-isopentyl-4-(oxetan-3-ylamino)nicotinamide (560); N-butyl-6-(5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-4-(oxetan-3-ylamino)nicotinamide (561); (R)-6-(5-fluoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((tetrahydro- 2H-pyran-4-yl)amino)nicotinamide (562); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3,3,3-trifluoropropyl)amino)nicotinamide (563); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(isopropylamino)-N-(5- methoxypyrazin-2-yl)nicotinamide (564); N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- ((2-morpholinopropyl)amino)-6-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)nicotinam (565); N-((2H-tetrazol-5-yl)methyl)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4- (isopropylamino)nicotinamide (566); (R)-6-(5-cyano-2,3-dihydro-lH-pyrrolo[2,3-b] pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(isopropylamino)nicotinamide (567); (R)-6-(6-cyano-3H-imidazo[4,5-b]pyridin-3-yl)-4-(ethylamino)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (568); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)- N-((R)-2-fluoro-3 -hydroxy-3 -methylbuty l)-4-(((S)- 1 -hydroxy-3 -methylbutan-2-yl)amino) nicotinamide (569); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3 - hydroxy-3-methylbutyl)-4-((2-methyl-2-morpholinopropyl)amino)nicotinamide (570); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)- 4-((oxazol-4-ylmethyl)amino)nicotinamide (571); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)-3 -hydroxybutyl)amino) nicotinamide (572); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3 - hydroxy-3 -methylbutyl)-4-(((R)-3 -hydroxybutyl)amino)nicotinamide (573); (R)-6-(5 - cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-((2,2-difluoroethyl)amino)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (574); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)- 4-((2-fluoro-3 -hydroxy-2-methylpropyl)amino)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (575); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2- fluoro-3-hydroxy-3-methylbutyl)-4-(neopentylamino)nicotinamide (576); (R)-6-(6- amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-(ethylamino)-N-(2-fluoro-3 -hydro xy- 3 -methylbuty l)nicotinamide (577); (R)-6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(propylamino)nicotinamide (578); (R)-6-(6- amino- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (isopropylamino Nicotinamide (579); (R)-6-(6-amino-l H-pyrazolo [3, 4-d]pyrimidin-l -yl)- 4-(ethylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (580); (R)-6-(5- cyano-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((l- fluorocyclobutyl)methyl)amino)nicotinamide (581); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((R)-2-fluoropropyl)amino) nicotinamide (582); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-(((S)-2-fluoropropyl)amino)nicotinamide (583); 6-(5-cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(isopropylamino)-N-( 1 -(1 -(methylsulfonyl)azetidine- 3-carbonyl)piperidin-4-yl)nicotinamide (584); (R)-4-((3-amino-2,2-dimethylpropyl) amino)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-(2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (585); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2- fluoro-3-hydroxy-3-methylbutyl)-4-((2-(methylsulfonamido)ethyl)amino)nicotinam (586); (R)- 1,1,1 -trifluoro-2-methylpropan-2-yl (2-((2-(5 -cyano- 1 H-pyrazolo [3 ,4-b] pyridin- 1 -yl)-5 -((2-fluoro-3 -hydroxy-3 -methylbutyl)carbamoyl)pyridin-4-yl)amino)ethyl) carbamate (587); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3 - hydroxy-3 -methylbutyl)-4-(((S)-l-hydroxybutan-2-yl)amino)nicotinamide (588); 6-(5- chloro-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((S)- 1 -hydroxybutan-2-yl)amino)nicotinamide (589); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((S)-2-fluoropropyl) amino)nicotinamide (590); 6-(6-amino-5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)- 2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)-2-fluoropropyl)amino)nicotinamide (591); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)- 4-(propylamino)nicotinamide (592); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((2-methoxy-2-methylpropyl)amino)nicotinamide (593); 6-(5-chloro-l H-pyrazolo [3, 4-b]pyridin-l-y l)-N-((R)-2-fluoro-3 -hydroxy-3 - methylbutyl)-4-((2-hydroxy-3-methylbutyl)amino)nicotinamide (594); (R)-6-(5-cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3- fluoropropyl)amino)nicotinamide (595); 6-(5 -chloro-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((2-hydroxy-3 -methylbutyl)amino) nicotinamide (596); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3 - hydroxy-3 -methylbutyl)-4-((2 -hydroxy-3 -methylbutyl)amino)nicotinamide (597); (R)-6- (5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-((2-(difluoromethoxy)ethyl)amino)-N-(2- fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (598); (R)-6-(6-amino-5 -cyano- 1 H- pyrazo lo [3, 4-b]pyridin-l-yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3-fluoro-3- methylbutyl)amino)nicotinamide (599); (R)-6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)- N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-fluoro-3-methylbutyl)amino)nicotinamide (600); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-((2-(difluoromethoxy)-2- methylpropyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (601); 6-(5- chloro-1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((R)-2-fluorobutyl)amino)nicotinamide (602); (R)-6-(5 -chloro-1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-4-((2-(difluoromethoxy)-2-methylpropyl)amino)-N-(2-fluoro-3 -hydroxy-3 - methylbutyl)nicotinamide (603); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -fluorobutyl)amino)nicotinamide (604); (R)-6-(5 - cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-((cyclopropylmethyl)amino)-N-(2-fluoro-3- hydroxy-3 -methylbutyl)nicotinamide (605); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)- N-(( )-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((lR,4R)-4-(2-hydroxypropan-2- yl)cyclohexyl)amino)nicotinamide (606); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N- ((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((ls,4S)-4-hydroxy-4-methylcyclohexyl) amino)nicotinamide (607); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro- 3 -hydroxy-3 -methylbutyl)-4-((( 1 R,4R)-4-hydroxy-4-methylcyclohexyl)amino) nicotinamide (608); 6-(5-fluoro-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-hydroxycyclopentyl)amino)nicotinamide (609); 6-(5- fluoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 - hydroxy cyclopentyl)amino)nicotinamide (610); 6-(5 -fluoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -hydroxy cyclopentyl)amino) nicotinamide (611); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3 - hydroxy-3 -methylbutyl)-4-((( 1 R,3 S)-3 -(2-hydroxypropan-2-yl)cyclohexyl)amino) nicotinamide (612); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-(2-fluoro-3 - hydroxy-3-methylbutyl)-4-((4-hydroxybicyclo[2.2.1 Jheptan- 1 -yl)amino)nicotinamide (613); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-((3 ,3-difluorocyclopentyl)amino)- N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (614); 6-(5 -cyano- 1 H-pyrazolo [3,4-b]pyridin-l-yl)-4-((3,3-difluorocyclopentyl)amino)-N-((R)-2-fluoro-3-hydroxy-3- methylbutyl)nicotinamide (615); (R)-6-(5-cyano-2,3-dihydro- lH-pyrrolo[2,3-b]pyridin- 1 - yl)-4-(cyclopropylamino)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (616); 6- (5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((lS,3S)-3-(2-hydroxypropan-2-yl)cyclopentyl)amino)nicotinamide (617); 6-(5-fluoro- lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorocyclopentyl)amino)nicotinamide (618); 6-(5 -fluoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3 -f uorocyclopentyl)amino) nicotinamide (619); 6-(5-f uoro- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-((R)-2-f uoro-3 - hydroxy-3-methylbutyl)-4-((3-f uorocyclopentyl)amino)nicotinamide (620); 6-(5-f uoro- lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- f uorocyclopentyl)amino)nicotinamide (621 ); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((lR,4R)-4-(oxetan-3-ylamino) cyclohexyl)amino)nicotinamide (622); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4- (((lR,4R)-4-(cyclopropanecarboxamido)cyclohexyl)amino)-N-((R)-2-fluoro-3 -hydroxy- 3-methylbutyl)nicotinamide (623); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2- fluoro-3 -hydroxy-3 -methylbutyl)-4-((( 1 R,5 S)-3 -hydroxyadamantan- 1 -yl)amino) nicotinamide (624); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3- hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (625); 6-(5-cyano- lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3- fluorocyclopentyl)amino)nicotinamide (626); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l- yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((3-fluorocyclopentyl)amino) nicotinamide (627); 6-(5-chloro-l H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro-3 - hydroxy-3 -methylbutyl)-4-((( 1 S ,3 S)-3 -(2-hydroxypropan-2-yl)cyclopentyl)amino) nicotinamide (628); 6-(6-amino-5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-((( 1 R,2R)-2- fluorocyclohexyl)amino)-N-((lR,4R)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (629); 6-(6-amino-5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(((lS,2S)-2- fluorocyclohexyl)amino)-N-((lR,4S)-4-(methylcarbamoyl)cyclohexyl)nicotinamide (630); (R)-6-(6-amino-5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-4-(cyclopropylamino)- N-(2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (631); 6-(6-amino-5 -cyano- 1 H- pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((lR,5S)-3- hydroxyadamantan- l-yl)amino)nicotinamide (632); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin-l-yl)-4-(((lR,4R)-4-(2,2-difluoroacetamido)cyclohexyl)amino)-N-((R)-2-fluoro- 3 -hydroxy-3 -methylbutyl)nicotinamide (633); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((lR,4R)-4-(2-fluorobenzamido) cyclohexyl)amino)nicotinamide (634); (R)-4-(bicyclo[ 1.1.1 ]pentan-2-ylamino)-6-(5- cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-N-(2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (635); 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2,3-difluoro-3- methylbutyl)-4-(((lR,5S)-3-hydroxyadamantan-l-yl)amino)nicotinamide (636); (R)-6-(6- amino-5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 -yl)-4-(bicyclo [1.1.1 Jpentan- 1 -ylamino)-N- (2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (637); 4-((3 -aminocyclopentyl)amino)- 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl) nicotinamide (638); 4-((3-aminocyclopentyl)amino)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b] pyridin- 1 -yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)nicotinamide (639); 4-((3 - aminocyclopentyl)amino)-6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-N-((R)-2-fluoro- 3 -hydroxy-3 -methylbutyl)nicotinamide (640); 6-(5 -cyano- 1 H-pyrazolo [3 ,4-b]pyridin- 1 - yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-(((lR,4R)-4-(isopropylcarbamoyl) cyclohexyl)amino)nicotinamide (641 ); 6-(5-cyano- 1 H-pyrazolo[3 ,4-b]pyridin- 1 -yl)-N- ((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((( 1 R,2R)-2-(hydroxymethyl)cyclopropyl) amino)nicotinamide (642); 6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l -yl)-N-((R)-2-fluoro- 3 -hydroxy-3 -methylbutyl)-4-((( 1 R,2R)-2-(hydroxymethyl)cyclopropyl)amino) nicotinamide (643); (R)-6-(5 -cyano- 1 H-pyrazolo [3, 4-b]pyridin-l-yl)-4-((3, 3- difluorocyclobutyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (644); 6- (5 -chloro-1 H-pyrazolo [3 ,4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4- (((lR,2R)-2-(hydroxymethyl)cyclopropyl)amino)nicotinamide (645); and 6-(5 -chloro-1 H- pyrazolo [3, 4-b]pyridin-l-yl)-N-((R)-2-fluoro-3 -hydroxy-3 -methylbutyl)-4-((( lR,2R)-2- (hydroxymethyl)cyclopropyl)amino)nicotinamide (646) . 9. A pharmaceutical composition comprising one or more compounds according to any one of claims 1-6 and a pharmaceutically acceptable carrier or diluent.
10. A compound according to any one of claims 1-8 for use in therapy in treating of inflammatory or autoimmune disease.
11. The compound according to claim 10, wherein the disease is selected from
Crohn's disease, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis, cryopyrin-associated periodic syndromes, TNF receptor associated periodic syndrome, familial Mediterranean fever, adult onset stills, systemic onset juvenile idiopathic arthritis, multiple sclerosis, neuropathic pain, gout, and gouty arthritis.
12. Use of a compound according to any one of claims 1-8 in the manufacture of a medicament for the treatment of inflammatory or autoimmune disease.
PCT/US2015/010006 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds WO2015103453A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN201580011617.6A CN106061967B (en) 2014-01-03 2015-01-02 The nicotinamide compounds replaced through heteroaryl
SG11201605340QA SG11201605340QA (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
CA2935329A CA2935329A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
MX2016008723A MX2016008723A (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds.
KR1020167020884A KR20160101191A (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
EP15700518.2A EP3089973B1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
AU2015204045A AU2015204045A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
TN2016000271A TN2016000271A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds.
ES15700518T ES2804707T3 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
JP2016544410A JP6475252B2 (en) 2014-01-03 2015-01-02 Heteroaryl-substituted nicotinamide compounds
EA201691343A EA201691343A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
MA39162A MA39162A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds
PH12016501164A PH12016501164A1 (en) 2014-01-03 2016-06-16 Heteroaryl substituted nicotinamide compounds
IL246474A IL246474A0 (en) 2014-01-03 2016-06-27 Heteroaryl substituted nicotinamide compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03
US61/923,403 2014-01-03

Publications (1)

Publication Number Publication Date
WO2015103453A1 true WO2015103453A1 (en) 2015-07-09

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/010006 WO2015103453A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds

Country Status (21)

Country Link
US (1) US9169252B2 (en)
EP (1) EP3089973B1 (en)
JP (1) JP6475252B2 (en)
KR (1) KR20160101191A (en)
CN (1) CN106061967B (en)
AR (1) AR098991A1 (en)
AU (1) AU2015204045A1 (en)
CA (1) CA2935329A1 (en)
CL (1) CL2016001706A1 (en)
EA (1) EA201691343A1 (en)
ES (1) ES2804707T3 (en)
IL (1) IL246474A0 (en)
MA (1) MA39162A1 (en)
MX (1) MX2016008723A (en)
PE (1) PE20161292A1 (en)
PH (1) PH12016501164A1 (en)
SG (1) SG11201605340QA (en)
TN (1) TN2016000271A1 (en)
TW (1) TW201609693A (en)
UY (1) UY35935A (en)
WO (1) WO2015103453A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210037A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
US9546153B2 (en) 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2017067848A1 (en) * 2015-10-19 2017-04-27 Galapagos Nv 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
US9657009B2 (en) 2012-11-08 2017-05-23 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018152368A1 (en) * 2017-02-16 2018-08-23 Gilead Sciences, Inc. Pyrrolo [1,2-b] pyridazine derivatives
KR20190019187A (en) * 2015-06-24 2019-02-26 브리스톨-마이어스 스큅 컴퍼니 A heteroaryl substituted aminopyridine compound
WO2019054427A1 (en) 2017-09-14 2019-03-21 第一三共株式会社 Compound having cyclic structure
US10294229B2 (en) 2015-06-24 2019-05-21 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US10501436B2 (en) 2014-01-01 2019-12-10 Medivation Technologies Llc Compounds and methods of use
CN112513044A (en) * 2018-07-13 2021-03-16 吉利德科学公司 Pyrrolo [1,2-B ] pyridazine derivatives
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11976071B2 (en) 2021-08-18 2024-05-07 Gilead Sciences, Inc. Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JP7266576B2 (en) * 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー [1,2,4]triazolo[4,3-a]pyridinyl-substituted indole compounds
KR20190043437A (en) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 Heterocylic compound as a protein kinase inhibitor
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
TW201927769A (en) * 2017-12-18 2019-07-16 德商歌林達有限公司 Substituted pyrrolidine amides II
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
TWI727392B (en) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 Thiadiazole irak4 inhibitors
KR20230019396A (en) * 2021-07-29 2023-02-08 프라비바이오 주식회사 Novel benzene derivative and immunosuppressive-related use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237590A1 (en) * 2008-11-28 2011-09-29 Takahiro Kitamura Pyridine-3-carboxyamide derivative
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2014074657A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2014074675A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
DE60232510D1 (en) 2001-06-15 2009-07-16 Vertex Pharma 5- (2-AMINOPYRIMIDIN-4-YL) BENZOXOXOLEA AS PROTEIN KINASE INHIBITOR
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
US7449456B2 (en) 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
WO2004065378A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
WO2005007646A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (en) 2006-01-23 2012-07-13 Aventis Pharma Sa NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
WO2008148889A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Sa Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
CN102686569B (en) 2009-10-30 2014-11-26 詹森药业有限公司 Phenoxy-substituted pyrimidines as opioid receptor modulators
CN102971304A (en) 2010-02-01 2013-03-13 日本化学医药株式会社 GPR119 agonist
AU2012249240A1 (en) 2011-04-29 2013-11-07 Icahn School Of Medicine At Mount Sinai Kinase inhibitors
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237590A1 (en) * 2008-11-28 2011-09-29 Takahiro Kitamura Pyridine-3-carboxyamide derivative
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2014074657A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2014074675A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs", 1985, ELSEVIER
BUNDGAARD, H. ET AL.: "A Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS, article "Design and Application of Prodrugs", pages: 113 - 191
CARIO, E., INFLAMM. BOWEL DIS., vol. 16, 2010, pages 1583 - 1597
CHUNG, Y. ET AL., IMMUNITY, vol. 30, 2009, pages 576 - 587
COUILLIN, I. ET AL., J. IMMUNOL., vol. 183, 2009, pages 8195 - 8202
DINARELLO, C.A., EUR. J. IMMUNOL., vol. 41, 2011, pages 1203 - 1217
FLANNERY, S. ET AL., BIOCHEM. PHARMACOL., vol. 80, 2010, pages 1981 - 1991
FRACZEK, J. ET AL., J. BIOL. CHEM., vol. 283, 2008, pages 31697 - 31705
GOLDSTEIN, D.R. ET AL., J. HEART LUNG TRANSPLANT., vol. 24, 2005, pages 1721 - 1729
GREENE ET AL.: "Protective Groups in Organic Synthesis", 1999, WILEY AND SONS
HORTON, C.G. ET AL., MEDIATORS INFLAMM., 2010
KAWAGOE, T. ET AL., J. EXP. MED., vol. 204, 2007, pages 1013 - 1024
KAWAI, T. ET AL., NATURE IMMUNOL., vol. 11, 2010, pages 373 - 384
KEOGH, B. ET AL., TRENDS PHARMACOL. SCI., vol. 32, 2011, pages 435 - 442
KIM, T.W. ET AL., J. IMMUNOL., vol. 186, 2011, pages 2871 - 2880
KITAZAWA, M. ET AL., J. IMMUNOL., vol. 187, 2011, pages 6539 - 6549
KOZICZAK-HOLBRO, M. ET AL., ARTHRITIS RHEUM., vol. 60, 2009, pages 1661 - 1671
KOZICZAK-HOLBRO, M. ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 13552 - 13560
KU, C. ET AL., J. EXP. MED., vol. 204, 2007, pages 2407 - 2422
LIN, S. ET AL., NATURE, vol. 465, 2010, pages 885 - 890
MAEKAWA, Y. ET AL., CIRCULATION, vol. 120, 2009, pages 1401 - 1414
MANN, D.L., CIRC. RES., vol. 108, 2011, pages 1133 - 1145
NGO, V.N. ET AL., NATURE, vol. 470, 2011, pages 115 - 119
NGO, V.N. ET AL., NATURE, vol. 470, 2011, pages 115 - 121
PICARD, C. ET AL., SCIENCE, vol. 299, 2003, pages 2076 - 2079
PUENTE, X.S. ET AL., NATURE, vol. 475, 2011, pages 101 - 105
RAULT ET AL., TETRAHEDRON LETTERS, vol. 47, 2006, pages 4665 - 4669
REKHTER, M. ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 367, 2008, pages 642 - 648
RHYASEN, G.W. ET AL., CANCER CELL, vol. 24, 2013, pages 90 - 104
SIMS, J.E. ET AL., NATURE REV. IMMUNOL., vol. 10, 2010, pages 89 - 102
STASCHKE, K.A. ET AL., J. IMMUNOL., vol. 183, 2009, pages 568 - 577
SUZUKI, N. ET AL., NATURE, vol. 416, 2002, pages 750 - 754
SWANTEK, J.L. ET AL., J. IMMUNOL., vol. 164, 2000, pages 4301 - 4306
TESTA, B. ET AL.: "Hydrolysis in Drug and Prodrug Metabolism", 2003, WILEY-VCH
THOMAS, J.A. ET AL., J. IMMUNOL., vol. 163, 1999, pages 978 - 984
TREON, S.P. ET AL., N. ENGL. J. MED., vol. 367, 2012, pages 826 - 833
WAN, Y. ET AL., J. BIOL. CHEM., vol. 284, 2009, pages 10367 - 10375
WANG, J.Q. ET AL., FRONTIERS IMMUNOL., vol. 5, 2014, pages 367 - 377
WERMUTH C G: "MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS", PRACTICE OF MEDICINAL CHEMISTRY, XX, XX, 1996, pages 203 - 237, XP002190259 *
WERMUTH, C.G. ET AL.: "The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS
WILKE, C.M. ET AL., TRENDS IMMUNOL., vol. 32, 2011, pages 603 - 661

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10544133B2 (en) 2012-11-08 2020-01-28 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
US9546153B2 (en) 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
US9657009B2 (en) 2012-11-08 2017-05-23 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
US10023562B2 (en) 2012-11-08 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
US10501436B2 (en) 2014-01-01 2019-12-10 Medivation Technologies Llc Compounds and methods of use
US11702401B2 (en) 2014-01-01 2023-07-18 Medivation Technologies Llc Compounds and methods of use
US11053216B2 (en) 2014-01-01 2021-07-06 Medivation Technologies Llc Compounds and methods of use
US10202390B2 (en) 2015-06-24 2019-02-12 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
US10294229B2 (en) 2015-06-24 2019-05-21 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2016210037A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CN109641906B (en) * 2015-06-24 2021-10-01 百时美施贵宝公司 Heteroaryl substituted aminopyridine compounds
KR20190019187A (en) * 2015-06-24 2019-02-26 브리스톨-마이어스 스큅 컴퍼니 A heteroaryl substituted aminopyridine compound
JP2019522656A (en) * 2015-06-24 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Heteroaryl-substituted aminopyridine compounds
CN109641906A (en) * 2015-06-24 2019-04-16 百时美施贵宝公司 The aminopyridine compounds that heteroaryl replaces
JP2018524331A (en) * 2015-06-24 2018-08-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Heteroaryl-substituted aminopyridine compounds
KR102641263B1 (en) 2015-06-24 2024-02-26 브리스톨-마이어스 스큅 컴퍼니 Heteroaryl Substituted Aminopyridine Compounds
JP2018530617A (en) * 2015-10-19 2018-10-18 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 6- [5-Amino-6- (2-ethoxyethoxy) -imidazo [4,5-b] pyridin-3-yl] -nicotinonitrile derivatives and their use as IRAK inhibitors
WO2017067848A1 (en) * 2015-10-19 2017-04-27 Galapagos Nv 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
US10508111B2 (en) 2015-10-19 2019-12-17 Galapagos Nv 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-B]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK inhibitors
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
CN110300754A (en) * 2017-02-16 2019-10-01 吉利德科学公司 Pyrrolo- [1,2-b] pyridyl derivatives
WO2018152368A1 (en) * 2017-02-16 2018-08-23 Gilead Sciences, Inc. Pyrrolo [1,2-b] pyridazine derivatives
WO2019054427A1 (en) 2017-09-14 2019-03-21 第一三共株式会社 Compound having cyclic structure
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11318205B1 (en) 2017-12-26 2022-05-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11723980B2 (en) 2017-12-26 2023-08-15 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11932635B2 (en) 2018-01-12 2024-03-19 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US11897882B2 (en) 2018-07-06 2024-02-13 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
CN112513044A (en) * 2018-07-13 2021-03-16 吉利德科学公司 Pyrrolo [1,2-B ] pyridazine derivatives
CN112513044B (en) * 2018-07-13 2023-11-07 吉利德科学公司 Pyrrolo [1,2-B ] pyridazine derivatives
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11976071B2 (en) 2021-08-18 2024-05-07 Gilead Sciences, Inc. Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases

Also Published As

Publication number Publication date
EP3089973B1 (en) 2020-04-29
SG11201605340QA (en) 2016-07-28
PE20161292A1 (en) 2016-11-23
MX2016008723A (en) 2016-09-07
CN106061967B (en) 2019-04-19
JP6475252B2 (en) 2019-02-27
CA2935329A1 (en) 2015-07-09
AR098991A1 (en) 2016-06-22
PH12016501164A1 (en) 2016-08-15
US20150191464A1 (en) 2015-07-09
EP3089973A1 (en) 2016-11-09
CL2016001706A1 (en) 2017-02-10
IL246474A0 (en) 2016-08-31
AU2015204045A1 (en) 2016-08-18
EA201691343A1 (en) 2016-11-30
CN106061967A (en) 2016-10-26
ES2804707T3 (en) 2021-02-09
TW201609693A (en) 2016-03-16
JP2017501202A (en) 2017-01-12
TN2016000271A1 (en) 2017-10-06
KR20160101191A (en) 2016-08-24
US9169252B2 (en) 2015-10-27
MA39162A1 (en) 2017-12-29
UY35935A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
JP6475252B2 (en) Heteroaryl-substituted nicotinamide compounds
EP3313840B1 (en) Heteroaryl substituted aminopyridine compounds
AU2018221812B2 (en) Pyrrolo [1,2-b] pyridazine derivatives
KR102641263B1 (en) Heteroaryl Substituted Aminopyridine Compounds
IL268469A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
JP2018524331A (en) Heteroaryl-substituted aminopyridine compounds
US10239873B2 (en) 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
JP2021511363A (en) Aminopyrrolotriazine as a kinase inhibitor
TW202229283A (en) Bicyclic compounds
US20220332709A1 (en) Thiophene derivatives for the treatment of disorders caused by IgE
EP3475270B1 (en) Heteroaryl substituted aminopyridine compounds
TW202409011A (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
EA042342B1 (en) AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS
EA045220B1 (en) Cot MODULATORS AND METHODS OF THEIR APPLICATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15700518

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12016501164

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 246474

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2935329

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/008723

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016544410

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 39162

Country of ref document: MA

Ref document number: 000991-2016

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016015178

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015700518

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015700518

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201691343

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20167020884

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2016/0000573

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2015204045

Country of ref document: AU

Date of ref document: 20150102

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016015178

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160628